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Antibiotic-resistant bacteria have become an increasing burden worldwide. A highly 
resistant species is Pseudomonas aeruginosa, a nosocomial pathogen that produces a 
biofilm that enhances its resistance. This project examined the possibility of using 
bacteriocin, an internal protective toxin produced by some species of bacteria, as a 
potential treatment for resistant bacteria. In this study, standard broad spectrum 
antibiotics were used to treat P. aeruginosa to prevent biofilm formation. The biofilm 
was then analyzed to determine if the biofilm is inhibited or facilitated by each treatment. 
Optimal concentrations of antibiotics were determined to be effective at a concentration 
of 0.07mg/mL for gentamicin, rifampicin, and polymyxin B. These antibiotics were used 
to test 48 clinical samples obtained in 2006. Out of the 48 isolates, a Pseudomonas strain 
of unknown origin was resistant to both gentamicin and rifampicin (p<0.001). Extraction 
of Colicin V from E. coli and Pyocin S2 from P. aeruginosa was unsuccessful. Nanodrop 
analysis determined that there was minimal  protein in each sample (concentrations 
between 0.196-3.118mg/mL). In the future, bacteriocin extractions should be successfully 
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 In the clinical setting, new medical treatments are developed to help treat 
critically ill patients. Where bacterial infections are involved, there is a pressing need to 
find new kinds of treatment. Antibiotics are beneficial for treating pathogens, but 
emerging “super bugs” are lessening their ability to work. This increased resistance can 
be seen in many bacterial species, including Pseudomonas aeruginosa. Antibiotic 
resistance is a very important issue in the medical community and research into newer 
treatments is vital. Researchers have found that bacteria can produce other natural 
products that can inhibit other species of bacteria. With the development of these 
alternative treatments, it is hoped that clinicians can stay a step ahead of evolving 
bacteria. 
  Antibiotic treatment is a critical therapy in today’s medical world. The first 
antibiotic discovered, penicillin, is known to have decreased mortality to many bacterial 
infections. Since their discovery, researchers have worked tirelessly to develop new 
antibiotics to inhibit the growth of many bacterial species.  
 Antibiotics can usually be categorized into one of four groups: aminoglycosides, 
beta-lactams, quinolones, and macrolides (1). It is important to understand these types of 
antibiotics and how they are used to treat disease in modern medicine. Antibiotics 
function in one of two ways: slowing the growth (inhibition) of bacteria, or killing them. 
Both of these functions can be critical in stopping pathogenic bacteria that are causing an 
infection in a patient. 
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 Not only are antibiotics critical to the treatment of infections in patients, they are 
also used in animals that are raised for human consumption. Cattle are treated with 
antibiotics to increase their growth and prevent disease (2). This use of antibiotics 
increases the amount of animal products that are available for use by consumers. The 
everyday use of antibiotics is widespread. The applications of these drugs are necessary 
not only in the clinical setting, but also in agriculture.  
Antibiotics are either derived from living organisms or modified from versions of 
these products. Natural products are made by bacteria or fungi that have their 
environment manipulated in an industrial setting (3). These substances are then used in a 
way that is beneficial to human health; most of the early antibiotics were produced in this 
manner. Biosynthetic antibiotics are made from the modification of other antibiotics. 
Using older drugs (like first generation antibiotics) as a template can serve as a means to 
develop newer drugs (3). The establishment of new substances that have specific 
bacterial targets and that are not harmful to humans is imperative. 
When antibiotics were first discovered to be effective against bacteria, the true 
mechanisms were not known (3). There are several ways for antibiotics to attack and 
disable a bacterial pathogen.  Targeting specific bacterial structures and processes,such as 
prokaryotic cell walls, ribosomes, and DNA replication, are important because they are 
less likely to cause adverse effects in humans (3). Prokaryotes have cell walls that are 
made of a substance known as peptidoglycan. Penicillin interferes with peptidoglycan 
production causing the cell to leak or degrade. The prokaryotic ribosomal structure 
consists of a 70S ribosomal unit that is different from that of a eukaryote. This structure 
can be inhibited to prevent the prokaryotic cell from producing vital proteins. Bacterial 
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DNA processes are different from eukaryotes due to variation in the enzymes involved in 
their overall strand structure; these can be targeted to prevent future cell replication. The 
major types of antibiotics work by interfering with one of these prokaryote-unique 
functions. 
When targeting the cell wall, knowing the specific bacterial structure is important. 
Gram-positive bacteria have a single thick layer of peptidoglycan with an inner 
membrane. Gram-negative bacteria have an outer membrane, a thin peptidoglycan layer, 
and an inner membrane. Many antibiotics that quickly kill gram-positive bacteria may 
have a harder time penetrating through the outer membrane of gram-negative bacteria (3). 
Gram stain identification of the species involved in a bacterial infection is therefore 
crucial to picking the appropriate antibiotic for treatment. 
Several groups of antibiotics target cell wall synthesis. The first group is the beta-
lactams; they include penicillin, cephalosporin, carbapenems, and vancomycin. Penicillin 
are classified in one of five groups. These include: (1) narrow spectrum penicillins that 
are sensitive to penicillinase (an enzyme produced by some organisms that can destroy 
penicillin); (2) narrow spectrum penicillins that are penicillinase-resistant; (3) broad 
spectrum aminopenicillins; (4) anti-pseudomonal broad-spectrum penicillins; (5) and 
extended-spectrum penicillins.  
Another group classified as members of the beta-lactams is the cephalosporins, 
which can be categorized as first, second, third, or fourth-generation. Penicillin, 
cephalosporins, and carbapenems work by inhibiting transpeptidases from producing the 
peptidoglycan layer (3).  Vancomycin and its derivatives work to bind to 
transglycosylases, which is an enzyme that produces chains that can be linked together to 
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form peptidoglycan (3). Using an antibiotic that targets a bacterial cell wall causes the 
cell to leak and will eventually cause cell lysis (4). Preventing normal cell wall 
development is an effective way to prevent bacteria multiplication. 
Protein synthesis can also be inhibited by antibiotics. These antibiotics, 
aminoglycosides and tetracycline, target the 30S or 50S ribosomal subunits. The 30S 
subunit can be inhibited by aminoglycosides and tetracycline; these bind to the decoding 
region, reducing its ability to interpret codons (5). The 50S subunit can be prevented from 
functioning by members of the macrolides; these block the polypeptide exit tunnel (3). 
Impeding these subunits can halt protein production, eventually slowing down or killing 
the individual bacterium. 
Antibiotics can also inhibit bacterial growth by interfering with prokaryotic DNA 
replication. Bacterial DNA gyrase, an enzyme which aids DNA replication by dealing 
with the torsion of the supercoil of the double helix (6), is targeted by fluoroquinolones 
such as ciprofloxacin. By blocking DNA replication processes, bacteria are unable to 
replicate new genetic material causing cell death.  
Rifampin targets RNA polymerase, an enzyme that is involved in DNA 
transcription during the process of protein manufacturing (3). Interfering with protein 
production can stop appropriate functioning of the cell. Without transcription to produce 
mRNA, the cell cannot produce proteins that are vital to their survival. 
Although antibiotics are extremely beneficial in treating infections, there are also 
problems that have arisen since they have been put into use. Discovery of new options for 
treatment are becoming critical to staying ahead of the bacterial evolutionary curve.  
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Antibiotic-resistant bacteria are an increasing burden in regards to medical 
treatment across the globe. This resistance is primarily a result of the over-prescription of 
these drugs by physicians and their improper use by patients (7). People with viral 
infections are sometimes prescribed antibiotics, leading to exposure of microbiota to the 
antibiotics.  When an individual takes an antibiotic without following directions, e.g. not 
completing the treatment or not taking them appropriately, patients also increase their 
chances of developing resistant bacteria in their system. Due to this concern, measures 
must be taken to help combat the development of resistance. Efforts have been made to 
educate both physicians and patients in order to prevent misuse. In addition, government 
legislation is attempting to lessen the amount of antibiotics put into the food the public 
ingests (8). Making these changes will play a role in combating antibiotic resistance, but 
new treatments also need to be developed. The different types of antibiotics have had 
their effectiveness lowered due to increasing resistance. Pharmaceutical companies have 
worked to develop new antibiotics, but these are compounds that use similar mechanisms 
to previously developed antibiotics for therapeutic effect (1). Due to the rapid generation 
time of bacteria, mutations leading to antibiotic resistance are increasing rapidly. 
Many bacteria are becoming resistant to the major classes of antibiotics by 
targeting the mechanisms of action. One mechanism is through the inactivation of the 
antibiotic itself by the bacteria. This can occur when bacteria prevent the antibiotic from 
taking its active state once it is inside the cell. Bacteria become resistant to mitomycin C 
by altering the oxidation state of the drug.This process renders the drug inactive (3).  
A second mechanism by which antibiotic resistance develops is through the 
function of bacterial efflux pumps that remove the antibiotic from inside the bacterium. 
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Both Gram negative and Gram positive bacteria use efflux pumps and porins, which are 
protein channels through the membrane, to remove antibiotics quickly from the interior 
of the cell (3), keeping the antibiotic from being effective. 
Bacterial modification is the third mechanism through which antibiotic resistance 
occurs. Modification can change susceptible molecular targets causing decreased potency 
of the antibiotic. The cell makes modifications the synthesis of the cell wall, ribosomes, 
or DNA so that the antibiotic cannot function. Bacteria that acquire macrolide resistance 
make modifications in translation processes. Not only does the bacterium change the 
binding site of the 50S ribosomal subunit to reduce affinity of the drug, it additionally 
expresses both a higher exportation of macrolides and an ability to keep macrolides in an 
inactive form (3). Drugs such as ciprofloxacin can induce  resistance in bacteria by 
causing a mutation in bacterial DNA gyrase, resulting  in a modification of the ATP 
binding site, making the drug less potent (3). Bacteria develop resistance to vancomycin 
and aminoglycosides by promoting reprogramming of the DNA in the cell, resulting in 
the alteration of enzymes that are affected by the drug, causing greater resistance (3). 
Antibiotic resistance can happen through modification of different structures, as shown in 
Table 1: 
Tab le 1 
Listing of Antibiotics and Where Resistance Occurs 
Drug Class Structure Altered to 
Promote Resistance 
Imipenem Carbapenem Envelope 
Gentamicin Aminoglycoside Ribosome 
Erythromycin Macrolide Ribosome 
Ciprofloxacin Fluoroquinolone Replication 
Rifampin Ansamycin RNA Polymerase 
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Table 1 (Continued) 
Drug Class Structure Altered to 
Promote Resistance 
Polymyxin B Peptide Envelope 
 
Source: Walsh C. 2003. Antibiotics: actions, origins, resistance. ASM Press, Washington, D.C. 
 
Since resistance has developed via these mechanisms, treatments have become 
less effective.  There exists a definite need for further research into the treatment of 
bacterial infections in ways that minimize the development of resistance. 
Pseudomonas aeruginosa (Figure 1) is a gram-negative, coccobacillus-shaped 
bacterium that can cause a wide variety of infections. It causes opportunistic lung 
infections in cystic fibrosis patients as well as urinary tract infections (UTIs) in patients 
hospitalized with catheters (9)(10). P. aeruginosa is of concern to people who are 
immunocompromised, either through underlying disease or introduction of foreign 
material into the body. Antibiotic resistance in this bacterium is an issue in hospital 
settings, where people are more likely to be susceptible and resistant strains are more 
prevalent (11). This bacterium can cause severe illness in an already afflicted patient and 




Figure 1: Pseudomonas aeruginosa  
 
Source: Sandle T. 2014. Understanding how Pseudomonas aeruginosa infects. Pharm Microbiol.(12) 
 
 Cystic fibrosis is a devastating inherited respiratory disease. It primarily infects 
the Caucasian population, causing mucus buildup in the respiratory tract due to deficient 
chloride ion channels (7). A high percentage of people with this disease become infected 
with P. aeruginosa. Their susceptibility to P. aeruginosa is due to the mucus buildup 
causing a lessened ability to rid the body of pathogenic bacteria (7). It is said that up to 
70 to 80 percent of people with cystic fibrosis have an infection with P. aeruginosa that 
negatively affects their lives (1). This pathogen causes an enormous impact on young 
adults who are already are burdened with a serious disease.  
 Hospital patients are also very susceptible to P. aeruginosa infection through 
catheterization. P. aeruginosa readily adheres to the surface of a catheter, forming a 
biofilm (9). This biofilm formation is crucial because once it has anchored onto a surface, 
it is impossible to treate or remove. The longer the catheter is inserted, the more likely an 
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infection is to occur in a patient (9). Due to this, asceptic methods and newer 
technologies are critical in catheterization in a hospital setting. 
 Pseudomonas aeruginosa is difficult to treat because it has developed multiple 
mechanisms of resistance to antibiotic treatment. It has been reported that its outer 
membranes have a 100-fold resistance to cephalosporins (3). P. aeruginosa has 
regulatory systems that work to protect the bacterium against antibiotics. These include 
sensors, porins, and proteins (3).  These mechanisms can activate a protective response 
that keeps antibiotics from being bacteriostatic or bacteriocidal. Sensors in P. aeruginosa 
can identify an environmental stressor and send a signal to a reaction protein, causing the 
cell to respond to the antibiotic (13). Porins can effectively send stressors outside the cell 
through their channels.  P. aeruginosa prevents high antibiotic concentrations inside the 
cell through the use of efflux pumps and also by restricting uptake of the antibiotics (3). 
Proteins can be made to inactivate specific antibiotics, such as fluroquinolone-modifying 
enzymes that alter fluoroquinolone drugs and prevent them from functioning to kill the 
bacteria (3,14). Overall, the modifications of this pathogen and the development of 
virulence factors make it an important opportunistic species. 
P. aeruginosa is a highly virulent pathogen due to numerous virulence factors. 
These factors include biofilm-producing genes, endotoxins, and exotoxins. Some 
virulence factors cause antibiotic resistance by promoting biofilm formation in the 
bacterium (10). These factors are activated when the bacteria is under some sort of 
distress and helps its chance of survival. Biofilm formation, along with toxin production, 




It is through the use of either cooperation or spite mechanisms that bacteria 
survive potential hazards or competition (15). Virulence factors including biofilm genes 
and bacteriocin, are of use to help the bacterium survive. These factors can inhbiti or 
even kill other bacteria in order to allow the producer to survive.  
Biofilm production is a well-known virulence capability of P. aeruginosa. 
Biofilms are a secreted matrix that forms around the P. aeruginosa cells and binds them 
to surfaces (7). Its matrix provides a protective boundary that allows it to adhere to an 
environmental substrate. This coating plays a role in the antibiotic resistance of the 
bacterium. Biofilms can confer from 10- to 1000-fold more protection against antibiotic 
treatment (7,16). Once a biofilm has formed (Figure 2), there is a greater chance of P. 
aeruginosa becoming resistant to antibiotic therapies.  Biofilms are harder for antibiotics 
to pass through, and they also change the environment to be unfavorable for therapeutics 
to work efficiently (7). The genes involved in biofilm production and antibiotic resistance 
in P. aeruginosa have been the subject of much research (17,18). P. aeruginosa biofilm 
production requires several genes (listed in Table 2). Their deletion affects the production 
of biofilm, and how the expression of the genes produces resistance to antibiotics is 
currently being investigated. As biofilm production is a known virulence factor of P. 
aeruginosa, new treatments that effectively decrease its production in infections caused 







Genes involved in biofilm formation in Pseudomonas aeruginosa 
Gene name NCBI description 
PA0756 F4 and R4 Two-component response regulator 
PA2070 F4 and R4 Hypothetical Protein 
PA5033 F4 and R4 Hypothetical Protein 
PA3064 PelA Protein 
PA3063 PelB Protein 
PA3062 PelC Protein 
PA3061 PelD Protein 
PA3060 PelE Protein 
PA3059 PelF Protein 
PA3058 PelG Protein 
 
Sources: Zhang L, Fritsch M, Hammond L, Landreville R, Slatculescu C, Colavita A, Mah T-F. 2013. 
Identification of Genes Involved in Pseudomonas aeruginosa Biofilm-Specific Resistance to Antibiotics. 
PLoS ONE 8:1–8. Friedman L, Kolter R. 2004. Genes involved in matrix formation in Pseudomonas 
aeruginosa PA14 biofilms. Mol Microbiol 51:675–690. 
 
 
Figure 2: The life cycle of biofilm  
 
Source: Peters Smith B. Lab studying new ways to fight infection. Her-Trib. Sarasota, Florida.(19) 
 
Bacteriocins, toxins produced by bacteria as a competitive advantage against 
other bacteria, have been proposed as an alternative treatment to antibiotics for bacterial 
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infections (8). These toxins can target and kill particular bacteria. Bacteriocins are 
thought to be the most significant specific antibiotic used by microbial populations (20). 
These toxins are important because they are a defense mechanism produced by one 
bacterial species to target the removal of other bacterial species. Almost all bacteria 
produce and use them to improve survival (15). Production of this toxin by one species 
has been found to cause damage to another unrelated bacterial species. Bacteriocins are 
made up of protein (20,21). Because of their lethality, they can be used to cause various 
forms of damage to competing cells by targeting cell membranes and transcription. 
There are several classes of bacteriocins. Gram positive bacteria can produce one 
of four classes of bacteriocins, Classes I through IV. Post-transcriptional alterations are a 
characteristic of the Class I bacteriocins (21). After DNA is transcribed to produce RNA, 
modifications may occur to produce the final product.  
Class II bacteriocins consist of three subclasses: Classes IIa,  IIb, IIc, and  IId 
(21,22). These classes can perform an array of functions. Class IIa is a pediocin-like 
compound that is of interest in treating food products to increase safety for human use. 
This is because it is thought to be non-toxic, making it safe to consume (23). Two bound 
proteins comprise Class IIb bacteriocins, which work by permeating membranes of the 
susceptible bacterium (24). The permeation can cause cell death, making this type of 
bacteriocin of interest to researchers in treating infections. Class IIc bacteriocins are 
circular proteins thought to be effective in treating dairy products (21). Class IId is little 
understood, although it is a bacteriocin that is most unlike pediocin and class IIa 
bacteriocins (25).  
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Class III bacteriocins are large and are modified by heat exposure (26). Class IV 
is thought to be circular proteins like enterocin (27). There are also bacteriocins in gram 
negative bacteria, including colicins, colicin-like bacteriocins, phage-like bacteriocins, 
and microcins (27). The pyocins of P. aeruginosa fall into colicin-like and phage-like 
bacteriocins, while the colicins of E.coli are in a category of their own. 
Bacteriocins are thought to have deadly effects on cells (28). The toxins have 
different structures they target on bacterial cells, causing both DNA and RNA damage. 
Bacteriocins can also induce pore formation in the cell membrane as well as cause 
inhibition of enzyme production (7,15). This genetic damage and cell membrane pore 
formation can cause the affected bacterium to go through cell death. Toxin production 
comes at a cost to the bacteria either through metabolic loss or cell death (15). The need 
for killing the competitor must outweigh the cost of perishing. The production of 
bacteriocin might also come with immunity genes for the producers, which makes it 
beneficial to use in particular environments (15). These genes can help the producer 
survive in an area of high competition. Bacteriocin production is advantageous when the 
bacterial population concentration is neither high nor low, but rather in intermediate 
numbers (20). This advantage means that a producer will not produce bacteriocin when it 
is not under stress or when it knows the effect will not be beneficial. What makes 
bacteriocin an alternative to antibiotics is its ability to be species-specific (7,8). This 
specificity is what makes this a promising future treatment for infections in humans. 
Because bacteriocins can target a particular bacteria species without harming the 
host microbiota, it decreases the likelihood of resistance developing. Broad-spectrum 
antibiotics can allow surviving biota to become resistant; those bacteria can then use 
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horizontal gene transfer to spread resistance (29). Killing microbiota is one of the most 
significant causes of antibiotic resistance development in bacteria. Bacteriocins show 
specificity to target their alike species as well as some non-related individuals (8,15). The 
producer cell will form immunity protein factors that will help them withstand the toxin 
that they have released (15). Bacteriocins from within the same species can be effective 
at killing other strains of the same species.  
In some studies, bacteriocins have been found to not cause stimulation of biofilm 
in targeted bacteria (30). Since bacteriocin has the capability of being a species-specific 
antibiotic, the use of it as a treatment is desirable. 
Not only can these compounds be used in antibiotic resistance research, but it also 
has commercial applications. The use of bacteriocins as an alternative to chemicals for 
food preservation is being investigated (31). Adding bacteriocin to food products can 
prevent bacterial growth without using chemicals. There is also a push to stop using 
antibiotics in food products (32). Using bacteriocin could accomplish safe, and chemical-
free treatment of food. It was found to be useful in the case of LAC bacteriocin in wine 
(31).Using these compounds in food can aid in making safer items with a longer shelf 
life.  
 Pyocins are bacteriocins produced by Pseudomonas aeruginosa and related 
species. It is thought to have killing ability against other strains of P. aeruginosa and 
closely related species (33). Pyocin is not produced in significant amounts by the 
bacterium, but its production can be stimulated by UV light or mitomycin C exposure 
(33)(34). It is thought that by stressing the cell, the bacteriocin production increases 
significantly. Pyocin is induced when DNA is damaged inside the cell (7). Pyocins attack 
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the membrane on susceptible cells, causing cell death (33). Production of pyocin does 
have a negative aspect, in that cells that produce pyocin will eventually break apart and 
die (35). A cell will only resort to pyocin production when overall survival of the 
population can be benefitted. 
 Pyocins can be typed as R, F, and S. Pyocin type R (Figure 3) has a structure with 
phage type tails similar to bacteriophages (36). These toxins have a tall column-like 
section attached to a tail portion. R-type pyocins have high molecular weight and a 
substantial capacity to kill many types of bacteria (37). The proteins use their tails to 
anchor to certain receptors and use a sharp structure to penetrate the membrane (38). The 
pyocin does not put any type of material into the cell; it only disrupts the membrane 
potential.  With this ability, this protein can be versatile in future research into infection 
control. In previous studies, the tail of the R-type pyocin was replaced with modified tails 
of other species and used to treat a greater variety of pathogenic bacteria (37). Using this 
technology for treatment can help further the fight against the arms race of antibiotic 
resistance. 
 
Figure 3: R-type Pyocins  
 
Source: Williams SR, Gebhart D, Martin DW, Scholl D. 2008. Retargeting R-Type Pyocins To Generate 
Novel Bactericidal Protein Complexes. Appl Environ Microbiol 74:3868–3876. 
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F-type pyocins, or flexuous pyocins, have tail-like structures like R-type pyocins 
except have flexible sheath segments (34). They have an immunological response that is 
cross-reactive (39). F-type pyocins are composed of six protein subunits and a fiber 
subunit that attaches to the targeted cells (39). When attached, this type of pyocin causes 
the destruction of bacteria sensitive to its effects. 
S-type pyocins exhibit DNAse activity and inhibit lipid synthesis (33). This type 
of pyocin enters the cell and causes DNA damage. This damage can block important 
functions inside the cell. S-type pyocin is protease-sensitive, and is made of two protein 
subunits: a killing and an immunity protein (40,41). The killing protein does the work 
against susceptible bacteria, and the immunity protein keeps the producer resistant. The 
S-type of pyocin is very similar in function to E-type colicins, which have been 
substantially investigated. 
Colicins are species-specific antibiotic peptides that have been considered for 
treatment of Escherichia coli infections. Each colicin consists of three subunits: a 
cytotoxic site (C), a receptor binding site (R), and a subunit that aids in translocation (T)  
(7). Different types of colicins attack the cells with differing mechanisms. It is said that 
enzymatic colicins cause damage to nucleotides and prevent cell wall synthesis while 
other colicins cause pores to form in the membrane of gram-negative bacteria (7). The 
result of this is cell death for the targeted bacterium (Figure 4). Colicins are transported 
outside the cell or secreted (42). This means that it does not have to lyse the producing 




Figure 4: The mechanism for which colicin interferes with protein formation  
 
Source: Yang S-C, Lin C-H, Sung CT, Fang J-Y. 2014. Antibacterial activities of bacteriocins: application in 
foods and pharmaceuticals. Food Microbiol 5:241. 
 
There are a number of different types of colicins. Colicin V is produced by E. 
coli. It is translated by the RNA in the cell and is exported out of the cell through an ABC 
exporter (43). This type of colicin does not require cell death in order to be released 
outside the cell. Colicin V is active against certain cells by incorporating itself into and 
disrupting the cell membrane (44). By opening the membrane up, it causes death in 
sensitive cells. 
  Colicin M works by inhibiting growth and metabolic reactions within the target 
cell (45). It does this by preventing peptidoglycan synthesis in the cell (30).  By 
preventing synthesis, the growth of the targeted bacteria will remain static.  
Similar to S-type pyocins in structure, colicin type E causes DNA damage in sensitive 




With antibiotic resistance on the rise, it is critical to find new treatments for 
serious bacterial infections. If not, mortality rates will continue to rise steadily. Sufferers 
of P. aeruginosa infections are at high risk due to their impaired immune system, 
rendering them unable to fight the pathogen without an effective treatment. With new 
research into species-specific therapies, resistance rates can hopefully be lower to a 


















 In Escherichia coli, the effects of bacteriocin on various genes are currently 
being studied (30), but the influence of bacteriocin on the genetics of P. aeruginosa and 
its production of biofilm has not been studied. Due to biofilm playing an important role in 
protecting Pseudomonas aeruginosa against antibiotic treatment, it needs to be 
determined if treatment with bacteriocin could inhibit its formation. At the beginning of 
this research project, it was hypothesized that biofilm growth was not induced by 
bacteriocins in other species, but the presence of these substances did cause an increase in 
the expression of biofilm regulating genes in Pseudomonas (30). This study hypothesized 
further that the presence of bacteriocins from E. coli will cause the P. aeruginosa 
biofilm-inducing genes to upregulate, but not trigger greater biofilm production. 
 Bacteriocins have been said to be species-specific. Producers also protect 
themselves from the protein by using immunity genes. It is beneficial to know how 
pyocins affect the production of biofilm within the same species. Pyocins are the 
bacteriocins made by P. aeruginosa that are produced in times of environmental stress in 
order to kill off competing bacteria. There are types of pyocins can adversely effect P. 
aeruginosa, so comparing their effect to that conferred by antibiotics would give an 
insight into how pyocins work to inhibit biofilm production. It was also hypothesized that 
pyocins will downregulate biofilm production genes where antibiotics upregulate it. 
So-called “cocktail treatments” used in combined therapy using antibiotics and 
bacteriocins may be more efficient at inhibiting or killing P. aeruginosa (8). 
Understanding what happens to the biofilm in the presence of a “cocktail” is vital to the 
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future of treatment development. The effect on biofilms analyzed when treated with 
mixtures of antibiotics and bacteriocins was the ultimate goal of this project. It was 
hypothesized that mixed bacteriocin cocktails will have a down-regulating effect on the 
genes compared to mixed antibiotic cocktails. 
The role of biofilm-expressing genes in antibiotic resistance is being studied, but 
the effect of bacteriocin treatment on biofilm formation in Pseudomonas aeruginosa has 
not yet been elucidated. By analyzing the different impacts of the bacteriocins of E. coli 
and P. aeruginosa in comparison to antibiotics, the new perspective on both antibiotic 
resistance and bacteriocin treatment can aid the production of new therapeutic agents. 
The overall hypothesis of this study is that bacteriocins cause a decreased expression of 
















MATERIALS AND METHODS 
 The methods of this project are illustrated in Figure 5 to show how each part is 
linked to the next. Growing of control (P. aeruginosa ATCC 47085), clinical, and 
bacteriocin producing isolates were conducted to assess viability. Biofilm assays were 
performed using the control isolates to test overall procedures and determine appropriate 
antibiotic concentrations. The bacteriocin-producing strains underwent extraction 
procedures and protein quantification to determine success of the procedure. The clinical 
isolates were also grown and tested with antibiotic concentrations as determined by the 
control assays. 
 




Clinical isolates of P. aeruginosa were obtained in 2005 on blood agar plates 
from the University of Kentucky Medical Center in Lexington, KY by Sari Liggett, a 
graduate student at EKU (47). The isolates came from different types of clinical 
specimens including: urine, catheterized urine, sputum, cystic fibrosis sputum, catheter 
tips, wounds, and blood. They were kept frozen at -80°C in a 10% serum sorbitol 
solution. 
Ten of the clinical isolates were thawed to assess for viability. The samples were 
mixed with a sterilized inoculating loop to allow the bacteria to be evenly dispersed. A 
loopful of the ten clinical isolates were then added to blood agar plates from Hardy 
Diagnostics (Santa Maria, CA) and streaked for isolation. The plates were placed in the 
37° C incubator for 24 hours (Figure 6). 
Figure 6: Assessment of viability of clinical samples 
 
P. aeruginosa ATCC 47085 and E. coli ATCC 700928 were purchased from 
ATCC. These strains are both documented as being bacteriocin producers(48)(49). Upon 
arrival, the strains were rehydrated and grown on a blood agar plate from Hardy 
Diagnostics (Santa Maria, CA). A Bunsen burner was used to heat the outer glass vial of 
the samples to break it open. The vial of bacteria was removed, and the pellet was 
rehydrated with 5-6 mL of Tryptic Soy Broth (TSB). Once rehydrated, 100 μL of the 
bacterial solution was added to a blood agar plate (4 plates for each culture). Aseptic 
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streaking was performed with an inoculating loop, and the plates were incubated at 37°C 
for 24 hours (Figure 7). 
Figure 7: Rehydrating and Growing Bacteriocin Strain 
 
After the initial growth of the bacteriocin producing species on blood agar plates, 
they were frozen down to preserve them for future experiments. A 10% sorbitol solution 
was made with 100 mL of water and 10 g of sorbitol, and sterilized in an autoclave. The 
10% serum-sorbitol freezing mixture was made by mixing nine mL of sorbitol with one 
mL of FBS from Atlanta Biologicals (Atlanta, GA) to make a solution. One milliliter of 
the serum-sorbitol mixture was added to a 1.5 Eppendorf tube (Hamburg, Germany), and 
several isolated colonies of one species were added and vortexed to mix. Ten tubes of 
each strain were made and placed in the -20° C freezer overnight. The tubes were moved 
to a -80° C freezer the following day. Five days later, one tube of each strain was thawed 
and streaked on a blood agar plate to assess for viability (Figure 8). 
 




 A control assay was performed using P. aeruginosa ATCC 47085. The sample 
was thawed on the countertop and streaked on a blood agar plate from Hardy Diagnostics 
(Santa Maria, CA). The plates were incubated at 37°C for 24 to 26 hours. After initially 
growing the bacteria, three isolated colonies were transferred into each of four different 
tubes of TSB. These were allowed to incubate at 37°C for 16-20 hours. After incubation, 
the sample was diluted 1:100 by adding 0.25 mL of the broth culture into 25 mL of TSB. 
The diluted sample was added to a sterile multichannel reservoir, and an eight-channel 
multichannel pipette was used to load into columns 3-12 of a 96-well microtitre plate 
from Falcon (Bookings, SD). A new multichannel reservoir from VWR (Radnor, PA) 
was used to load sterile TSB to columns 1-2 to serve as a control. A total of three plates 
were prepared. The plates were incubated at a temperature of 37 °C for 24, 48, and 72 
hours to assess biofilm formation based on time. The plates columns were loaded into a 
microtitre plate  as seen in Table 3:  
Table 3 


























After incubation, four disposal bins were prepared. The first bin was empty, but 
the following three were filled with tap water. The microtitre plate was removed from the 
incubator, and its contents were dumped into the first bin. The plate was then washed in 
the second bin and allowed to dry. When the plate had sufficiently dried, 125μL of 0.1% 
of crystal violet was added to each well. The crystal violet was allowed to stain each well 
for 10 minutes. The plates were emptied into the first bin and washed in the third bin. 
After the wash, the plate was emptied into the first bin, and the process was repeated in 
the fourth bin. The plate was allowed to dry after the washes. The plates then received 
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200μL of 30% acetic acid in each well. The acetic acid was left in the wells for 10-15 




Figure 9: Microtitre assay 
 
Control trials were continued with several modifications. Some trials were carried 
out by only adding the crystal violet dye and drying, skipping the acetic acid step. Other 
trials were carried out with a new incubator to determine if more accurate results could be 
obtained. Twenty-four well plates were also used to determine if biofilm analysis would 
be less varied. The 24-well plate columns were set up as shown in Table 4: 
Table 4 














 After testing the control cultures in the biofilm assay, the antibiotics were tested 
against each strain. Ciprofloxacin (5μg/mL), ceftazidime (10μg/mL), gentamicin 
(10μg/mL), and imipenem (10μg/mL) were purchased from Fisher Scientific (Pittsburg, 
PA). These antibiotics were used to attempt to inhibit biofilm levels in the control strain 
of P. aeruginosa. 100μL of antibiotic was added to 100μL of bacteria suspension in the 
microtitre plates as previously described. The layout of the plate’s columns is shown in 
Table 5. After 48 hours, these plates were read on the Tecan Genios at 595nm to 
determine the absorbance.  
Table 5 
Column layout for antibiotic treatments 































The antibiotic control protocol was altered to do serial dilutions in the next study. 
The wells were loaded with 100μL of TSB and then 100μL of the antibiotic. The 
antibiotic doses were changed to gentamicin (20μg/mL), ceftazidime (20μg/mL), 
imipenem (20μg/mL), and ciprofloxacin (10μg/mL). After the antibiotics had been added, 
a clean tip was used to move 100μL to the next well to mix. This process was continued 
until the plate was filled with columns of decreasing concentrations of the appropriate 






Figure 10: Setup of antibiotic microtitre assay 
 
The bacterium was tested for its susceptibility to antibiotics using the Kirby-
Bauer procedure. This procedure was performed by thawing the stock and clinical 
bacteria isolates, streaking on blood agar plates and incubating for 24 hours at 37°C. 
After incubation, the test was initiated by adding 1mL of sterile saline to a sterile tube. 
An inoculating loop was sterilized, a small amount of the P. aeruginosa was added to the 
saline, and it was mixed on a vortex until uniform. This mixture was then compared to 
the #0.5 McFarland Standard for a consistent bacterium cell concentration. If the mixture 
was too cloudy, more saline was added. If the mixture was too transparent, more bacteria 
were inoculated into the tube. After achieving the right concentration of bacteria in the 
tube, a sterile swab was inserted into it and used to streak a Mueller Hinton plate. The 




Figure 11: Kirby-Bauer Plate setup 
 
After the plate had been streaked with the selected samples, they were treated 
with antibiotic disks. The disks were added by using sterilized forceps. The plate was 
then incubated for 24 hours at 37° C (Figure 12). 
 
Figure 12: Adding disks to Kirby-Bauer plate 
 
After 24 hours of incubation, the zones of inhibition were measured. The 
measurements were obtained by measuring the circumference surrounding each antibiotic 
disk in millimeters. After obtaining the millimeter clearances on the P. aeruginosa, each 
value was compared with the BD BBL™ Sensi-Disc™ Antimicrobial Susceptibility Test 
Discs Sheet.  
 In a 96-well microtitre plate, 100 µL of TSB was added to every well. The TSB in 
column two was diluted with 100 µL of distilled water and 100µL of the mixture was 
discarded. Ciprofloxacin (25mg/mL), Gentamicin (50mg/mL), Rifampicin (2.5mg/mL), 
and Polymyxin B (50mg/mL) were purchased from Sigma-Aldrich (St. Louis, MO). 
Using a multi-channel pipette, the antibiotics were mixed with its appropriate solvent and 
100µL of it was added to each well of column three. The solution in column 3 was 
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combined and 100µL of the mixture was added to column four. The multichannel pipette 
tips were changed, and the solution in column four was mixed and 100µL of the mixture 
was added to column five. This technique was repeated until all 12 columns were filled 
with a concentration of antibiotic. After the plate was loaded with treatments,  a #0.5 
McFarland Standard was used to compare equal concentrations of the P. aeruginosa 
isolates that were grown previously on blood agar plates mixed with sterile saline. After 
making tubes with similar bacterium levels, 100µL of the bacteria were added to columns 
2-12. Those plates were then incubated for 24 hours at 37°C. The plates were read using 
the Tecan GENios spectrophotometer reader at an absorbance of 595nm. The plates were 
organized as shown in Table 6: 
Table 6 















































Minimum inhibitory concentrations were performed again, starting at smaller 
concentrations. Ciprofloxacin (12.5mg/mL and 6.25mg/mL), gentamicin (25mg/mL and 
12.5mg/mL), rifampicin (1.25mg/mL and 0.625mg/mL), and polymyxin B (25mg/mL 
and 12.5mg/mL) were mixed for microtitre plates.  One plate was set up for each starting 
concentration as described previously. 
 Antibiotic concentrations were adjusted, and ciprofloxacin was eliminated from 
the study. Gentamicin (5mg/mL), polymyxin B (5mg/mL and 4mg/mL), and rifampicin 
(0.078125mg/mL) were mixed in distilled water. Plating of the bacteria and antibiotics 
did not change. Absorbance reading parameters also remained the same.  
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 It was determined that a concentration of 0.7mg/mL of gentamicin, polymyxin B, 
and rifampicin was effective at inhibiting the growth of the clinical isolates. Clinical 
samples 1-8, 10-31, 33-35, and 37-53 were grown on blood agar plates for 24 hours at 
37°C. Each isolate was added to the saline to match a #0.5 McFarland Standard tube. 
Each plate was loaded as in shown Table 7: 
Table 7 
























The plates were incubated for 24 hours at 37°C. After incubation, the absorbance 
for each plate was read on the Tecan GENios at 595nm. 
 Tryptone-yeast colicin media (TY) was used as previously documented (50). This 
media was made by mixing one liter of distilled water with a mixture of tryptone (6g), 
yeast extract (5g), and NaCl (5g). This mixture was heated on a hot plate while stirring 
until the ingredients were dissolved. The stir bars were removed, and the media was 
autoclaved. After the media had been sterilized, the media was stored at 4 °C until use 
(Figure 13). 
 
Figure 13: Media preparation 
 
 E. coli ATCC 700928 was used to produce colicin. The strain was taken from the 
-80°C freezer and thawed. After the sample had been thawed, the sample was streaked on 
a blood agar plate from Hardy Diagnostics (Santa Maria, CA). After incubating the plate 
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for 24 hours at 37° C, isolated colonies were added to a tube of TY and then incubated 
for an additional 24 hours at 37°C.  Following this incubation, the contents of the TY 
tube were added to 250mL of TY broth that was incubated for an additional 24 hours at 
37°C (Figure 14).  
 
Figure 14: Preparing E. coli for colicin extraction 
 
Mitomycin C (0.05mg/mL) was added to the flask of E. coli. The flask was 
shaken and incubated at 37°C for four hours. After agitating the bacterium, the E. coli 
was transferred to a 50mL conical tube and centrifuged at 4°C for 15 minutes at 4,000xg. 
The supernatant was poured off, and the pellet was suspended in 5mL of distilled water. 
The mixture was centrifuged again at 4,000xg for 15minutes at 4°C. This wash was 
repeated once more and the pellet was resuspended in 5mL of distilled water. The tube 
was sonicated at 24kHz for one minute with 6 second pulses. The tube was centrifuged 
once more at 4°C for 15 minutes at 4,000xg, and the supernatant was frozen at -80°C for 






Figure 15: Colicin Extraction 
 
Alterations were made to this procedure as the extraction process continued. The 
incubation of the initial TY tube was changed to four hours to start the agitation at the 
exponential growth phase of the bacterium. Another change was also made after the 
supernatant was obtained by sonication and centrifugation. The addition of overnight 
exposure to chloroform vapors at 4°C was added due to the recommendation of Dr. 
Smajs. 
 After obtaining the crude colicin, a spot test was made to assess activity. TY agar 
was made adding 15 g/L of agar to the same recipe previously mentioned to produce TY 
plates and 3 mL agar deeps (tubes). P. aeruginosa was grown on blood agar plates for 24 
hours and then moved to TSB tubes for 24 hours similarly to previous procedures.  When 
the TSB tube had incubated for a day, a 3mL TY agar deep was boiled and then cooled at 
55°C for an hour. The tube of P. aeruginosa was mixed well, and 1mL of the bacteria 
33 
 
was added to the liquid 3mL agar deep of TY agar. The tube was rolled to mix and 
poured over a warmed TY agar plate. The liquid agar and bacteria were swirled around 
the plate evenly. The plates were allowed to dry, and the crude colicin was thawed. The 
colicin was diluted in 1:10 dilutions to 10-5 . Ten microliters from each dilution were 
spotted on the prepared plate and incubated at 37°C for 24 hours (Figure 16). 
 
 
Figure 16: Spot Test 
 
 There were several changes made to this protocol. Shigella (ATCC 25931) and 
Salmonella (ATCC 202165) species were used as indicator strains (43). There was also a 
change to spot the colicin before the agar was overlaid on the TY plate. 
 G medium was made by mixing sodium glutamate, glucose, magnesium sulfate 
heptahydrate, sodium phosphate dibasic dodecahydrate, potassium phosphate monobasic, 
yeast extract, and tryptophan as previously described (33).  
P.aeruguinosa ATCC 47085 was grown on blood agar plates and then transferred 
to a tube of G medium. After overnight incubation at 37°C, the tube was transferred to 
1000 mL of G medium and shaken and incubated at 37°C for 3 hours. Mitomycin C 
(2µg/mL) was added to the flask and it continued to be incubated and shaken for an 
additional 3 hours. Chloroform (10mL) was added and the mixture was allowed to sit for 
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an additional hour. The mixture was centrifuged at 10,000Xg for 10 minutes at 4°C. After 
the centrifugation, the supernatant was stored at -80°C (Figure 17). 
 
Figure 17: Pyocin extraction 
 
 It was determined that protein extraction would be more accurate and the extract 
more pure if the crude extract was run through a Sephadex size exclusion column. Five 
grams of Sephadex G-75 from Sigma-Aldrich (St. Louis, MO) was mixed with 300mL 
NaCl and KH2SO4 buffer and vacuumed to remove air bubbles. The Sephadex mixture 
was applied to a column supplied by Dr. Martin Brock.  The Sephadex was allowed to 
settle before the sample was applied. One milliliter was mixed with 500µL of glycerol 
and 200µL of Cytochrome C marker (14kDa). The mixture was applied to the column 
and allowed to pass through the matrix. When the color marker reached the end of the 
column, tubes were used to collect the desired fractions. The tubes were switched every 
minute and a total of twenty tubes were collected. The three tubes following the 
Cytochrome C marker were mixed and concentrated using a Millipore Amicon Ultra-4 
Centrifugal Filter Unit until it was concentrated to a milliliter. The concentrated protein 
(10kDa) was then added to a 1.5mL Eppendorf tube and stored at -80°C until further use 
 Gel electrophoresis using a 1% agarose gel was performed to analyze the purity of 
the colicin obtained through the Sephadex.  In the first lane, a Bio-Rad Kaleidoscope Gel 
Marker (Hercules, CA) was used. Cytochrome C from Sigma-Aldrich (St. Louis, MO) 
35 
 
was used in lane two. The Cytochrome C captured through the Sephadex column was 
loaded in lane three (Figure 18). 
 
Figure 18: SDS-PAGE Layout 
 
 The protein samples were loaded into lane four of the gel, which was then 
electrophoresced for 60 minutes at 100V. After completion, Coomassie Brilliant Blue 
Dye was used to stain the gel for one hour. The gel was then decolorized with a mixture 
of acetic acid and methanol changed every 30 minutes. 
SDS-PAGE was also performed to assess protein purity. A pre-made gel was 
purchased from Edvotek (Washington D.C., USA) and assembled on an electrophoresis 
unit.  27µL of 2X Laemmli Sample buffer (BioRad) was added to the protein samples 
(40µL) before heating for 10 minutes in a 100°C water bath. The kaleidoscope standard 
(BioRad), containing cytochrome C (14kDa), colicin extract (10kDa), control cytochrome 
C extract (14kDa), conalbumin (75kDa), pyocin (74kDa), and bovine serum albumin 
(66kDa), was used for reference. After the samples were heated, twenty microliters of 
each sample were loaded into the wells as seen in figure 19. The unit was filled with Bio-
Rad 1X Tris/Glycine/SDS buffer and electrophoresed at 70 volts for 1.5 hours. When 
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completed, the gel was removed and placed in a mixture of Coomassie Brilliant Blue 
stain for an hour. The gel was then decolorized using a mixture of acetic acid and 
methanol. The mixture was changed every 30 minutes over a two hour period of time. 
 
Figure 19: SDS-PAGE layout with Colicin and Pyocin 
 
 The statistical analysis was performed with SigmaPlot 11. Raw data, descriptive 















 Initially, a control assay was performed using sterile TSB and untreated P. 
aeruginosa ATCC 47085. These control microtitre assays were performed to determine 
appropriate incubation times, concentrations of staining materials, and incubation 
environment.  Higher biofilm formation correlated with a higher absorbance reading on 
the GENios system. A total of three plates were assessed, each corresponding to 24, 48, 
and 72 hours in this trial. Each plate was analyzed for absorbance twice: once after 
staining and once after the stain was dissolved using acetic acid. Trials were only 
performed once, although like-treated wells were averaged for statistical analysis. 
 After 24 hours, there was no statistical difference between the wells containing 
stained sterile TSB and those containing stained untreated bacteria (Figure 20). After 
doing a two-tailed T-test, there was no significant difference between the two groups at 
an alpha level of 0.05. Using the data found in Appendix A, the t was 1.513 and the p-
value of a two-tailed T-test was 0.134. At that p-value, it cannot be determined that the 
control sample population and the TSB population are not the same. The biofilm 






Figure 20: Average Biofilm Absorbance at 24 Hours without Acetic Acid using P. aeruginosa ATCC 
47085  
 
Note: Standard Error Shown 
 
The stained biofilm at 24 hours was then treated with acetic acid and its 
absorbance analyzed. The difference between bacterial wells and control wells was more 
apparent than without the acetic acid (Figure 21). With statistical analysis, the t was -
8.992 and the p-value was 2.553 x 10-14 . At a significance level of α=0.05, it can be 
determined that the absorbance of the wells containing bacteria is significantly greater 
than the control. 
 
Figure 21: Average Biofilm Absorbance at 24 Hours with Acetic Acid using P. aeruginosa ATCC 47085  
 




When the assays were performed after 48 hours, averages for the biofilm were 
higher than the control TSB numbers (Figure 22). However, when a two-tailed T-test was 
performed, the t was -1.718 and the p-value was determined to be 0.0890. At a 
significance level of α=0.05, it cannot be determined that the P. aeruginosa wells had 
significantly greater absorbance than the TSB control. 
 
Figure 22: Average Biofilm Absorbance at 48 Hours without Acetic Acid using P. aeruginosa ATCC 
47085  
 
Note: Standard error shown 
 
After dissolving the stained biofilm with acetic acid, the averages of the bacterial 
wells and the TSB control wells were visually different (Figure 23). After a two-tailed T-
test was performed, the t value was -8.339 and the p-value was 1.011 x 10-12. At a 
significance level of α=0.05, the bacterial sample average was statistically greater than 




Figure 23: Average Biofilm Absorbance at 48 Hours with Acetic Acid using P. aeruginosa ATCC 47085  
 
Note: Standard error shown 
 
 At 72 hours, there seemed to be a greater occurrence of the variance for the 
absorbance at 595nm (Figure 24). The two-tailed T-test had a t of -3.190 and p-value of 
0.00193. At a significance level of α=0.05, it can be determined that the P. aeruginosa 
wells have a greater optical density than the TSB control. 
 
Figure 24: Average Biofilm Absorbance at 72 Hours without Acetic Acid using P. aeruginosa ATCC 
47085  
 
Note: Standard error shown 
 
With the addition of acetic acid, there were 29 out of 96 wells that read as OVER 
in the absorbance assay (Appendix A). This reading means the absorbance reading was 
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too high for the GENios to register. The graphical representation seemed to show a 
difference between the control bacteria in comparison to the sterile TSB (Figure 25). A 
two-tail T-test determined a t of -9.807 and a p-value of 1.920 x 10-14 . At a significance 
level of α=0.05, it can be determined that the bacterial wells had significantly greater 
absorbance than the TSB control. 
 
Figure 25: Average Biofilm Absorbance at 72 Hours with Acetic Acid using P. aeruginosa ATCC 47085  
 
Note: Standard error shown 
 
At this point, the incubation method was altered by using a different incubator 
with a more consistent heating system. It is noted that the readings in the first incubator 
(Figures 20-25) were significantly greater (p-value <0.001) than those obtained in the 
newer incubator (Figure 26-31). The trials with the new incubator were performed in the 
same manner as the trials described in the previous section. 
  The averages visually appear to be close between the control and test wells on the 
plate that was only stained with crystal violet (Figure 26), but were actually statistically 
different. In the two-tailed T-test, the t was -5.617 and the p-value was 0.000000197. At a 





Figure 26: Average Biofilm Absorbance at 24 Hours without Acetic Acid- Changed Incubator using P. 
aeruginosa ATCC 47085  
 
Note: Standard error shown 
 
When acetic acid dissolved the biofilm, the difference between the control and 
sample is more apparent (Figure 27). When a two-tailed T-test was performed, the t was  
-4.777 and the p-value was 0.000000654. At a significance level of α=0.05, the bacterial 
sample was significantly greater than the control TSB. 
 
Figure 27: Average Absorbance at 24 Hours with Acetic Acid- Changed Incubator using P. aeruginosa 
ATCC 47085  
 
Note: Standard error shown 
 
Using the new incubator at 48 hours incubation, the sample seemed to have 
several variations in like-treated wells. These variations between wells led to greater 
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standard deviations (Figure 28). When a two-sample T-test was performed on the data, 
the t was -1.001 and the p-value was 0.319. At a significance level of α=0.05, the P. 
aeruginosa samples were not significantly greater than the control TSB wells. 
 
Figure 28: Average Absorbance at 48 Hours without Acetic Acid- Changed Incubator using P. aeruginosa 
ATCC 47085  
 
Note: Standard error shown 
 
 When acetic acid was added to the 48-hour biofilm assay, the averages of samples 
become greater in comparison (Figure 29). In a two-tailed T-test, the t was -2.550 and the 
p-value was 0.0124. At a significance level of α=0.05, the sterile TSB samples were 





Figure 29: Average Biofilm Absorbance at 48 Hours with Acetic Acid- Changed Incubator using P. 
aeruginosa ATCC 47085  
 
Note: Standard error shown 
 
 At 72 hours, the difference between the bacteria and TSB wells without the acetic 
acid is less pronounced (Figure 30). In the data listed in Appendix A, there is an outlier 
greater than three standard deviations away in column twelve (2.4602). When a two-
tailed T-test was performed, the t was -0.823 and the p-value was 0.413. At a significance 
level of α=0.05, the bacterial samples are not significantly different from the TSB 
control.  
 
Figure 30: Average Biofilm Absorbance at 72 Hours without Acetic Acid- Change Incubator using P. 
aeruginosa ATCC 47085  
 
Note: Standard error shown 
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When the acetic acid was added to the 72-hour biofilm assay, the average of the 
sample populations was greater than the TSB control (Figure 31). When a two-tailed T-
test was performed, the t was -3.435 and the p-value was 0.000937. At a significance 
level of α=0.05, the sample was significantly higher than the TSB control. 
 
Figure 31: Average Biofilm Absorbance at 72 Hours with Acetic Acid- Changed Incubator using P. 
aeruginosa ATCC 47085  
 
Note: Standard error shown 
 
Based on the previous trials, it was determined that an incubation time of 48 hours 
with the addition of acetic acid was the most effective means of assaying for biofilm 
production in Pseudomonase aeruginosa. “OVER” readings in the raw data were fewer, 
and there were greater differences between the sterile TSB and the untreated P. 
aeruginosa. Trials continued with an analysis of the type of plates themselves because 
standard deviations still seemed to be very high. A trial was conducted using the 96-well 
plates used in the previous trials; 24-well plates were also used. Each set of data 
represents two plates, which had multiple wells averaged to calculate the overall result. 
The 96-well plate seemed to have a higher biofilm absorbance reading in the 
wells with the control P. aeruginosa in comparison to the sterile TSB (Figure 32). When 
a two-tailed T-test was performed on the 96-well plates, the t was -5.723 and the p-value 
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was established to be less than 0.001. At a significance level of α=0.05, the bacterial 
sample average was significantly greater than the sterile TSB. 
 
Figure 32: Average Biofilm Absorbance at 48 Hours  using P. aeruginosa ATCC 47085  
 
Note: Standard error shown 
 
 A trial using a 24-well microtitre plate was used to determine if variations could 
be fixed with the utilization of a different plate (Figure 33). After a two-tailed T-test had 
been performed, the t was -2.323 and the p-value was 0.025. At a significance level of 
α=0.05, the P. aeruginosa sample averages were significantly greater than that of the 
control. 
 
Figure 33: Average Biofilm Absorbance at 48 Hours Using a 24 well plate using P. aeruginosa ATCC 
47085  
 
Note: Standard error shown 
47 
 
 Analysis was continued by testing the antibiotics on the control bacterium. The 
starting concentrations are listed previously in the methods section. When this trial was 
set up, there was one plate for control samples and each antibiotic individually and each 
similarly treated well was averaged to use in statistical analysis.  
The antibiotic treatment well readings seemed to be similar to the absorbance 
reading for the control TSB wells (Figures 34-35). When a one-way ANOVA (Holm-
Sidak) was performed using both the negative and positive control as a comparison. For 
ciprofloxacin, the calculated F-value was 15.898 that gave a P-value of less than 0.001. 
With a significance value of 0.05, the treatment groups are significantly different from 
the positive control. For ceftazidime, the calculated F-value was 16.260 that gave a P-
value of less than 0.001. With a significance value of 0.05, the ceftazidime treatment 
groups are significantly different from the positive control. 
 
Figure 34: Average of Biofilm Absorbance at 48 Hours Trial 1- Ciprofloxacin  
 





Figure 35: Average of Biofilm Absorbance at 48 Hours Trial 1- Ceftazidime 
 
Note: Standard error shown 
 
 When the antibiotic treatments were retested due to low optical density readings, 
the ceftazidime and ciprofloxacin showed similar readings to the TSB on the GENios 
(Figures 36-37). In a one-way ANOVA, the F-value of the ciprofloxacin plate was 0.527 
with a P-value of 0.867, and the ceftazidime plate had an F-value of 0.990 with a P-value 
of 0.458. At a significance level of α=0.05, there is no significance difference between 




Figure 36:  Average of Biofilm Formation at 48 Hours Trial 2- Ciprofloxacin  
 
Note: Standard error shown 
 
 
Figure 37: Average Biofilm Formation at 48 Hours Trial 2- Ceftazidime  
 
Note: Standard error shown 
 
 Another dilution series was performed using concentrations mentioned previously 
with an altered procedure by allowing the bacteria to grow 24 hours before treatment. 
Four plates were loaded with each of the following: bacteria, ciprofloxacin, ceftazidime, 
and gentamicin (Figures 38-40). A one-way ANOVA test revealed that the ciprofloxacin 
plate had an F-score of 12.309 with P-value less than 0.001. The test for ceftazidime 
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showed an F-score of 17.391 and a P-value less than 0.001. The ANOVA for gentamicin 
revealed an F-score of 5.332 with P-value less than 0.001. At a significance level of 0.05, 
the positive bacterial control was significantly greater than the antibiotic treatments. 
 
Figure 38: Average of Biofilm Formation at 48 Hours Trial 3- Ciprofloxacin  
 
Note: Standard error shown 
 
 
Figure 39: Average of Biofilm Formation at 48 Hours Trial 3- Ceftazidime  
 





Figure 40: Average of Biofilm Formation at 48 Hours Trial 3- Gentamicin  
 
Note: Standard error shown 
 
 Another dilution series was performed using a different plate layout due to 
contamination causing variation between the same columns. 24-well plates were set up 
for each of the following: ciprofloxacin, ceftazidime, gentamicin, and imipenem (Figures 
41-44). The F- score for ciprofloxacin was 27.790 with a P-value of less than 0.001. 
Ceftazidime was 46.519 with a P-value of less than 0.001. Gentamicin was 27.647 with a 
P-value of less than 0.001. Imipenem was 28.549 with a P-value less than 0.001. At a 






Figure 41: Average of Biofilm Formation using 24-well plate at 48 Hours- Ciprofloxacin  
 
Note: Standard error shown 
 
 
Figure 42: Average of Biofilm Formation using 24-well plate at 48 Hours- Ceftazidime  
 




Figure 43: Average of Biofilm Formation using 24-well plate at 48 Hours- Gentamicin  
 
Note: Standard error shown 
 
 
Figure 44: Average of Biofilm Formation using 24-well plate at 48 Hours- Imipenem  
 
Note: Standard error shown 
 
 The bacteria concentration was measured on the GENios system using a similar 
method with 24-well plate. The raw data for ciprofloxacin, ceftazidime, gentamicin, and 
imipenem (Figures 45-48) is listed in Appendix A. The ciprofloxacin seemed to inhibit 
the growth concentration of bacteria comparable to the sterile TSB negative control. 
Ceftazidime had a high absorbance level in the 10µg/mL that registered as an ‘OVER’ 
reading and was excessive throughout all dilutions. Gentamicin and imipenem had a level 
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of absorbance similar to the bacteria. The F-score from the ANOVA for ciprofloxacin 
was 357.243 with a P-value less than 0.001, ceftazidime was 366.865 with a P-value less 
than 0.001, gentamicin was 166. 753 with a P-value less than 0.001, and imipenem was 
137.368 with a P-value of less than 0.001. At a significance level of 0.05, the antibiotic 
treatment shows significantly less biofilm formation than the positive bacterial control.  
 
Figure 45: Average of Biofilm Formation at 48 Hours Trial 4- Ciprofloxacin 
 
Note: Standard error shown 
 
 
Figure 46: Average of Biofilm Formation at 48 Hours Trial 4-Ceftazidime 
 





Figure 47: Average of Biofilm Formation at 48 Hours Trial 4- Gentamicin 
 
Note: Standard error shown 
 
 
Figure 48: Average of Biofilm Formation at 48 Hours Trial 4- Imipenem 
 
Note: Standard error shown 
 
 Another round of 24- well plates was analyzed on the GENios system using 
ciprofloxacin, gentamicin, ceftazidime, and imipenem (Figures 49-51). Ciprofloxacin 
optical density readings were low initially and peaked at 0.625mg/mL. Gentamicin also 
had a similar peak to ciprofloxacin. Ceftazidime peaked at 5mg/mL and 1.25mg/mL. 
Imipenem started low and peaked at 1.25mg/mL. When an ANOVA was performed, the 
F-score for ciprofloxacin was 19.560 with a P-value less than 0.001. Ceftazidime had an 
F-score of 11.312 and a P-value of less than 0.001. Gentamicin has an F-score of 19.840 
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and a P-value of less than 0.001. Imipenem had an F-score of 20.524 and a P-value of 
less than 0.001. 
 
Figure 49: Average of Biofilm Formation using 24-well plate at 48 Hours Trial 2-Ciprofloxacin  
 
Note: Standard error shown 
 
 
Figure 50: Average of Biofilm Formation using 24-well plate at 48 Hours Trial 2-Ceftazidime 
 





Figure 51: Average of Biofilm Formation using 24-well plate at 48 Hours Trial 2- Imipenem  
 
Note: Standard error shown 
 
 After setting up several inconclusive antibiotic microtitre dilution series, a Kirby- 
Bauer was performed using tetracycline, ciprofloxacin, cephalothin, erythromycin, and 
gentamicin. The inhibition zones for each of the disks placed on the plates were measured 
in millimeters, as shown in (Table 8): 
Table 8 
Results from Kirby-Bauer 
Treatment Ciprofloxacin Gentamicin Cephalothin Erythromycin Tetracycline
Sample
Stock 28mm (S) 18mm (S) 6mm ( R ) 6mm ( R ) 6mm ( R )
17 29mm (S) 16mm (S) 6mm ( R ) 6mm ( R ) 10mm ( R )
25 36mm (S) 19mm (S) 6mm ( R ) 6mm ( R ) 13mm ( R )
14 28mm (S) 12mm ( R ) 6mm ( R ) 6mm ( R ) 11mm ( R )
6 29mm (S) 20mm (S) 6mm ( R ) 6mm ( R ) 13mm ( R )
8 37mm (S) 21mm (S) 6mm ( R ) 6mm ( R ) 13mm ( R )  
 
 The samples were resistant to ciprofloxacin and mostly resistant to gentamicin. 
The control strain of Pseudomonas aeruginosa used in earlier assaysand clinical strains 
were resistant to all other antibiotics. 
 Additional antibiotics were purchased from Sigma-Aldrich. These were 
ciprofloxacin, gentamicin, rifampicin, and polymyxin B (Figures 52-55). The antibiotics 
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were mixed at the maximum solubility of the recommended solute (Sigma-Aldrich).  
Each data set represents one plate where like-treated wells are averaged together. 
Ciprofloxacin had a low level of bacterial growth at all dilutions in comparison to the 
control bacteria. The F-score was 18.506 during the P-value of less than 0.001. 
Gentamicin had a low level of bacterial growth similar to ciprofloxacin. It had an F-value 
of 18.550 while the P-value was less than 0.001. Rifampicin had an initial high reading 
due to the opaque nature of the antibiotic and then decreased until less than 1mg/mL. The 
F-value was 34.222, and the P-value was less than 0.001. The polymyxin B remained at a 
low level of bacterial concentration in comparison to the control. The F-value of the 
polymyxin B plate was 17.920 and the P-value was less than 0.001. 
 
Figure 52: Average of Biofilm Formation Trial 5- Ciprofloxacin  
 





Figure 53: Average of Biofilm Formation Trial 5- Gentamicin 
 
Note: Standard error shown 
 
 
Figure 54: Average of Biofilm Formation Trial 5- Rifampicin  
 





Figure 55: Average of Biofilm Formation Trial 5- Polymyxin B 
 
 Note: Standard error shown 
 
 The next antibiotic dilution was done with two plates each. Each plate for the 
antibiotic had a different starting concentration and diluted down (Figures 56-63). The 
highest ciprofloxacin plate had low concentrations of bacteria throughout compared to 
the control bacteria. The data had an F-value of 3.218 and a P-value of less than 0.001. 
The second ciprofloxacin plate also had a low concentrations of bacteria compared to the 
control bacteria. That data had an F-value of 8.452 and a P-value of less than 0.001. The 
gentamicin of a higher concentration (0.02-12.5mg/mL) had a low bacteria concentration 
throughout compared to the control bacteria wells. The data had an F-value of 3.993 and 
a P-value of less than 0.001. The lower concentration (0.01-6.25mg/mL) of gentamicin 
had a low bacterial absorbance when compared to the control bacterial wells. It had an F-
value of 8.800 and a P-value of less than 0.001.  The higher rifampicin concentration 
(0.001-0.625mg/mL) started higher in optical density and then dropped to a low bacterial 
absorbance. The F-value for the rifampicin data was 40.614, and the P-value was less 
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than 0.001. Growth of bacteria at a lower concentration of rifampicin (0.0006-
0.312mg/mL) started high in optical density and dipped at 0.01mg. At 0.01mg/mL it the 
optical density rose again, indicating a likely minimum inhibitory concentration (MIC).  
The F-value was 17.624 and a P-value of less than 0.001. The higher concentration of 
polymyxin B (0.02-12.5mg/mL) had a low absorbance level throughout all the dilutions 
on the plate.. The F-value of this data was 4.025, and the P-value was less than 0.001. 
The lower concentration of polymyxin B (0.01-6.25mg/mL) had a low bacterial 
absorbance throughout the well dilution series in comparison to the control. The F-value 
of the polymyxin B data was 8.640 and a P-value of less than 0.001. At a significance 
level of 0.05, the treatments were significantly less than the bacteria control. 
 
Figure 56: Average of Biofilm Formation at 48 Hours Trial 6- Ciprofloxacin 
 





Figure 57: Average of Biofilm Formation at 48 Hours Trial 6- Lower Ciprofloxacin  
 
Note: Standard error shown 
 
 
Figure 58: Average of Biofilm Formation at 48 Hours Trial 6- Gentamicin  
 
Note: Standard error shown 
 
 
Figure 59: Average of Biofilm Formation at 48 Hours Trial 6- Lower Gentamicin  




Figure 60: Average of Biofilm Formation at 48 Hours Trial 6- Rifampicin  
 
Note: Standard error shown 
 
 
Figure 61: Average of Biofilm Formation at 48 Hours Trial 6- Lower Rifampicin  
 



























Figure 62: Average of Biofilm Formation at 48 Hours Trial 6- Polymyxin B  
 
Note: Standard error shown 
 
 
Figure 63: Average of Biofilm Formation at 48 Hours Trial 6- Lower Polymyxin B  
 
Note: Standard error shown 
 
 Due to inconsistencies, ciprofloxacin was removed from the project scope. The 
antibiotic dilutions were retested using duplicate plates of each (Figures 64-66). The 
gentamicin plates had a consistent low level of bacteria concentration in comparison to 
the bacteria control. The F- value for gentamicin data was 2,224.134 and the P-value was 
less than 0.001. The averages for rifampicin show a low bacteria concentration at 
concentrations higher than 0.02mg/mL and then rose to levels greater than the bacteria 
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control as the antibiotic concentration decreased further. The F-value for the rifampicin 
data was 2,728.768, and the P-value was less than 0.001. The averages for polymyxin B-
treated bacterial concentrations remained low in comparison to the control bacteria. The 
F-value for the polymyxin data was 1,109.414, and the P-value was less than 0.001. At a 
significance level of 0.05, the antibiotic treatments are significantly less than the control 
bacteria. 
 
Figure 64: Average of Biofilm Formation at 48 Hours Trial 7- Gentamicin using P. aeruginosa ATCC 
47085  
 
Note: Standard error shown   
 
 
Figure 65: Average of Biofilm Formation at 48 Hours Trial 7- Rifampicin using P. aeruginosa ATCC 
47085  
 






Figure 66: Average of Biofilm Formation at 48 Hours Trial 7- Polymyxin B using P. aeruginosa ATCC 
47085  
 
Note: Standard error shown 
 
After determining that a dose of 0.07mg/mL of each antibiotic was effective at 
inhibiting bacterial growth of the control strain of Pseudomonas, the clinical isolates 
were tested for resistance. Plates were set up with the following wells containing:  sterile 
TSB; untreated clinical isolate; gentamicin treated isolates; rifampicin treated isolates; 













Statistical significance of antibiotic treatments in comparison to negative (TSB) and positive (untreated 





TSB Comparison Bacteria Comparison 
  t p-value t p-value 
1 Gentamicin 1.644 0.106 58.917 <0.001 
Rifampicin 2.462 0.033 58.098 <0.001 
Polymyxin B 6.922 <0.001 53.639 <0.001 
2 Gentamicin 0.199 0.843 11.530 <0.001 
Rifampicin 1.435 0.289 10.294 <0.001 
Polymyxin B 3.721 0.001 8.008 <0.001 
3 Gentamicin 0.268 0.790 14.469 <0.001 
Rifampicin 0.466 0.873 14.271 <0.001 
Polymyxin B 3.997 <0.001 10.740 <0.001 
4 Gentamicin 1.466 0.148 29.967 <0.001 
Rifampicin 1.577 0.226 29.856 <0.001 
Polymyxin B 6.277 <0.001 25.155 <0.001 
5 Gentamicin 0.777 0.440 121.140 <0.001 
Rifampicin 1.446 0.283 120.471 <0.001 
Polymyxin B 8.635 <0.001 113.282 <0.001 
6 Gentamicin 0.801 0.426 102.720 <0.001 
Rifampicin 1.350 0.331 102.171 <0.001 
Polymyxin B 4.198 <0.001 99.324 <0.001 
7 Gentamicin 0.694 0.491 105.998 <0.001 
Rifampicin 1.404 0.304 105.288 <0.001 
Polymyxin B 5.720 <0.001 100.972 <0.001 
8 Gentamicin 0.970 0.336 90.036 <0.001 
Rifampicin 2.217 0.060 88.789 <0.001 
Polymyxin B 3.970 <0.001 87.036 <0.001 
10 Gentamicin 0.953 0.344 48.083 <0.001 
Rifampicin 3.578 0.001 45.458 <0.001 
Polymyxin B 14.270 <0.001 42.467 <0.001 
11 Gentamicin 3.351 0.001 41.527 <0.001 
Rifampicin 5.568 <0.001 39.311 <0.001 
Polymyxin B 7.883 <0.001 36.996 <0.001 
12 Gentamicin 0.425 0.672 87.900 <0.001 
Rifampicin 3.614 0.013 84.711 <0.001 
Polymyxin B 2.811 0.002 85.515 <0.001 
13 Gentamicin 0.742 0.461 81.270 <0.001 
Rifampicin 2.744 0.024 79.268 <0.001 
Polymyxin B 2.224 0.059 79.789 <0.001 
 









TSB Comparison Bacteria Comparison 
  t p-value t p-value 
14 Gentamicin 0.798 0.428 90.412 <0.001 
Rifampicin 1.770 0.157 89.440 <0.001 
Polymyxin B 8.338 <0.001 82.872 <0.001 
15 Gentamicin 2.912 0.010 54.188 <0.001 
Rifampicin 4.814 <0.001 52.286 <0.001 
Polymyxin B 2.709 0.009 54.391 <0.001 
16 Gentamicin 0.608 0.546 29.255 <0.001 
Rifampicin 2.331 0.068 27.532 <0.001 
Polymyxin B 1.258 0.381 28.604 <0.001 
17 Gentamicin 0.197 0.845 18.186 <0.001 
Rifampicin 0.432 0.667 17.951 <0.001 
Polymyxin B 2.373 0.021 16.009 <0.001 
18 Gentamicin 0.182 0.856 12.453 <0.001 
Rifampicin 0.351 0.727 12.285 <0.001 
Polymyxin B 3.556 <0.001 9.079 <0.001 
19 Gentamicin 0.315 0.754 24.313 <0.001 
Rifampicin 1.945 0.057 22.684 <0.001 
Polymyxin B 1.986 0.052 22.643 <0.001 
20 Gentamicin 1.466 0.148 49.368 <0.001 
Rifampicin 2.478 0.016 48.357 <0.001 
Polymyxin B 0.856 0.396 49.979 <0.001 
21 Gentamicin 0.925 0.359 35.656 <0.001 
Rifampicin 2.608 0.012 33.972 <0.001 
Polymyxin B 0.891 0.376 35.689 <0.001 
22 Gentamicin 1.807 0.076 19.669 <0.001 
Rifampicin 2.753 0.008 18.723 <0.001 
Polymyxin B 3.103 0.003 18.373 <0.001 
23 Gentamicin 0.683 0.498 25.285 <0.001 
Rifampicin 1.170 0.247 24.797 <0.001 
Polymyxin B 2.504 0.015 23.464 <0.001 
24 Gentamicin 0.607 0.546 25.123 <0.001 
Rifampicin 1.153 0.253 24.577 <0.001 
Polymyxin B 3.375 0.001 22.355 <0.001 
25 Gentamicin 1.090 0.280 74.128 <0.001 
Rifampicin 3.412 0.001 71.806 <0.001 
Polymyxin B 2.481 0.016 72.737 <0.001 
 












TSB Comparison Bacteria Comparison 
  t p-value t p-value 
26 Gentamicin 0.301 0.765 14.776 <0.001 
Rifampicin 0.815 0.418 14.261 <0.001 
Polymyxin B 2.280 0.026 12.796 <0.001 
27 Gentamicin 1.546 0.127 68.441 <0.001 
Rifampicin 2.470 0.016 67.516 <0.001 
Polymyxin B 3.047 0.003 66.940 <0.001 
28 Gentamicin 2.678 0.010 71.329 <0.001 
Rifampicin 4.354 <0.001 69.653 <0.001 
Polymyxin B 4.471 <0.001 69.536 <0.001 
29 Gentamicin 0.0185 0.985 54.377 <0.001 
Rifampicin 52.094 <0.001 2.302 0.025 
Polymyxin B 0.176 0.861 54.220 <0.001 
30 Gentamicin 0.866 0.390 102.382 <0.001 
Rifampicin 2.906 0.005 100.342 <0.001 
Polymyxin B 1.427 0.159 101.821 <0.001 
33 Gentamicin 1.540 0.129 121.313 <0.001 
Rifampicin 4.090 <0.001 118.763 <0.001 
Polymyxin B 0.961 0.340 121.892 <0.001 
34 Gentamicin 1.259 0.213 56.100 <0.001 
Rifampicin 2.957 0.004 54.402 <0.001 
Polymyxin B 0.493 0.623 56.866 <0.001 
35 Gentamicin 23.509 <0.001 1.908 0.061 
Rifampicin 25.745 <0.001 4.144 <0.001 
Polymyxin B 0.218 0.828 21.383 <0.001 
37 Gentamicin 0.916 0.364 86.153 <0.001 
Rifampicin 2.430 0.018 84.639 <0.001 
Polymyxin B 1.488 0.142 85.581 <0.001 
38 Gentamicin 0.175 0.862 120.746 <0.001 
Rifampicin 1.842 0.071 118.729 <0.001 
Polymyxin B 0.444 0.659 121.015 <0.001 
39 Gentamicin 0.0668 0.947 100.290 <0.001 
Rifampicin 1.977 0.053 98.246 <0.001 
Polymyxin B 1.019 0.313 101.242 <0.001 
40 Gentamicin 0.248 0.805 95.975 <0.001 
Rifampicin 1.766 0.083 94.457 <0.001 
Polymyxin B 0.394 0.695 96.616 <0.001 
 












TSB Comparison Bacteria Comparison 
  t p-value t p-value 
42 Gentamicin 1.969 0.054 66.728 <0.001 
Rifampicin 4.027 <0.001 64.669 <0.001 
Polymyxin B 1.921 0.060 66.776 <0.001 
44 Gentamicin 1.642 0.106 136.372 <0.001 
Rifampicin 4.126 <0.001 133.888 <0.001 
Polymyxin B 1.150 0.255 136.864 <0.001 
45 Gentamicin 0.616 0.540 57.571 <0.001 
Rifampicin 6.061 <0.001 52.126 <0.001 
Polymyxin B 0.926 0.358 57.261 <0.001 
47 Gentamicin 0.602 0.549 30.937 <0.001 
Rifampicin 2.754 0.008 28.786 <0.001 
Polymyxin B 0.130 0.130 31.409 <0.001 
49 Gentamicin 0.339 0.736 71.963 <0.001 
Rifampicin 1.853 0.069 70.449 <0.001 
Polymyxin B 0.312 0.756 71.990 <0.001 
50 Gentamicin 0.751 0.456 55.780 <0.001 
Rifampicin 1.732 0.088 54.798 <0.001 
Polymyxin B 0.0678 0.946 56.463 <0.001 
52 Gentamicin 0.219 0.827 35.023 <0.001 
Rifampicin 1.048 0.299 33.755 <0.001 
Polymyxin B 0.0506 0.960 34.753 <0.001 
53a Gentamicin 1.935 0.058 127.062 <0.001 
Rifampicin 2.877 0.006 126.121 <0.001 
Polymyxin B 0.335 0.738 128.662 <0.001 
53b Gentamicin 1.142 0.258 93.893 <0.001 
Rifampicin 2.581 0.012 92.454 <0.001 
Polymyxin B 0.532 0.597 94.503 <0.001 
 
Note: Shading represents statistical significant difference 
 
When conducting the clinical isolate study, the isolates seemed to be sensitive to 
antibiotic treatment. Most treatments had a small p-value in comparison to the untreated, 
meaning there is statistical significant difference between the control and the treatment. 
As shown in Table 9, many of the treated bacteria are significantly different (as shown by 
the shaded columns) than the untreated bacteria. This indicated that the wells that were 
treated had significantly less optical density than the untreated bacteria wells. 
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 In comparison to the negative control (TSB), there were several treated wells of 
clinical isolates that were significantly different. This primarily was in the rifampicin 
treated wells. Rifampicin could possibly be less effective as a treatment than the other 
antibiotics. These small differences could also possibly be an indication of lessened 
susceptibility. 
All but one isolate had a significant difference between the antibiotics and the 
untreated bacteria. This isolate (Clinical Isolate 35) had comparable absorbance levels in 
gentamicin treatment to untreated bacteria. This resistance only represents a small portion 
of the data, indicating that resistance in these isolates is low (Figures 67-111). 
 
Figure 67: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 1 
 
Note: Standard error shown 
 
 
Figure 68: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 2  
 




Figure 69: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 3  
 
Note: Standard error shown 
 
 
Figure 70: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 4  
 
Note: Standard error shown 
 
 
Figure 71: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 5  
 





Figure 72: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 6  
 
Note: Standard error shown 
 
 
Figure 73: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 7  
 
Note: Standard error shown 
 
 
Figure 74: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 8  
 





Figure 75: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 10  
 
Note: Standard error shown 
 
 
Figure 76: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 11 
 
Note: Standard error shown 
 
 
Figure 77: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 12  
 




Figure 78: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 13  
 
Note: Standard error shown 
 
 
Figure 79: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 14  
 
Note: Standard error shown 
 
 
Figure 80: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 15  
 





Figure 81: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 16  
 
Note: Standard error shown 
 
 
Figure 82: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 17  
 
Note: Standard error shown 
 
 
Figure 83: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 18  
 




Figure 84: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 19  
 
Note: Standard error shown 
 
 
Figure 85: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 20  
 
Note: Standard error shown 
 
 
Figure 86: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 21  
 





Figure 87: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 22  
 
Note: Standard error shown 
 
 
Figure 88: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 23  
 
Note: Standard error shown 
 
 
Figure 89: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 24  
 




Figure 90: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 25  
 
Note: Standard error shown 
 
 
Figure 91: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 26  
 
Note: Standard error shown 
 
 
Figure 92: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 27  
 





Figure 93: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 28  
 
Note: Standard error shown 
 
 
Figure 94: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 29  
 





Figure 95: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 31 
 
Note: Standard error shown 
 
 
Figure 96: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 33  
 
Note: Standard error shown 
 
 
Figure 97: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 34  
 





Figure 98: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 35  
 
Note: Standard error shown 
 
 
Figure 99: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 37  
 
Note: Standard error shown 
 
 
Figure 100: Average of Biofilm Formation with Antibiotic Treatments- Clinical Isolate 38  
 




Figure 101: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 39  
 
Note: Standard error shown 
 
 
Figure 102: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 40  
 
Note: Standard error shown 
 
 
Figure 103: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 42  
 




Figure 104: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 44  
 
Note: Standard error shown 
 
 
Figure 105: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 45  
 
Note: Standard error shown 
 
 
Figure 106: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 47  
 





Figure 107: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 49  
 
Note: Standard error shown 
 
 
Figure 108: Antibiotic Biofilm Formation with Antibiotic Treatments- Clinical Isolate 50  
 
Note: Standard error shown 
 
 
Figure 109: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 52  
 





Figure 110: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 53a  
 
Note: Standard error shown 
 
 
Figure 111: Average Biofilm Formation with Antibiotic Treatments- Clinical Isolate 53b  
 
Note: Standard error shown 
 
 When looking at the graphical data (Figure 67-111), it is apparent that the 
untreated bacteria optical density is much greater than the treated wells. Although several 
graphs like isolate 22, 29, and 35 had higher reading on the treated wells. 
 Through graphical representation, there are great differences between the treated 
bacteria and the untreated control. The Pseudomonas aeruginosa isolates seem to be 
susceptible to these antibiotic treatments. 
 After testing all of the clinical isolates, a comparison was done based on the 
source from which the bacteria came. Each sample fell into one of the following 
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categories: sputum, sputum from CF patient, total sputum, catheter tip, urine, fluid, 
blood, tissue, wound, routine, bone, and unknown (Appendix B). Based on the sources, 
each treatment was compared for statistical significance. 
 In the case of gentamicin, bacterial concentrations tended to be low except in the 
unknown category (Figure 112). The standard deviation for the unknown was sizable. 
After statistical analysis, the F-value was found to be 743.415 with a p-value of less than 
0.001. At a significance level of 0.05, it can be assumed that the treated bacteria are 
significantly less than the untreated bacteria. The unknown was also found to be 
statistically different than the negative control with a p-value of less than 0.001. 
 
Figure 112: A Source Comparison for Gentamicin Treatments  
 
Note: Standard error shown 
 
 For rifampicin, we see a similar graphical representation to gentamicin (Figure 
113).  The unknown group is also more elevated in comparison to the other groups, but 
the standard deviation is also high. In a one-way ANOVA, the f-score was found to be 
535.883 with a p-value of less than 0.001. At a significance level of 0.05, the treated 
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wells have significantly less bacteria than the untreated wells. The unknown, sputum, and 
sputum with CF all were significantly different than the TSB negative control with a p-
value of less than 0.05.  
 
Figure 113: A Source Comparison for Rifampicin Treatments  
 
Note: Standard error shown 
 
 The graphical representation of the data for polymyxin B show lower levels of 
bacteria in the treated wells in comparison to the untreated well (Figure 114). After a one-
way ANOVA test, the F-value was found to be 840.571 with a p-value of less than 0.001. 
At a significance level of 0.001, the antibiotic-treated wells were found to have 
significantly less bacteria than the untreated wells. The urine, catheter tip, blood, and 




Figure 114: A Source Comparison for Polymyxin B Treatments  
 
Note: Standard error shown 
 
 The colicin extractions yielded unsuccessful results over a four month period.  
The first trials yielded no results due to the addition of mitomycin C when the E. coli was 
in stationary phase, which is an inappropriate time to add it. When a plate was overlaid 
with the P. aeruginosa and spotted with the extract, no inhibition of the bacterial growth 
occurred. Another problem with the extraction was that the protocol based on previous 
work from Smajs was unclear. The author was contacted and the protocol specified was 




Figure 115: Spot Test Result 
 After this assay yielded no results, it was determined that using a form of 
chromatography (HPLC or Gel) would be appropriate. The same protocol was performed 
and then filtered through a column containing Sephadex-G75 with color gel size markers. 
The filtered sample was collected and concentrated. The samples were electrophoresced 
on an SDS-PAGE gel and the results are shown in Figure 116: 
 
Figure 116: SDS-PAGE Gel Results 
 
The only proteins detected were in lanes one, two, five, and seven (control lanes). 
That could mean there is either no protein or low protein in the sample. Another gel was 
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electrophoresced with a previous extract and also yielded no banding in the protein 
example. A pyocin extraction was also performed and stored to test further. 
Those protein samples (including pyocin) were analyzed using a Nanodrop (Thermo 
Scientific) and the results are shown in Table 10. The results seem to show that there was 
a low amount of protein, but there is protein content. 
Table 10 
Nanodrop results 
Protein Concentration mg/mL 260/280 
Control 0.195 1.07 
Colicin 0.312 1.84 
Pyocin 3.118 1.20 
 
The results of the tests can mean many things about the bacteria themselves, but 
also about future treatments with antibiotics. In specimens of P. aeruginosa from 
hospitals today, the resistance to many of these drugs would be increased.Using a toxin, 
like bacteriocin, that is not widely used would be a great addition to standard procedures 












 The first experiments helped produce results that could be used to improve the 
future microtitre assays. Firstly, it was found that 48 hours was an optimal time to allow 
the Pseudomonas biofilm to develop in 96-well plates. This is indicated by the stark 
differences in the data in the results section, but also by the raw data included in appendix 
A. The 72 hour data produced readings that could not be measured by the GENios. This 
decreased the number of wells we could statistically analyze.The 24 hour period did not 
allow sufficient growth of the biofilm to produce a statistical difference as did the 48 and 
72 hour. One other concept learned from the trial assays was that the addition of acetic 
acid to destain the crystal violet was crucial to yielding readable results. When not treated 
with acetic acid, the stain remained adhered to the sides of the wells. With the addition of 
the acetic acid, the stain would not adhere to the side surfaces and the plate was read 
more easily using the GENios. It also resulted in less variability. Finally, as the trials 
went on the incubation chamber was changed, leading to a significant decrease in 
variability between the wells. This is due to more even temperature throughout the entire 
plate. Although the wells did seem to vary at some points through the study, there were 
more consistent readings using the new incubator as well as decreased human error. 
 The change in microtitre plate from 96 and 24-well plates seemed to yield no 
difference in results. The 24-well plate was used as an attempt to decrease variability. 
When it did not, further assays were carried out using 96-well plates exclusively. This 
resulted in a larger sample size for statistical analysis, and had the benefit of 
accommodating more treatments on to a single plate. 
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 When the first antibiotics were tested, the results seemed to indicate that 
ciprofloxacin and ceftazidime were killing 100 percent of the bacteria within the wells. 
Theses antibiotics, regardless of concentration, had absorbances test comparable (p>0.05) 
to the TSB negative control wells. When retesting these, the results were varied and 
trendless. The use of gentamicin and imipenem in the trials also produced variable 
results. This inconsistency pointed to either the bacteria or the antibiotics themselves.  
 The results of the Kirby-Bauer assay seemed to indicate the antibiotics were 
causing variation in the absorbance readings. The bacteria seemed to be inhibited by both 
ciprofloxacin and gentamicin. They were also resistant to cephalothin, erythromycin, and 
tetracycline. Resistance to these drugs would be expected, because these antibiotics are 
found to be ineffective towards P. aeruginosa. Based on the results, additional antibiotics 
were chosen for the study. 
 Rifampicin was a red color when placed in solution, making higher doses have 
high optical density. When Rifampicin dosing was lowered, a minimum inhibitory 
concentration was observed (~0.02mg/mL).  Ciprofloxacin continued to produce 
variability in absorbances and was finally deleted from the project. Polymyxin B and 
gentamicin had killing power on every control test. It was determined that a 0.07mg/mL 
concentration of each antbiotic was effective killing the control samples and the clinical 
isolates. 
 When assessing resistance based on optical density for the clinical isolates, a 
surprising number did not show resistance to the antibiotics used. The only isolate that 
had significant resistance was Clinical Isolate 35, which came from an unknown patient 
origin. Although, some isolates did show a significant difference in absorbance between 
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the negative control wells and the treatment wells. These statistical differences could 
indicate partial resistance, which could originate through a number of microbial 
mechanisms.  
 One mechanism by which resistance can develop in response to these drugs is 
through a change in the targeted prokaryote site. Polymyxin B targets the cellular 
envelope; rifampicin targets the RNA polymerase; while gentamicin targets the ribosome. 
Changes can be made to the bacterial cell that can block the attachment of the antibiotic 
and prevent destruction of the bacteria. P. aeruginosa also carries numerous porins. 
Therefore, if the drug was able to cross the barrier, efflux pumps and porins will keep the 
concentration below a level effective at neutralizing the bacteria (3).  Using efflux pumps 
will make developing resistance to antibiotics faster, because the lower concentration of 
drugs will encourage selection for resistant strains. Finally, resistance can  develop due to 
the ability of Pseudomonas to form biofilm as well as its ability to modulate virulence 
factor production (3). This constant change and improvement in biofilm could be 
effective in keeping the antibiotic out of the cell. It could be inferred that the resistance of 
clinical isolates nine years later could be much higher, since resistance rates are 
increasing for P. aeruginosa. If a comparison study was performed, it could be expected 
that more resistant strains will be isolated. 
 When comparing the sources of the isolates, few generalizations can be made. 
Polymyxin B seemed to have slightly less effect on the two types of urinary tract isolates 
as well as the blood related isolates in comparison to the positive control (t values of 44 
and 45 in comparison to 86). Urinary isolates of P. aeruginosa are very likely to form 
biofilm and that might be the cause for lowered effectiveness of some antibiotics. The 
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blood and wound isolates also showed a small increase in absorbance readings when 
compared to the control Pseudomonas. For rifampicin, the sputum with CF and the 
sample of unknown origin have higher readings in comparison to positive control. This 
could be due to increased changes in the RNA polymerase binding sites making the drug 
less effective against these isolates. The gentamicin treated wells had higher bacteria 
concentrations in the unknown samples in comparison to the positive control. This mild 
resistance to gentamicin could be caused by an alteration in the binding site for the 
ribosomal unit to which it attaches. Overall, there were only low levels of resistance in 
these isolates for rifampicin, gentamicin, and polymyxin B. 
 Producing bacteriocin for the study proved to be a difficult task. Using procedures 
described by Smajs, little to no colicin was extracted. This procedure would possibly be 
more effective on a larger scale, using many gallons of bacteria to produce detectable 
toxin production. This was not feasible and the equipment involved would have been 
costly.  One problem with the initial procedure was the use of mitomycin C to stimulate 
colicin production was performed during stationary phase of the bacteria. After some 
modifications, it was apparent that the time of addition of the drug was too late in the 
growth cycle to be effective for production.  Another reason the colicin procedure was 
ineffective was due to the spot testing. Originally the test was performed with a lawn of 
P. aeruginosa with colicin extract spotted on top of it, but it was determined through 
literature research that using a mixture of P. aeruginosa and soft agar inlay with the 
colicin spotted on top was the correct protocol. Even though this was performed, no 
clearance in the bacteria was observed.  Another hardship in getting bacteriocin in 
general was the inability to use FPLC. With a large volume FPLC, the ability to run the 
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crude extract through and to take the filtered, size inclusive extract for used in assays 
would have been hugely beneficial. This would have allowed for a greater concentration 
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Average Biofilm Absorbance at 24 Hours without Acetic Acid using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0653 0.0643 0.0836 0.0897 0.1124 0.0628 0.0687 0.0622 0.5293 0.0643 0.4491 0.0660
B 0.0626 0.0653 0.0807 0.0772 0.1252 0.0619 0.0731 0.0621 0.2675 0.0612 0.0838 0.6108
C 0.0647 0.0645 0.0990 0.0763 0.0759 0.0596 0.0627 0.0625 0.2494 0.4883 0.0862 0.2982
D 0.0628 0.0630 0.0794 0.0753 1.2071 0.0629 0.0563 0.0571 0.0702 0.3158 0.0944 0.4003
E 0.0671 0.0606 0.0712 0.1017 0.0797 0.0703 0.0611 0.0836 0.0670 0.0716 0.0716 0.0647
F 0.0604 0.0640 0.0798 0.0669 0.0759 0.0770 0.0779 0.0646 0.0658 0.0594 0.0626 0.1299
G 0.0609 0.0603 0.0694 0.0783 0.0747 0.0665 0.0616 0.0726 0.0645 0.0713 0.0650 0.1567
H 0.0617 0.0628 0.0764 0.0781 0.0705 0.0896 0.0718 0.0757 0.0743 0.0690 0.0721 0.0679
Average 0.0632 0.0631 0.0799 0.0804 0.2277 0.0688 0.0667 0.0676 0.1735 0.1501 0.1231 0.2243
Range 0.0067 0.0050 0.0296 0.0348 1.1366 0.0300 0.0216 0.0265 0.4648 0.4289 0.3865 0.5461  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.0631 0.00202 0.000504 0.00107  
Control 80 0 0.126 0.166 0.0186 0.0369  
 
Column Range Max Min  Median  25% 75%  
TSB 0.00680 0.0671 0.0603 0.0629 0.0611 0.0646  
Control 1.151 1.207 0.0563 0.0737 0.0652 0.0856  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.146 -0.739 0.117 0.714 0.952 0.521  
Control 4.395 23.552 0.384 <0.001 0.421 <0.001  
 
Column Sum Sum of Squares  
TSB 1.010 0.0639  
Control       10.097              3.452   
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.0631 0.00202 0.000504  




t = -1.513  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.146 to 0.0197 
 
Two-tailed P-value = 0.134 
 
The difference in the mean values of the two groups is not great enough to reject the possibility that the difference is due to random 
sampling variability. There is not a statistically significant difference between the input groups (P = 0.134). 
 
One-tailed P-value = 0.0668 
 
The sample mean of group Control does not exceed the sample mean of the group TSB by an amount great enough to exclude the 
possibility that the difference is due to random sampling variability. The hypothesis that the population mean of group TSB is greater 
than or equal to the population mean of group Control cannot be rejected. (P = 0.067). 
 
Power of performed two-tailed test with alpha = 0.050: 0.322 
 
The power of the performed test (0.322) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results should be 
interpreted cautiously. 
 
Power of performed one-tailed test with alpha = 0.050: 0.443 
 
The power of the performed test (0.443) is below the desired power of 0.800. 





Average Biofilm Absorbance at 24 Hours with Acetic Acid using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1487 0.1578 0.6248 0.8904 1.3972 1.0838 1.2104 0.7382 2.3589 0.8830 0.9607 0.8928
B 0.1613 0.1620 0.7087 0.8581 1.2763 0.8670 0.8083 0.7276 1.2907 0.7140 1.0322 1.4906
C 0.1465 0.1662 0.4922 0.7856 1.2499 1.1486 0.9677 1.2285 1.8813 1.3968 0.9541 1.1351
D 0.1588 0.1864 0.9047 0.8240 2.9341 1.0665 1.0698 0.9143 1.9300 1.3864 1.1056 1.7271
E 0.1639 0.1796 0.5395 0.9023 1.2779 0.9465 0.8087 1.3415 0.9460 0.9048 0.7508 1.1712
F 0.1462 0.1875 0.4805 0.5778 1.0152 1.1378 1.7069 1.0431 0.9603 1.0996 1.0613 0.9215
G 0.1347 0.1546 0.6345 0.6388 1.2744 1.5518 1.3907 1.4509 1.4033 1.3969 1.0940 1.0633
H 0.1668 0.2028 0.7788 1.1201 1.0399 1.6727 2.4320 1.3917 1.0862 1.7512 1.4913 0.8460
Average 0.153363 0.174613 0.645463 0.824638 1.433113 1.184338 1.299313 1.104475 1.482088 1.191588 1.05625 1.15595
Range 0.0321 0.0482 0.4242 0.5423 1.9189 0.8057 1.6237 0.7233 1.4129 1.0372 0.7405 0.8811  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.164 0.0177 0.00442 0.00943  
Control Sample 80 0 1.138 0.431 0.0482 0.0960  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0681 0.203 0.135 0.162 0.150 0.176  
Control Sample 2.454 2.934 0.480 1.065 0.871 1.375  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.628 0.236 0.187 0.139 0.956 0.583  
Control Sample 1.573 3.887 0.127 0.003 0.890 <0.001  
 
Column Sum Sum of Squares  
TSB 2.624 0.435  
Control Sample       91.018                 118.245 
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.164 0.0177 0.00442  




t = -8.992  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -1.189 to -0.759 
 
Two-tailed P-value = 2.553E-014 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = <0.001). 
 
One-tailed P-value = 1.277E-014 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = <0.001). 
 
Power of performed two-tailed test with alpha = 0.050: 1.000 
 





Average Biofilm Absorbance at 48 Hours without Acidic Acid using P. aeruginosa ATCC 
47085
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0487 0.0493 0.0867 0.0612 0.1333 1.0184 0.0569 0.7976 0.0645 0.7541 0.1291 0.0593
B 0.0486 0.0521 0.0618 0.1098 0.0636 0.0980 0.1707 0.0771 0.0924 0.1514 0.0611 0.0803
C 0.0438 0.0460 0.0746 0.0885 0.0827 0.0628 0.0792 0.0589 0.0596 0.0583 0.0774 0.1038
D 0.0608 0.0495 0.0736 0.0983 0.0676 0.0631 0.0799 0.1062 0.0558 0.0581 0.0632 0.1706
E 0.0591 0.0479 0.0684 0.0826 0.0674 0.0812 0.0600 0.0918 0.0597 0.0624 0.0621 0.0643
F 0.0862 0.0977 0.0836 0.0863 0.0690 0.0653 0.1088 0.0905 0.0642 0.0620 0.0670 0.0829
G 0.0575 0.0585 0.0736 0.0725 0.0701 0.1675 0.7263 0.8028 0.1061 0.0587 0.0852 0.0771
H 0.0627 0.0537 0.1576 0.0724 0.6322 0.0896 0.1879 0.1990 0.1643 0.0729 0.0939 0.1221
Average 0.058425 0.056838 0.084988 0.08395 0.148238 0.205738 0.183713 0.277988 0.083325 0.159738 0.079875 0.09505
Range 0.0424 0.0517 0.0958 0.0486 0.5686 0.9556 0.6694 0.7439 0.1085 0.696 0.068 0.1113  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.0576 0.0147 0.00367 0.00781  
Control Sample 80 0 0.140 0.191 0.0214 0.0426  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0539 0.0977 0.0438 0.0529 0.0486 0.0604  
Control Sample 0.963 1.018 0.0558 0.0796 0.0638 0.106  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.931 3.475 0.240 0.015 0.761 <0.001  
Control Sample 3.302 10.045 0.351 <0.001 0.435 <0.001  
 
Column Sum Sum of Squares  
TSB 0.922 0.0564  
Control Sample 11.221 4.469  
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.0576 0.0147 0.00367  




t = -1.718  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.178 to 0.0128 
 
Two-tailed P-value = 0.0890 
 
The difference in the mean values of the two groups is not great enough to reject the possibility that the difference is due to random 
sampling variability. There is not a statistically significant difference between the input groups (P = 0.089). 
 
One-tailed P-value = 0.0445 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = 0.045). 
 
Power of performed two-tailed test with alpha = 0.050: 0.398 
 






Average Biofilm Absorbance at 48 Hours with Acetic Acid using P. aeruginosa ATCC 
47085
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1552 0.1698 1.6932 1.3348 1.8567 OVER 0.8036 OVER 0.9974 OVER 1.7151 1.1564
B 0.1576 0.1514 1.1500 1.7404 1.4545 1.9667 1.6976 1.2303 2.6820 1.5226 0.6106 2.9920
C 0.1438 0.1745 1.1448 1.9287 1.4142 2.0489 1.2005 1.7669 0.7900 0.6551 1.2777 1.3469
D 0.1897 0.1512 1.0494 1.6322 0.8960 1.3134 1.1730 0.5436 0.7402 1.2250 0.6647 1.0102
E 0.1700 0.1588 1.1522 1.7968 0.6146 2.0541 1.7980 1.3722 0.9942 1.0565 0.4777 0.6408
F 0.2708 0.2251 1.1911 1.7978 1.8630 1.4521 1.8123 1.8493 0.6083 0.6599 1.7667 0.6695
G 0.1922 0.4783 1.2981 1.7522 1.9341 2.7560 OVER OVER 2.4819 1.5424 0.9556 0.8048
H 0.2497 0.2155 2.3098 1.8174 OVER 1.5724 1.5415 2.4043 OVER 0.8404 1.1753 0.7462
Average 0.191125 0.215575 1.373575 1.725038 1.4333 1.880514 1.432357 1.527767 1.327714 1.0717 1.080425 1.17085
Range 0.127 0.3271 1.2604 0.5939 1.3195 1.4426 1.0087 1.8607 2.0737 0.8873 1.289 2.3512  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.203 0.0823 0.0206 0.0439  
Control Sample 73 0 1.397 0.569 0.0666 0.133  
 
Column Range Max Min  Median  25% 75%  
TSB 0.335 0.478 0.144 0.172 0.156 0.223  
Control Sample 2.514 2.992 0.478 1.335 0.975 1.797  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 2.774 8.840 0.241 0.013 0.664 <0.001  
Control Sample 0.534 -0.00328 0.0674 0.531 0.962 0.027  
 
Column Sum Sum of Squares  
TSB 3.254 0.763  
Control Sample        101.985               165.774 
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.203 0.0823 0.0206  




t = -8.339  with 87 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -1.478 to -0.909 
 
Two-tailed P-value = 1.011E-012 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = <0.001). 
 
One-tailed P-value = 5.057E-013 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = <0.001). 
 
Power of performed two-tailed test with alpha = 0.050: 1.000 
 











Average Biofilm Absorbance at 72 Hours without Acetic Acid using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0550 0.0534 0.7709 1.0373 0.8916 0.2369 0.4322 0.0712 0.0696 0.0564 0.0537 0.1516
B 0.0538 0.0559 0.1338 0.4940 0.6368 0.2842 0.4016 0.9585 0.3842 0.0949 0.1911 0.3281
C 0.0547 0.0547 0.1206 0.5070 0.2585 0.2304 0.3839 0.2468 0.0620 0.0705 0.3117 0.1592
D 0.0585 0.0544 0.1708 0.2034 0.5387 0.8078 0.1596 0.2895 0.1208 0.1472 0.0697 0.1861
E 0.0588 0.0567 0.1483 0.1087 0.2973 0.4814 0.1577 0.1959 0.2066 0.0548 0.0927 0.1353
F 0.0681 0.0579 0.1173 0.1334 0.1986 0.2214 0.3155 0.1699 0.4770 0.4237 0.5338 0.4451
G 0.0597 0.0599 0.2209 0.5370 0.9389 0.5956 0.4645 0.7637 0.4984 0.2852 0.1815 0.1161
H 0.0560 0.0643 1.7869 0.7550 0.8068 0.0794 0.0977 0.0761 0.0696 2.4450 0.0627 1.1343
Average 0.058075 0.05715 0.433688 0.471975 0.5709 0.367138 0.301588 0.34645 0.236025 0.447213 0.187113 0.331975
Range 0.0143 0.0109 1.6696 0.9286 0.7403 0.7284 0.3668 0.8873 0.4364 2.3902 0.4801 1.0182  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.0576 0.00399 0.000999 0.00213  
Control Sample 80 0 0.369 0.389 0.0435 0.0866  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0147 0.0681 0.0534 0.0563 0.0547 0.0595  
Control Sample 2.391 2.445 0.0537 0.226 0.124 0.491  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.477 2.156 0.158 0.333 0.857 0.017  
Control Sample 2.822 11.011 0.209 <0.001 0.716 <0.001  
 
Column Sum Sum of Squares  
TSB 0.922 0.0533  
Control Sample       29.552                 22.891 
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.0576 0.00399 0.000999  




t = -3.190  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.506 to -0.118 
 
Two-tailed P-value = 0.00193 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = 0.002). 
 
One-tailed P-value = 0.000967 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = <0.001). 
 
Power of performed two-tailed test with alpha = 0.050: 0.884 
 












Average Biofilm Absorbance at 72 Hours with Acetic Acid using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1472 0.1646 OVER OVER OVER 1.6151 OVER 2.9739 1.1501 0.2798 0.2282 1.4277
B 0.1510 0.1921 1.8187 OVER OVER 2.1113 2.4833 OVER 1.1813 0.9006 1.4579 2.3263
C 0.1479 0.1854 2.5570 OVER OVER OVER OVER OVER 2.1811 1.0976 2.5628 2.5782
D 0.1845 0.2056 OVER 2.7870 OVER OVER OVER OVER OVER 1.0639 2.1456 1.3033
E 0.1764 0.2240 1.5804 2.1051 OVER OVER 2.1306 2.9854 2.5207 0.6376 1.9864 1.7870
F 0.1961 0.2097 1.3386 2.0920 OVER 2.4165 2.6503 2.7241 OVER 2.2693 2.0135 2.3440
G 0.1542 0.2060 2.0207 OVER 2.4040 1.5662 1.9392 OVER 2.1715 1.8282 1.2838 1.7219
H 0.1598 0.1726 OVER OVER OVER 1.9337 1.6703 1.3327 0.6736 OVER 1.0751 OVER
Average 0.164638 0.195 1.86308 2.328033 2.404 1.92856 2.17474 2.504025 1.646383 1.153857 1.594163 1.926914
Range 0.0489 0.0594 1.2184 0.695 0 0.8503 0.98 1.6527 1.8471 1.9895 2.3346 1.2749  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.180 0.0244 0.00610 0.0130  
Control Sample 51 0 1.832 0.670 0.0938 0.188  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0768 0.224 0.147 0.180 0.156 0.203  
Control Sample 2.757 2.985 0.228 1.939 1.333 2.344  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.181 -1.145 0.109 0.774 0.946 0.435  
Control Sample -0.460 -0.301 0.0897 0.369 0.973 0.294  
 
Column Sum Sum of Squares  
TSB 2.877 0.526  
Control Sample        93.433                193.630  
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.180 0.0244 0.00610  




t = -9.807  with 65 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -1.989 to -1.316 
 
Two-tailed P-value = 1.920E-014 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = <0.001). 
 
One-tailed P-value = 9.599E-015 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = <0.001). 
 
Power of performed two-tailed test with alpha = 0.050: 1.000 
 











Average Biofilm Absorbance at 24 Hours without Acetic Acid- Changed Incubator using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0438 0.0481 0.0515 0.0509 0.0527 0.0506 0.0661 0.0580 0.0532 0.0532 0.0579 0.0570
B 0.0401 0.0390 0.0467 0.0494 0.0543 0.0482 0.0474 0.0522 0.0481 0.0523 0.0468 0.0523
C 0.0384 0.0406 0.0468 0.0512 0.0510 0.0472 0.0463 0.0447 0.0489 0.0469 0.0471 0.0536
D 0.0419 0.0462 0.0473 0.0455 0.0546 0.0467 0.0453 0.0466 0.0478 0.0443 0.0462 0.0442
E 0.0411 0.0413 0.0458 0.0464 0.0457 0.0451 0.0489 0.0544 0.0492 0.0440 0.0455 0.0500
F 0.0368 0.0386 0.0435 0.0652 0.0568 0.0499 0.0486 0.0487 0.0482 0.0615 0.0440 0.0484
G 0.0398 0.0392 0.0454 0.0457 0.0509 0.0871 0.0471 0.0485 0.0504 0.0491 0.0450 0.0445
H 0.0410 0.0413 0.0454 0.0559 0.0487 0.0503 0.0486 0.0521 0.0484 0.0535 0.0453 0.0480
Average 0.0404 0.0418 0.0466 0.0513 0.0518 0.0531 0.0498 0.0507 0.0493 0.0506 0.0472 0.0498
Range 0.0070 0.0095 0.0080 0.0197 0.0111 0.0420 0.0208 0.0133 0.0054 0.0175 0.0139 0.0128  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.0411 0.00290 0.000725 0.00154  
Control Sample 80 0 0.0500 0.00621 0.000694 0.00138  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0113 0.0481 0.0368 0.0408 0.0391 0.0418  
Control Sample 0.0436 0.0871 0.0435 0.0485 0.0463 0.0522  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.161 1.428 0.219 0.039 0.904 0.094  
Control Sample 3.232 15.834 0.154 <0.001 0.725 <0.001  
 
Column Sum Sum of Squares 
TSB 0.657 0.0271  
Control Sample      4.001                 0.203 
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.0411 0.00290 0.000725  




t = -5.617  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.0121 to -0.00578 
 
Two-tailed P-value = 0.000000197 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = <0.001). 
 
One-tailed P-value = 0.0000000984 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = <0.001). 
 
Power of performed two-tailed test with alpha = 0.050: 1.000 
 











Average Absorbance at 24 Hours with Acetic Acid- Changed Incubator using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0958 0.0903 1.1261 1.4608 1.2696 1.0537 2.1043 0.7038 0.6631 0.8704 0.3377 0.5476
B 0.0835 0.0878 0.4395 0.4876 0.7970 0.4081 0.3760 0.4356 0.4289 0.2491 0.2265 0.3615
C 0.0868 0.0948 0.2900 0.3650 0.5667 0.4508 0.4167 0.2519 0.2643 0.4661 0.2702 0.4900
D 0.0922 0.0945 0.3093 0.2436 0.4759 0.3136 0.2255 0.3197 0.2772 0.2250 0.2663 0.3183
E 0.1000 0.1214 0.2897 0.3912 0.3282 0.3242 0.4314 0.3008 0.3078 0.2744 0.2352 0.3385
F 0.0861 0.0914 0.2439 0.4568 0.4521 0.4419 0.4024 0.2362 0.2247 0.2826 0.2389 0.3051
G 0.1067 0.1465 0.3655 0.3343 0.6605 0.9312 0.4243 0.5523 0.6443 0.4682 0.3303 0.3811
H 0.1204 0.1120 0.3325 0.5645 0.3231 0.6447 0.3684 0.3603 0.3825 0.2902 0.4970 0.3851
Average 0.0964 0.1048 0.4246 0.5380 0.6091 0.5710 0.5936 0.3951 0.3991 0.3908 0.3003 0.3909
Range 0.0369 0.0587 0.8822 1.2172 0.9465 0.7401 1.8788 0.4676 0.4384 0.6454 0.2705 0.2425  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.101 0.0170 0.00424 0.00903  
Control Sample 80 0 0.461 0.301 0.0336 0.0669  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0630 0.146 0.0835 0.0946 0.0884 0.111  
Control Sample 1.880 2.104 0.225 0.372 0.293 0.485  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.547 2.325 0.237 0.016 0.837 0.009  
Control Sample 3.102 12.232 0.240 <0.001 0.666 <0.001  
 
Column Sum Sum of Squares  
TSB 1.610 0.166  
Control Sample       36.899               24.158  
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.101 0.0170 0.00424  




t = -4.777  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.510 to -0.211 
 
Two-tailed P-value = 0.00000654 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = <0.001). 
 
One-tailed P-value = 0.00000327 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = <0.001). 
 
Power of performed two-tailed test with alpha = 0.050: 0.997 
 







Average Absorbance at 48 Hours without Acetic Acid- Changed Incubator using P. aeruginosa ATCC 
47085
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0699 0.0784 0.5855 0.0900 0.4639 0.3141 0.1691 0.4741 0.0670 0.0589 0.0537 0.0533
B 0.0520 0.0542 0.0613 0.0651 0.0547 0.0610 0.0680 0.0524 0.0509 0.0552 0.0530 0.0504
C 0.0640 0.0467 0.0656 0.0666 0.0516 0.0583 0.0550 0.0501 0.0596 0.0596 0.0489 0.0561
D 0.0519 0.0428 0.0600 0.0587 0.0584 0.0617 0.0618 0.0540 0.0463 0.0528 0.0469 0.0614
E 0.0676 0.0733 0.0659 0.0584 0.0562 0.0558 0.0550 0.0555 0.0571 0.0527 0.0481 0.0717
F 0.0595 0.0385 0.0605 0.0630 0.0573 0.0598 0.0550 0.0468 0.0506 0.0483 0.0517 0.0639
G 0.0567 0.0467 0.0550 0.0544 0.0644 0.0638 0.0618 0.0491 0.0481 0.0508 0.0469 0.0521
H 0.0423 0.0409 0.0605 0.0729 0.0533 0.0517 0.0532 0.0507 0.0464 0.0502 0.0477 0.0743
Average 0.0580 0.0527 0.1268 0.0661 0.1075 0.0908 0.0724 0.1041 0.0533 0.0536 0.0496 0.0604
Range 0.0276 0.0399 0.5305 0.0356 0.4123 0.2624 0.1159 0.4273 0.0207 0.0113 0.0068 0.0239  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.0553 0.0124 0.00310 0.00660  
Control Sample 80 0 0.0784 0.0918 0.0103 0.0204  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0399 0.0784 0.0385 0.0531 0.0438 0.0667  
Control Sample 0.539 0.586 0.0463 0.0560 0.0517 0.0618  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.416 -0.966 0.132 0.579 0.947 0.450  
Control Sample 4.411 19.210 0.443 <0.001 0.316 <0.001  
 
Column Sum Sum of Squares 
TSB 0.885 0.0513  
Control Sample 6.276 1.157  
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.0553 0.0124 0.00310  




t = -1.001  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.0689 to 0.0227 
 
Two-tailed P-value = 0.319 
 
The difference in the mean values of the two groups is not great enough to reject the possibility that the difference is due to random 
sampling variability. There is not a statistically significant difference between the input groups (P = 0.319). 
 
One-tailed P-value = 0.160 
 
The sample mean of group Control Sample does not exceed the sample mean of the group TSB by an amount great enough to exclude 
the possibility that the difference is due to random sampling variability. The hypothesis that the population mean of group TSB is 
greater than or equal to the population mean of group Control Sample cannot be rejected. (P = 0.160). 
 
Power of performed two-tailed test with alpha = 0.050: 0.168 
 
The power of the performed test (0.168) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results should be 
interpreted cautiously. 
 
Power of performed one-tailed test with alpha = 0.050: 0.258 
 
The power of the performed test (0.258) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously. 
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Average Biofilm Absorbance at 48 Hours with Acetic Acid- Changed Incubator using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1350 0.2318 0.2115 OVER 2.9513 OVER 2.9362 1.4330 0.8800 0.2534 0.3219 0.2593
B 0.1368 0.2426 0.6666 0.7365 0.2653 0.2675 0.2238 0.2923 0.3495 0.4160 0.4235 0.2989
C 0.0846 0.4734 0.3024 0.3132 0.3137 0.3523 0.3040 0.3653 0.6648 1.8348 1.1143 1.2237
D 0.1021 0.8868 0.5396 0.2732 0.3387 0.2684 0.2037 0.2767 0.2796 0.4992 0.5744 1.7988
E 0.0779 0.2337 0.2673 0.1432 0.2057 0.2769 0.2651 0.6598 1.3987 1.5713 0.7821 OVER
F 0.0576 0.3954 0.2630 0.3561 0.1711 0.2822 0.2814 0.2773 0.2751 0.4621 0.5221 1.4365
G 0.0570 0.3634 0.1065 0.2365 0.2912 0.2359 0.3814 0.9664 1.2750 1.6490 1.2481 1.2603
H 0.0589 0.2202 0.2351 0.6089 0.5527 0.3942 0.6375 0.3667 0.3693 0.3634 0.3933 0.3251
Average 0.0887 0.3809 0.3240 0.3811 0.6362 0.2968 0.6541 0.5797 0.6865 0.8812 0.6725 0.9432
Range 0.0798 0.6666 0.5601 0.5933 2.7802 0.1583 2.7325 1.1563 1.1236 1.5814 0.9262 1.5395  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.235 0.216 0.0541 0.115  
Control Sample 77 0 0.608 0.575 0.0655 0.130  
 
Column Range Max Min  Median  25% 75%  
TSB 0.830 0.887 0.0570 0.178 0.0796 0.333  
Control Sample 2.845 2.951 0.107 0.356 0.274 0.666  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 2.019 4.885 0.236 0.018 0.779 0.001  
Control Sample 2.288 5.814 0.249 <0.001 0.698 <0.001  
 
Column Sum Sum of Squares  
TSB 3.757 1.585  
Control Sample 46.821 53.591  
t-test  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.235 0.216 0.0541  




t = -2.550  with 91 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.664 to -0.0825 
 
Two-tailed P-value = 0.0124 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = 0.012). 
 
One-tailed P-value = 0.00622 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = 0.006). 
 
Power of performed two-tailed test with alpha = 0.050: 0.713 
 





Average Biofilm Absorbance at 72 Hours without Acetic Acid- Change Incubator using P. aeruginosa ATCC 
47085
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0477 0.0436 0.0643 0.0691 0.1374 0.0848 0.0694 0.0876 0.1414 0.0697 0.0693 0.0937
B 0.1014 0.0481 0.0902 0.0548 0.0741 0.0664 0.0542 0.0532 0.0573 0.0487 0.0522 0.0677
C 0.0548 0.0382 0.0525 0.0507 0.0654 0.0630 0.0511 0.0577 0.0546 0.0728 0.0582 0.0833
D 0.0603 0.0410 0.0526 0.0499 0.0577 0.0652 0.0528 0.0486 0.0700 0.0518 0.0765 0.0631
E 0.0522 0.0411 0.0497 0.0497 0.0562 0.0520 0.0583 0.0542 0.0480 0.0519 0.0749 2.4602
F 0.0450 0.0399 0.0517 0.0477 0.0521 0.0497 0.0496 0.0496 0.0591 0.0578 0.0809 0.1753
G 0.0513 0.0471 0.0625 0.0653 0.0619 0.0532 0.0604 0.0551 0.0532 0.0642 0.0636 0.2709
H 0.0524 0.0487 0.0745 0.0711 0.0926 0.0749 0.0830 0.0851 0.0717 0.0781 0.1090 0.8290
Average 0.0581 0.0435 0.0623 0.0573 0.0747 0.0637 0.0599 0.0614 0.0694 0.0619 0.0731 0.5054
Range 0.0564 0.0105 0.0405 0.0234 0.0853 0.0351 0.0334 0.0390 0.0934 0.0294 0.0568 2.3971  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.0508 0.0147 0.00369 0.00786  
Control Sample 80 0 0.109 0.281 0.0314 0.0626  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0632 0.101 0.0382 0.0479 0.0417 0.0524  
Control Sample 2.413 2.460 0.0477 0.0628 0.0527 0.0748  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 2.965 10.270 0.269 0.003 0.658 <0.001  
Control Sample 7.809 64.267 0.434 <0.001 0.182 <0.001  
 
Column Sum Sum of Squares 
TSB 0.813 0.0445  




Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.0508 0.0147 0.00369  




t = -0.823  with 94 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.198 to 0.0821 
 
Two-tailed P-value = 0.413 
 
The difference in the mean values of the two groups is not great enough to reject the possibility that the difference is due to random 
sampling variability. There is not a statistically significant difference between the input groups (P = 0.413). 
 
One-tailed P-value = 0.206 
 
The sample mean of group Control Sample does not exceed the sample mean of the group TSB by an amount great enough to exclude 
the possibility that the difference is due to random sampling variability. The hypothesis that the population mean of group TSB is 
greater than or equal to the population mean of group Control Sample cannot be rejected. (P = 0.206). 
 
Power of performed two-tailed test with alpha = 0.050: 0.129 
 
The power of the performed test (0.129) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results should be 
interpreted cautiously. 
 
Power of performed one-tailed test with alpha = 0.050: 0.204 
 
The power of the performed test (0.204) is below the desired power of 0.800. 
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Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results should be 
interpreted cautiously. 
 
Average Biofilm Absorbance at 72 Hours with Acetic Acid- Changed Incubator using P. aeruginosa ATCC 47085 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0971 0.0773 0.9015 1.3058 OVER OVER 0.7851 2.5045 1.5637 0.3032 0.3863 OVER
B 0.1598 0.0775 0.8501 0.7320 0.2011 0.1734 0.1853 0.3280 0.1663 0.1821 0.2076 1.6863
C 0.1012 0.0868 0.2217 0.7609 0.1521 0.2685 0.2159 0.2220 0.2058 0.2237 0.2433 OVER
D 0.0980 0.0843 1.2689 0.5833 0.2171 0.2836 0.2792 0.2663 0.1887 0.2165 0.2474 2.2514
E 0.0963 0.1159 0.4517 1.0184 0.1886 0.2197 1.0311 0.4464 0.2061 0.3271 0.2832 OVER
F 0.1047 0.0853 1.8608 0.8970 0.4999 0.2129 0.3150 0.3296 0.1870 0.2777 0.3148 OVER
G 0.1139 0.1528 2.4653 1.4560 0.7692 0.2396 0.8656 0.4515 0.4389 0.4565 0.3708 OVER
H 0.1359 0.1098 2.2783 0.3931 0.8182 1.3530 OVER OVER OVER OVER OVER OVER
Average 0.1134 0.0987 1.2873 0.8933 0.4066 0.3930 0.5253 0.6498 0.4224 0.2838 0.2933 1.9689
Range 0.0635 0.0755 2.2436 1.0629 0.6661 1.1796 0.8458 2.2825 1.3974 0.2744 0.1787 0.5651  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.106 0.0249 0.00623 0.0133  
Control Sample 67 0 0.630 0.607 0.0742 0.148  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0825 0.160 0.0773 0.0996 0.0857 0.115  
Control Sample 2.352 2.505 0.152 0.328 0.220 0.850  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.034 0.384 0.159 0.331 0.893 0.062  
Control Sample 1.731 2.285 0.254 <0.001 0.740 <0.001  
 
Column Sum Sum of Squares  
TSB 1.697 0.189  




Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.106 0.0249 0.00623  




t = -3.435  with 81 degrees of freedom.  
 
95 percent two-tailed confidence interval for difference of means: -0.827 to -0.220 
 
Two-tailed P-value = 0.000937 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = <0.001). 
 
One-tailed P-value = 0.000469 
 
The sample mean of group Control Sample exceeds the sample mean of group TSB by an amount that is greater than would be 
expected by chance, rejecting the hypothesis that the population mean of group TSB is greater than or equal to the population mean of 
group Control Sample. (P = <0.001). 
 
Power of performed two-tailed test with alpha = 0.050: 0.924 
 
Power of performed one-tailed test with alpha = 0.050: 0.96 
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Average Biofilm Absorbance at 48 Hours using using P. aeruginosa ATCC 
47085
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0832 0.1067 0.3852 0.2196 0.2039 0.2181 0.2467 0.4373 0.2779 0.4225 0.2965 0.4514
B 0.0811 0.0721 0.1781 0.2509 0.2347 0.1933 0.1913 0.1900 0.1785 0.0837 0.2745 0.3962
C 0.0787 0.0964 0.3554 0.1314 0.1472 0.3756 0.3396 0.2500 0.1571 0.5164 0.2632 0.4680
D 0.0936 0.0770 0.1959 0.1601 0.1865 0.2171 0.7598 0.2446 0.2707 0.1739 0.2945 0.5503
E 0.1008 0.1042 0.2367 0.1421 0.2589 0.2987 0.2087 0.2716 0.1939 0.1470 0.2397 0.5142
F 0.1021 0.0836 0.3100 0.1681 0.2642 2.3245 0.2030 0.2199 0.2055 0.2697 0.2731 0.6778
G 0.1454 0.1643 0.4891 0.2291 0.3601 0.1863 0.2400 0.3589 0.2039 0.4091 0.4301 0.5305
H 0.1509 0.0994 0.4518 0.1613 0.3181 0.4184 0.4391 0.4913 0.5050 0.4416 0.5132 0.8754
Average 0.104475 0.100463 0.325275 0.182825 0.2467 0.529 0.328525 0.30795 0.249063 0.307988 0.3231 0.557975
Range 0.0722 0.0922 0.311 0.1195 0.2129 2.1382 0.5685 0.3013 0.3479 0.4327 0.2735 0.4792  
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0698 0.0766 0.1452 0.3380 0.1833 0.2453 0.3079 0.4106 0.4561 0.4679 0.2118 0.4091
B 0.0786 0.0760 0.1598 0.3078 0.2152 0.1867 0.1530 0.1538 0.1470 0.2280 0.1533 0.5030
C 0.0655 0.0708 0.6973 0.2770 0.2788 0.2714 0.2172 0.3219 0.4523 0.1783 0.2247 0.3326
D 0.0740 0.0804 0.2093 0.2541 0.2614 0.2391 0.2980 0.3269 0.8730 0.2051 0.2038 0.3425
E 0.0708 0.0840 0.5402 1.1103 0.7470 0.2349 0.2044 0.5227 0.2313 0.2609 OVER 0.3951
F 0.0779 0.0828 0.1942 0.6375 0.3626 0.3462 0.9888 0.3772 0.2808 0.7021 0.3061 0.5243
G 0.1033 0.1043 0.2057 0.7248 0.2702 0.2356 0.3363 0.4535 0.5197 0.3567 0.1643 1.0784
H 0.1083 0.0866 0.2769 0.5269 0.2602 0.2974 0.4071 0.4438 1.6507 0.3548 0.8493 OVER
Average 0.0810 0.082688 0.303575 0.52205 0.322338 0.257075 0.364088 0.3763 0.576363 0.344225 0.3019 0.512143
Range 0.0428 0.0335 0.5521 0.8562 0.5637 0.1595 0.8358 0.3689 1.5037 0.5238 0.696 0.7458  
t-test  
 
Data source: Data 1 in Notebook1 
 
Normality Test: Failed (P < 0.050) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0922 0.0237 0.00419  




t = -5.723  with 188 degrees of freedom. (P = <0.001) 
 
95 percent confidence interval for difference of means: -0.362 to -0.176 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = <0.001). 
 
























Average Biofilm Absorbance at 48 Hours Using a 24 well plate 
<> 1 2 3 4 5 6
A 0.0631 0.1096 0.2030 1.0251 1.2108 OVER
B 0.0609 0.1029 0.1193 0.1409 0.1586 0.1726
C 0.0703 0.0966 0.1132 0.5468 0.6744 0.2248
D 0.1139 0.1157 0.1118 0.1584 0.1708 0.5520
Average 0.0771 0.1062 0.1368 0.4678 0.5537 0.3165
Range 0.0530 0.0191 0.0912 0.8842 1.0522 0.3794
. 
<> 1 2 3 4 5 6
A 0.0457 0.1939 0.0856 0.1159 0.6822 0.6826
B 0.0404 0.0601 0.0500 0.0648 0.3846 0.8522
C 0.0508 0.0830 0.0693 0.0794 0.6240 0.8169
D 0.0539 0.1509 0.1150 0.2479 1.1107 0.7069
Average 0.0477 0.121975 0.079975 0.127 0.700375 0.76465




Data source: Data 1 in Notebook1 
 
Normality Test: Failed (P < 0.050) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0624 0.0230 0.00811  




t = -2.323  with 45 degrees of freedom. (P = 0.025) 
 
95 percent confidence interval for difference of means: -0.515 to -0.0366 
 
The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant 
difference between the input groups (P = 0.025). 
 


























Antibiotic testing trial 1 on 7/5/14 at 48 hours- Control Plate 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1096 0.2206 OVER 1.3772 1.5783 0.8470 0.5027 0.3457 0.4322 0.7172 0.6797 0.2890
B 0.1036 0.1407 1.2218 0.1375 0.1231 0.3151 0.8118 0.1167 0.5487 0.0872 0.5768 OVER
C 0.1108 0.1210 1.4518 0.1339 0.1413 1.2669 0.5122 0.3500 0.4935 1.1325 0.6963 OVER
D 0.1213 0.1167 1.5088 1.1459 1.3179 1.8519 0.4510 0.9611 OVER 0.4435 0.5965 0.5643
E 0.1150 0.1849 1.6671 0.1171 0.6650 0.9809 OVER 1.1047 1.0108 0.6014 0.4711 0.3856
F 0.1462 0.1511 2.0117 0.1738 1.1866 0.8891 1.2834 1.0973 0.9984 0.6742 0.6780 0.3455
G 0.1499 0.1769 OVER 0.1699 1.6218 2.3066 0.9253 0.8017 0.6566 0.6354 0.2422 0.4415
H 0.1501 0.1352 OVER 0.9895 2.8169 OVER 2.4273 OVER 0.5961 1.6754 OVER 0.4975
Average 0.1258 0.155888 1.57224 0.5306 1.181363 1.208214 0.987671 0.682457 0.676614 0.74585 0.562943 0.420567
Range 0.0465 0.1039 0.7899 1.2601 2.6938 1.9915 1.9763 0.988 0.5786 1.5882 0.4541 0.2753  
Antibiotic testing trial 2 on 7/5/14 at 48 hours- Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1145 0.1013 0.0922 0.1006 0.1018 0.0799 0.1083 0.0706 0.1108 0.0871 0.1030 0.0908
B 0.0840 0.2534 0.1275 0.1112 0.1203 0.1249 0.1162 0.1177 0.1482 0.0870 0.0796 0.0938
C 0.1430 0.1362 0.1028 0.1221 0.1494 0.1354 0.1167 0.1049 0.1153 0.1133 0.1289 0.1250
D 0.1155 0.0976 0.1359 0.1327 0.1311 0.1381 0.1179 0.1223 0.1156 0.1094 0.1156 0.1215
E 0.1338 0.1306 0.1662 0.1713 0.1842 0.1534 0.1514 0.1263 0.0975 0.0974 0.1045 0.0950
F 0.1502 0.1434 0.1725 0.1806 0.1939 0.2109 0.1644 0.1184 0.1417 0.1431 0.0940 0.1131
G 0.1553 0.1476 0.1669 0.2127 0.2078 0.2023 0.1666 0.1386 0.1296 0.1108 0.1010 0.1219
H 0.1451 0.1031 0.3151 0.1864 0.1441 0.1269 0.1080 0.1529 0.1294 0.1108 0.1362 0.1498
Average 0.130175 0.13915 0.159888 0.1522 0.154075 0.146475 0.131188 0.118963 0.123513 0.107363 0.10785 0.113863
Range 0.0713 0.1558 0.2229 0.1121 0.106 0.131 0.0586 0.0823 0.0507 0.0561 0.0566 0.059  
Antibiotic testing trial 3 on 7/5/14 at 48 hours- Ceftazidime 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1005 0.0897 0.1018 0.1093 0.0899 0.0935 0.0986 0.0887 0.1116 0.1047 0.1027 0.1078
B 0.1048 0.1044 0.0985 0.0913 0.0945 0.0993 0.0822 0.0911 0.0950 0.0993 0.0940 0.1376
C 0.1152 0.1178 0.0953 0.1080 0.1215 0.0904 0.1020 0.0934 0.0976 0.1143 0.0966 0.1081
D 0.1217 0.0942 0.1334 0.1157 0.1152 0.1140 0.1027 0.1007 0.0949 0.0984 0.1299 0.1150
E 0.1098 0.1089 0.1434 0.1416 0.1101 0.1191 0.1112 0.1146 0.1078 0.1478 0.1097 0.1150
F 0.1425 0.1082 0.1163 0.1301 0.1105 0.1419 0.1207 0.1003 0.1243 0.1263 0.1122 0.1021
G 0.1378 0.1539 0.1745 0.1853 0.1355 0.1739 0.1373 0.1794 0.1606 0.1357 0.1258 0.1039
H 0.1171 0.1112 0.1601 0.1343 0.1631 0.1395 0.1459 0.1384 0.1410 0.1494 0.1466 0.1533
Average 0.118675 0.111038 0.127913 0.12695 0.117538 0.12145 0.112575 0.113325 0.1166 0.121988 0.114688 0.11785
Range 0.042 0.0642 0.0792 0.094 0.0732 0.0835 0.0637 0.0907 0.0657 0.051 0.0526 0.0512  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 48 0 0.130 0.0318 0.00459 0.00924  
Control 70 0 0.841 0.592 0.0707 0.141  
Ciprofloxacin 5mg/mL 8 0 0.160 0.0695 0.0246 0.0581  
Ciprofloxacin 2.5mg/mL 8 0 0.152 0.0408 0.0144 0.0341  
Ciprofloxacin 1.25mg/mL 8 0 0.154 0.0376 0.0133 0.0314  
Ciprofloxacin 0.625mg/mL 8 0 0.146 0.0427 0.0151 0.0357  
Ciprofloxacin 0.3125mg/mL 8 0 0.131 0.0252 0.00890 0.0211  
Ciprofloxacin 0.1563mg/mL 8 0 0.119 0.0243 0.00860 0.0203  
Ciprofloxacin 0.0781mg/mL 8 0 0.124 0.0168 0.00595 0.0141  
Ciprofloxacin 0.0391mg/mL 8 0 0.107 0.0180 0.00636 0.0150  
Ciprofloxacin 0.0195mg/mL 8 0 0.108 0.0184 0.00652 0.0154  
Ciprofloxacin 0.0098mg/mL 8 0 0.114 0.0201 0.00711 0.0168  
 
Column Range Max Min  Median  25% 75%  
TSB 0.169 0.253 0.0840 0.121 0.109 0.146  
Control 2.730 2.817 0.0872 0.676 0.439 1.156  
Ciprofloxacin 5mg/mL 0.223 0.315 0.0922 0.151 0.109 0.171  
Ciprofloxacin 2.5mg/mL 0.112 0.213 0.101 0.152 0.114 0.185  
Ciprofloxacin 1.25mg/mL 0.106 0.208 0.102 0.147 0.123 0.191  
Ciprofloxacin 0.625mg/mL 0.131 0.211 0.0799 0.137 0.125 0.190  
Ciprofloxacin 0.3125mg/mL 0.0586 0.167 0.108 0.117 0.110 0.161  
Ciprofloxacin 0.1563mg/mL 0.0823 0.153 0.0706 0.120 0.108 0.136  
Ciprofloxacin 0.0781mg/mL 0.0507 0.148 0.0975 0.123 0.112 0.139  
Ciprofloxacin 0.0391mg/mL 0.0561 0.143 0.0870 0.110 0.0897 0.113  
Ciprofloxacin 0.0195mg/mL 0.0566 0.136 0.0796 0.104 0.0958 0.126  
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Ciprofloxacin 0.0098mg/mL 0.0590 0.150 0.0908 0.117 0.0941 0.124  
 
Column                            Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB                                       1.737 4.523 0.146 0.012 0.860 <0.001  
Control                                  1.143 1.292 0.140 0.002 0.912 <0.001  
Ciprofloxacin 5mg/mL          1.815 4.119 0.303 0.029 0.811 0.037  
Ciprofloxacin 2.5mg/mL       0.142 -1.618 0.184 0.521 0.931 0.521  
Ciprofloxacin 1.25mg/mL     0.182 -1.349 0.174 0.582 0.950 0.716  
Ciprofloxacin 0.625mg/mL   0.310 -0.0752 0.203 0.396 0.921 0.439  
Ciprofloxacin 0.3125mg/mL  0.669 -1.791 0.326 0.012 0.796 0.026  
Ciprofloxacin 0.1563mg/mL -0.911 1.946 0.229 0.240 0.934 0.551  
Ciprofloxacin 0.0781mg/mL 0.0315 -0.719 0.181 0.540 0.966 0.864  
Ciprofloxacin 0.0391mg/mL  0.923 1.596 0.246 0.166 0.881 0.191  
Ciprofloxacin 0.0195mg/mL  0.210 -0.379 0.197 0.433 0.966 0.863  
Ciprofloxacin 0.0098mg/mL   0.509 -0.152 0.201 0.407 0.910 0.357  
 
Column Sum Sum of Squares  
TSB 6.246 0.860  
Control 58.872 73.676  
Ciprofloxacin 5mg/mL 1.279 0.238  
Ciprofloxacin 2.5mg/mL 1.218 0.197  
Ciprofloxacin 1.25mg/mL 1.233 0.200  
Ciprofloxacin 0.625mg/mL 1.172 0.184  
Ciprofloxacin 0.3125mg/mL 1.049 0.142  
Ciprofloxacin 0.1563mg/mL 0.952 0.117  
Ciprofloxacin 0.0781mg/mL 0.988 0.124  
Ciprofloxacin 0.0391mg/mL 0.859 0.0945  
Ciprofloxacin 0.0195mg/mL 0.863 0.0954  
Ciprofloxacin 0.0098mg/mL 0.911 0.107  
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM 
TSB 48 0 0.130 0.0318 0.00459  
Control 70 0 0.841 0.592 0.0707  
Ciprofloxacin 5mg/mL 8 0 0.160 0.0695 0.0246  
Ciprofloxacin 2.5mg/mL 8 0 0.152 0.0408 0.0144  
Ciprofloxacin 1.25mg/mL 8 0 0.154 0.0376 0.0133  
Ciprofloxacin 0.625mg/mL 8 0 0.146 0.0427 0.0151  
Ciprofloxacin 0.3125mg/mL 8 0 0.131 0.0252 0.00890  
Ciprofloxacin 0.1563mg/mL 8 0 0.119 0.0243 0.00860  
Ciprofloxacin 0.0781mg/mL 8 0 0.124 0.0168 0.00595  
Ciprofloxacin 0.0391mg/mL 8 0 0.107 0.0180 0.00636  
Ciprofloxacin 0.0195mg/mL 8 0 0.108 0.0184 0.00652  
Ciprofloxacin 0.0098mg/mL 8 0 0.114 0.0201 0.00711  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 22.843 2.077 15.898 <0.001  
Residual 186 24.296 0.131    
Total 197 47.139     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.711 10.496 <0.001 Yes   
Control vs. Ciprofloxaci 0.734 5.439 <0.001 Yes   
Control vs. Ciprofloxaci 0.733 5.436 <0.001 Yes   
Control vs. Ciprofloxaci 0.727 5.391 <0.001 Yes   
Control vs. Ciprofloxaci 0.722 5.353 <0.001 Yes   
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Control vs. Ciprofloxaci 0.718 5.319 <0.001 Yes   
Control vs. Ciprofloxaci 0.710 5.263 <0.001 Yes   
Control vs. Ciprofloxaci 0.695 5.149 <0.001 Yes   
Control vs. Ciprofloxaci 0.689 5.107 <0.001 Yes   
Control vs. Ciprofloxaci 0.687 5.093 <0.001 Yes   
Control vs. Ciprofloxaci 0.681 5.050 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.711 10.496 <0.001 Yes   
TSB vs. Ciprofloxacin 5mg/mL 0.0298 0.216 1.000 No   
TSB vs. Ciprofloxaci 0.0240 0.174 1.000 No   
TSB vs. Ciprofloxaci 0.0228 0.165 1.000 No   
TSB vs. Ciprofloxaci 0.0223 0.161 1.000 No   
TSB vs. Ciprofloxacin 2.5mg/mL 0.0221 0.160 1.000 No   
TSB vs. Ciprofloxaci 0.0164 0.118 1.000 No   
TSB vs. Ciprofloxaci 0.0163 0.118 1.000 No   
TSB vs. Ciprofloxaci 0.0112 0.0809 1.000 No   
TSB vs. Ciprofloxaci 0.00661 0.0479 0.999 No   
TSB vs. Ciprofloxaci 0.00106 0.00771 0.994 No   
 
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 48 0 0.130 0.0318 0.00459 0.00924  
Control 70 0 0.841 0.592 0.0707 0.141  
Ceftazidime 10mg/mL 8 0 0.128 0.0298 0.0105 0.0249  
Ceftazidime 5mg/mL 8 0 0.127 0.0287 0.0101 0.0240  
Ceftazidime 2.5mg/mL 8 0 0.118 0.0234 0.00826 0.0195  
Ceftazidime 1.25mg/mL 8 0 0.121 0.0288 0.0102 0.0240  
Ceftazidime 0.625mg/mL 8 0 0.113 0.0211 0.00746 0.0176  
Ceftazidime 0.3125mg/mL 8 0 0.113 0.0312 0.0110 0.0261  
Ceftazidime 0.1563mg/mL 8 0 0.117 0.0239 0.00844 0.0200  
Ceftazidime 0.0781mg/mL 8 0 0.122 0.0209 0.00738 0.0175  
Ceftazidime 0.0391mg/mL 8 0 0.115 0.0181 0.00641 0.0152  
Ceftazidime 0.0195mg/mL 8 0 0.118 0.0181 0.00641 0.0152  
 
Column Range Max Min  Median  25% 75%  
TSB 0.169 0.253 0.0840 0.121 0.109 0.146  
Control 2.730 2.817 0.0872 0.676 0.439 1.156  
Ceftazidime 10mg/mL 0.0792 0.174 0.0953 0.125 0.0993 0.156  
Ceftazidime 5mg/mL 0.0940 0.185 0.0913 0.123 0.108 0.140  
Ceftazidime 2.5mg/mL 0.0732 0.163 0.0899 0.113 0.0984 0.132  
Ceftazidime 1.25mg/mL 0.0835 0.174 0.0904 0.117 0.0949 0.141  
Ceftazidime 0.625mg/mL 0.0637 0.146 0.0822 0.107 0.0994 0.133  
Ceftazidime 0.3125mg/mL 0.0907 0.179 0.0887 0.101 0.0917 0.132  
Ceftazidime 0.1563mg/mL 0.0657 0.161 0.0949 0.110 0.0956 0.137  
Ceftazidime 0.0781mg/mL 0.0510 0.149 0.0984 0.120 0.101 0.145  
Ceftazidime 0.0391mg/mL 0.0526 0.147 0.0940 0.111 0.0981 0.129  
Ceftazidime 0.0195mg/mL 0.0512 0.153 0.102 0.112 0.105 0.132  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 1.737 4.523 0.146 0.012 0.860 <0.001
  
Control 1.143 1.292 0.140 0.002 0.912 <0.001
  
Ceftazidime 10mg/mL 0.423 -1.339 0.184 0.517 0.920 0.429
  
Ceftazidime 5mg/mL 1.158 1.956 0.180 0.548 0.919 0.420
  
Ceftazidime 2.5mg/mL 0.991 1.187 0.183 0.529 0.928 0.495
  




Ceftazidime 0.625mg/mL 0.401 -0.538 0.180 0.546 0.954 0.754
  
Ceftazidime 0.3125mg/mL 1.666 2.419 0.282 0.060 0.793 0.024
  
Ceftazidime 0.1563mg/mL 1.010 0.0374 0.208 0.363 0.878 0.179
  
Ceftazidime 0.0781mg/mL 0.210 -1.816 0.171 0.603 0.896 0.266
  
Ceftazidime 0.0391mg/mL 0.663 -0.411 0.180 0.549 0.941 0.617
  
Ceftazidime 0.0195mg/mL 1.394 0.967 0.312 0.021 0.814 0.040
  
 
Column Sum Sum of Squares  
TSB 6.246 0.860  
Control 58.872 73.676  
Ceftazidime 10mg/mL 1.023 0.137  
Ceftazidime 5mg/mL 1.016 0.135  
Ceftazidime 2.5mg/mL 0.940 0.114  
Ceftazidime 1.25mg/mL 0.972 0.124  
Ceftazidime 0.625mg/mL 0.901 0.105  
Ceftazidime 0.3125mg/mL 0.907 0.110  
Ceftazidime 0.1563mg/mL 0.933 0.113  
Ceftazidime 0.0781mg/mL 0.976 0.122  
Ceftazidime 0.0391mg/mL 0.917 0.108  
Ceftazidime 0.0195mg/mL 0.943 0.113  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 48 0 0.130 0.0318 0.00459  
Control 70 0 0.841 0.592 0.0707  
Ceftazidime 10mg/mL 8 0 0.128 0.0298 0.0105  
Ceftazidime 5mg/mL 8 0 0.127 0.0287 0.0101  
Ceftazidime 2.5mg/mL 8 0 0.118 0.0234 0.00826  
Ceftazidime 1.25mg/mL 8 0 0.121 0.0288 0.0102  
Ceftazidime 0.625mg/mL 8 0 0.113 0.0211 0.00746  
Ceftazidime 0.3125mg/mL 8 0 0.113 0.0312 0.0110  
Ceftazidime 0.1563mg/mL 8 0 0.117 0.0239 0.00844  
Ceftazidime 0.0781mg/mL 8 0 0.122 0.0209 0.00738  
Ceftazidime 0.0391mg/mL 8 0 0.115 0.0181 0.00641  
Ceftazidime 0.0195mg/mL 8 0 0.118 0.0181 0.00641  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 23.322 2.120 16.260 <0.001  
Residual 186 24.253 0.130    
Total 197 47.575     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.711 10.505 <0.001 Yes   
Control vs. Ceftazidime  0.728 5.405 <0.001 Yes   
Control vs. Ceftazidime  0.728 5.400 <0.001 Yes   
Control vs. Ceftazidime  0.726 5.390 <0.001 Yes   
Control vs. Ceftazidime  0.724 5.375 <0.001 Yes   
Control vs. Ceftazidime  0.723 5.369 <0.001 Yes   
Control vs. Ceftazidime  0.723 5.366 <0.001 Yes   
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Control vs. Ceftazidime  0.720 5.340 <0.001 Yes   
Control vs. Ceftazidime  0.719 5.336 <0.001 Yes   
Control vs. Ceftazidime 5mg/mL 0.714 5.299 <0.001 Yes   
Control vs. Ceftazidime  0.713 5.292 <0.001 Yes  
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.711 10.505 <0.001 Yes   
TSB vs. Ceftazidime 0.625mg/mL 0.0175 0.127 1.000 No   
TSB vs. Ceftazidime  0.0168 0.122 1.000 No   
TSB vs. Ceftazidime  0.0154 0.112 1.000 No   
TSB vs. Ceftazidime  0.0135 0.0981 1.000 No   
TSB vs. Ceftazidime 2.5mg/mL 0.0126 0.0913 1.000 No   
TSB vs. Ceftazidime  0.0123 0.0890 1.000 No   
TSB vs. Ceftazidime 1.25mg/mL 0.00867 0.0629 1.000 No   
TSB vs. Ceftazidime  0.00814 0.0590 1.000 No   
TSB vs. Ceftazidime 5mg/mL 0.00317 0.0230 1.000 No   
TSB vs. Ceftazidime 10mg/mL 0.00221 0.0160 0.987 No   
 
Antibiotic testing trial 4 on 7/11/14 at 48 hours-Ciprofloxacin (Dilution series) 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0695 0.0871 0.1027 0.0732 0.0881 0.0946 0.0896 0.0714 0.0708 0.0712 0.0610 0.0662
B 0.0629 0.0725 0.0730 0.0902 0.0668 0.0879 0.0683 0.0746 0.0692 0.0642 0.0672 0.0597
C 0.0809 2.6128 0.1298 0.1199 0.1152 0.1075 0.1191 0.1087 0.1047 0.0872 0.0811 0.0642
D 0.0994 0.0762 0.0901 0.0952 0.0781 0.0915 0.0898 0.0819 0.0722 0.0699 0.0815 0.0816
E 0.1140 0.3531 0.1444 0.1588 0.1187 0.1112 0.1800 0.1584 0.1448 0.1303 0.1135 0.1019
F 0.1270 0.1006 0.1429 0.1183 0.1011 0.1105 0.0966 0.1217 0.0963 0.1040 0.1003 0.1204
G 0.1500 0.1941 0.1631 0.1956 0.1922 0.1514 0.1697 0.1802 0.1599 0.1974 0.1897 0.1699
H 0.1416 0.1178 0.1620 0.1818 0.1401 0.1492 0.1447 0.1173 0.1276 0.1212 0.1221 0.1675
Average 0.1057 0.4518 0.1260 0.1291 0.1125 0.1130 0.1197 0.1143 0.1057 0.1057 0.1021 0.1039
Range 0.0871 2.5403 0.0901 0.1224 0.1254 0.0635 0.1117 0.1088 0.0907 0.1332 0.1287 0.1102  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.279 0.626 0.157 0.334  
Ciprofloxacin 5mg/mL 8 0 0.126 0.0337 0.0119 0.0282  
Ciprofloxacin 2.5mg/mL 8 0 0.129 0.0448 0.0159 0.0375  
Ciprofloxacin 1.25mg/mL 8 0 0.113 0.0399 0.0141 0.0334  
Ciprofloxacin 0.625mg/mL 8 0 0.113 0.0247 0.00872 0.0206  
Ciprofloxacin 0.3125mg/mL 8 0 0.120 0.0409 0.0145 0.0342  
Ciprofloxacin 0.1563mg/mL 8 0 0.114 0.0394 0.0139 0.0329  
Ciprofloxacin 0.0781mg/mL 8 0 0.106 0.0353 0.0125 0.0295  
Ciprofloxacin 0.0391mg/mL 8 0 0.106 0.0444 0.0157 0.0371  
Ciprofloxacin 0.0195mg/mL 8 0 0.102 0.0414 0.0146 0.0346  
Ciprofloxacin 0.0098mg/mL 8 0 0.104 0.0449 0.0159 0.0376  
 
Column Range Max Min  Median  25% 75%  
TSB 2.550 2.613 0.0629 0.107 0.0774 0.148  
Ciprofloxacin 5mg/mL 0.0901 0.163 0.0730 0.136 0.0933 0.158  
Ciprofloxacin 2.5mg/mL 0.122 0.196 0.0732 0.119 0.0915 0.176  
Ciprofloxacin 1.25mg/mL 0.125 0.192 0.0668 0.108 0.0806 0.135  
Ciprofloxacin 0.625mg/mL 0.0635 0.151 0.0879 0.109 0.0923 0.140  
Ciprofloxacin 0.3125mg/mL 0.112 0.180 0.0683 0.108 0.0896 0.163  
Ciprofloxacin 0.1563mg/mL 0.109 0.180 0.0714 0.113 0.0764 0.149  
Ciprofloxacin 0.0781mg/mL 0.0907 0.160 0.0692 0.101 0.0711 0.141  
Ciprofloxacin 0.0391mg/mL 0.133 0.197 0.0642 0.0956 0.0702 0.128  
Ciprofloxacin 0.0195mg/mL 0.129 0.190 0.0610 0.0909 0.0707 0.120  
Ciprofloxacin 0.0098mg/mL 0.110 0.170 0.0597 0.0917 0.0647 0.156  
 
Column                              Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB                                         3.917 15.508 0.429 <0.001 0.353 <0.001  
Ciprofloxacin 5mg/mL           -0.492 -1.282 0.192 0.467 0.915 0.391  
Ciprofloxacin 2.5mg/mL         0.404 -1.385 0.207 0.372 0.928 0.497  
Ciprofloxacin 1.25mg/mL       1.120 1.445 0.189 0.489 0.926 0.480  
Ciprofloxacin 0.625mg/mL     0.918 -0.610 0.279 0.067 0.839 0.073  
Ciprofloxacin 0.3125mg/mL   0.435 -1.396 0.214 0.326 0.918 0.415  
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Ciprofloxacin 0.1563mg/mL   0.617 -0.669 0.175 0.577 0.918 0.413  
Ciprofloxacin 0.0781mg/mL   0.435 -1.415 0.204 0.389 0.899 0.281  
Ciprofloxacin 0.0391mg/mL   1.363 1.929 0.175 0.578 0.868 0.143  
Ciprofloxacin 0.0195mg/mL   1.489 2.579 0.190 0.478 0.868 0.144  
Ciprofloxacin 0.0098mg/mL   0.703 -1.200 0.190 0.477 0.856 0.111  
 
Column Sum Sum of Squares  
TSB 4.460 7.129  
Ciprofloxacin 5mg/mL 1.008 0.135  
Ciprofloxacin 2.5mg/mL 1.033 0.147  
Ciprofloxacin 1.25mg/mL 0.900 0.112  
Ciprofloxacin 0.625mg/mL 0.904 0.106  
Ciprofloxacin 0.3125mg/mL 0.958 0.126  
Ciprofloxacin 0.1563mg/mL 0.914 0.115  
Ciprofloxacin 0.0781mg/mL 0.845 0.0981  
Ciprofloxacin 0.0391mg/mL 0.845 0.103  
Ciprofloxacin 0.0195mg/mL 0.816 0.0953  
Ciprofloxacin 0.0098mg/mL 0.831 0.101  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM 
TSB 16 0 0.279 0.626 0.157  
Ciprofloxacin 5mg/mL 8 0 0.126 0.0337 0.0119  
Ciprofloxacin 2.5mg/mL 8 0 0.129 0.0448 0.0159  
Ciprofloxacin 1.25mg/mL 8 0 0.113 0.0399 0.0141  
Ciprofloxacin 0.625mg/mL 8 0 0.113 0.0247 0.00872  
Ciprofloxacin 0.3125mg/mL 8 0 0.120 0.0409 0.0145  
Ciprofloxacin 0.1563mg/mL 8 0 0.114 0.0394 0.0139  
Ciprofloxacin 0.0781mg/mL 8 0 0.106 0.0353 0.0125  
Ciprofloxacin 0.0391mg/mL 8 0 0.106 0.0444 0.0157  
Ciprofloxacin 0.0195mg/mL 8 0 0.102 0.0414 0.0146  
Ciprofloxacin 0.0098mg/mL 8 0 0.104 0.0449 0.0159  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 10 0.372 0.0372 0.527 0.867  
Residual 85 5.994 0.0705    
Total 95 6.366     
 
The differences in the mean values among the treatment groups are not great enough to exclude the possibility that the difference is 
due to random sampling variability; there is not a statistically significant difference  (P = 0.867). 
 
Power of performed test with alpha = 0.050: -- 
 
Antibiotic testing trial 5 on 7/11/14 at 48 hours-Ceftazidime (Dilution series) 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0821 0.0986 0.0953 0.0922 0.0813 0.0790 0.0828 0.0698 0.0672 0.0751 0.0784 0.0758
B 0.0835 0.0902 0.0830 0.0809 0.0763 0.0750 0.0684 0.0690 0.0769 0.0774 0.0802 0.0823
C 0.0805 0.0926 0.0905 0.0949 0.1200 0.0919 0.0782 0.0794 0.0800 0.0814 0.0805 0.0798
D 0.0904 0.0860 0.1092 0.1176 0.0844 0.0848 0.0791 0.0877 0.0855 0.0727 0.0916 0.1024
E 0.0856 0.0949 0.1152 0.1194 0.0916 0.1004 0.0957 0.0969 0.0869 0.0973 0.0911 0.1062
F 0.1072 0.1169 0.1072 0.1328 0.1053 0.0895 0.1027 0.0881 0.1197 0.1091 0.1199 0.1163
G 0.1079 0.2016 0.1389 0.1417 0.1359 0.1208 0.1167 0.1482 0.1107 0.1021 0.1044 0.1109
H OVER 0.1041 0.1232 0.1574 0.1256 0.1052 0.1301 0.1075 0.1026 0.1184 0.1334 0.1493
Average 0.0910 0.1106 0.1078 0.1171 0.1026 0.0933 0.0942 0.0933 0.0912 0.0917 0.0974 0.1029
Range 0.0274 0.1156 0.0559 0.0765 0.0596 0.0458 0.0617 0.0792 0.0525 0.0457 0.0550 0.0735  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 15 0 0.101 0.0297 0.00767 0.0165  
Ceftazidime 10mg/mL 8 0 0.108 0.0183 0.00645 0.0153  
Ceftazidime 5mg/mL 8 0 0.117 0.0265 0.00936 0.0221  
Ceftazidime 2.5mg/mL 8 0 0.103 0.0225 0.00796 0.0188  
Ceftazidime 1.25mg/mL 8 0 0.0933 0.0150 0.00531 0.0125  
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Ceftazidime 0.625mg/mL 8 0 0.0942 0.0212 0.00750 0.0177  
Ceftazidime 0.3125mg/mL 8 0 0.0933 0.0257 0.00909 0.0215  
Ceftazidime 0.1563mg/mL 8 0 0.0912 0.0180 0.00638 0.0151  
Ceftazidime 0.0781mg/mL 8 0 0.0917 0.0173 0.00613 0.0145  
Ceftazidime 0.0391mg/mL 8 0 0.0974 0.0202 0.00716 0.0169  
Ceftazidime 0.0195mg/mL 8 0 0.103 0.0242 0.00856 0.0202  
 
Column Range Max Min  Median  25% 75%  
TSB 0.121 0.202 0.0805 0.0926 0.0856 0.107  
Ceftazidime 10mg/mL 0.0559 0.139 0.0830 0.108 0.0917 0.121  
Ceftazidime 5mg/mL 0.0765 0.157 0.0809 0.118 0.0929 0.139  
Ceftazidime 2.5mg/mL 0.0596 0.136 0.0763 0.0985 0.0821 0.124  
Ceftazidime 1.25mg/mL 0.0458 0.121 0.0750 0.0907 0.0804 0.104  
Ceftazidime 0.625mg/mL 0.0617 0.130 0.0684 0.0892 0.0784 0.113  
Ceftazidime 0.3125mg/mL 0.0792 0.148 0.0690 0.0879 0.0722 0.105  
Ceftazidime 0.1563mg/mL 0.0525 0.120 0.0672 0.0862 0.0777 0.109  
Ceftazidime 0.0781mg/mL 0.0457 0.118 0.0727 0.0893 0.0757 0.107  
Ceftazidime 0.0391mg/mL 0.0550 0.133 0.0784 0.0914 0.0803 0.116  
Ceftazidime 0.0195mg/mL 0.0735 0.149 0.0758 0.104 0.0804 0.115  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 3.063 10.508 0.281 0.002 0.618 <0.001
  
Ceftazidime 10mg/mL 0.366 -0.308 0.128 0.791 0.978 0.954
  
Ceftazidime 5mg/mL 0.105 -1.123 0.174 0.583 0.962 0.827
  
Ceftazidime 2.5mg/mL 0.329 -1.674 0.187 0.502 0.919 0.422
  
Ceftazidime 1.25mg/mL 0.733 0.189 0.163 0.653 0.958 0.794
  
Ceftazidime 0.625mg/mL 0.638 -0.668 0.205 0.383 0.939 0.599
  
Ceftazidime 0.3125mg/mL 1.545 2.807 0.206 0.378 0.857 0.111
  
Ceftazidime 0.1563mg/mL 0.445 -0.979 0.219 0.297 0.948 0.695
  
Ceftazidime 0.0781mg/mL 0.374 -1.584 0.224 0.270 0.905 0.323
  
Ceftazidime 0.0391mg/mL 0.939 -0.333 0.238 0.196 0.874 0.164
  
Ceftazidime 0.0195mg/mL 0.836 0.779 0.177 0.563 0.915 0.388
  
 
Column Sum Sum of Squares  
TSB 1.522 0.167  
Ceftazidime 10mg/mL 0.863 0.0953  
Ceftazidime 5mg/mL 0.937 0.115  
Ceftazidime 2.5mg/mL 0.820 0.0877  
Ceftazidime 1.25mg/mL 0.747 0.0713  
Ceftazidime 0.625mg/mL 0.754 0.0742  
Ceftazidime 0.3125mg/mL 0.747 0.0743  
Ceftazidime 0.1563mg/mL 0.730 0.0688  
Ceftazidime 0.0781mg/mL 0.734 0.0694  
Ceftazidime 0.0391mg/mL 0.779 0.0788  
Ceftazidime 0.0195mg/mL 0.823 0.0888  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 15 0 0.101 0.0297 0.00767  
Ceftazidime 10mg/mL 8 0 0.108 0.0183 0.00645  
Ceftazidime 5mg/mL 8 0 0.117 0.0265 0.00936  
Ceftazidime 2.5mg/mL 8 0 0.103 0.0225 0.00796  
Ceftazidime 1.25mg/mL 8 0 0.0933 0.0150 0.00531  
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Ceftazidime 0.625mg/mL 8 0 0.0942 0.0212 0.00750  
Ceftazidime 0.3125mg/mL 8 0 0.0933 0.0257 0.00909  
Ceftazidime 0.1563mg/mL 8 0 0.0912 0.0180 0.00638  
Ceftazidime 0.0781mg/mL 8 0 0.0917 0.0173 0.00613  
Ceftazidime 0.0391mg/mL 8 0 0.0974 0.0202 0.00716  
Ceftazidime 0.0195mg/mL 8 0 0.103 0.0242 0.00856  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 10 0.00517 0.000517 0.990 0.458  
Residual 84 0.0438 0.000522    
Total 94 0.0490     
 
The differences in the mean values among the treatment groups are not great enough to exclude the possibility that the difference is 
due to random sampling variability; there is not a statistically significant difference  (P = 0.458). 
 
Power of performed test with alpha = 0.050: -- 
 
Antibiotic testing trial 6 on 7/25/14 at 48 hours- Control 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0988 0.1090 0.7887 1.0906 0.5827 0.7144 0.7528 0.6937 0.5808 0.6519 0.5386 0.8051
B 0.0999 0.1075 0.4570 0.5741 0.3573 0.4845 0.3641 0.3724 0.3983 0.3737 0.3623 0.9386
C 0.1151 0.1252 0.4379 0.6193 0.4366 0.4215 0.4602 0.3759 0.4794 0.4454 0.4797 1.1935
D 0.1213 0.1216 0.4552 0.6672 0.3976 0.3804 0.3480 0.3770 0.3506 0.7066 0.4589 1.2333
E 0.1175 0.1608 0.4626 0.9729 0.9987 0.4601 0.4913 0.4510 0.5050 0.4626 0.4224 1.6727
F 0.1409 0.1823 0.5359 0.9605 0.8177 0.6466 0.4221 0.4206 0.6156 0.4849 0.4959 1.7892
G 0.1563 0.2080 0.5751 0.7413 0.5674 0.4826 0.6579 0.5351 0.7911 0.5080 0.8362 1.8488
H 0.1457 0.1308 1.3826 1.8731 0.9951 1.4522 1.5853 1.4221 1.9545 1.3954 2.8554 2.4296
Average 0.1244 0.1432 0.6369 0.9374 0.6441 0.6303 0.6352 0.5810 0.7094 0.6286 0.8062 1.4889
Range 0.0575 0.1005 0.9447 1.2990 0.6414 1.0718 1.2373 1.0497 1.6039 1.0217 2.4931 1.6245  
Antibiotic testing trial 7 on 7/25/14 at 48 hours- Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0720 0.0778 0.6228 0.7006 1.5363 0.7827 0.7230 1.2858 0.9963 0.7708 0.8462 1.3672
B 0.0826 0.6220 0.4943 0.5373 0.7170 0.5596 0.7581 0.7713 0.8807 1.1304 0.8428 0.6497
C 1.6836 0.5439 0.3431 0.5444 0.9678 1.0240 0.5896 1.2512 0.9870 1.0721 1.2086 0.8380
D 2.0100 0.5135 0.6149 0.7303 1.0810 1.3624 0.8204 1.1408 1.0901 1.3356 1.2609 0.8514
E 1.1845 0.6098 0.6452 0.4079 1.4602 1.0457 0.6984 1.2197 0.9980 1.2007 1.0300 1.8774
F 0.1081 0.6466 0.5806 0.5470 0.7788 1.5012 0.9421 1.1984 1.0880 1.4936 1.3395 1.7891
G 1.3169 0.2995 0.5464 0.9236 1.2052 0.7558 0.7550 2.1181 1.6312 1.4213 1.8588 2.3581
H 1.6438 1.3519 0.7543 0.9478 1.5388 0.8556 0.7136 2.6253 1.6584 2.1795 1.9024 OVER
Average 1.0127 0.5831 0.5752 0.6674 1.1606 0.9859 0.7500 1.4513 1.1662 1.3255 1.2862 1.3901
Range 1.9380 1.2741 0.4112 0.5399 0.8218 0.9416 0.3525 1.8540 0.7777 1.4087 1.0596 1.7084  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 64 0 0.311 0.447 0.0558 0.112  
Control 80 0 0.770 0.509 0.0569 0.113  
Ciprofloxacin 5mg/mL 8 0 0.575 0.121 0.0427 0.101  
Ciprofloxacin 2.5mg/mL 8 0 0.667 0.194 0.0686 0.162  
Ciprofloxacin 1.25mg/mL 8 0 1.161 0.330 0.117 0.276  
Ciprofloxacin 0.625mg/mL 8 0 0.986 0.317 0.112 0.265  
Ciprofloxacin 0.3125mg/mL 8 0 0.750 0.102 0.0360 0.0850  
Ciprofloxacin 0.1563mg/mL 8 0 1.451 0.606 0.214 0.506  
Ciprofloxacin 0.0781mg/mL 8 0 1.166 0.303 0.107 0.253  
Ciprofloxacin0.0391mg/mL 8 0 1.325 0.413 0.146 0.345  
Ciprofloxacin 0.0195mg/mL 8 0 1.286 0.409 0.145 0.342  
Ciprofloxacin 0.0098mg/mL 7 0 1.390 0.643 0.243 0.594  
 
Column Range Max Min  Median  25% 75%  
TSB 1.939 2.010 0.0713 0.110 0.0841 0.277  
Control 2.507 2.855 0.348 0.571 0.452 0.913  
Ciprofloxacin 5mg/mL 0.411 0.754 0.343 0.598 0.507 0.640  
Ciprofloxacin 2.5mg/mL 0.540 0.948 0.408 0.624 0.539 0.875  
Ciprofloxacin 1.25mg/mL 0.822 1.539 0.717 1.143 0.826 1.517  
Ciprofloxacin 0.625mg/mL 0.942 1.501 0.560 0.940 0.763 1.283  
Ciprofloxacin 0.3125mg/mL 0.353 0.942 0.590 0.739 0.702 0.805  
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Ciprofloxacin 0.1563mg/mL 1.854 2.625 0.771 1.235 1.155 1.910  
Ciprofloxacin 0.0781mg/mL 0.778 1.658 0.881 1.043 0.989 1.496  
Ciprofloxacin0.0391mg/mL 1.409 2.180 0.771 1.268 1.087 1.476  
Ciprofloxacin 0.0195mg/mL 1.060 1.902 0.843 1.235 0.892 1.729  
Ciprofloxacin 0.0098mg/mL 1.708 2.358 0.650 1.367 0.838 1.877  
 
Column                                Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB                                         2.362 4.891 0.351 <0.001 0.583 <0.001  
Control                                    1.972 3.988 0.206 <0.001 0.752 <0.001  
Ciprofloxacin 5mg/mL           -0.735 1.557 0.156 0.690 0.953 0.737  
Ciprofloxacin 2.5mg/mL         0.415 -1.076 0.233 0.224 0.913 0.372  
Ciprofloxacin 1.25mg/mL      -0.0880 -1.722 0.193 0.459 0.904 0.315  
Ciprofloxacin 0.625mg/mL      0.538 -0.561 0.175 0.577 0.947 0.679  
Ciprofloxacin 0.3125mg/mL       0.562 1.695 0.218 0.300 0.944 0.655  
Ciprofloxacin 0.1563mg/mL       1.312 1.041 0.358 0.003 0.817 0.043  
Ciprofloxacin 0.0781mg/mL       1.238 -0.208 0.349 0.005 0.755 0.009  
Ciprofloxacin0.0391mg/mL        1.171 2.583 0.217 0.308 0.914 0.387  
Ciprofloxacin 0.0195mg/mL       0.645 -0.843 0.198 0.426 0.885 0.208  
Ciprofloxacin 0.0098mg/mL       0.313 -1.466 0.228 0.314 0.923 0.490  
 
Column Sum Sum of Squares  
TSB 19.921 18.775  
Control 61.583 67.850  
Ciprofloxacin 5mg/mL 4.602 2.749  
Ciprofloxacin 2.5mg/mL 5.339 3.826  
Ciprofloxacin 1.25mg/mL 9.285 11.539  
Ciprofloxacin 0.625mg/mL 7.887 8.481  
Ciprofloxacin 0.3125mg/mL 6.000 4.573  
Ciprofloxacin 0.1563mg/mL 11.611 19.417  
Ciprofloxacin 0.0781mg/mL 9.330 11.522  
Ciprofloxacin0.0391mg/mL 10.604 15.248  
Ciprofloxacin 0.0195mg/mL 10.289 14.406  
Ciprofloxacin 0.0098mg/mL 9.731 16.005  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 64 0 0.311 0.447 0.0558  
Control 80 0 0.770 0.509 0.0569  
Ciprofloxacin 5mg/mL 8 0 0.575 0.121 0.0427  
Ciprofloxacin 2.5mg/mL 8 0 0.667 0.194 0.0686  
Ciprofloxacin 1.25mg/mL 8 0 1.161 0.330 0.117  
Ciprofloxacin 0.625mg/mL 8 0 0.986 0.317 0.112  
Ciprofloxacin 0.3125mg/mL 8 0 0.750 0.102 0.0360  
Ciprofloxacin 0.1563mg/mL 8 0 1.451 0.606 0.214  
Ciprofloxacin 0.0781mg/mL 8 0 1.166 0.303 0.107  
Ciprofloxacin0.0391mg/mL 8 0 1.325 0.413 0.146  
Ciprofloxacin 0.0195mg/mL 8 0 1.286 0.409 0.145  
Ciprofloxacin 0.0098mg/mL 7 0 1.390 0.643 0.243  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 27.576 2.507 12.309 <0.001  
Residual 211 42.974 0.204    
Total 222 70.550     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 










Antibiotic testing trial 8 on 7/25/14 at 48 hours- Ceftazidime 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0987 0.0898 1.7913 1.0160 1.4733 0.9038 1.5660 1.0711 1.9882 1.0693 1.6047 1.7279
B 0.0865 0.3546 0.6113 0.8018 0.5766 0.4820 0.7928 0.5275 0.7742 0.4956 1.1756 1.0241
C 0.0714 0.0908 0.8244 0.5234 0.8521 0.6389 0.6814 0.9982 1.2658 1.4034 1.5363 2.0213
D 0.0884 0.4546 1.1913 0.8524 0.5500 0.5375 0.7628 1.0493 1.5639 1.6738 2.3417 2.3147
E 0.0840 0.0966 1.3853 0.8891 0.9367 0.6387 0.6741 1.6969 1.5470 2.6578 2.5122 1.9211
F 0.1108 0.0816 1.7291 0.8411 0.9883 0.6050 0.8419 2.4624 1.7140 0.9785 2.1810 2.3869
G 0.0844 0.1585 2.0357 1.4621 1.2755 0.8200 1.4767 2.6926 2.0181 1.9607 OVER 1.9879
H 0.1455 0.1025 OVER 2.6237 1.4223 1.7522 1.7258 2.4230 OVER OVER OVER 2.0203
Average 0.0962 0.1786 1.3669 1.1262 1.0094 0.7973 1.0652 1.6151 1.5530 1.4627 1.8919 1.9255
Range 0.0741 0.3730 1.4244 2.1003 0.9233 1.2702 1.0517 2.1651 1.2439 2.1622 1.3366 1.3628  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 64 0 0.311 0.447 0.0558 0.112  
Control 80 0 0.770 0.509 0.0569 0.113  
Ceftazidime 10mg/mL 7 0 1.367 0.525 0.199 0.486  
Ceftazidime 5mg/mL 8 0 1.126 0.660 0.233 0.552  
Ceftazidime 2.5mg/mL 8 0 1.009 0.356 0.126 0.297  
Ceftazidime 1.25mg/mL 8 0 0.797 0.410 0.145 0.343  
Ceftazidime 0.625mg/mL 8 0 1.065 0.443 0.157 0.370  
Ceftazidime 0.3125mg/mL 8 0 1.615 0.821 0.290 0.686  
Ceftazidime 0.1563mg/mL 7 0 1.553 0.432 0.163 0.400  
Ceftazidime 0.0781mg/mL 7 0 1.463 0.713 0.269 0.659  
Ceftazidime 0.0391mg/mL 6 0 1.892 0.528 0.215 0.554  
Ceftazidime 0.0195mg/mL 8 0 1.926 0.421 0.149 0.352  
 
Column Range Max Min  Median  25% 75%  
TSB 1.939 2.010 0.0713 0.110 0.0841 0.277  
Control 2.507 2.855 0.348 0.571 0.452 0.913  
Ceftazidime 10mg/mL 1.424 2.036 0.611 1.385 0.824 1.791  
Ceftazidime 5mg/mL 2.100 2.624 0.523 0.871 0.812 1.351  
Ceftazidime 2.5mg/mL 0.923 1.473 0.550 0.962 0.645 1.386  
Ceftazidime 1.25mg/mL 1.270 1.752 0.482 0.639 0.554 0.883  
Ceftazidime 0.625mg/mL 1.052 1.726 0.674 0.817 0.702 1.544  
Ceftazidime 0.3125mg/mL 2.165 2.693 0.527 1.384 1.011 2.453  
Ceftazidime 0.1563mg/mL 1.244 2.018 0.774 1.564 1.266 1.988  
Ceftazidime 0.0781mg/mL 2.162 2.658 0.496 1.403 0.979 1.961  
Ceftazidime 0.0391mg/mL 1.337 2.512 1.176 1.893 1.446 2.384  
Ceftazidime 0.0195mg/mL 1.363 2.387 1.024 2.004 1.776 2.241  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 2.362 4.891 0.351 <0.001 0.583 <0.001
  
Control 1.972 3.988 0.206 <0.001 0.752 <0.001
  
Ceftazidime 10mg/mL -0.279 -1.332 0.183 0.580 0.954 0.765
  
Ceftazidime 5mg/mL 2.044 4.500 0.316 0.018 0.750 0.008
  
Ceftazidime 2.5mg/mL 0.0292 -1.456 0.149 0.726 0.921 0.442
  
Ceftazidime 1.25mg/mL 2.230 5.379 0.275 0.075 0.722 0.004
  
Ceftazidime 0.625mg/mL 0.676 -1.836 0.318 0.017 0.794 0.025
  
Ceftazidime 0.3125mg/mL 0.180 -1.863 0.246 0.163 0.890 0.234
  
Ceftazidime 0.1563mg/mL -0.893 0.726 0.209 0.425 0.924 0.500
  
Ceftazidime 0.0781mg/mL 0.490 0.125 0.138 0.774 0.982 0.968
  




Ceftazidime 0.0195mg/mL -1.488 3.104 0.246 0.165 0.856 0.110
  
 
Column Sum Sum of Squares  
TSB 19.921 18.775  
Control 61.583 67.850  
Ceftazidime 10mg/mL 9.568 14.734  
Ceftazidime 5mg/mL 9.010 13.195  
Ceftazidime 2.5mg/mL 8.075 9.036  
Ceftazidime 1.25mg/mL 6.378 6.263  
Ceftazidime 0.625mg/mL 8.521 10.449  
Ceftazidime 0.3125mg/mL 12.921 25.587  
Ceftazidime 0.1563mg/mL 10.871 18.004  
Ceftazidime 0.0781mg/mL 10.239 18.026  
Ceftazidime 0.0391mg/mL 11.352 22.869  
Ceftazidime 0.0195mg/mL 15.404 30.899  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 64 0 0.311 0.447 0.0558  
Control 80 0 0.770 0.509 0.0569  
Ceftazidime 10mg/mL 7 0 1.367 0.525 0.199  
Ceftazidime 5mg/mL 8 0 1.126 0.660 0.233  
Ceftazidime 2.5mg/mL 8 0 1.009 0.356 0.126  
Ceftazidime 1.25mg/mL 8 0 0.797 0.410 0.145  
Ceftazidime 0.625mg/mL 8 0 1.065 0.443 0.157  
Ceftazidime 0.3125mg/mL 8 0 1.615 0.821 0.290  
Ceftazidime 0.1563mg/mL 7 0 1.553 0.432 0.163  
Ceftazidime 0.0781mg/mL 7 0 1.463 0.713 0.269  
Ceftazidime 0.0391mg/mL 6 0 1.892 0.528 0.215  
Ceftazidime 0.0195mg/mL 8 0 1.926 0.421 0.149  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 48.680 4.425 17.391 <0.001  
Residual 207 52.675 0.254    
Total 218 101.356     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. Ceftazidime  1.156 6.179 <0.001 Yes   
Control vs. TSB 0.459 5.420 <0.001 Yes   
Control vs. Ceftazidime  1.122 5.255 <0.001 Yes   
Control vs. Ceftazidime  0.845 4.519 <0.001 Yes   
Control vs. Ceftazidime  0.783 3.939 <0.001 Yes   
Control vs. Ceftazidime  0.693 3.485 0.004 Yes   
Control vs. Ceftazidime  0.597 3.003 0.015 Yes   
Control vs. Ceftazidime 5mg/mL 0.356 1.905 0.213 No   
Control vs. Ceftazidime  0.295 1.579 0.309 No   
Control vs. Ceftazidime  0.240 1.281 0.363 No   
Control vs. Ceftazidime  0.0275 0.147 0.883 No   
 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Ceftazidime  1.614 8.533 <0.001 Yes   
TSB vs. Ceftazidime  1.581 7.339 <0.001 Yes   
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TSB vs. Ceftazidime  1.304 6.893 <0.001 Yes   
TSB vs. Ceftazidime  1.242 6.183 <0.001 Yes   
TSB vs. Ceftazidime  1.151 5.734 <0.001 Yes   
TSB vs. Control 0.459 5.420 <0.001 Yes   
TSB vs. Ceftazidime 10mg/mL 1.056 5.257 <0.001 Yes   
TSB vs. Ceftazidime 5mg/mL 0.815 4.308 <0.001 Yes   
TSB vs. Ceftazidime 0.625mg/mL 0.754 3.985 <0.001 Yes   
TSB vs. Ceftazidime 2.5mg/mL 0.698 3.690 <0.001 Yes   
TSB vs. Ceftazidime 1.25mg/mL                                     0.486                     2.569             0.011                 Yes   
 
Antibiotic testing trial 9 on 7/25/14 at 48 hours- Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0759 0.0765 0.5968 0.6297 0.5078 0.3260 0.3758 0.2782 0.3549 0.3185 0.2809 0.5696
B 0.0713 0.0725 0.5124 0.7339 0.4446 0.2844 0.3372 0.3206 0.1863 0.2345 0.2870 0.4743
C 0.5133 0.0779 0.6137 0.8532 0.3955 0.2981 0.3453 0.3261 0.2326 0.3647 0.4009 0.6577
D 0.0828 0.0834 0.6198 0.5761 0.4644 0.3762 0.3006 0.3604 0.2018 0.2630 0.4489 0.7667
E 0.0769 0.0747 0.9822 0.9741 0.5557 0.3367 0.6575 0.7474 0.4048 0.3045 0.4754 1.1905
F 0.1041 0.0889 0.5458 1.1490 0.9444 0.4186 0.3823 0.8859 0.1709 0.5505 0.3796 1.0252
G 0.0811 1.1093 0.8160 0.9350 0.4998 0.6545 0.8478 0.9627 0.5211 0.4514 0.6540 1.3990
H 0.1000 0.1270 0.8607 1.3634 1.2191 1.0762 0.9676 0.9346 0.7885 0.8530 0.9109 1.9013
Average 0.1382 0.2138 0.6934 0.9018 0.6289 0.4713 0.5268 0.6020 0.3576 0.4175 0.4797 0.9980
Range 0.4420 1.0368 0.4698 0.7873 0.8236 0.7918 0.6670 0.6845 0.6176 0.6185 0.6300 1.4270  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 64 0 0.311 0.447 0.0558 0.112  
Control 80 0 0.770 0.509 0.0569 0.113  
Gentamicin 10mg/mL 8 0 0.693 0.170 0.0601 0.142  
Gentamicin 5mg/mL 8 0 0.902 0.265 0.0937 0.221  
Gentamicin 2.5mg/mL 8 0 0.629 0.293 0.104 0.245  
Gentamicin 1.25mg/mL 8 0 0.471 0.271 0.0959 0.227  
Gentamicin 0.625mg/mL 8 0 0.527 0.261 0.0924 0.219  
Gentamicin 0.3125mg/mL 8 0 0.602 0.307 0.109 0.257  
Gentamicin 0.1563mg/mL 8 0 0.358 0.213 0.0754 0.178  
Gentamicin 0.0781mg/mL 8 0 0.418 0.204 0.0721 0.171  
Gentamicin 0.0391mg/mL 8 0 0.480 0.210 0.0744 0.176  
Gentamicin 0.0195mg/mL 8 0 0.998 0.484 0.171 0.405  
 
Column Range Max Min  Median  25% 75%  
TSB 1.939 2.010 0.0713 0.110 0.0841 0.277  
Control 2.507 2.855 0.348 0.571 0.452 0.913  
Gentamicin 10mg/mL 0.470 0.982 0.512 0.617 0.559 0.850  
Gentamicin 5mg/mL 0.787 1.363 0.576 0.894 0.656 1.105  
Gentamicin 2.5mg/mL 0.824 1.219 0.396 0.504 0.450 0.847  
Gentamicin 1.25mg/mL 0.792 1.076 0.284 0.356 0.305 0.596  
Gentamicin 0.625mg/mL 0.667 0.968 0.301 0.379 0.339 0.800  
Gentamicin 0.3125mg/mL 0.685 0.963 0.278 0.554 0.322 0.922  
Gentamicin 0.1563mg/mL 0.618 0.788 0.171 0.294 0.190 0.492  
Gentamicin 0.0781mg/mL 0.619 0.853 0.234 0.342 0.273 0.526  
Gentamicin 0.0391mg/mL 0.630 0.911 0.281 0.425 0.310 0.609  
Gentamicin 0.0195mg/mL 1.427 1.901 0.474 0.896 0.592 1.347  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 2.362 4.891 0.351 <0.001 0.583 <0.001
  
Control 1.972 3.988 0.206 <0.001 0.752 <0.001
  
Gentamicin 10mg/mL 0.763 -0.922 0.293 0.042 0.884 0.204
  
Gentamicin 5mg/mL 0.557 -0.256 0.142 0.752 0.962 0.826
  
Gentamicin 2.5mg/mL 1.588 1.474 0.349 0.005 0.754 0.009
  




Gentamicin 0.625mg/mL 0.962 -0.886 0.335 0.009 0.804 0.032
  
Gentamicin 0.3125mg/mL 0.121 -2.494 0.284 0.056 0.802 0.030
  
Gentamicin 0.1563mg/mL 1.317 1.400 0.221 0.285 0.855 0.107
  
Gentamicin 0.0781mg/mL 1.630 2.675 0.227 0.252 0.836 0.069
  
Gentamicin 0.0391mg/mL 1.408 1.836 0.258 0.120 0.861 0.123
  
Gentamicin 0.0195mg/mL 0.896 0.200 0.184 0.523 0.927 0.490
  
 
Column Sum Sum of Squares  
TSB 19.921 18.775  
Control 61.583 67.850  
Gentamicin 10mg/mL 5.547 4.049  
Gentamicin 5mg/mL 7.214 6.997  
Gentamicin 2.5mg/mL 5.031 3.764  
Gentamicin 1.25mg/mL 3.771 2.293  
Gentamicin 0.625mg/mL 4.214 2.698  
Gentamicin 0.3125mg/mL 4.816 3.560  
Gentamicin 0.1563mg/mL 2.861 1.342  
Gentamicin 0.0781mg/mL 3.340 1.686  
Gentamicin 0.0391mg/mL 3.838 2.151  
Gentamicin 0.0195mg/mL 7.984 9.610  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 64 0 0.311 0.447 0.0558  
Control 80 0 0.770 0.509 0.0569  
Gentamicin 10mg/mL 8 0 0.693 0.170 0.0601  
Gentamicin 5mg/mL 8 0 0.902 0.265 0.0937  
Gentamicin 2.5mg/mL 8 0 0.629 0.293 0.104  
Gentamicin 1.25mg/mL 8 0 0.471 0.271 0.0959  
Gentamicin 0.625mg/mL 8 0 0.527 0.261 0.0924  
Gentamicin 0.3125mg/mL 8 0 0.602 0.307 0.109  
Gentamicin 0.1563mg/mL 8 0 0.358 0.213 0.0754  
Gentamicin 0.0781mg/mL 8 0 0.418 0.204 0.0721  
Gentamicin 0.0391mg/mL 8 0 0.480 0.210 0.0744  
Gentamicin 0.0195mg/mL 8 0 0.998 0.484 0.171  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 10.660 0.969 5.332 <0.001  
Residual 212 38.528 0.182    
Total 223 49.188     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 0.999 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.459 6.413 <0.001 Yes   
Control vs. Gentamicin 0 0.412 2.607 0.094 No   
Control vs. Gentamicin 0 0.352 2.228 0.218 No   
Control vs. Gentamicin 1 0.298 1.888 0.392 No   
Control vs. Gentamicin 0 0.290 1.835 0.389 No   
Control vs. Gentamicin 0 0.243 1.537 0.553 No   
Control vs. Gentamicin 0 0.228 1.444 0.557 No   
Control vs. Gentamicin 0 0.168 1.061 0.745 No   
Control vs. Gentamicin 2 0.141 0.891 0.755 No   
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Control vs. Gentamicin 5mg/mL 0.132 0.835 0.645 No   
Control vs. Gentamicin 10mg/mL                0.0764              0.483         0.630            No 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.459 6.413 <0.001 Yes   
TSB vs. Gentamicin 0.0195mg/mL 0.687 4.296 <0.001 Yes   
TSB vs. Gentamicin 5mg/mL 0.591 3.694 0.003 Yes   
TSB vs. Gentamicin 10mg/mL 0.382 2.390 0.133 No   
TSB vs. Gentamicin 2.5mg/mL 0.318 1.987 0.292 No   
TSB vs. Gentamicin 0.3125mg/mL 0.291 1.819 0.355 No   
TSB vs. Gentamicin 0.625mg/mL 0.215 1.348 0.627 No   
TSB vs. Gentamicin 0.0391mg/mL 0.168 1.054 0.751 No   
TSB vs. Gentamicin 1.25mg/mL 0.160 1.001 0.683 No   
TSB vs. Gentamicin 0.0781mg/mL 0.106 0.665 0.757 No   
TSB vs. Gentamicin 0.1563mg/mL                                 0.0463                    0.290             0.772                   No  
  
Antibiotic testing trial 10 on 8/1/14 at 48 hours- Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1034 0.0450 OVER 0.0631 0.5238 0.0851 0.9985 0.1004 0.7405 0.5971 0.7709 0.0599
B 0.1017 0.0641 0.6818 0.0914 0.7558 0.0585 0.5292 0.0409 0.6144 0.0363 1.0432 0.0369
C 0.0956 0.0477 2.3573 0.0433 1.0607 0.0460 0.9102 0.2695 1.0296 0.0361 1.8102 0.0368
D 0.3287 0.0461 OVER 0.0437 0.5111 0.0504 1.2767 0.0384 0.7863 0.0536 1.7118 0.0378
E 0.6651 0.0447 OVER 0.0463 0.6479 0.0544 1.3752 0.0353 1.0870 0.0452 1.5705 0.0465
F 0.4106 0.0481 0.7449 0.0495 0.8356 0.0478 1.7180 0.0492 1.0629 0.0401 2.0857 0.1229
G 0.1725 0.0523 0.4827 0.0477 0.7505 0.1612 1.3097 0.0538 0.8041 0.0424 1.6104 0.0449
H 1.0768 0.2223 2.3703 0.0479 0.8051 0.0682 1.2594 0.0473 1.6627 0.0493 1.8843 0.0489
Average 0.3693 0.0713 1.3274 0.0541 0.7363 0.0715 1.1721 0.0794 0.9734 0.1125 1.5609 0.0543
Range 0.9812 0.1776 1.8876 0.0481 0.5496 0.1152 1.1888 0.2342 1.0483 0.5610 1.3148 0.0861  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.194 0.200 0.0353 0.0721  
Control 27 0 1.279 0.624 0.120 0.247  
Ciprofloxacin 5mg/mL 8 0 0.736 0.179 0.0633 0.150  
Ciprofloxacin 2.5mg/mL 8 0 1.172 0.356 0.126 0.298  
Ciprofloxacin 1.25mg/mL 8 0 0.973 0.326 0.115 0.273  
Ciprofloxacin 0.625mg/mL 8 0 1.561 0.441 0.156 0.368  
 
Column Range Max Min  Median  25% 75%  
TSB 0.996 1.077 0.0807 0.133 0.104 0.171  
Control 2.047 2.507 0.460 1.206 0.745 1.487  
Ciprofloxacin 5mg/mL 0.550 1.061 0.511 0.753 0.555 0.828  
Ciprofloxacin 2.5mg/mL 1.189 1.718 0.529 1.268 0.932 1.359  
Ciprofloxacin 1.25mg/mL 1.048 1.663 0.614 0.917 0.752 1.081  
Ciprofloxacin 0.625mg/mL 1.315 2.086 0.771 1.661 1.175 1.866  
 
Column                         Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB                                     3.431 12.913 0.373 <0.001 0.525 <0.001  
Control                                0.796 -0.443 0.147 0.134 0.893 0.009  
Ciprofloxacin 5mg/mL        0.457 0.408 0.164 0.644 0.940 0.612  
Ciprofloxacin 2.5mg/mL    -0.478 0.789 0.222 0.281 0.956 0.772  
Ciprofloxacin 1.25mg/mL   1.421 2.573 0.239 0.194 0.869 0.147  
Ciprofloxacin 0.625mg/mL -0.966 0.121 0.259 0.119 0.905 0.321  
 
Column Sum Sum of Squares  
TSB 6.199 2.440  
Control 34.538 54.309  
Ciprofloxacin 5mg/mL 5.891 4.561  
Ciprofloxacin 2.5mg/mL 9.377 11.880  
Ciprofloxacin 1.25mg/mL 7.787 8.327  
Ciprofloxacin 0.625mg/mL 12.487 20.850  
 
One Way Analysis of Variance  
 




Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.194 0.200 0.0353  
Control 27 0 1.279 0.624 0.120  
Ciprofloxacin 5mg/mL 8 0 0.736 0.179 0.0633  
Ciprofloxacin 2.5mg/mL 8 0 1.172 0.356 0.126  
Ciprofloxacin 1.25mg/mL 8 0 0.973 0.326 0.115  
Ciprofloxacin 0.625mg/mL 8 0 1.561 0.441 0.156  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 23.841 4.768 27.790 <0.001  
Residual 85 14.584 0.172    
Total 90 38.425     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 1.085 10.028 <0.001 Yes   
Control vs. Ciprofloxaci 0.543 3.256 0.006 Yes   
Control vs. Ciprofloxaci 0.306 1.834 0.196 No   
Control vs. Ciprofloxaci 0.282 1.689 0.181 No   
Control vs. Ciprofloxaci 0.107 0.642 0.522 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 1.085 10.028 <0.001 Yes   
TSB vs. Ciprofloxaci 1.367 8.350 <0.001 Yes   
TSB vs. Ciprofloxacin 2.5mg/mL 0.978 5.975 <0.001 Yes   
TSB vs. Ciprofloxaci 0.780 4.762 <0.001 Yes   
TSB vs. Ciprofloxacin 5mg/mL 0.543 3.314 0.001 Yes   
 
Antibiotic testing trial 11 on 8/1/14 at 48 hours- Ceftazidime 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0897 0.0365 1.4616 0.0354 OVER 0.0376 2.4066 0.0493 2.0302 0.0370 2.1114 0.0373
B 0.3433 0.0348 1.0168 0.0366 OVER 0.0354 1.1315 0.1174 1.6173 0.0386 2.6386 0.0398
C 0.1350 0.0346 0.8401 0.0360 2.3995 0.0359 1.0791 0.0451 1.2676 0.0376 2.1363 0.0428
D 0.1125 0.0351 1.3213 0.0369 2.4942 0.0362 1.5769 0.0512 1.7745 0.0386 2.6924 0.0385
E 0.1178 0.0349 1.7423 0.0592 1.4938 0.0358 1.8846 0.0525 1.9314 0.0423 OVER 0.0398
F 0.1351 0.0365 0.9720 0.0373 2.7684 0.0397 1.8145 0.0584 2.4607 0.0423 OVER 0.0469
G 0.1661 0.0370 0.7445 0.0440 OVER 0.0363 2.0393 0.0463 2.3945 0.0404 OVER 0.0454
H 0.1147 0.0520 2.2096 0.0408 OVER 0.0377 OVER 0.0517 OVER 0.0386 OVER 0.0532
Average 0.1518 0.0377 1.2885 0.0408 2.2890 0.0368 1.7046 0.0590 1.9252 0.0394 2.3947 0.0430
Range 0.2536 0.0174 1.4651 0.0238 1.2746 0.0043 1.3275 0.0723 1.1931 0.0053 0.5810 0.0159  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
Ceftazidime 1.25mg/mL 4 0 2.395 0.314 0.157 0.499  
TSB 32 0 0.194 0.200 0.0353 0.0721  
Control 27 0 1.279 0.624 0.120 0.247  
Ceftazidime 10mg/mL 4 0 2.289 0.553 0.276 0.879  
Ceftazidime 5mg/mL 7 0 1.705 0.481 0.182 0.444  
Ceftazidime 2.5mg/mL 7 0 1.925 0.422 0.159 0.390  
Ceftazidime 1.25mg/mL 4 0 2.395 0.314 0.157 0.499  
 
Column Range Max Min  Median  25% 75%  
Ceftazidime 1.25mg/mL 0.581 2.692 2.111 2.387 2.118 2.679  
TSB 0.996 1.077 0.0807 0.133 0.104 0.171  
Control 2.047 2.507 0.460 1.206 0.745 1.487  
Ceftazidime 10mg/mL 1.275 2.768 1.494 2.447 1.720 2.700  
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Ceftazidime 5mg/mL 1.328 2.407 1.079 1.815 1.132 2.039  
Ceftazidime 2.5mg/mL 1.193 2.461 1.268 1.931 1.617 2.394  
Ceftazidime 1.25mg/mL 0.581 2.692 2.111 2.387 2.118 2.679  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
Ceftazidime 1.25mg/mL 0.0200 -5.822 0.295 0.244 0.790 0.085  
TSB 3.431 12.913 0.373 <0.001 0.525 <0.001  
Control 0.796 -0.443 0.147 0.134 0.893 0.009  
Ceftazidime 10mg/mL -1.511 2.735 0.329 0.137 0.868 0.289  
Ceftazidime 5mg/mL -0.0938 -0.867 0.169 0.658 0.948 0.707  
Ceftazidime 2.5mg/mL -0.183 -0.579 0.153 0.732 0.965 0.858  
Ceftazidime 1.25mg/mL 0.0200 -5.822 0.295 0.244 0.790 0.085  
 
Column Sum Sum of Squares  
Ceftazidime 1.25mg/mL 9.579 23.233  
TSB 6.199 2.440  
Control 34.538 54.309  
Ceftazidime 10mg/mL 9.156 21.874  
Ceftazidime 5mg/mL 11.933 21.726  
Ceftazidime 2.5mg/mL 13.476 27.012  
Ceftazidime 1.25mg/mL 9.579 23.233  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.194 0.200 0.0353  
Control 27 0 1.279 0.624 0.120  
Ceftazidime 10mg/mL 4 0 2.289 0.553 0.276  
Ceftazidime 5mg/mL 7 0 1.705 0.481 0.182  
Ceftazidime 2.5mg/mL 7 0 1.925 0.422 0.159  
Ceftazidime 1.25mg/mL 4 0 2.395 0.314 0.157  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 46.614 9.323 46.519 <0.001  
Residual 75 15.031 0.200    
Total 80 61.645     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 1.085 9.279 <0.001 Yes   
Control vs. Ceftazidime  1.115 4.651 <0.001 Yes   
Control vs. Ceftazidime  1.010 4.210 <0.001 Yes   
Control vs. Ceftazidime  0.646 3.402 0.002 Yes   
Control vs. Ceftazidime 5mg/mL 0.425 2.241 0.028 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 1.085 9.279 <0.001 Yes   
TSB vs. Ceftazidime 1.25mg/mL 2.201 9.271 <0.001 Yes   
TSB vs. Ceftazidime 2.5mg/mL 1.731 9.269 <0.001 Yes   
TSB vs. Ceftazidime 10mg/mL 2.095 8.825 <0.001 Yes   







Antibiotic testing 12 on 8/1/14 at hours- Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0917 0.0609 1.4869 0.0505 1.1331 0.0906 0.9546 0.0318 1.0163 0.0392 0.6855 0.0409
B 0.1050 0.0487 0.7206 0.0524 0.8318 0.0286 1.2492 0.0350 0.6514 0.0358 0.8720 0.0386
C 0.1045 0.0447 2.4485 0.0403 1.0314 0.0383 1.7117 0.0391 0.9416 0.0396 1.0989 0.0422
D 0.1416 0.0454 OVER 0.0474 0.9322 0.0931 2.1606 0.0383 1.2454 0.0367 1.3210 0.0453
E 0.1374 0.0417 OVER 0.0469 1.1831 0.0484 1.6473 0.0662 1.2071 0.0398 1.1939 0.0423
F 0.1549 0.0426 1.4413 0.0565 1.7365 0.0484 2.2899 0.0378 2.0283 0.0454 1.5966 0.0394
G 0.1077 0.0434 0.7025 0.0409 2.1685 0.0395 2.2333 0.0390 1.4565 0.0430 1.4143 0.0390
H 0.1743 0.0469 0.9995 0.0369 2.6128 0.0402 1.4778 0.0372 1.6283 0.0410 1.0067 0.0432
Average 0.1271 0.0468 1.2999 0.0465 1.4537 0.0534 1.7156 0.0406 1.2719 0.0401 1.1486 0.0414
Range 0.0826 0.0192 1.7460 0.0196 1.7810 0.0645 1.3353 0.0344 1.3769 0.0096 0.9111 0.0067  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.194 0.200 0.0353 0.0721  
Controll 27 0 1.279 0.624 0.120 0.247  
Gentamicin 10mg/mL 8 0 1.454 0.649 0.229 0.542  
Gentamicin 5mg/mL 8 0 1.716 0.486 0.172 0.406  
Gentamicin 2.5mg/mL 8 0 1.272 0.431 0.152 0.360  
Gentamicin 1.25mg/mL 8 0 1.149 0.297 0.105 0.248  
 
Column Range Max Min  Median  25% 75%  
TSB 0.996 1.077 0.0807 0.133 0.104 0.171  
Controll 2.047 2.507 0.460 1.206 0.745 1.487  
Gentamicin 10mg/mL 1.781 2.613 0.832 1.158 0.957 2.060  
Gentamicin 5mg/mL 1.335 2.290 0.955 1.680 1.306 2.215  
Gentamicin 2.5mg/mL 1.377 2.028 0.651 1.226 0.960 1.585  
Gentamicin 1.25mg/mL 0.911 1.597 0.686 1.146 0.906 1.391  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 3.431 12.913 0.373 <0.001 0.525 <0.001  
Control 0.796 -0.443 0.147 0.134 0.893 0.009  
Gentamicin 10mg/mL 1.000 -0.367 0.287 0.052 0.863 0.129  
Gentamicin 5mg/mL -0.231 -1.179 0.195 0.446 0.933 0.547  
Gentamicin 2.5mg/mL 0.460 0.180 0.150 0.722 0.983 0.977  
Gentamicin 1.25mg/mL -0.0699 -0.552 0.0943 0.770 0.995 0.999  
 
Column Sum Sum of Squares  
TSB 6.199 2.440  
Control 34.538 54.309  
Gentamicin 10mg/mL 11.629 19.853  
Gentamicin 5mg/mL 13.724 25.199  
Gentamicin 2.5mg/mL 10.175 14.239  
Gentamicin 1.25mg/mL 9.189 11.171  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.194 0.200 0.0353  
Control 27 0 1.279 0.624 0.120  
Gentamicin 10mg/mL 8 0 1.454 0.649 0.229  
Gentamicin 5mg/mL 8 0 1.716 0.486 0.172  
Gentamicin 2.5mg/mL 8 0 1.272 0.431 0.152  
Gentamicin 1.25mg/mL 8 0 1.149 0.297 0.105  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 29.080 5.816 27.647 <0.001  
Residual 85 17.881 0.210    
Total 90 46.961     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 




Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 1.085 9.056 <0.001 Yes   
Control vs. Gentamicin 5mg/mL 0.436 2.363 0.079 No   
Control vs. Gentamicin 1 0.174 0.945 0.722 No   
Control vs. Gentamicin 1 0.131 0.707 0.731 No   
Control vs. Gentamicin 2 0.00734 0.0398 0.968 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 1.085 9.056 <0.001 Yes   
TSB vs. Gentamicin 5mg/mL 1.522 8.394 <0.001 Yes   
TSB vs. Gentamicin 10mg/mL 1.260 6.949 <0.001 Yes   
TSB vs. Gentamicin 2.5mg/mL 1.078 5.947 <0.001 Yes   
TSB vs. Gentamicin 1.25mg/mL 0.955 5.267 <0.001 Yes   
 
Antibiotic testing 13 on 8/1/14 at 48 hours- Imipenem 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1201 0.0833 0.7832 0.0420 0.5757 0.0408 0.9301 0.0504 0.8593 0.0421 1.2806 0.0439
B 0.1792 0.0562 1.2079 0.0413 0.3973 0.0423 1.3884 0.0397 0.8392 0.0418 OVER 0.0403
C 0.0807 0.0385 1.3340 0.0467 0.4423 0.0384 1.5353 0.0413 1.9072 0.0423 OVER 0.0437
D 0.0993 0.0691 0.9141 0.0408 0.4425 0.0422 1.5692 0.0410 1.9076 0.0488 OVER 0.0399
E 0.0983 0.0507 1.3820 0.0407 0.7160 0.0428 2.6566 0.0517 2.9073 0.0502 OVER 0.1161
F 0.1579 0.0400 1.2059 0.0424 0.7320 0.0390 1.5677 0.0523 1.6805 0.0397 OVER 0.0439
G 0.1481 0.0405 0.4602 0.0428 0.3554 0.0389 1.3266 0.0406 1.1521 0.0376 OVER 0.0414
H 0.1302 0.0465 2.5067 0.0421 0.4138 0.0434 1.9436 0.0356 1.9533 0.0574 2.8977 0.0420
Average 0.1267 0.0531 1.2243 0.0424 0.5094 0.0410 1.6147 0.0441 1.6508 0.0450 2.0892 0.0514
Range 0.0985 0.0448 2.0465 0.0060 0.3766 0.0050 1.7265 0.0167 2.0681 0.0198 1.6171 0.0762  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.194 0.200 0.0353 0.0721  
Control 27 0 1.279 0.624 0.120 0.247  
Imipenem 10mg/mL 8 0 0.509 0.147 0.0519 0.123  
Imipenem 5mg/mL 8 0 1.615 0.508 0.180 0.425  
Imipenem 2.5mg/mL 8 0 1.651 0.690 0.244 0.577  
Imipenem 1.25mg/mL 2 0 2.089 1.143 0.809 10.274  
 
Column Range Max Min  Median  25% 75%  
TSB 0.996 1.077 0.0807 0.133 0.104 0.171  
Control 2.047 2.507 0.460 1.206 0.745 1.487  
Imipenem 10mg/mL 0.377 0.732 0.355 0.442 0.401 0.681  
Imipenem 5mg/mL 1.727 2.657 0.930 1.552 1.342 1.850  
Imipenem 2.5mg/mL 2.068 2.907 0.839 1.794 0.932 1.942  
Imipenem 1.25mg/mL 1.617 2.898 1.281 2.089 1.281 2.898  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 3.431 12.913 0.373 <0.001 0.525 <0.001  
Control 0.796 -0.443 0.147 0.134 0.893 0.009  
Imipenem 10mg/mL 0.818 -1.113 0.301 0.032 0.844 0.083  
Imipenem 5mg/mL 1.176 2.401 0.286 0.054 0.897 0.272  
Imipenem 2.5mg/mL 0.515 0.227 0.206 0.377 0.910 0.354  
Imipenem 1.25mg/mL -- -- 0.260 0.481 -- --  
 
Column Sum Sum of Squares  
TSB 6.199 2.440  
Control 34.538 54.309  
Imipenem 10mg/mL 4.075 2.227  
Imipenem 5mg/mL 12.918 22.665  
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Imipenem 2.5mg/mL 13.207 25.138  
Imipenem 1.25mg/mL 4.178 10.037  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.194 0.200 0.0353  
Control 27 0 1.279 0.624 0.120  
Imipenem 10mg/mL 8 0 0.509 0.147 0.0519  
Imipenem 5mg/mL 8 0 1.615 0.508 0.180  
Imipenem 2.5mg/mL 8 0 1.651 0.690 0.244  
Imipenem 1.25mg/mL 2 0 2.089 1.143 0.809  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 32.467 6.493 28.549 <0.001  
Residual 79 17.968 0.227    
Total 84 50.435     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 1.085 8.710 <0.001 Yes   
Control vs. Imipenem 10mg/mL 0.770 4.010 <0.001 Yes   
Control vs. Imipenem 1.25mg/mL 0.810 2.317 0.068 No   
Control vs. Imipenem 2.5mg/mL 0.372 1.936 0.110 No   
Control vs. Imipenem 5mg/mL 0.335 1.748 0.084 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 1.085 8.710 <0.001 Yes   
TSB vs. Imipenem 2.5mg/mL 1.457 7.729 <0.001 Yes   
TSB vs. Imipenem 5mg/mL 1.421 7.538 <0.001 Yes   
TSB vs. Imipenem 1.25mg/mL 1.895 5.453 <0.001 Yes   
TSB vs. Imipenem 10mg/mL 0.316 1.674 0.098 No   
 
Antibiotic testing 14 on 8/8/14 at 48 hours- Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0776 0.0390 OVER 0.0425 0.0727 0.0431 0.0752 0.0414 0.0734 0.0381 0.0677 0.0420
B 0.0595 0.0427 2.7391 0.0425 0.0792 0.0429 0.0615 0.0475 0.0717 0.0653 0.0962 0.0378
C 0.0679 0.0430 OVER 0.0461 0.0854 0.0413 0.0782 0.0465 0.0790 0.0418 0.0836 0.0412
D 0.0920 0.0421 1.9688 0.0421 0.0778 0.0416 0.0711 0.0441 0.0692 0.0430 0.0779 0.0438
E 0.0786 0.0414 OVER 0.0451 0.1160 0.0414 0.1184 0.0420 0.0983 0.0444 0.0718 0.0401
F 0.0908 0.0450 2.5287 0.0423 0.1170 0.0420 0.0920 0.0476 0.0871 0.0505 0.0945 0.0426
G 0.0983 0.0436 OVER 0.0435 0.1405 0.0416 0.1380 0.0401 0.1136 0.0915 0.1061 0.0406
H 0.1359 0.0400 OVER 0.0429 0.1198 0.0405 0.1380 0.0407 0.1017 0.0466 0.1339 0.0415
Average 0.0876 0.0421 2.4122 0.0434 0.1011 0.0418 0.0966 0.0437 0.0868 0.0527 0.0915 0.0412
Range 0.0764 0.0060 0.7703 0.0040 0.0678 0.0026 0.0765 0.0075 0.0444 0.0534 0.0662 0.0060  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 30 0 0.115 0.0303 0.00553 0.0113  
Control 22 0 2.285 0.398 0.0849 0.177  
Ciprofloxacin 5mg/mL 8 0 0.101 0.0252 0.00892 0.0211  
Ciprofloxacin 2.5mg/mL 8 0 0.0965 0.0307 0.0109 0.0257  
Ciprofloxacin 1.25mg/mL 8 0 0.0867 0.0163 0.00575 0.0136  




Column Range Max Min  Median  25% 75%  
TSB 0.116 0.176 0.0595 0.119 0.0901 0.139  
Control 1.394 2.951 1.557 2.385 1.961 2.599  
Ciprofloxacin 5mg/mL 0.0678 0.141 0.0727 0.101 0.0781 0.119  
Ciprofloxacin 2.5mg/mL 0.0765 0.138 0.0615 0.0851 0.0721 0.133  
Ciprofloxacin 1.25mg/mL 0.0444 0.114 0.0692 0.0830 0.0721 0.101  
Ciprofloxacin 0.625mg/mL 0.0662 0.134 0.0677 0.0890 0.0733 0.104  
 
Column                           Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB                                     0.122 -0.775 0.108 0.467 0.973 0.631  
Control                               -0.462 -0.655 0.136 0.347 0.945 0.255  
Ciprofloxacin 5mg/mL        0.306 -1.606 0.233 0.224 0.882 0.196  
Ciprofloxacin 2.5mg/mL     0.508 -1.670 0.225 0.263 0.870 0.151  
Ciprofloxacin 1.25mg/mL    0.557 -1.128 0.183 0.525 0.916 0.397  
Ciprofloxacin 0.625mg/mL  1.063 1.160 0.163 0.653 0.923 0.456  
 
Column Sum Sum of Squares  
TSB 3.447 0.423  
Control 50.265 118.175  
Ciprofloxacin 5mg/mL 0.808 0.0861  
Ciprofloxacin 2.5mg/mL 0.772 0.0812  
Ciprofloxacin 1.25mg/mL 0.694 0.0621  
Ciprofloxacin 0.625mg/mL 0.732 0.0702  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM 
TSB 30 0 0.115 0.0303 0.00553  
Control 22 0 2.285 0.398 0.0849  
Ciprofloxacin 5mg/mL 8 0 0.101 0.0252 0.00892  
Ciprofloxacin 2.5mg/mL 8 0 0.0965 0.0307 0.0109  
Ciprofloxacin 1.25mg/mL 8 0 0.0867 0.0163 0.00575  
Ciprofloxacin 0.625mg/mL 8 0 0.0915 0.0215 0.00761  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 77.227 15.445 357.243 <0.001  
Residual 78 3.372 0.0432    
Total 83 80.599     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 2.170 37.178 <0.001 Yes   
Control vs. Ciprofloxaci 2.198 25.604 <0.001 Yes   
Control vs. Ciprofloxaci 2.193 25.549 <0.001 Yes   
Control vs. Ciprofloxaci 2.188 25.490 <0.001 Yes   
Control vs. Ciprofloxaci 2.184 25.438 <0.001 Yes  
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 2.170 37.178 <0.001 Yes   
TSB vs. Ciprofloxaci 0.0282 0.340 0.995 No   
TSB vs. Ciprofloxaci 0.0235 0.283 0.989 No   
TSB vs. Ciprofloxacin 2.5mg/mL 0.0184 0.222 0.969 No   






Antibiotic testing 15 on 8/8/14 at 48 hours- Ceftazidime 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1322 0.0566 1.9288 0.0601 OVER 0.0643 2.5550 0.0876 OVER 0.0712 OVER 0.0490
B 0.1440 0.0688 1.5571 0.0617 OVER 0.0540 2.7738 0.0501 OVER 0.0598 2.8251 0.0545
C 0.1386 0.0610 1.5846 0.0556 OVER 0.0472 OVER 0.0583 OVER 0.0595 OVER 0.0524
D 0.1406 0.0530 2.4229 0.0485 OVER 0.0469 OVER 0.0490 2.5221 0.0461 OVER 0.0594
E 0.1435 0.0545 2.7322 0.0487 OVER 0.0529 OVER 0.0469 2.5024 0.0460 OVER 0.0579
F OVER 0.0467 2.6666 0.0489 OVER 0.0541 OVER 0.0476 OVER 0.0575 OVER 0.0499
G 0.1760 0.0571 2.9513 0.0515 OVER 0.0526 OVER 0.0958 OVER 0.0464 OVER 0.0680
H 0.1484 0.0515 OVER 0.0488 OVER 0.0488 OVER 0.0896 OVER 0.0515 OVER 0.0489
Average 0.1462 0.0562 2.2634 0.0530 #DIV/0! 0.0526 2.6644 0.0656 2.5123 0.0548 2.8251 0.0550
Range 0.0438 0.0221 1.3942 0.0132 0.0000 0.0174 0.2188 0.0489 0.0197 0.0252 0.0000 0.0191  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 30 0 0.115 0.0303 0.00553 0.0113  
Control 22 0 2.285 0.398 0.0849 0.177  
Ceftazidime 10mg/mL 7 7 -- -- -- --  
Ceftazidime 5mg/mL 2 0 2.664 0.155 0.109 1.390  
Ceftazidime 2.5mg/mL 2 0 2.512 0.0139 0.00985 0.125  
Ceftazidime 1.25mg/mL 1 0 2.825 -- -- --  
 
Column Range Max Min  Median  25% 75%  
TSB 0.116 0.176 0.0595 0.119 0.0901 0.139  
Control 1.394 2.951 1.557 2.385 1.961 2.599  
Ceftazidime 10mg/mL -- -- -- -- -- --  
Ceftazidime 5mg/mL 0.219 2.774 2.555 2.664 2.555 2.774  
Ceftazidime 2.5mg/mL 0.0197 2.522 2.502 2.512 2.502 2.522  
Ceftazidime 1.25mg/mL 0.000 2.825 2.825 2.825 2.825 2.825  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 0.122 -0.775 0.108 0.467 0.973 0.631  
Control -0.462 -0.655 0.136 0.347 0.945 0.255  
Ceftazidime 10mg/mL -- -- -- -- -- --  
Ceftazidime 5mg/mL -- -- 0.260 0.481 -- --  
Ceftazidime 2.5mg/mL -- -- 0.260 0.481 -- --  
Ceftazidime 1.25mg/mL -- -- -- -- -- --  
 
Column Sum Sum of Squares  
TSB 3.447 0.423  
Control 50.265 118.175  
Ceftazidime 10mg/mL -- --  
Ceftazidime 5mg/mL 5.329 14.222  
Ceftazidime 2.5mg/mL 5.024 12.623  
Ceftazidime 1.25mg/mL 2.825 7.981  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 30 0 0.115 0.0303 0.00553  
Control 22 0 2.285 0.398 0.0849  
Ceftazidime 10mg/mL 7 7 -- -- --  
Ceftazidime 5mg/mL 2 0 2.664 0.155 0.109  
Ceftazidime 2.5mg/mL 2 0 2.512 0.0139 0.00985  
Ceftazidime 1.25mg/mL 1 0 2.825 0.000 0.000  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 3 71.545 23.848 366.865 <0.001  
Residual 52 3.380 0.0650    
Total 55 74.925     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 




Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 2.170 30.320 <0.001 Yes   
Control vs. Ceftazidime  0.540 2.073 0.124 No   
Control vs. Ceftazidime 5mg/mL 0.380 2.016 0.096 No   
Control vs. Ceftazidime  0.227 1.208 0.233 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 2.170 30.320 <0.001 Yes   
TSB vs. Ceftazidime 5mg/mL 2.549 13.692 <0.001 Yes   
TSB vs. Ceftazidime 2.5mg/mL 2.397 12.875 <0.001 Yes   
TSB vs. Ceftazidime 1.25mg/mL 2.710 10.457 <0.001 Yes   
 
Antibiotic testing 16 on 8/8/14 at 48 hours- Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.1012 0.0552 OVER 0.0535 2.3373 0.0571 OVER 0.0499 1.5373 0.0537 1.9152 0.1182
B 0.1232 0.0583 1.9798 0.0755 1.6866 0.0800 2.3000 0.0534 OVER 0.0585 2.8258 0.0561
C 0.1001 0.0501 2.3464 0.0485 2.8278 0.0441 2.3967 0.0490 1.6415 0.0475 2.2176 0.0452
D 0.1339 0.0569 2.2890 0.0451 OVER 0.0423 OVER 0.0463 OVER 0.0473 2.1797 0.0450
E 0.1058 0.0443 2.4460 0.0483 OVER 0.0438 2.3844 0.0464 2.5395 0.0453 OVER 0.0528
F 0.1224 0.0431 1.6007 0.0495 OVER 0.0431 2.6499 0.0449 OVER 0.0457 OVER 0.0461
G OVER 0.0473 2.5193 0.0436 OVER 0.0452 OVER 0.0418 2.6141 0.0421 2.7967 0.0558
H 0.1711 0.0443 OVER 0.0509 OVER 0.0458 OVER 0.0441 2.9080 0.0468 2.8261 0.0440
Average 0.1225 0.0499 2.1969 0.0519 2.2839 0.0502 2.4328 0.0470 2.2481 0.0484 2.4602 0.0579
Range 0.0710 0.0152 0.9186 0.0319 1.1412 0.0377 0.3499 0.0116 1.3707 0.0164 0.9109 0.0742  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 30 0 0.115 0.0303 0.00553 0.0113  
Control 22 0 2.285 0.398 0.0849 0.177  
Gentamicin 10mg/mL 3 0 2.284 0.572 0.331 1.422  
Gentamicin 5mg/mL 4 0 2.433 0.151 0.0755 0.240  
Gentamicin 2.5mg/mL 5 0 2.248 0.618 0.276 0.767  
Gentamicin 1.25mg/mL 6 0 2.460 0.404 0.165 0.424  
 
Column Range Max Min  Median  25% 75%  
TSB 0.116 0.176 0.0595 0.119 0.0901 0.139  
Control 1.394 2.951 1.557 2.385 1.961 2.599  
Gentamicin 10mg/mL 1.141 2.828 1.687 2.337 1.687 2.828  
Gentamicin 5mg/mL 0.350 2.650 2.300 2.391 2.321 2.587  
Gentamicin 2.5mg/mL 1.371 2.908 1.537 2.539 1.589 2.761  
Gentamicin 1.25mg/mL 0.911 2.826 1.915 2.507 2.114 2.826  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 0.122 -0.775 0.108 0.467 0.973 0.631  
Control -0.462 -0.655 0.136 0.347 0.945 0.255  
Gentamicin 10mg/mL -0.416 -- 0.204 0.623 0.993 0.846  
Gentamicin 5mg/mL 1.498 2.788 0.344 0.102 0.860 0.259  
Gentamicin 2.5mg/mL -0.390 -2.811 0.281 0.213 0.859 0.226  
Gentamicin 1.25mg/mL -0.284 -2.394 0.298 0.099 0.821 0.090  
 
Column Sum Sum of Squares  
TSB 3.447 0.423  
Control 50.265 118.175  
Gentamicin 10mg/mL 6.852 16.304  
Gentamicin 5mg/mL 9.731 23.742  
Gentamicin 2.5mg/mL 11.240 26.797  
Gentamicin 1.25mg/mL 14.761 37.130  
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One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 30 0 0.115 0.0303 0.00553  
Control 22 0 2.285 0.398 0.0849  
Gentamicin 10mg/mL 3 0 2.284 0.572 0.331  
Gentamicin 5mg/mL 4 0 2.433 0.151 0.0755  
Gentamicin 2.5mg/mL 5 0 2.248 0.618 0.276  
Gentamicin 1.25mg/mL 6 0 2.460 0.404 0.165  
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 83.675 16.735 166.753 <0.001  
Residual 64 6.423 0.100    
Total 69 90.098     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 2.170 24.402 <0.001 Yes   
Control vs. Gentamicin 1 0.175 1.202 0.655 No   
Control vs. Gentamicin 5mg/mL 0.148 0.859 0.777 No   
Control vs. Gentamicin 2 0.0367 0.234 0.966 No   
Control vs. Gentamicin 10mg/mL 0.000891 0.00457 0.996 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 2.170 24.402 <0.001 Yes   
TSB vs. Gentamicin 1.25mg/mL 2.345 16.554 <0.001 Yes   
TSB vs. Gentamicin 2.5mg/mL 2.133 13.940 <0.001 Yes   
TSB vs. Gentamicin 5mg/mL 2.318 13.745 <0.001 Yes   
TSB vs. Gentamicin 10mg/mL 2.169 11.307 <0.001 Yes   
 
Antibiotic testing 17 on 8/8/14 at 48 hours- Imipenem 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0947 0.0435 2.2396 0.0696 2.6209 0.0426 OVER 0.1601 2.0167 0.0428 2.0937 0.0582
B 0.0816 0.0457 2.5889 0.0493 2.1605 0.0521 2.4168 0.0483 1.8782 0.1263 1.7130 0.0570
C 0.0852 0.0469 2.1860 0.0439 1.7422 0.0516 1.9103 0.0482 1.7991 0.0453 2.9666 0.0590
D 0.0879 0.0446 2.6273 0.0447 1.2362 0.0458 1.3407 0.0464 1.2147 0.1179 OVER 0.0636
E 0.1196 0.0479 1.9371 0.0447 1.2736 0.0405 1.6572 0.0449 1.1309 0.0490 2.8228 0.0445
F 0.1515 0.0470 2.4252 0.0443 1.6329 0.0443 2.1042 0.0444 1.3933 0.0537 OVER 0.0381
G 0.1177 0.0490 OVER 0.0439 1.7954 0.0469 OVER 0.0409 1.7636 0.0443 OVER 0.0451
H 0.1277 0.0451 OVER 0.0470 OVER 0.0462 OVER 0.0463 OVER 0.0544 OVER 0.0490
Average 0.1082 0.0462 2.3340 0.0484 1.7802 0.0463 1.8858 0.0599 1.5995 0.0667 2.3990 0.0518
Range 0.0699 0.0055 0.6902 0.0257 1.3847 0.0116 1.0761 0.1192 0.8858 0.0835 1.2536 0.0255  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 30 0 0.115 0.0303 0.00553 0.0113  
Control 22 0 2.285 0.398 0.0849 0.177  
Imipenem 10mg/mL 7 0 1.780 0.488 0.184 0.451  
Imipenem 5mg/mL 5 0 1.886 0.412 0.184 0.512  
Imipenem 2.5mg/mL 7 0 1.600 0.348 0.132 0.322  
Imipenem 1.25mg/mL 4 0 2.399 0.596 0.298 0.948  
 
Column Range Max Min  Median  25% 75%  
TSB 0.116 0.176 0.0595 0.119 0.0901 0.139  
Control 1.394 2.951 1.557 2.385 1.961 2.599  
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Imipenem 10mg/mL 1.385 2.621 1.236 1.742 1.274 2.160  
Imipenem 5mg/mL 1.076 2.417 1.341 1.910 1.499 2.261  
Imipenem 2.5mg/mL 0.886 2.017 1.131 1.764 1.215 1.878  
Imipenem 1.25mg/mL 1.254 2.967 1.713 2.458 1.808 2.931  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.122 -0.775 0.108 0.467 0.973 0.631  
Control -0.462 -0.655 0.136 0.347 0.945 0.255  
Imipenem 10mg/mL 0.713 0.160 0.202 0.467 0.934 0.584  
Imipenem 5mg/mL -0.0823 -0.518 0.124 0.733 0.997 0.997  
Imipenem 2.5mg/mL -0.342 -1.901 0.253 0.192 0.901 0.337  
Imipenem 1.25mg/mL -0.291 -3.824 0.261 0.381 0.907 0.464  
 
Column Sum Sum of Squares  
TSB 3.447 0.423  
Control 50.265 118.175  
Imipenem 10mg/mL 12.462 23.612  
Imipenem 5mg/mL 9.429 18.462  
Imipenem 2.5mg/mL 11.197 18.637  
Imipenem 1.25mg/mL 9.596 24.087  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 30 0 0.115 0.0303 0.00553  
Control 22 0 2.285 0.398 0.0849  
Imipenem 10mg/mL 7 0 1.780 0.488 0.184  
Imipenem 5mg/mL 5 0 1.886 0.412 0.184  
Imipenem 2.5mg/mL 7 0 1.600 0.348 0.132  
Imipenem 1.25mg/mL 4 0 2.399 0.596 0.298  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 72.242 14.448 137.368 <0.001  
Residual 69 7.257 0.105    
Total 74 79.500     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.00 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 2.170 23.836 <0.001 Yes   
Control vs. Imipenem 2.5mg/mL 0.685 4.869 <0.001 Yes   
Control vs. Imipenem 10mg/mL 0.505 3.585 0.002 Yes   
Control vs. Imipenem 5mg/mL 0.399 2.483 0.031 Yes   
Control vs. Imipenem 1.25mg/mL 0.114 0.648 0.519 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 2.170 23.836 <0.001 Yes   
TSB vs. Imipenem 1.25mg/mL 2.284 13.231 <0.001 Yes   
TSB vs. Imipenem 10mg/mL 1.665 12.233 <0.001 Yes   
TSB vs. Imipenem 5mg/mL 1.771 11.304 <0.001 Yes   










Antibiotic Testing 18 on 8/15/14-Ciprofloxacin 
<> 1 2 3 4 5 6
A 0.0453 0.5095 0.3864 0.2747 1.1528 0.7258
B 0.9867 0.5154 0.1701 0.1106 0.5220 0.8989
C 0.0505 0.5709 0.1567 0.2305 0.8388 0.9261
D 0.0577 0.6515 0.4478 0.3138 1.5467 0.6167
Average 0.2851 0.561825 0.29025 0.2324 1.015075 0.791875
Range 0.9867 0.6515 0.4478 0.3138 1.5467 0.9261  
 
Descriptive Statistics:  
Data source: Data 1 in Notebook1 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.112 0.233 0.0584 0.124  
Control 16 0 0.538 0.0947 0.0237 0.0505  
Ciprofloxacin 2.5mg/mL 4 0 0.290 0.149 0.0744 0.237  
Ciprofloxacin 1.25mg/mL 4 0 0.232 0.0880 0.0440 0.140  
Ciprofloxacin 0.625mg/mL 4 0 1.015 0.438 0.219 0.697  
Ciprofloxacin 0.3125mg/mL 4 0 0.792 0.147 0.0733 0.233  
 
Column Range Max Min  Median  25% 75%  
TSB 0.941 0.987 0.0453 0.0511 0.0480 0.0597  
Control 0.372 0.670 0.298 0.523 0.492 0.619  
Ciprofloxacin 2.5mg/mL 0.291 0.448 0.157 0.278 0.160 0.432  
Ciprofloxacin 1.25mg/mL 0.203 0.314 0.111 0.253 0.141 0.304  
Ciprofloxacin 0.625mg/mL 1.025 1.547 0.522 0.996 0.601 1.448  
Ciprofloxacin 0.3125mg/mL 0.309 0.926 0.617 0.812 0.644 0.919  
 
Column                              Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB                                       3.992 15.957 0.501 <0.001 0.299 <0.001  
Control                                 -0.816 1.399 0.131 0.588 0.932 0.266  
Ciprofloxacin 2.5mg/mL       0.139 -5.128 0.290 0.261 0.840 0.195  
Ciprofloxacin 1.25mg/mL    -1.164 1.323 0.241 0.470 0.929 0.590  
Ciprofloxacin 0.625mg/mL    0.218 -0.803 0.156 0.710 0.994 0.976  
Ciprofloxacin 0.3125mg/mL -0.427 -3.293 0.267 0.356 0.903 0.448  
 
Column Sum Sum of Squares  
TSB 1.790 1.018  
Control 8.611 4.768  
Ciprofloxacin 2.5mg/mL 1.161 0.403  
Ciprofloxacin 1.25mg/mL 0.930 0.239  
Ciprofloxacin 0.625mg/mL 4.060 4.697  
Ciprofloxacin 0.3125mg/mL 3.168 2.573  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.112 0.233 0.0584  
Control 16 0 0.538 0.0947 0.0237  
Ciprofloxacin 2.5mg/mL 4 0 0.290 0.149 0.0744  
Ciprofloxacin 1.25mg/mL 4 0 0.232 0.0880 0.0440  
Ciprofloxacin 0.625mg/mL 4 0 1.015 0.438 0.219  
Ciprofloxacin 0.3125mg/mL 4 0 0.792 0.147 0.0733  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 3.916 0.783 19.560 <0.001  
Residual 42 1.682 0.0400    
Total 47 5.598     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 





Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.426 6.025 <0.001 Yes   
Control vs. Ciprofloxaci 0.477 4.263 <0.001 Yes   
Control vs. Ciprofloxaci 0.306 2.733 0.027 Yes   
Control vs. Ciprofloxaci 0.254 2.268 0.056 No   
Control vs. Ciprofloxaci 0.248 2.216 0.032 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Ciprofloxaci 0.903 8.074 <0.001 Yes   
TSB vs. Ciprofloxaci 0.680 6.079 <0.001 Yes   
TSB vs. Control 0.426 6.025 <0.001 Yes   
TSB vs. Ciprofloxacin 2.5mg/mL 0.178 1.595 0.223 No   
TSB vs. Ciprofloxaci 0.121 1.077 0.287 No   
 
Antibiotic Testing 19 at 8/15/14-Ceftazidime 
<> 1 2 3 4 5 6
A 0.0516 0.4783 OVER 1.5037 2.9968 0.7828
B 0.0468 0.3715 2.5755 0.8590 0.7259 1.1181
C 0.0512 0.3447 2.9094 0.8664 0.9228 0.9106
D 0.0658 0.4918 0.2292 0.2394 1.4174 0.6202
Average 0.05385 0.421575 1.9047 0.867125 1.515725 0.857925
Range 0.0658 0.4918 2.9094 1.5037 2.9968 1.1181  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.112 0.233 0.0584 0.124  
Control 16 0 0.538 0.0947 0.0237 0.0505  
Ceftazidime 5mg/mL 3 0 1.905 1.461 0.843 3.628  
Ceftazidime 2.5mg/mL 4 0 0.867 0.516 0.258 0.821  
Ceftazidime 1.25mg/mL 4 0 1.516 1.029 0.515 1.638  
Ceftazidime 0.625mg/mL 4 0 0.858 0.210 0.105 0.335  
 
Column Range Max Min  Median  25% 75%  
TSB 0.941 0.987 0.0453 0.0511 0.0480 0.0597  
Control 0.372 0.670 0.298 0.523 0.492 0.619  
Ceftazidime 5mg/mL 2.680 2.909 0.229 2.575 0.229 2.909  
Ceftazidime 2.5mg/mL 1.264 1.504 0.239 0.863 0.394 1.344  
Ceftazidime 1.25mg/mL 2.271 2.997 0.726 1.170 0.775 2.602  
Ceftazidime 0.625mg/mL 0.498 1.118 0.620 0.847 0.661 1.066  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 3.992 15.957 0.501 <0.001 0.299 <0.001
  
Control -0.816 1.399 0.131 0.588 0.932 0.266
  
Ceftazidime 5mg/mL -1.631 -- 0.344 0.179 0.842 0.219
  
Ceftazidime 2.5mg/mL 0.0514 1.500 0.251 0.430 0.947 0.699
  
Ceftazidime 1.25mg/mL 1.557 2.310 0.288 0.270 0.849 0.224
  
Ceftazidime 0.625mg/mL 0.280 -0.170 0.151 0.710 0.996 0.986
  
 
Column Sum Sum of Squares  
TSB 1.790 1.018  
Control 8.611 4.768  
Ceftazidime 5mg/mL 5.714 15.150  
Ceftazidime 2.5mg/mL 3.469 3.807  
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Ceftazidime 1.25mg/mL 6.063 12.368  
Ceftazidime 0.625mg/mL 3.432 3.077  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.112 0.233 0.0584  
Control 16 0 0.538 0.0947 0.0237  
Ceftazidime 5mg/mL 3 0 1.905 1.461 0.843  
Ceftazidime 2.5mg/mL 4 0 0.867 0.516 0.258  
Ceftazidime 1.25mg/mL 4 0 1.516 1.029 0.515  
Ceftazidime 0.625mg/mL 4 0 0.858 0.210 0.105  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 12.870 2.574 11.312 <0.001  
Residual 41 9.329 0.228    
Total 46 22.199     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. Ceftazidime 5mg/mL 1.367 4.553 <0.001 Yes   
Control vs. Ceftazidime  0.978 3.666 0.003 Yes   
Control vs. TSB 0.426 2.528 0.046 Yes   
Control vs. Ceftazidime  0.329 1.234 0.398 No   
Control vs. Ceftazidime  0.320 1.199 0.237 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Ceftazidime 5mg/mL 1.793 5.974 <0.001 Yes   
TSB vs. Ceftazidime 1.25mg/mL 1.404 5.265 <0.001 Yes   
TSB vs. Ceftazidime 2.5mg/mL 0.755 2.832 0.021 Yes   
TSB vs. Ceftazidime 0.625mg/mL 0.746 2.798 0.016 Yes   
TSB vs. Control 0.426 2.528 0.015 Yes   
 
Antibiotic Testing 20 8/15/14-Gentamicin 
<> 1 2 3 4 5 6
A 0.0553 0.6701 0.6995 0.8535 1.2017 0.7345
B 0.0475 0.6024 0.3491 0.5565 0.6417 0.9077
C 0.0467 0.6241 0.3969 0.3654 0.8388 0.9377
D 0.0497 0.4564 0.5112 0.5684 1.5597 0.6358
Average 0.0498 0.58825 0.489175 0.58595 1.060475 0.803925
Range 0.0553 0.6701 0.6995 0.8535 1.5597 0.9377  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.112 0.233 0.0584 0.124  
Control 16 0 0.538 0.0947 0.0237 0.0505  
Gentamicin 5mg/mL 4 0 0.489 0.156 0.0779 0.248  
Gentamicin 2.5mg/mL 4 0 0.586 0.201 0.101 0.320  
Gentamicin 1.25mg/mL 4 0 1.060 0.406 0.203 0.645  
Gentamicin 0.625mg/mL 4 0 0.804 0.143 0.0717 0.228  
 
Column Range Max Min  Median  25% 75%  
TSB 0.941 0.987 0.0453 0.0511 0.0480 0.0597  
Control 0.372 0.670 0.298 0.523 0.492 0.619  
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Gentamicin 5mg/mL 0.350 0.700 0.349 0.454 0.361 0.652  
Gentamicin 2.5mg/mL 0.488 0.854 0.365 0.562 0.413 0.782  
Gentamicin 1.25mg/mL 0.918 1.560 0.642 1.020 0.691 1.470  
Gentamicin 0.625mg/mL 0.302 0.938 0.636 0.821 0.660 0.930  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 3.992 15.957 0.501 <0.001 0.299 <0.001  
Control -0.816 1.399 0.131 0.588 0.932 0.266  
Gentamicin 5mg/mL 1.018 0.146 0.223 0.548 0.927 0.575  
Gentamicin 2.5mg/mL 0.687 1.748 0.285 0.283 0.938 0.642  
Gentamicin 1.25mg/mL 0.428 -1.722 0.208 0.607 0.968 0.829  
Gentamicin 0.625mg/mL -0.356 -3.599 0.265 0.365 0.904 0.452  
 
Column Sum Sum of Squares  
TSB 1.790 1.018  
Control 8.611 4.768  
Gentamicin 5mg/mL 1.957 1.030  
Gentamicin 2.5mg/mL 2.344 1.495  
Gentamicin 1.25mg/mL 4.242 4.992  
Gentamicin 0.625mg/mL 3.216 2.647  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.112 0.233 0.0584  
Control 16 0 0.538 0.0947 0.0237  
Gentamicin 5mg/mL 4 0 0.489 0.156 0.0779  
Gentamicin 2.5mg/mL 4 0 0.586 0.201 0.101  
Gentamicin 1.25mg/mL 4 0 1.060 0.406 0.203  
Gentamicin 0.625mg/mL 4 0 0.804 0.143 0.0717  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 4.019 0.804 19.840 <0.001  
Residual 42 1.702 0.0405    
Total 47 5.720     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.426 5.990 <0.001 Yes   
Control vs. Gentamicin 1 0.522 4.642 <0.001 Yes   
Control vs. Gentamicin 0 0.266 2.362 0.067 No   
Control vs. Gentamicin 5mg/mL 0.0490 0.435 0.888 No   
Control vs. Gentamicin 2 0.0478 0.425 0.673 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Gentamicin 1.25mg/mL 0.949 8.431 <0.001 Yes   
TSB vs. Gentamicin 0.625mg/mL 0.692 6.151 <0.001 Yes   
TSB vs. Control 0.426 5.990 <0.001 Yes   
TSB vs. Gentamicin 2.5mg/mL 0.474 4.213 <0.001 Yes   








Antibiotic Testing 21 on 8/15/14- Imipenem 
<> 1 2 3 4 5 6
A 0.0744 0.5311 0.3738 0.9290 1.8250 0.8145
B 0.0510 0.2985 0.0772 0.2197 0.7846 1.0995
C 0.0604 0.4469 0.0794 0.0906 1.0445 0.9462
D 0.0494 0.4864 0.1990 0.1789 2.3112 0.7119
Average 0.0588 0.440725 0.18235 0.35455 1.491325 0.893025
Range 0.0744 0.5311 0.3738 0.929 2.3112 1.0995  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 16 0 0.112 0.233 0.0584 0.124  
Control 16 0 0.538 0.0947 0.0237 0.0505  
Imipenem 5mg/mL 4 0 0.182 0.140 0.0699 0.222  
Imipenem 2.5mg/mL 4 0 0.355 0.387 0.193 0.615  
Imipenem 1.25mg/mL 4 0 1.491 0.703 0.352 1.119  
Imipenem 0.625mg/mL 4 0 0.893 0.168 0.0839 0.267  
 
Column Range Max Min  Median  25% 75%  
TSB 0.941 0.987 0.0453 0.0511 0.0480 0.0597  
Control 0.372 0.670 0.298 0.523 0.492 0.619  
Imipenem 5mg/mL 0.297 0.374 0.0772 0.139 0.0778 0.330  
Imipenem 2.5mg/mL 0.838 0.929 0.0906 0.199 0.113 0.752  
Imipenem 1.25mg/mL 1.527 2.311 0.785 1.435 0.850 2.190  
Imipenem 0.625mg/mL 0.388 1.099 0.712 0.880 0.738 1.061  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 3.992 15.957 0.501 <0.001 0.299 <0.001  
Control -0.816 1.399 0.131 0.588 0.932 0.266  
Imipenem 5mg/mL 1.165 0.294 0.269 0.347 0.854 0.241  
Imipenem 2.5mg/mL 1.882 3.641 0.386 0.037 0.757 0.045  
Imipenem 1.25mg/mL 0.280 -3.216 0.237 0.487 0.938 0.639  
Imipenem 0.625mg/mL 0.357 -1.129 0.180 0.684 0.984 0.927  
 
Column Sum Sum of Squares  
TSB 1.790 1.018  
Control 8.611 4.768  
Imipenem 5mg/mL 0.729 0.192  
Imipenem 2.5mg/mL 1.418 0.952  
Imipenem 1.25mg/mL 5.965 10.379  
Imipenem 0.625mg/mL 3.572 3.274  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 16 0 0.112 0.233 0.0584  
Control 16 0 0.538 0.0947 0.0237  
Imipenem 5mg/mL 4 0 0.182 0.140 0.0699  
Imipenem 2.5mg/mL 4 0 0.355 0.387 0.193  
Imipenem 1.25mg/mL 4 0 1.491 0.703 0.352  
Imipenem 0.625mg/mL 4 0 0.893 0.168 0.0839  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 7.394 1.479 20.524 <0.001  
Residual 42 3.026 0.0721    
Total 47 10.420     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
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Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. Imipenem 1.25mg/mL 0.953 6.352 <0.001 Yes   
Control vs. TSB 0.426 4.492 <0.001 Yes   
Control vs. Imipenem 5mg/mL 0.356 2.371 0.066 No   
Control vs. Imipenem 0.6 0.355 2.365 0.045 Yes   
Control vs. Imipenem 2.5mg/mL 0.184 1.224 0.228 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Imipenem 1.25mg/mL 1.379 9.193 <0.001 Yes   
TSB vs. Imipenem 0.625mg/mL 0.781 5.206 <0.001 Yes   
TSB vs. Control 0.426 4.492 <0.001 Yes   
TSB vs. Imipenem 2.5mg/mL 0.243 1.617 0.214 No   
TSB vs. Imipenem 5mg/mL 0.0705 0.470 0.641 No   
 
Antibiotic Testing 22 on 8/25/14- Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0478 0.8052 2.6809 2.3576 2.0776 1.6631 0.8981 0.3866 0.1647 0.0905 0.0846 0.0936
B 0.1259 0.9401 2.6485 2.4146 2.1615 1.6420 0.6019 0.3758 0.1856 0.1075 0.1026 0.1089
C 0.1263 0.8057 2.5381 2.3940 2.1396 1.4165 0.7350 0.4132 0.2556 0.1716 0.1583 0.1606
D 0.1652 0.8201 2.8623 2.1641 2.0973 1.2878 0.5897 0.3794 0.2336 0.1647 0.1649 0.1638
E 0.1657 0.8826 2.6448 2.4350 2.1476 1.8685 0.8990 0.5380 0.3118 0.2070 0.1919 0.1915
F 0.1851 0.2010 2.6432 2.3745 2.1756 1.5243 0.5972 0.4794 0.2263 0.1967 0.1892 0.1973
G 0.1857 0.8940 2.6051 2.3871 2.1339 1.5453 0.7211 0.4424 0.2418 0.2239 0.1991 0.2235
H 0.1761 0.9593 2.5637 2.3648 2.0895 1.4119 0.6753 0.4154 0.2342 0.2023 0.1906 0.2100
Average 0.1472 0.7885 2.6483 2.3615 2.1278 1.5449 0.7147 0.4288 0.2317 0.1705 0.1602 0.1687
Range 0.1379 0.7583 0.3242 0.2709 0.0980 0.5807 0.3093 0.1622 0.1471 0.1334 0.1145 0.1299  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 24 0 0.131 0.0451 0.00921 0.0190  
Control 24 0 0.591 0.278 0.0568 0.117  
Ciprofloxacin 5mg/mL 8 0 2.648 0.0986 0.0349 0.0824  
Ciprofloxacin 2.5mg/mL 8 0 2.361 0.0837 0.0296 0.0700  
Ciprofloxacin 1.25mg/mL 8 0 2.128 0.0357 0.0126 0.0298  
Ciprofloxacin 0.625mg/mL 8 0 1.545 0.181 0.0639 0.151  
Ciprofloxacin 0.3125mg/mL 8 0 0.715 0.126 0.0447 0.106  
Ciprofloxacin 0.1563mg/mL 8 0 0.429 0.0562 0.0199 0.0470  
Ciprofloxacin 0.0781mg/mL 8 0 0.232 0.0443 0.0157 0.0370  
Ciprofloxacin0.0391mg/mL 8 0 0.171 0.0482 0.0171 0.0403  
Ciprofloxacin 0.0195mg/mL 8 0 0.160 0.0437 0.0154 0.0365  
Ciprofloxacin 0.0098mg/mL 8 0 0.169 0.0468 0.0166 0.0392  
 
Column Range Max Min  Median  25% 75%  
TSB 0.138 0.186 0.0478 0.130 0.101 0.169  
Control 0.943 1.004 0.0610 0.571 0.489 0.817  
Ciprofloxacin 5mg/mL 0.324 2.862 2.538 2.644 2.574 2.673  
Ciprofloxacin 2.5mg/mL 0.271 2.435 2.164 2.381 2.359 2.409  
Ciprofloxacin 1.25mg/mL 0.0980 2.176 2.078 2.137 2.091 2.158  
Ciprofloxacin 0.625mg/mL 0.581 1.869 1.288 1.535 1.413 1.658  
Ciprofloxacin 0.3125mg/mL 0.309 0.899 0.590 0.698 0.598 0.857  
Ciprofloxacin 0.1563mg/mL 0.162 0.538 0.376 0.414 0.381 0.470  
Ciprofloxacin 0.0781mg/mL 0.147 0.312 0.165 0.234 0.196 0.252  
Ciprofloxacin0.0391mg/mL 0.133 0.224 0.0905 0.184 0.122 0.206  
Ciprofloxacin 0.0195mg/mL 0.115 0.199 0.0846 0.177 0.117 0.192  
Ciprofloxacin 0.0098mg/mL 0.130 0.224 0.0936 0.178 0.122 0.207  
 
Column                            Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB                                     -0.590 -0.748 0.128 0.374 0.907 0.031  
Control                                -0.469 -0.510 0.139 0.261 0.934 0.120  
Ciprofloxacin 5mg/mL         1.551 3.440 0.249 0.151 0.853 0.102  
Ciprofloxacin 2.5mg/mL     -2.298 5.946 0.357 0.003 0.718 0.004  
Ciprofloxacin 1.25mg/mL   -0.229 -1.499 0.193 0.462 0.934 0.552  
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Ciprofloxacin 0.625mg/mL  0.482 0.299 0.136 0.773 0.972 0.910  
Ciprofloxacin 0.3125mg/mL 0.697 -1.019 0.189 0.487 0.850 0.095  
Ciprofloxacin 0.1563mg/mL 1.163 0.798 0.219 0.296 0.882 0.196  
Ciprofloxacin 0.0781mg/mL 0.284 0.986 0.201 0.404 0.944 0.650  
Ciprofloxacin0.0391mg/mL  -0.870 -0.582 0.206 0.373 0.887 0.219  
Ciprofloxacin 0.0195mg/mL -1.094 -0.329 0.247 0.160 0.819 0.046  
Ciprofloxacin 0.0098mg/mL -0.678 -0.809 0.187 0.498 0.916 0.396  
 
Column Sum Sum of Squares  
TSB 3.133 0.456  
Control 14.180 10.157  
Ciprofloxacin 5mg/mL 21.187 56.177  
Ciprofloxacin 2.5mg/mL 18.892 44.661  
Ciprofloxacin 1.25mg/mL 17.023 36.230  
Ciprofloxacin 0.625mg/mL 12.359 19.323  
Ciprofloxacin 0.3125mg/mL 5.717 4.198  
Ciprofloxacin 0.1563mg/mL 3.430 1.493  
Ciprofloxacin 0.0781mg/mL 1.854 0.443  
Ciprofloxacin0.0391mg/mL 1.364 0.249  
Ciprofloxacin 0.0195mg/mL 1.281 0.219  
Ciprofloxacin 0.0098mg/mL 1.349 0.243  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM 
TSB 24 0 0.131 0.0451 0.00921  
Control 24 0 0.591 0.278 0.0568  
Ciprofloxacin 5mg/mL 8 0 2.648 0.0986 0.0349  
Ciprofloxacin 2.5mg/mL 8 0 2.361 0.0837 0.0296  
Ciprofloxacin 1.25mg/mL 8 0 2.128 0.0357 0.0126  
Ciprofloxacin 0.625mg/mL 8 0 1.545 0.181 0.0639  
Ciprofloxacin 0.3125mg/mL 8 0 0.715 0.126 0.0447  
Ciprofloxacin 0.1563mg/mL 8 0 0.429 0.0562 0.0199  
Ciprofloxacin 0.0781mg/mL 8 0 0.232 0.0443 0.0157  
Ciprofloxacin0.0391mg/mL 8 0 0.171 0.0482 0.0171  
Ciprofloxacin 0.0195mg/mL 8 0 0.160 0.0437 0.0154  
Ciprofloxacin 0.0098mg/mL 8 0 0.169 0.0468 0.0166  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 90.562 8.233 402.417 <0.001  
Residual 116 2.373 0.0205    
Total 127 92.935     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. Ciprofloxaci 2.058 35.235 <0.001 Yes   
Control vs. Ciprofloxaci 1.771 30.323 <0.001 Yes   
Control vs. Ciprofloxaci 1.537 26.322 <0.001 Yes   
Control vs. Ciprofloxaci 0.954 16.339 <0.001 Yes   
Control vs. TSB 0.460 11.147 <0.001 Yes   
Control vs. Ciprofloxaci 0.431 7.375 <0.001 Yes   
Control vs. Ciprofloxaci 0.422 7.230 <0.001 Yes   
Control vs. Ciprofloxaci 0.420 7.198 <0.001 Yes   
Control vs. Ciprofloxaci 0.359 6.150 <0.001 Yes   
Control vs. Ciprofloxaci 0.162 2.775 0.013 Yes   




Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Ciprofloxacin 5mg/mL 2.518 43.118 <0.001 Yes   
TSB vs. Ciprofloxacin 2.5mg/mL 2.231 38.205 <0.001 Yes   
TSB vs. Ciprofloxaci 1.997 34.204 <0.001 Yes   
TSB vs. Ciprofloxaci 1.414 24.222 <0.001 Yes   
TSB vs. Control 0.460 11.147 <0.001 Yes   
TSB vs. Ciprofloxaci 0.584 10.003 <0.001 Yes   
TSB vs. Ciprofloxaci 0.298 5.107 <0.001 Yes   
TSB vs. Ciprofloxaci 0.101 1.732 0.302 No   
TSB vs. Ciprofloxaci 0.0400 0.685 0.871 No   
TSB vs. Ciprofloxaci 0.0381 0.653 0.765 No   
TSB vs. Ciprofloxaci 0.0296 0.507 0.613 No   
 
Antibiotic Testing 23 on 8/25/14-Ceftazidime 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0500 0.0610 0.0793 0.0597 0.0713 0.0601 0.0597 0.0581 0.0557 0.0659 0.0600 0.0632
B 0.0956 0.0987 0.0980 0.0953 0.0907 0.0811 0.0754 0.0700 0.0658 0.0647 0.0609 0.0633
C 0.0860 0.0943 0.0965 0.0974 0.0936 0.0905 0.0965 0.1083 0.1060 0.1023 0.1017 0.1206
D 0.1226 0.5124 0.1431 0.1491 0.1305 0.1235 0.1253 0.1222 0.1136 0.1111 0.1134 0.1174
E 0.1265 0.6296 0.1611 0.1508 0.1583 0.1372 0.1407 0.1524 0.1454 0.1453 0.1405 0.1397
F 0.1417 0.5141 0.1840 0.1721 0.1621 0.1533 0.1426 0.1554 0.1501 0.1423 0.1408 0.1459
G 0.1338 1.0044 0.1761 0.1817 0.1806 0.1581 0.1628 0.1618 0.1570 0.1390 0.1330 0.1234
H 0.0634 0.7350 0.1049 0.1155 0.1068 0.1023 0.1026 0.1035 0.1078 0.1035 0.1308 0.1247
Average 0.1025 0.4562 0.1304 0.1277 0.1242 0.1133 0.1132 0.1165 0.1127 0.1093 0.1101 0.1123
Range 0.0917 0.9434 0.1047 0.1220 0.1093 0.0980 0.1031 0.1037 0.1013 0.0806 0.0808 0.0827  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 24 0 0.131 0.0451 0.00921 0.0190  
Control 24 0 0.591 0.278 0.0568 0.117  
Ceftazidime 8 0 0.130 0.0406 0.0143 0.0339  
Ceftazidime 0.5 8 0 0.128 0.0425 0.0150 0.0355  
Ceftazidime 0.5 8 0 0.124 0.0396 0.0140 0.0331  
Ceftazidime 0.125 8 0 0.113 0.0354 0.0125 0.0296  
Ceftazidime 0.0625 8 0 0.113 0.0357 0.0126 0.0298  
Ceftazidime 0.03125 8 0 0.116 0.0391 0.0138 0.0327  
Ceftazidime 0.015625 8 0 0.113 0.0377 0.0133 0.0315  
Ceftazidime 0.0078125 8 0 0.109 0.0321 0.0114 0.0269  
Ceftazidime 0.00391 8 0 0.110 0.0334 0.0118 0.0280  
Ceftazidime 0.00195 8 0 0.112 0.0318 0.0112 0.0266  
 
Column Range Max Min  Median  25% 75%  
TSB 0.138 0.186 0.0478 0.130 0.101 0.169  
Control 0.943 1.004 0.0610 0.571 0.489 0.817  
Ceftazidime 0.105 0.184 0.0793 0.124 0.0969 0.172  
Ceftazidime 0.5 0.122 0.182 0.0597 0.132 0.0958 0.167  
Ceftazidime 0.5 0.109 0.181 0.0713 0.119 0.0914 0.161  
Ceftazidime 0.125 0.0980 0.158 0.0601 0.113 0.0834 0.149  
Ceftazidime 0.0625 0.103 0.163 0.0597 0.114 0.0807 0.142  
Ceftazidime 0.03125 0.104 0.162 0.0581 0.115 0.0784 0.155  
Ceftazidime 0.015625 0.101 0.157 0.0557 0.111 0.0759 0.149  
Ceftazidime 0.0078125 0.0806 0.145 0.0647 0.107 0.0750 0.141  
Ceftazidime 0.00391 0.0808 0.141 0.0600 0.122 0.0711 0.139  
Ceftazidime 0.00195 0.0827 0.146 0.0632 0.122 0.0768 0.136  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB -0.590 -0.748 0.128 0.374 0.907 0.031
  
Control -0.469 -0.510 0.139 0.261 0.934 0.120
  
Ceftazidime 0.166 -1.966 0.235 0.213 0.898 0.277
  




Ceftazidime 0.5 0.162 -1.613 0.180 0.545 0.936 0.574
  
Ceftazidime 0.125 -0.118 -1.358 0.125 0.797 0.953 0.738
  
Ceftazidime 0.0625 -0.180 -1.150 0.155 0.698 0.964 0.844
  
Ceftazidime 0.03125 -0.328 -1.304 0.196 0.440 0.918 0.416
  
Ceftazidime 0.015625 -0.405 -1.109 0.182 0.531 0.911 0.359
  
Ceftazidime 0.0078125 -0.353 -1.315 0.198 0.429 0.881 0.193
  
Ceftazidime 0.00391 -0.857 -0.958 0.232 0.229 0.828 0.057
  
Ceftazidime 0.00195 -1.028 -0.374 0.314 0.020 0.810 0.037
  
 
Column Sum Sum of Squares  
TSB 3.133 0.456  
Control 14.180 10.157  
Ceftazidime 1.043 0.148  
Ceftazidime 0.5 1.022 0.143  
Ceftazidime 0.5 0.994 0.134  
Ceftazidime 0.125 0.906 0.111  
Ceftazidime 0.0625 0.906 0.111  
Ceftazidime 0.03125 0.932 0.119  
Ceftazidime 0.015625 0.901 0.112  
Ceftazidime 0.0078125 0.874 0.103  
Ceftazidime 0.00391 0.881 0.105  
Ceftazidime 0.00195 0.898 0.108  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 24 0 0.131 0.0451 0.00921  
Control 24 0 0.591 0.278 0.0568  
Ceftazidime 8 0 0.130 0.0406 0.0143  
Ceftazidime 0.5 8 0 0.128 0.0425 0.0150  
Ceftazidime 0.5 8 0 0.124 0.0396 0.0140  
Ceftazidime 0.125 8 0 0.113 0.0354 0.0125  
Ceftazidime 0.0625 8 0 0.113 0.0357 0.0126  
Ceftazidime 0.03125 8 0 0.116 0.0391 0.0138  
Ceftazidime 0.015625 8 0 0.113 0.0377 0.0133  
Ceftazidime 0.0078125 8 0 0.109 0.0321 0.0114  
Ceftazidime 0.00391 8 0 0.110 0.0334 0.0118  
Ceftazidime 0.00195 8 0 0.112 0.0318 0.0112  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 4.328 0.393 23.758 <0.001  
Residual 116 1.921 0.0166    
Total 127 6.250     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.460 12.389 <0.001 Yes   
Control vs. Ceftazidime  0.482 9.166 <0.001 Yes   
Control vs. Ceftazidime  0.481 9.149 <0.001 Yes   
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Control vs. Ceftazidime  0.479 9.108 <0.001 Yes   
Control vs. Ceftazidime  0.478 9.101 <0.001 Yes   
Control vs. Ceftazidime 0.0625 0.478 9.091 <0.001 Yes   
Control vs. Ceftazidime 0.125 0.478 9.089 <0.001 Yes   
Control vs. Ceftazidime  0.474 9.028 <0.001 Yes   
Control vs. Ceftazidime 0.5 0.467 8.880 <0.001 Yes   
Control vs. Ceftazidime 0.5 0.463 8.815 <0.001 Yes   
Control vs. Ceftazidime 0.460 8.764 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.460 12.389 <0.001 Yes   
TSB vs. Ceftazidime 0.0078125 0.0213 0.405 1.000 No   
TSB vs. Ceftazidime 0.00391 0.0204 0.388 1.000 No   
TSB vs. Ceftazidime 0.00195 0.0183 0.348 1.000 No   
TSB vs. Ceftazidime 0.015625 0.0179 0.340 1.000 No   
TSB vs. Ceftazidime 0.0625 0.0173 0.330 1.000 No   
TSB vs. Ceftazidime 0.125 0.0173 0.329 0.999 No   
TSB vs. Ceftazidime 0.03125 0.0141 0.268 0.998 No   
TSB vs. Ceftazidime 0.5 0.00631 0.120 0.999 No   
TSB vs. Ceftazidime 0.5 0.00285 0.0542 0.998 No   
TSB vs. Ceftazidime 0.000171 0.00325 0.997 No   
 
Antibiotic Testing 24 on 8/25/14- Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0513 0.3658 0.1270 0.1024 0.0834 0.0760 0.0677 0.1159 0.0994 0.1250 0.0780 0.0795
B 0.1182 0.5300 0.1601 0.1523 0.1328 0.1217 0.1095 0.1199 0.1297 0.0906 0.1012 0.0933
C 0.1165 0.5527 0.1818 0.1632 0.1558 0.1460 0.1481 0.1372 0.1855 0.1504 0.1461 0.1464
D 0.1604 0.6134 0.1831 0.1953 0.1793 0.1696 0.1702 0.1740 0.1843 0.1584 0.1677 0.1489
E 0.1704 0.5896 0.2014 0.2367 0.2032 0.1848 0.1940 0.2138 0.1985 0.1827 0.1886 0.1803
F 0.1813 0.5451 0.2212 0.2439 0.2499 0.2013 0.1993 0.2236 0.1992 0.1968 0.1927 0.1905
G 0.1822 0.5448 0.2424 0.3002 0.2228 0.2095 0.2234 0.2479 0.2214 0.2554 0.2044 0.1999
H 0.1554 0.4808 0.1775 0.2737 0.2139 0.2038 0.2065 0.2241 0.2360 0.2431 0.1894 0.2079
average 0.1420 0.5278 0.1868 0.2085 0.1801 0.1641 0.1648 0.1821 0.1818 0.1753 0.1585 0.1558
range 0.1309 0.2476 0.1154 0.1978 0.1665 0.1335 0.1557 0.1320 0.1366 0.1648 0.1264 0.1284  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 24 0 0.131 0.0451 0.00921 0.0190  
Control 24 0 0.591 0.278 0.0568 0.117  
Gentamicin 8 0 0.187 0.0357 0.0126 0.0298  
Gentamicin 0.5 8 0 0.208 0.0669 0.0237 0.0559  
Gentamicin 0.25 8 0 0.180 0.0542 0.0192 0.0453  
Gentamicin 0.125 8 0 0.164 0.0469 0.0166 0.0392  
Gentamicin 0.0625 8 0 0.165 0.0535 0.0189 0.0447  
Gentamicin 0.03125 8 0 0.182 0.0523 0.0185 0.0437  
Gentamicin 0.015625 8 0 0.182 0.0457 0.0162 0.0382  
Gentamicin 0.0078125 8 0 0.175 0.0562 0.0199 0.0470  
Gentamicin 0.00391 8 0 0.159 0.0465 0.0164 0.0389  
Gentamicin 0.00195 8 0 0.156 0.0483 0.0171 0.0404  
 
Column Range Max Min  Median  25% 75%  
TSB 0.138 0.186 0.0478 0.130 0.101 0.169  
Control 0.943 1.004 0.0610 0.571 0.489 0.817  
Gentamicin 0.115 0.242 0.127 0.182 0.164 0.216  
Gentamicin 0.5 0.198 0.300 0.102 0.216 0.155 0.266  
Gentamicin 0.25 0.167 0.250 0.0834 0.191 0.139 0.221  
Gentamicin 0.125 0.134 0.209 0.0760 0.177 0.128 0.203  
Gentamicin 0.0625 0.156 0.223 0.0677 0.182 0.119 0.205  
Gentamicin 0.03125 0.132 0.248 0.116 0.194 0.124 0.224  
Gentamicin 0.015625 0.137 0.236 0.0994 0.192 0.143 0.216  
Gentamicin 0.0078125 0.165 0.255 0.0906 0.171 0.131 0.232  
Gentamicin 0.00391 0.126 0.204 0.0780 0.178 0.112 0.192  




Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB -0.590 -0.748 0.128 0.374 0.907 0.031  
Control -0.469 -0.510 0.139 0.261 0.934 0.120  
Gentamicin -0.0777 0.253 0.166 0.632 0.980 0.964  
Gentamicin 0.5 -0.222 -0.937 0.163 0.649 0.972 0.912  
Gentamicin 0.25 -0.668 -0.0657 0.165 0.642 0.964 0.845  
Gentamicin 0.125 -1.016 0.250 0.172 0.599 0.895 0.261  
Gentamicin 0.0625 -0.937 -0.0583 0.207 0.367 0.913 0.379  
Gentamicin 0.03125 -0.208 -1.967 0.228 0.247 0.885 0.211  
Gentamicin 0.015625 -0.934 0.186 0.272 0.083 0.905 0.321  
Gentamicin 0.0078125 0.0865 -0.758 0.136 0.773 0.970 0.900  
Gentamicin 0.00391 -0.981 -0.475 0.241 0.184 0.861 0.123  
Gentamicin 0.00195 -0.689 -0.981 0.194 0.455 0.895 0.262  
 
Column Sum Sum of Squares  
TSB 3.133 0.456  
Control 14.180 10.157  
Gentamicin 1.494 0.288  
Gentamicin 0.5 1.668 0.379  
Gentamicin 0.25 1.441 0.280  
Gentamicin 0.125 1.313 0.231  
Gentamicin 0.0625 1.319 0.237  
Gentamicin 0.03125 1.456 0.284  
Gentamicin 0.015625 1.454 0.279  
Gentamicin 0.0078125 1.402 0.268  
Gentamicin 0.00391 1.268 0.216  
Gentamicin 0.00195 1.247 0.211  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 24 0 0.131 0.0451 0.00921  
Control 24 0 0.591 0.278 0.0568  
Gentamicin 8 0 0.187 0.0357 0.0126  
Gentamicin 0.5 8 0 0.208 0.0669 0.0237  
Gentamicin 0.25 8 0 0.180 0.0542 0.0192  
Gentamicin 0.125 8 0 0.164 0.0469 0.0166  
Gentamicin 0.0625 8 0 0.165 0.0535 0.0189  
Gentamicin 0.03125 8 0 0.182 0.0523 0.0185  
Gentamicin 0.015625 8 0 0.182 0.0457 0.0162  
Gentamicin 0.0078125 8 0 0.175 0.0562 0.0199  
Gentamicin 0.00391 8 0 0.159 0.0465 0.0164  
Gentamicin 0.00195 8 0 0.156 0.0483 0.0171  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 3.586 0.326 18.820 <0.001  
Residual 116 2.009 0.0173    
Total 127 5.595     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.460 12.115 <0.001 Yes   
Control vs. Gentamicin 0.00195 0.435 8.096 <0.001 Yes   
Control vs. Gentamicin 0.00391 0.432 8.046 <0.001 Yes   
Control vs. Gentamicin 0.125 0.427 7.942 <0.001 Yes   
Control vs. Gentamicin 0.0625 0.426 7.928 <0.001 Yes   
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Control vs. Gentamicin 0 0.416 7.734 <0.001 Yes   
Control vs. Gentamicin 0.25 0.411 7.644 <0.001 Yes   
Control vs. Gentamicin 0 0.409 7.614 <0.001 Yes   
Control vs. Gentamicin 0.03125 0.409 7.608 <0.001 Yes   
Control vs. Gentamicin 0.404 7.519 <0.001 Yes   
Control vs. Gentamicin 0.5 0.382 7.116 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.460 12.115 <0.001 Yes   
TSB vs. Gentamicin 0.5 0.0779 1.450 0.802 No   
TSB vs. Gentamicin 0.0563 1.047 0.958 No   
TSB vs. Gentamicin 0.03125 0.0515 0.959 0.964 No   
TSB vs. Gentamicin 0.015625 0.0512 0.953 0.947 No   
TSB vs. Gentamicin 0.25 0.0496 0.923 0.930 No   
TSB vs. Gentamicin 0.0078125 0.0448 0.833 0.926 No   
TSB vs. Gentamicin 0.0625 0.0343 0.638 0.949 No   
TSB vs. Gentamicin 0.125 0.0335 0.624 0.899 No   
TSB vs. Gentamicin 0.00391 0.0280 0.521 0.843 No   
TSB vs. Gentamicin 0.00195 0.0253 0.471 0.639 No   
 
New Antibiotic Testing on 9/24/14 at 48 Hours-Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0283 0.0571 0.0656 0.0700 0.0402 0.0421 0.0412 0.0376 0.0381 0.0399 0.0384 0.0377
B 0.0311 0.0490 0.0664 0.0765 0.0435 0.0391 0.0402 0.0370 0.0390 0.0356 0.0415 0.0388
C 0.0314 0.0451 0.0809 0.0729 0.0475 0.0544 0.0409 0.0399 0.0375 0.0393 0.0402 0.0512
D 0.0355 0.0554 0.0726 0.0696 0.0543 0.0537 0.0456 0.0434 0.0399 0.0383 0.0377 0.0458
E 0.0328 0.0565 0.0800 0.0779 0.0599 0.0533 0.0475 0.0422 0.0401 0.0416 0.0378 0.0460
F 0.0343 0.0550 0.0624 0.0871 0.0518 0.0480 0.0438 0.0463 0.0472 0.0403 0.0450 0.0463
G 0.0433 0.0776 0.0931 0.1234 0.0699 0.0590 0.0578 0.0539 0.0524 0.2513 0.0526 0.0494
H 0.0402 0.0593 0.0912 0.1183 0.0739 0.0552 0.0480 0.0575 0.0565 0.0464 0.0465 0.0618
average 0.0346 0.0569 0.0765 0.0870 0.0551 0.0506 0.0456 0.0447 0.0438 0.0666 0.0425 0.0471
range 0.0150 0.0325 0.0307 0.0538 0.0337 0.0199 0.0176 0.0205 0.0190 0.2157 0.0149 0.0241  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0443 0.0171 0.00302 0.00616  
Control 32 0 0.888 0.601 0.106 0.217  
12.5mg 8 0 0.0765 0.0117 0.00414 0.00978  
6.25mg 8 0 0.0870 0.0217 0.00766 0.0181  
3.125mg 8 0 0.0551 0.0121 0.00427 0.0101  
1.5625mg 8 0 0.0506 0.00691 0.00244 0.00578  
0.78125mg 8 0 0.0456 0.00576 0.00204 0.00481  
0.390625mg 8 0 0.0447 0.00748 0.00264 0.00625  
0.1953125mg 8 0 0.0438 0.00728 0.00257 0.00609  
0.09765625mg 8 0 0.0666 0.0747 0.0264 0.0624  
0.04882813mg 8 0 0.0425 0.00524 0.00185 0.00438  
0.02441406mg 8 0 0.0471 0.00755 0.00267 0.00631  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0653 0.0916 0.0263 0.0364 0.0331 0.0517  
Control 1.504 1.549 0.0451 1.066 0.183 1.446  
12.5mg 0.0307 0.0931 0.0624 0.0763 0.0658 0.0886  
6.25mg 0.0538 0.123 0.0696 0.0772 0.0707 0.110  
3.125mg 0.0337 0.0739 0.0402 0.0531 0.0445 0.0674  
1.5625mg 0.0199 0.0590 0.0391 0.0535 0.0436 0.0550  
0.78125mg 0.0176 0.0578 0.0402 0.0447 0.0410 0.0479  
0.390625mg 0.0205 0.0575 0.0370 0.0428 0.0382 0.0520  
0.1953125mg 0.0190 0.0565 0.0375 0.0400 0.0383 0.0511  
0.09765625mg 0.216 0.251 0.0356 0.0401 0.0386 0.0452  
0.04882813mg 0.0149 0.0526 0.0377 0.0408 0.0379 0.0461  
0.02441406mg 0.0241 0.0618 0.0377 0.0461 0.0406 0.0507  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.404 1.092 0.232 <0.001 0.816 <0.001  
Control -0.316 -1.658 0.255 <0.001 0.808 <0.001  
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12.5mg 0.312 -1.475 0.182 0.536 0.916 0.401  
6.25mg 1.204 -0.303 0.287 0.051 0.772 0.014  
3.125mg 0.495 -0.974 0.152 0.710 0.944 0.652  
1.5625mg -0.784 -0.611 0.277 0.071 0.898 0.278  
0.78125mg 1.464 2.518 0.215 0.320 0.857 0.111  
0.390625mg 0.868 -0.471 0.195 0.445 0.897 0.273  
0.1953125mg 1.001 -0.639 0.321 0.015 0.822 0.050  
0.09765625mg 2.819 7.959 0.482 <0.001 0.456 <0.001  
0.04882813mg 1.103 0.612 0.198 0.428 0.878 0.178  
0.02441406mg 0.806 1.367 0.180 0.544 0.919 0.424  
 
Column Sum Sum of Squares  
TSB 1.418 0.0719  
Control 28.402 36.417  
12.5mg 0.612 0.0478  
6.25mg 0.696 0.0638  
3.125mg 0.441 0.0253  
1.5625mg 0.405 0.0208  
0.78125mg 0.365 0.0169  
0.390625mg 0.358 0.0164  
0.1953125mg 0.351 0.0157  
0.09765625mg 0.533 0.0745  
0.04882813mg 0.340 0.0146  
0.02441406mg 0.377 0.0182  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0443 0.0171 0.00302  
Control 32 0 0.888 0.601 0.106  
12.5mg 8 0 0.0765 0.0117 0.00414  
6.25mg 8 0 0.0870 0.0217 0.00766  
3.125mg 8 0 0.0551 0.0121 0.00427  
1.5625mg 8 0 0.0506 0.00691 0.00244  
0.78125mg 8 0 0.0456 0.00576 0.00204  
0.390625mg 8 0 0.0447 0.00748 0.00264  
0.1953125mg 8 0 0.0438 0.00728 0.00257  
0.09765625mg 8 0 0.0666 0.0747 0.0264  
0.04882813mg 8 0 0.0425 0.00524 0.00185  
0.02441406mg 8 0 0.0471 0.00755 0.00267  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 17.371 1.579 18.506 <0.001  
Residual 132 11.264 0.0853    
Total 143 28.635     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.843 11.547 <0.001 Yes   
Control vs. 0.04882813mg 0.845 7.319 <0.001 Yes   
Control vs. 0.1953125mg 0.844 7.307 <0.001 Yes   
Control vs. 0.390625mg 0.843 7.299 <0.001 Yes   
Control vs. 0.78125mg 0.842 7.291 <0.001 Yes   
Control vs. 0.02441406mg 0.840 7.278 <0.001 Yes   
Control vs. 1.5625mg 0.837 7.248 <0.001 Yes   
Control vs. 3.125mg 0.832 7.209 <0.001 Yes   
Control vs. 0.09765625mg 0.821 7.110 <0.001 Yes   
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Control vs. 12.5mg 0.811 7.024 <0.001 Yes   
Control vs. 6.25mg 0.801 6.933 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.843 11.547 <0.001 Yes   
TSB vs. 6.25mg 0.0427 0.369 1.000 No   
TSB vs. 12.5mg 0.0322 0.279 1.000 No   
TSB vs. 0.09765625mg 0.0223 0.193 1.000 No   
TSB vs. 3.125mg 0.0108 0.0937 1.000 No   
TSB vs. 1.5625mg 0.00630 0.0546 1.000 No   
TSB vs. 0.02441406mg 0.00283 0.0245 1.000 No   
TSB vs. 0.04882813mg 0.00184 0.0159 1.000 No   
TSB vs. 0.78125mg 0.00132 0.0115 1.000 No   
TSB vs. 0.1953125mg 0.000462 0.00401 1.000 No   
TSB vs. 0.390625mg 0.000425 0.00368 0.997 No   
 
New Antibiotic Testing on 9/24/14 at 48 Hours- Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0273 1.4444 0.1934 0.0348 0.0425 0.0373 0.0351 0.0373 0.0355 0.0368 0.0340 0.0350
B 0.0368 1.4464 0.0308 0.0380 0.0410 0.0366 0.0382 0.0370 0.0386 0.0365 0.0360 0.0369
C 0.0329 1.5225 0.0294 0.0525 0.0398 0.0454 0.0442 0.0422 0.0434 0.0466 0.0464 0.0465
D 0.0475 1.4564 0.0531 0.0649 0.0596 0.0598 0.0449 0.0490 0.0469 0.0443 0.0568 0.0546
E 0.0448 1.5387 0.0481 0.0535 0.0625 0.0489 0.0455 0.0490 0.0474 0.0501 0.0923 0.0420
F 0.0359 1.4015 0.0569 0.0807 0.0512 0.0514 0.0443 0.0525 0.0479 0.0480 0.0918 0.0600
G 0.0346 1.5486 0.0767 0.0736 0.0788 0.0638 0.0644 0.0839 0.0706 0.0709 0.0959 0.0729
H 0.0393 1.4607 0.0675 0.0868 0.0782 0.0646 0.0442 0.0517 0.0511 0.0458 0.0680 0.0814
average 0.0374 1.4774 0.0695 0.0606 0.0567 0.0510 0.0451 0.0503 0.0477 0.0474 0.0652 0.0537
range 0.0202 0.1471 0.1640 0.0520 0.0390 0.0280 0.0293 0.0469 0.0351 0.0344 0.0619 0.0464  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0443 0.0171 0.00302 0.00616  
Control 32 0 0.888 0.601 0.106 0.217  
25mg 8 0 0.0695 0.0526 0.0186 0.0440  
12.5mg 8 0 0.0606 0.0192 0.00677 0.0160  
6.25mg 8 0 0.0567 0.0158 0.00560 0.0132  
3.125mg 8 0 0.0510 0.0111 0.00391 0.00925  
1.5625mg 8 0 0.0451 0.00864 0.00305 0.00722  
0.78125mg 8 0 0.0503 0.0149 0.00526 0.0124  
0.390625mg 8 0 0.0477 0.0106 0.00375 0.00886  
0.1953125mg 8 0 0.0474 0.0107 0.00379 0.00896  
0.09765625mg 8 0 0.0652 0.0258 0.00910 0.0215  
0.04882813mg 8 0 0.0537 0.0169 0.00597 0.0141  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0653 0.0916 0.0263 0.0364 0.0331 0.0517  
Control 1.504 1.549 0.0451 1.066 0.183 1.446  
25mg 0.164 0.193 0.0294 0.0550 0.0351 0.0744  
12.5mg 0.0520 0.0868 0.0348 0.0592 0.0416 0.0789  
6.25mg 0.0390 0.0788 0.0398 0.0554 0.0414 0.0743  
3.125mg 0.0280 0.0646 0.0366 0.0502 0.0393 0.0628  
1.5625mg 0.0293 0.0644 0.0351 0.0442 0.0397 0.0454  
0.78125mg 0.0469 0.0839 0.0370 0.0490 0.0385 0.0523  
0.390625mg 0.0351 0.0706 0.0355 0.0471 0.0398 0.0503  
0.1953125mg 0.0344 0.0709 0.0365 0.0462 0.0387 0.0496  
0.09765625mg 0.0619 0.0959 0.0340 0.0624 0.0386 0.0922  
0.04882813mg 0.0464 0.0814 0.0350 0.0505 0.0382 0.0697  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.404 1.092 0.232 <0.001 0.816 <0.001  
Control -0.316 -1.658 0.255 <0.001 0.808 <0.001  
25mg 2.304 5.854 0.321 0.015 0.710 0.003  
12.5mg -0.0331 -1.406 0.145 0.744 0.946 0.670  
6.25mg 0.442 -1.430 0.190 0.480 0.881 0.193  
3.125mg -0.0539 -1.557 0.162 0.656 0.914 0.381  
158 
 
1.5625mg 1.730 4.391 0.357 0.003 0.778 0.017  
0.78125mg 1.892 4.431 0.317 0.018 0.783 0.019  
0.390625mg 1.512 3.387 0.248 0.155 0.860 0.119  
0.1953125mg 1.631 3.755 0.275 0.077 0.823 0.050  
0.09765625mg 0.0655 -1.989 0.225 0.265 0.878 0.180  
0.04882813mg 0.615 -0.890 0.164 0.645 0.929 0.506  
 
Column Sum Sum of Squares  
TSB 1.418 0.0719  
Control 28.402 36.417  
25mg 0.556 0.0580  
12.5mg 0.485 0.0319  
6.25mg 0.454 0.0275  
3.125mg 0.408 0.0216  
1.5625mg 0.361 0.0168  
0.78125mg 0.403 0.0218  
0.390625mg 0.381 0.0190  
0.1953125mg 0.379 0.0188  
0.09765625mg 0.521 0.0386  
0.04882813mg 0.429 0.0250  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0443 0.0171 0.00302  
Control 32 0 0.888 0.601 0.106  
25mg 8 0 0.0695 0.0526 0.0186  
12.5mg 8 0 0.0606 0.0192 0.00677  
6.25mg 8 0 0.0567 0.0158 0.00560  
3.125mg 8 0 0.0510 0.0111 0.00391  
1.5625mg 8 0 0.0451 0.00864 0.00305  
0.78125mg 8 0 0.0503 0.0149 0.00526  
0.390625mg 8 0 0.0477 0.0106 0.00375  
0.1953125mg 8 0 0.0474 0.0107 0.00379  
0.09765625mg 8 0 0.0652 0.0258 0.00910  
0.04882813mg 8 0 0.0537 0.0169 0.00597  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 17.395 1.581 18.550 <0.001  
Residual 132 11.253 0.0852    
Total 143 28.648     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.843 11.553 <0.001 Yes   
Control vs. 1.5625mg 0.842 7.300 <0.001 Yes   
Control vs. 0.1953125mg 0.840 7.280 <0.001 Yes   
Control vs. 0.390625mg 0.840 7.277 <0.001 Yes   
Control vs. 0.78125mg 0.837 7.254 <0.001 Yes   
Control vs. 3.125mg 0.837 7.249 <0.001 Yes   
Control vs. 0.04882813mg 0.834 7.225 <0.001 Yes   
Control vs. 6.25mg 0.831 7.199 <0.001 Yes   
Control vs. 12.5mg 0.827 7.165 <0.001 Yes   
Control vs. 0.09765625mg 0.822 7.126 <0.001 Yes   
Control vs. 25mg 0.818 7.088 <0.001 Yes   
 
Comparisons for factor:  
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Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.843 11.553 <0.001 Yes   
TSB vs. 25mg 0.0252 0.218 1.000 No   
TSB vs. 0.09765625mg 0.0209 0.181 1.000 No   
TSB vs. 12.5mg 0.0163 0.141 1.000 No   
TSB vs. 6.25mg 0.0124 0.107 1.000 No   
TSB vs. 0.04882813mg 0.00936 0.0811 1.000 No   
TSB vs. 3.125mg 0.00668 0.0578 1.000 No   
TSB vs. 0.78125mg 0.00603 0.0522 1.000 No   
TSB vs. 0.390625mg 0.00337 0.0292 1.000 No   
TSB vs. 0.1953125mg 0.00308 0.0266 1.000 No   
TSB vs. 1.5625mg 0.000800 0.00693 0.994 No   
 
New Antibiotic Testing on 9/25/14 at 48 hours- Rifampicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0353 0.6501 OVER OVER 1.5320 0.7365 0.3719 0.1919 0.1194 0.0659 0.2252 0.7813
B 0.0765 0.5346 OVER OVER 2.0327 1.0589 0.4907 0.2918 0.1273 0.0962 0.5531 0.7055
C 0.0916 0.8453 OVER OVER 1.8894 0.9186 0.4758 0.2550 0.1638 0.1092 0.8378 1.3727
D 0.0682 0.6510 OVER OVER 1.6420 0.8401 0.4798 0.2576 0.1623 0.2694 0.6621 1.4392
E 0.0666 0.6670 OVER 2.6735 1.3757 0.6984 0.4269 0.2346 0.1637 0.2120 0.8836 1.4783
F 0.0564 0.4973 OVER 2.3608 1.2939 0.6779 0.3833 0.2296 0.1537 0.4407 1.2628 1.4164
G 0.0531 0.5323 OVER 2.4477 1.2183 0.6364 0.4079 0.1957 0.1401 0.3212 1.2948 1.3516
H 0.0368 0.5077 OVER 2.1362 1.0949 0.5906 0.3524 0.1879 0.1071 0.3379 1.3089 1.2454
average 0.0606 0.6107 #DIV/0! 2.4046 1.5099 0.7697 0.4236 0.2305 0.1422 0.2316 0.8785 1.2238
range 0.0563 0.3480 0.0000 0.5373 0.9378 0.4683 0.1383 0.1039 0.0567 0.3748 1.0837 0.7728  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0443 0.0171 0.00302 0.00616  
Control 32 0 0.888 0.601 0.106 0.217  
2.5mg 8 8 -- -- -- --  
1.25mg 8 4 2.405 0.222 0.111 0.354  
0.625mg 8 0 1.510 0.329 0.116 0.275  
0.3125mg 8 0 0.770 0.158 0.0559 0.132  
0.15625mg 8 0 0.424 0.0535 0.0189 0.0447  
0.078125mg 8 0 0.231 0.0371 0.0131 0.0310  
0.039062mg 8 0 0.142 0.0222 0.00784 0.0185  
0.01953125mg 8 0 0.232 0.134 0.0474 0.112  
0.00976563mg 8 0 0.879 0.394 0.139 0.330  
0.00488281mg 8 0 1.224 0.305 0.108 0.255  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0653 0.0916 0.0263 0.0364 0.0331 0.0517  
Control 1.504 1.549 0.0451 1.066 0.183 1.446  
2.5mg -- -- -- -- -- --  
1.25mg 0.537 2.674 2.136 2.404 2.192 2.617  
0.625mg 0.938 2.033 1.095 1.454 1.237 1.828  
0.3125mg 0.468 1.059 0.591 0.717 0.647 0.899  
0.15625mg 0.138 0.491 0.352 0.417 0.375 0.479  
0.078125mg 0.104 0.292 0.188 0.232 0.193 0.257  
0.039062mg 0.0567 0.164 0.107 0.147 0.121 0.163  
0.01953125mg 0.375 0.441 0.0659 0.241 0.0994 0.334  
0.00976563mg 1.084 1.309 0.225 0.861 0.580 1.287  
0.00488281mg 0.773 1.478 0.706 1.362 0.897 1.434  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.404 1.092 0.232 <0.001 0.816 <0.001  
Control -0.316 -1.658 0.255 <0.001 0.808 <0.001  
2.5mg -- -- -- -- -- --  
1.25mg 0.00769 0.755 0.173 0.696 0.994 0.977  
0.625mg 0.488 -0.940 0.158 0.678 0.953 0.741  
0.3125mg 0.893 0.000407 0.208 0.362 0.928 0.495  
0.15625mg 0.0675 -1.828 0.211 0.346 0.912 0.368  
0.078125mg 0.328 -0.912 0.201 0.407 0.924 0.464  
0.039062mg -0.498 -1.433 0.198 0.424 0.885 0.212  
0.01953125mg 0.179 -1.259 0.194 0.450 0.940 0.608  
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0.00976563mg -0.358 -0.897 0.210 0.349 0.916 0.399  
0.00488281mg -1.253 -0.193 0.287 0.051 0.767 0.012  
 
Column Sum Sum of Squares  
TSB 1.418 0.0719  
Control 28.402 36.417  
2.5mg -- --  
1.25mg 9.618 23.276  
0.625mg 12.079 18.995  
0.3125mg 6.157 4.914  
0.15625mg 3.389 1.455  
0.078125mg 1.844 0.435  
0.039062mg 1.137 0.165  
0.01953125mg 1.852 0.555  
0.00976563mg 7.028 7.262  
0.00488281mg 9.790 12.633  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0443 0.0171 0.00302  
Control 32 0 0.888 0.601 0.106  
2.5mg 8 8 -- -- --  
1.25mg 8 4 2.405 0.222 0.111  
0.625mg 8 0 1.510 0.329 0.116  
0.3125mg 8 0 0.770 0.158 0.0559  
0.15625mg 8 0 0.424 0.0535 0.0189  
0.078125mg 8 0 0.231 0.0371 0.0131  
0.039062mg 8 0 0.142 0.0222 0.00784  
0.01953125mg 8 0 0.232 0.134 0.0474  
0.00976563mg 8 0 0.879 0.394 0.139  
0.00488281mg 8 0 1.224 0.305 0.108  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 10 40.151 4.015 34.222 <0.001  
Residual 121 14.196 0.117    
Total 131 54.347     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.843 9.848 <0.001 Yes   
Control vs. 1.25mg 1.517 8.351 <0.001 Yes   
Control vs. 0.039062mg 0.745 5.505 <0.001 Yes   
Control vs. 0.078125mg 0.657 4.853 <0.001 Yes   
Control vs. 0.01953125mg 0.656 4.845 <0.001 Yes   
Control vs. 0.625mg 0.622 4.596 <0.001 Yes   
Control vs. 0.15625mg 0.464 3.427 0.003 Yes   
Control vs. 0.00488281mg 0.336 2.483 0.043 Yes   
Control vs. 0.3125mg 0.118 0.871 0.623 No   
Control vs. 0.00976563mg 0.00903 0.0667 0.947 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. 1.25mg 2.360 12.993 <0.001 Yes   
TSB vs. 0.625mg 1.466 10.824 <0.001 Yes   
TSB vs. Control 0.843 9.848 <0.001 Yes   
TSB vs. 0.00488281mg 1.180 8.711 <0.001 Yes   
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TSB vs. 0.00976563mg 0.834 6.161 <0.001 Yes   
TSB vs. 0.3125mg 0.725 5.357 <0.001 Yes   
TSB vs. 0.15625mg 0.379 2.801 0.023 Yes   
TSB vs. 0.01953125mg 0.187 1.383 0.427 No   
TSB vs. 0.078125mg 0.186 1.375 0.314 No   
TSB vs. 0.039062mg 0.0979 0.723 0.471 No   
 
New Antibiotic Testing on 9/25/14 at 48 hours- Polymyxin B 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0263 1.2873 0.1417 0.1353 0.0602 0.0499 0.0551 0.0430 0.0461 0.0428 0.0423 0.0383
B 0.0339 1.4053 0.0689 0.0717 0.0502 0.0574 0.0569 0.0470 0.0386 0.0634 0.0413 0.0343
C 0.0353 1.4101 0.0739 0.0724 0.0575 0.0573 0.0584 0.0499 0.0582 0.0418 0.0427 0.0436
D 0.0447 1.4818 0.1027 0.1102 0.0898 0.0819 0.1002 0.0604 0.0476 0.0790 0.0488 0.0476
E 0.0829 1.4842 0.1058 0.0870 0.0873 0.0876 0.0705 0.0697 0.0477 0.0611 0.0394 0.0403
F 0.0316 1.4425 0.1478 0.0985 0.0749 0.0824 0.0975 0.0595 0.0453 0.0524 0.0599 0.0622
G 0.0669 1.3672 0.1511 0.1168 0.0889 0.1077 0.1003 0.1027 0.0757 0.1264 0.0656 0.1087
H 0.0355 1.3641 0.1988 0.1208 0.1057 0.0646 0.1286 0.0938 0.0842 0.0581 0.1179 0.0686
average 0.0446 1.4053 0.1238 0.1016 0.0768 0.0736 0.0834 0.0658 0.0554 0.0656 0.0572 0.0555
range 0.0566 0.1969 0.1299 0.0636 0.0555 0.0578 0.0735 0.0597 0.0456 0.0846 0.0785 0.0744  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0443 0.0171 0.00302 0.00616  
Control 32 0 0.888 0.601 0.106 0.217  
12.5mg 8 0 0.124 0.0440 0.0155 0.0368  
6.25mg 8 0 0.102 0.0232 0.00821 0.0194  
3.125mg 8 0 0.0768 0.0193 0.00684 0.0162  
1.5625mg 8 0 0.0736 0.0196 0.00691 0.0163  
0.78125mg 8 0 0.0834 0.0270 0.00955 0.0226  
0.390625mg 8 0 0.0658 0.0219 0.00774 0.0183  
0.1953125mg 8 0 0.0554 0.0162 0.00573 0.0136  
0.09765625mg 8 0 0.0656 0.0273 0.00965 0.0228  
0.04882813mg 8 0 0.0572 0.0263 0.00929 0.0220  
0.02441406mg 8 0 0.0554 0.0246 0.00869 0.0205  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0653 0.0916 0.0263 0.0364 0.0331 0.0517  
Control 1.504 1.549 0.0451 1.066 0.183 1.446  
12.5mg 0.130 0.199 0.0689 0.124 0.0811 0.150  
6.25mg 0.0636 0.135 0.0717 0.104 0.0761 0.120  
3.125mg 0.0555 0.106 0.0502 0.0811 0.0582 0.0896  
1.5625mg 0.0578 0.108 0.0499 0.0733 0.0573 0.0863  
0.78125mg 0.0735 0.129 0.0551 0.0840 0.0573 0.100  
0.390625mg 0.0597 0.103 0.0430 0.0600 0.0477 0.0878  
0.1953125mg 0.0456 0.0842 0.0386 0.0476 0.0455 0.0713  
0.09765625mg 0.0846 0.126 0.0418 0.0596 0.0452 0.0751  
0.04882813mg 0.0785 0.118 0.0394 0.0457 0.0415 0.0642  
0.02441406mg 0.0744 0.109 0.0343 0.0456 0.0388 0.0670  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.404 1.092 0.232 <0.001 0.816 <0.001  
Control -0.316 -1.658 0.255 <0.001 0.808 <0.001  
12.5mg 0.348 -0.484 0.159 0.674 0.942 0.632  
6.25mg -0.0779 -1.304 0.145 0.740 0.942 0.633  
3.125mg -0.0375 -1.290 0.206 0.374 0.936 0.573  
1.5625mg 0.536 -0.530 0.177 0.563 0.931 0.525  
0.78125mg 0.436 -1.082 0.199 0.422 0.881 0.191  
0.390625mg 0.904 -0.513 0.222 0.282 0.883 0.202  
0.1953125mg 1.101 -0.137 0.308 0.024 0.841 0.076  
0.09765625mg 1.859 3.925 0.282 0.060 0.803 0.031  
0.04882813mg 2.173 5.027 0.251 0.145 0.710 0.003  
0.02441406mg 1.713 3.031 0.250 0.148 0.814 0.040  
 
Column Sum Sum of Squares  
TSB 1.418 0.0719  
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Control 28.402 36.417  
12.5mg 0.991 0.136  
6.25mg 0.813 0.0863  
3.125mg 0.615 0.0498  
1.5625mg 0.589 0.0460  
0.78125mg 0.667 0.0608  
0.390625mg 0.526 0.0379  
0.1953125mg 0.443 0.0264  
0.09765625mg 0.525 0.0397  
0.04882813mg 0.458 0.0310  
0.02441406mg 0.444 0.0288  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0443 0.0171 0.00302  
Control 32 0 0.888 0.601 0.106  
12.5mg 8 0 0.124 0.0440 0.0155  
6.25mg 8 0 0.102 0.0232 0.00821  
3.125mg 8 0 0.0768 0.0193 0.00684  
1.5625mg 8 0 0.0736 0.0196 0.00691  
0.78125mg 8 0 0.0834 0.0270 0.00955  
0.390625mg 8 0 0.0658 0.0219 0.00774  
0.1953125mg 8 0 0.0554 0.0162 0.00573  
0.09765625mg 8 0 0.0656 0.0273 0.00965  
0.04882813mg 8 0 0.0572 0.0263 0.00929  
0.02441406mg 8 0 0.0554 0.0246 0.00869  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 16.822 1.529 17.920 <0.001  
Residual 132 11.265 0.0853    
Total 143 28.087     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.843 11.546 <0.001 Yes   
Control vs. 0.1953125mg 0.832 7.206 <0.001 Yes   
Control vs. 0.02441406mg 0.832 7.206 <0.001 Yes   
Control vs. 0.04882813mg 0.830 7.190 <0.001 Yes   
Control vs. 0.09765625mg 0.822 7.118 <0.001 Yes   
Control vs. 0.390625mg 0.822 7.117 <0.001 Yes   
Control vs. 1.5625mg 0.814 7.049 <0.001 Yes   
Control vs. 3.125mg 0.811 7.021 <0.001 Yes   
Control vs. 0.78125mg 0.804 6.964 <0.001 Yes   
Control vs. 6.25mg 0.786 6.806 <0.001 Yes   
Control vs. 12.5mg 0.764 6.614 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.843 11.546 <0.001 Yes   
TSB vs. 12.5mg 0.0795 0.689 0.999 No   
TSB vs. 6.25mg 0.0573 0.496 1.000 No   
TSB vs. 0.78125mg 0.0391 0.339 1.000 No   
TSB vs. 3.125mg 0.0325 0.282 1.000 No   
TSB vs. 1.5625mg 0.0293 0.254 1.000 No   
TSB vs. 0.390625mg 0.0215 0.186 1.000 No   
TSB vs. 0.09765625mg 0.0213 0.185 1.000 No   
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TSB vs. 0.04882813mg 0.0129 0.112 0.999 No   
TSB vs. 0.02441406mg 0.0112 0.0966 0.994 No   
TSB vs. 0.1953125mg 0.0111 0.0963 0.923 No   
 
New Antibiotic Testing on 10/1/15- Higher Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0454 0.0441 0.0447 0.0474 0.0357 0.0335 0.0365 0.0327 0.0317 0.0317 0.0298 0.0338
B 0.0460 0.0615 0.0597 0.0721 0.0515 0.0438 0.0439 0.0363 0.0314 0.0283 0.0318 0.0334
C 0.0622 0.0563 0.0596 0.0636 0.0453 0.0514 0.0573 0.0464 0.0494 0.0548 0.0559 0.0606
D 0.0844 0.0905 0.0933 0.1104 0.0899 0.0802 0.0803 0.0681 0.0627 0.0582 0.0595 0.0718
E 0.0610 0.0970 0.1083 0.1210 0.1012 0.0962 0.1203 0.0854 0.0895 0.0921 0.0841 0.0944
F 0.0850 0.1561 0.1407 0.1532 0.1175 0.1164 0.1057 0.1013 0.0969 0.0872 0.0830 0.1111
G 0.1175 0.1784 0.1615 0.1787 0.1468 0.1178 0.1606 0.1178 0.1265 0.1259 0.0920 0.1271
H 0.0369 0.1199 0.1070 0.1349 0.1006 0.0962 0.1072 0.1043 0.1055 0.1017 0.1079 0.1327
average 0.0673 0.1005 0.0969 0.1102 0.0861 0.0794 0.0890 0.0740 0.0742 0.0725 0.0680 0.0831
range 0.0806 0.1343 0.1168 0.1313 0.1111 0.0843 0.1241 0.0851 0.0951 0.0976 0.0781 0.0993  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0397 0.0211 0.00372 0.00759  
Control 32 0 0.325 0.444 0.0784 0.160  
6.25mg 8 0 0.0968 0.0411 0.0145 0.0344  
3.125mg 8 0 0.110 0.0460 0.0163 0.0385  
1.5625mg 8 0 0.0861 0.0388 0.0137 0.0324  
0.78125mg 8 0 0.0794 0.0329 0.0116 0.0275  
0.390625mg 8 0 0.0890 0.0424 0.0150 0.0355  
0.1953125mg 8 0 0.0740 0.0330 0.0117 0.0276  
0.09765625mg 8 0 0.0742 0.0356 0.0126 0.0297  
0.04882813mg 8 0 0.0725 0.0347 0.0123 0.0290  
0.02441406mg 8 0 0.0680 0.0284 0.0100 0.0237  
0.01220703mg 8 0 0.0831 0.0394 0.0139 0.0329  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0974 0.117 0.0201 0.0321 0.0295 0.0391  
Control 1.079 1.115 0.0359 0.0832 0.0488 0.799  
6.25mg 0.117 0.162 0.0447 0.100 0.0596 0.133  
3.125mg 0.131 0.179 0.0474 0.116 0.0657 0.149  
1.5625mg 0.111 0.147 0.0357 0.0953 0.0469 0.113  
0.78125mg 0.0843 0.118 0.0335 0.0882 0.0457 0.111  
0.390625mg 0.124 0.161 0.0365 0.0930 0.0473 0.117  
0.1953125mg 0.0851 0.118 0.0327 0.0767 0.0388 0.104  
0.09765625mg 0.0951 0.127 0.0314 0.0761 0.0361 0.103  
0.04882813mg 0.0976 0.126 0.0283 0.0727 0.0375 0.0993  
0.02441406mg 0.0781 0.108 0.0298 0.0713 0.0378 0.0900  
0.01220703mg 0.0993 0.133 0.0334 0.0831 0.0405 0.123  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 2.366 5.838 0.292 <0.001 0.696 <0.001  
Control 1.199 -0.568 0.380 <0.001 0.603 <0.001  
6.25mg 0.307 -1.012 0.192 0.467 0.942 0.633  
3.125mg 0.0288 -1.221 0.171 0.605 0.961 0.817  
1.5625mg 0.0816 -1.062 0.189 0.489 0.938 0.593  
0.78125mg -0.257 -1.709 0.195 0.447 0.904 0.315  
0.390625mg 0.351 -0.638 0.153 0.704 0.951 0.724  
0.1953125mg -0.0658 -1.843 0.174 0.587 0.915 0.392  
0.09765625mg 0.0723 -1.516 0.167 0.631 0.930 0.515  
0.04882813mg 0.116 -1.178 0.164 0.646 0.946 0.672  
0.02441406mg -0.172 -1.279 0.201 0.404 0.933 0.548  
0.01220703mg -0.0788 -1.654 0.145 0.742 0.917 0.406  
 
Column Sum Sum of Squares  
TSB 1.269 0.0641  
Control 10.406 9.482  
6.25mg 0.775 0.0869  
3.125mg 0.881 0.112  
1.5625mg 0.689 0.0698  
0.78125mg 0.635 0.0580  
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0.390625mg 0.712 0.0759  
0.1953125mg 0.592 0.0515  
0.09765625mg 0.594 0.0529  
0.04882813mg 0.580 0.0505  
0.02441406mg 0.544 0.0426  
0.01220703mg 0.665 0.0661  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0397 0.0211 0.00372  
Control 32 0 0.325 0.444 0.0784  
6.25mg 8 0 0.0968 0.0411 0.0145  
3.125mg 8 0 0.110 0.0460 0.0163  
1.5625mg 8 0 0.0861 0.0388 0.0137  
0.78125mg 8 0 0.0794 0.0329 0.0116  
0.390625mg 8 0 0.0890 0.0424 0.0150  
0.1953125mg 8 0 0.0740 0.0330 0.0117  
0.09765625mg 8 0 0.0742 0.0356 0.0126  
0.04882813mg 8 0 0.0725 0.0347 0.0123  
0.02441406mg 8 0 0.0680 0.0284 0.0100  
0.01220703mg 8 0 0.0831 0.0394 0.0139  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 1.666 0.151 3.218 <0.001  
Residual 132 6.210 0.0470    
Total 143 7.876     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.922 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.286 5.266 <0.001 Yes   
Control vs. 0.02441406mg 0.257 3.000 0.032 Yes   
Control vs. 0.04882813mg 0.253 2.947 0.034 Yes   
Control vs. 0.1953125mg 0.251 2.929 0.032 Yes   
Control vs. 0.09765625mg 0.251 2.928 0.028 Yes   
Control vs. 0.78125mg 0.246 2.866 0.029 Yes   
Control vs. 0.01220703mg 0.242 2.824 0.027 Yes   
Control vs. 1.5625mg 0.239 2.789 0.024 Yes   
Control vs. 0.390625mg 0.236 2.755 0.020 Yes   
Control vs. 6.25mg 0.228 2.663 0.017 Yes   
Control vs. 3.125mg 0.215 2.508 0.013 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.286 5.266 <0.001 Yes   
TSB vs. 3.125mg 0.0705 0.822 0.995 No   
TSB vs. 6.25mg 0.0572 0.667 0.998 No   
TSB vs. 0.390625mg 0.0493 0.575 0.999 No   
TSB vs. 1.5625mg 0.0464 0.541 0.998 No   
TSB vs. 0.01220703mg 0.0435 0.507 0.997 No   
TSB vs. 0.78125mg 0.0398 0.464 0.994 No   
TSB vs. 0.09765625mg 0.0345 0.403 0.990 No   
TSB vs. 0.1953125mg 0.0344 0.401 0.970 No   
TSB vs. 0.04882813mg 0.0328 0.383 0.911 No   





New Antibiotic Testing on 10/1/14 at 48 Hours- Lower Ciprofloxacin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0253 0.0495 0.0299 0.0295 0.0318 0.0328 0.0301 0.0347 0.0292 0.0286 0.0303 0.0292
B 0.0374 0.0619 0.0379 0.0376 0.0379 0.0312 0.0321 0.0306 0.0298 0.0258 0.0316 0.0308
C 0.0303 0.0676 0.0326 0.0347 0.0352 0.0303 0.0328 0.0375 0.0347 0.0428 0.0412 0.0479
D 0.0514 0.0913 0.0558 0.0589 0.0561 0.0509 0.0491 0.0502 0.0409 0.0469 0.0455 0.0483
E 0.0482 0.1096 0.0488 0.0530 0.0560 0.0503 0.0525 0.0630 0.0505 0.0536 0.0563 0.0612
F 0.0555 0.0977 0.0484 0.0619 0.0662 0.0555 0.0550 0.0567 0.0535 0.0531 0.0537 0.0663
G 0.0456 0.1145 0.0646 0.0481 0.0565 0.0388 0.0344 0.0390 0.0361 0.0390 0.0363 0.0549
H 0.0314 0.0777 0.0582 0.0599 0.0433 0.0427 0.0418 0.0406 0.0586 0.0441 0.0421 0.0630
average 0.0406 0.0837 0.0470 0.0480 0.0479 0.0416 0.0410 0.0440 0.0417 0.0417 0.0421 0.0502
range 0.0302 0.0650 0.0347 0.0324 0.0344 0.0252 0.0249 0.0324 0.0294 0.0278 0.0260 0.0371  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0319 0.00942 0.00167 0.00340  
Control 32 0 0.466 0.454 0.0803 0.164  
3.125mg 8 0 0.0470 0.0125 0.00443 0.0105  
1.5625mg 8 0 0.0480 0.0126 0.00444 0.0105  
0.78125mg 8 0 0.0479 0.0124 0.00440 0.0104  
0.390625mg 8 0 0.0416 0.00984 0.00348 0.00823  
0.1953125mg 8 0 0.0410 0.0100 0.00354 0.00838  
0.09765625mg 8 0 0.0440 0.0114 0.00402 0.00951  
0.04882813mg 8 0 0.0417 0.0112 0.00397 0.00938  
0.02441406mg 8 0 0.0417 0.0103 0.00363 0.00858  
0.01220703mg 8 0 0.0421 0.00950 0.00336 0.00794  
.0.00610352mg 8 0 0.0502 0.0141 0.00499 0.0118  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0363 0.0564 0.0201 0.0284 0.0255 0.0334  
Control 1.162 1.201 0.0391 0.275 0.0674 0.946  
3.125mg 0.0347 0.0646 0.0299 0.0486 0.0339 0.0576  
1.5625mg 0.0324 0.0619 0.0295 0.0505 0.0354 0.0596  
0.78125mg 0.0344 0.0662 0.0318 0.0497 0.0359 0.0564  
0.390625mg 0.0252 0.0555 0.0303 0.0408 0.0316 0.0508  
0.1953125mg 0.0249 0.0550 0.0301 0.0381 0.0323 0.0516  
0.09765625mg 0.0324 0.0630 0.0306 0.0398 0.0354 0.0551  
0.04882813mg 0.0294 0.0586 0.0292 0.0385 0.0310 0.0527  
0.02441406mg 0.0278 0.0536 0.0258 0.0435 0.0312 0.0515  
0.01220703mg 0.0260 0.0563 0.0303 0.0417 0.0328 0.0516  
.0.00610352mg 0.0371 0.0663 0.0292 0.0516 0.0351 0.0625  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.518 1.520 0.245 <0.001 0.809 <0.001  
Control 0.547 -1.418 0.281 <0.001 0.798 <0.001  
3.125mg -0.123 -1.387 0.169 0.618 0.945 0.662  
1.5625mg -0.370 -1.721 0.183 0.525 0.902 0.300  
0.78125mg 0.0603 -1.605 0.243 0.176 0.913 0.378  
0.390625mg 0.191 -1.800 0.188 0.490 0.905 0.319  
0.1953125mg 0.380 -1.938 0.244 0.172 0.874 0.164  
0.09765625mg 0.698 -0.818 0.244 0.173 0.921 0.437  
0.04882813mg 0.417 -1.540 0.190 0.480 0.910 0.357  
0.02441406mg -0.537 -0.833 0.166 0.633 0.919 0.420  
0.01220703mg 0.315 -1.051 0.138 0.766 0.941 0.623  
.0.00610352mg -0.603 -1.041 0.185 0.512 0.897 0.270  
 
Column Sum Sum of Squares 
TSB 1.020 0.0353  
Control 14.922 13.347  
3.125mg 0.376 0.0188  
1.5625mg 0.384 0.0195  
0.78125mg 0.383 0.0194  
0.390625mg 0.333 0.0145  
0.1953125mg 0.328 0.0141  
0.09765625mg 0.352 0.0164  
0.04882813mg 0.333 0.0148  
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0.02441406mg 0.334 0.0147  
0.01220703mg 0.337 0.0148  
.0.00610352mg 0.402 0.0216  
 
One Way Analysis of Variance 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0319 0.00942 0.00167  
Control 32 0 0.466 0.454 0.0803  
3.125mg 8 0 0.0470 0.0125 0.00443  
1.5625mg 8 0 0.0480 0.0126 0.00444  
0.78125mg 8 0 0.0479 0.0124 0.00440  
0.390625mg 8 0 0.0416 0.00984 0.00348  
0.1953125mg 8 0 0.0410 0.0100 0.00354  
0.09765625mg 8 0 0.0440 0.0114 0.00402  
0.04882813mg 8 0 0.0417 0.0112 0.00397  
0.02441406mg 8 0 0.0417 0.0103 0.00363  
0.01220703mg 8 0 0.0421 0.00950 0.00336  
.0.00610352mg 8 0 0.0502 0.0141 0.00499  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 4.508 0.410 8.452 <0.001  
Residual 132 6.401 0.0485    
Total 143 10.910     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.434 7.891 <0.001 Yes   
Control vs. 0.1953125mg 0.425 4.886 <0.001 Yes   
Control vs. 0.390625mg 0.425 4.879 <0.001 Yes   
Control vs. 0.04882813mg 0.425 4.878 <0.001 Yes   
Control vs. 0.02441406mg 0.425 4.877 <0.001 Yes   
Control vs. 0.01220703mg 0.424 4.873 <0.001 Yes   
Control vs. 0.09765625mg 0.422 4.851 <0.001 Yes   
Control vs. 3.125mg 0.419 4.817 <0.001 Yes   
Control vs. 0.78125mg 0.418 4.807 <0.001 Yes   
Control vs. 1.5625mg 0.418 4.806 <0.001 Yes   
Control vs. .0.00610352mg 0.416 4.780 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.434 7.891 <0.001 Yes   
TSB vs. .0.00610352mg 0.0183 0.210 1.000 No   
TSB vs. 1.5625mg 0.0161 0.185 1.000 No   
TSB vs. 0.78125mg 0.0160 0.184 1.000 No   
TSB vs. 3.125mg 0.0151 0.174 1.000 No   
TSB vs. 0.09765625mg 0.0122 0.140 1.000 No   
TSB vs. 0.01220703mg 0.0102 0.118 1.000 No   
TSB vs. 0.02441406mg 0.00985 0.113 1.000 No   
TSB vs. 0.04882813mg 0.00977 0.112 0.999 No   
TSB vs. 0.390625mg 0.00968 0.111 0.992 No   








New Antibiotic Testing on 10/1/14 at 48 Hours- High Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0201 0.0359 0.0270 0.0305 0.0289 0.0322 0.0335 0.0359 0.0269 0.0302 0.0282 0.0298
B 0.0313 0.0459 0.0210 0.0254 0.0293 0.0339 0.0286 0.0282 0.0313 0.0306 0.0335 0.0304
C 0.0258 0.0581 0.0212 0.0301 0.0336 0.0249 0.0301 0.0324 0.0285 0.0388 0.0337 0.0406
D 0.0391 0.0651 0.0293 0.0367 0.0386 0.0346 0.0316 0.0321 0.0343 0.0314 0.0327 0.0419
E 0.0357 0.0876 0.0318 0.0308 0.0386 0.0314 0.0341 0.0371 0.0389 0.0417 0.0380 0.0467
F 0.0318 0.0739 0.0315 0.0326 0.0373 0.0362 0.0342 0.0355 0.0330 0.0356 0.0406 0.0531
G 0.0315 0.0983 0.0402 0.0630 0.0480 0.0495 0.0635 0.0582 0.0540 0.0518 0.0609 0.0671
H 0.0354 0.0861 0.0503 0.0663 0.0551 0.0558 0.0531 0.0506 0.0481 0.0466 0.0679 0.0812
average 0.0313 0.0689 0.0315 0.0394 0.0387 0.0373 0.0386 0.0388 0.0369 0.0383 0.0419 0.0489
range 0.0190 0.0624 0.0293 0.0409 0.0262 0.0309 0.0349 0.0300 0.0271 0.0216 0.0397 0.0514  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0397 0.0211 0.00372 0.00759  
Control 32 0 0.325 0.444 0.0784 0.160  
12.5mg 8 0 0.0315 0.00979 0.00346 0.00818  
6.25mg 8 0 0.0394 0.0159 0.00562 0.0133  
3.125mg 8 0 0.0387 0.00901 0.00318 0.00753  
1.5625mg 8 0 0.0373 0.0102 0.00360 0.00851  
0.78125mg 8 0 0.0386 0.0126 0.00447 0.0106  
0.390625mg 8 0 0.0388 0.0103 0.00363 0.00857  
0.1963125mg 8 0 0.0369 0.00960 0.00340 0.00803  
0.09765625mg 8 0 0.0383 0.00795 0.00281 0.00665  
0.04882813mg 8 0 0.0419 0.0145 0.00511 0.0121  
0.02441406mg 8 0 0.0489 0.0178 0.00630 0.0149  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0974 0.117 0.0201 0.0321 0.0295 0.0391  
Control 1.079 1.115 0.0359 0.0832 0.0488 0.799  
12.5mg 0.0293 0.0503 0.0210 0.0304 0.0226 0.0381  
6.25mg 0.0409 0.0663 0.0254 0.0317 0.0302 0.0564  
3.125mg 0.0262 0.0551 0.0289 0.0379 0.0304 0.0456  
1.5625mg 0.0309 0.0558 0.0249 0.0343 0.0316 0.0462  
0.78125mg 0.0349 0.0635 0.0286 0.0338 0.0305 0.0484  
0.390625mg 0.0300 0.0582 0.0282 0.0357 0.0322 0.0472  
0.1963125mg 0.0271 0.0540 0.0269 0.0336 0.0292 0.0458  
0.09765625mg 0.0216 0.0518 0.0302 0.0372 0.0308 0.0454  
0.04882813mg 0.0397 0.0679 0.0282 0.0359 0.0329 0.0558  
0.02441406mg 0.0514 0.0812 0.0298 0.0443 0.0330 0.0636  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 2.366 5.838 0.292 <0.001 0.696 <0.001  
Control 1.199 -0.568 0.380 <0.001 0.603 <0.001  
12.5mg 0.990 0.843 0.239 0.193 0.910 0.354  
6.25mg 1.291 -0.121 0.318 0.017 0.746 0.007  
3.125mg 0.874 0.199 0.253 0.137 0.909 0.346  
1.5625mg 1.049 0.354 0.294 0.041 0.872 0.159  
0.78125mg 1.536 1.138 0.386 <0.001 0.747 0.007  
0.390625mg 1.278 0.651 0.314 0.020 0.839 0.074  
0.1963125mg 0.992 -0.148 0.231 0.233 0.892 0.245  
0.09765625mg 0.638 -0.788 0.183 0.523 0.914 0.382  
0.04882813mg 1.242 0.0886 0.287 0.052 0.810 0.036  
0.02441406mg 0.873 0.0717 0.173 0.591 0.918 0.415  
 
Column Sum Sum of Squares  
TSB 1.269 0.0641  
Control 10.406 9.482  
12.5mg 0.252 0.00863  
6.25mg 0.315 0.0142  
3.125mg 0.309 0.0125  
1.5625mg 0.298 0.0119  
0.78125mg 0.309 0.0130  
0.390625mg 0.310 0.0127  
0.1963125mg 0.295 0.0115  
0.09765625mg 0.307 0.0122  
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0.04882813mg 0.336 0.0155  
0.02441406mg 0.391 0.0213  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0397 0.0211 0.00372  
Control 32 0 0.325 0.444 0.0784  
12.5mg 8 0 0.0315 0.00979 0.00346  
6.25mg 8 0 0.0394 0.0159 0.00562  
3.125mg 8 0 0.0387 0.00901 0.00318  
1.5625mg 8 0 0.0373 0.0102 0.00360  
0.78125mg 8 0 0.0386 0.0126 0.00447  
0.390625mg 8 0 0.0388 0.0103 0.00363  
0.1963125mg 8 0 0.0369 0.00960 0.00340  
0.09765625mg 8 0 0.0383 0.00795 0.00281  
0.04882813mg 8 0 0.0419 0.0145 0.00511  
0.02441406mg 8 0 0.0489 0.0178 0.00630  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 2.037 0.185 3.993 <0.001  
Residual 132 6.122 0.0464    
Total 143 8.159     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.983 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.286 5.304 <0.001 Yes   
Control vs. 12.5mg 0.294 3.450 0.008 Yes   
Control vs. 0.1963125mg 0.288 3.387 0.008 Yes   
Control vs. 1.5625mg 0.288 3.382 0.008 Yes   
Control vs. 0.09765625mg 0.287 3.370 0.007 Yes   
Control vs. 0.78125mg 0.287 3.367 0.006 Yes   
Control vs. 3.125mg 0.287 3.366 0.005 Yes   
Control vs. 0.390625mg 0.286 3.365 0.004 Yes   
Control vs. 6.25mg 0.286 3.357 0.003 Yes   
Control vs. 0.04882813mg 0.283 3.328 0.002 Yes   
Control vs. 0.02441406mg 0.276 3.246 0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.286 5.304 <0.001 Yes   
TSB vs. 0.02441406mg 0.00919 0.108 1.000 No   
TSB vs. 12.5mg 0.00812 0.0954 1.000 No   
TSB vs. 0.1963125mg 0.00278 0.0327 1.000 No   
TSB vs. 1.5625mg 0.00235 0.0276 1.000 No   
TSB vs. 0.04882813mg 0.00228 0.0268 1.000 No   
TSB vs. 0.09765625mg 0.00132 0.0155 1.000 No   
TSB vs. 0.78125mg 0.00107 0.0126 1.000 No   
TSB vs. 3.125mg 0.000984 0.0116 1.000 No   
TSB vs. 0.390625mg 0.000909 0.0107 1.000 No   










New Antibiotic Testing on 10/1/14 at 48 Hours- Lower Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0201 0.0395 0.0221 0.0273 0.0237 0.0267 0.0303 0.0291 0.0270 0.0334 0.0288 0.0307
B 0.0283 0.0391 0.0182 0.0226 0.0284 0.0267 0.0291 0.0278 0.0296 0.0270 0.0305 0.0278
C 0.0285 0.0453 0.0220 0.0258 0.0276 0.0283 0.0268 0.0247 0.0255 0.0300 0.0288 0.0336
D 0.0306 0.0459 0.0258 0.0218 0.0237 0.0282 0.0297 0.0281 0.0238 0.0341 0.0297 0.0311
E 0.0279 0.0674 0.0238 0.0287 0.0269 0.0279 0.0340 0.0336 0.0282 0.0284 0.0297 0.0354
F 0.0335 0.0582 0.0324 0.0282 0.0290 0.0266 0.0301 0.0334 0.0296 0.0373 0.0329 0.0450
G 0.0320 0.0788 0.0473 0.0227 0.0381 0.0294 0.0358 0.0333 0.0315 0.0333 0.0440 0.0597
H 0.0333 0.0759 0.0535 0.0503 0.0470 0.0385 0.0386 0.0447 0.0337 0.0364 0.0688 0.0780
Average 0.0293 0.0563 0.0306 0.0284 0.0306 0.0290 0.0318 0.0318 0.0286 0.0325 0.0367 0.0427
Range 0.0134 0.0397 0.0353 0.0285 0.0233 0.0119 0.0118 0.0200 0.0099 0.0103 0.0400 0.0502  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0319 0.00942 0.00167 0.00340  
Control 32 0 0.466 0.454 0.0803 0.164  
6.25mg 8 0 0.0306 0.0130 0.00458 0.0108  
3.125mg 8 0 0.0284 0.00924 0.00327 0.00772  
1.5625mg 8 0 0.0306 0.00802 0.00284 0.00671  
0.78125mg 8 0 0.0290 0.00395 0.00140 0.00330  
0.390625mg 8 0 0.0318 0.00394 0.00139 0.00330  
0.1963125mg 8 0 0.0318 0.00612 0.00216 0.00511  
0.09765625mg 8 0 0.0286 0.00320 0.00113 0.00268  
0.04882813mg 8 0 0.0325 0.00369 0.00131 0.00309  
0.02441406mg 8 0 0.0367 0.0139 0.00493 0.0117  
0.01220703mg 8 0 0.0427 0.0176 0.00624 0.0147  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0363 0.0564 0.0201 0.0284 0.0255 0.0334  
Control 1.162 1.201 0.0391 0.275 0.0674 0.946  
6.25mg 0.0353 0.0535 0.0182 0.0248 0.0220 0.0436  
3.125mg 0.0285 0.0503 0.0218 0.0266 0.0226 0.0286  
1.5625mg 0.0233 0.0470 0.0237 0.0280 0.0245 0.0358  
0.78125mg 0.0119 0.0385 0.0266 0.0280 0.0267 0.0291  
0.390625mg 0.0118 0.0386 0.0268 0.0302 0.0292 0.0353  
0.1963125mg 0.0200 0.0447 0.0247 0.0312 0.0279 0.0335  
0.09765625mg 0.00990 0.0337 0.0238 0.0289 0.0259 0.0310  
0.04882813mg 0.0103 0.0373 0.0270 0.0334 0.0288 0.0358  
0.02441406mg 0.0400 0.0688 0.0288 0.0301 0.0290 0.0412  
0.01220703mg 0.0502 0.0780 0.0278 0.0345 0.0308 0.0560  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.518 1.520 0.245 <0.001 0.809 <0.001  
Control 0.547 -1.418 0.281 <0.001 0.798 <0.001  
6.25mg 1.134 -0.187 0.271 0.087 0.832 0.062  
3.125mg 2.361 6.077 0.363 0.003 0.684 0.002  
1.5625mg 1.531 1.818 0.327 0.012 0.807 0.034  
0.78125mg 2.492 6.558 0.338 0.007 0.639 <0.001  
0.390625mg 0.704 -0.470 0.273 0.080 0.922 0.449  
0.1963125mg 1.364 2.575 0.262 0.110 0.871 0.154  
0.09765625mg 0.0685 -0.407 0.129 0.791 0.988 0.992  
0.04882813mg -0.272 -1.216 0.212 0.338 0.942 0.627  
0.02441406mg 2.231 4.966 0.356 0.004 0.645 <0.001  
0.01220703mg 1.438 1.269 0.285 0.055 0.813 0.040  
 
Column Sum Sum of Squares  
TSB 1.020 0.0353  
Control 14.922 13.347  
6.25mg 0.245 0.00869  
3.125mg 0.227 0.00706  
1.5625mg 0.244 0.00792  
0.78125mg 0.232 0.00685  
0.390625mg 0.254 0.00820  
0.1963125mg 0.255 0.00837  
0.09765625mg 0.229 0.00662  
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0.04882813mg 0.260 0.00854  
0.02441406mg 0.293 0.0121  
0.01220703mg 0.341 0.0167  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0319 0.00942 0.00167  
Control 32 0 0.466 0.454 0.0803  
6.25mg 8 0 0.0306 0.0130 0.00458  
3.125mg 8 0 0.0284 0.00924 0.00327  
1.5625mg 8 0 0.0306 0.00802 0.00284  
0.78125mg 8 0 0.0290 0.00395 0.00140  
0.390625mg 8 0 0.0318 0.00394 0.00139  
0.1963125mg 8 0 0.0318 0.00612 0.00216  
0.09765625mg 8 0 0.0286 0.00320 0.00113  
0.04882813mg 8 0 0.0325 0.00369 0.00131  
0.02441406mg 8 0 0.0367 0.0139 0.00493  
0.01220703mg 8 0 0.0427 0.0176 0.00624  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 4.692 0.427 8.800 <0.001  
Residual 132 6.398 0.0485    
Total 143 11.091     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.434 7.892 <0.001 Yes   
Control vs. 3.125mg 0.438 5.031 <0.001 Yes   
Control vs. 0.09765625mg 0.438 5.029 <0.001 Yes   
Control vs. 0.78125mg 0.437 5.024 <0.001 Yes   
Control vs. 1.5625mg 0.436 5.007 <0.001 Yes   
Control vs. 6.25mg 0.436 5.006 <0.001 Yes   
Control vs. 0.390625mg 0.435 4.993 <0.001 Yes   
Control vs. 0.1963125mg 0.434 4.992 <0.001 Yes   
Control vs. 0.04882813mg 0.434 4.985 <0.001 Yes   
Control vs. 0.02441406mg 0.430 4.937 <0.001 Yes   
Control vs. 0.01220703mg 0.424 4.868 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.434 7.892 <0.001 Yes   
TSB vs. 0.01220703mg 0.0108 0.124 1.000 No   
TSB vs. 0.02441406mg 0.00476 0.0547 1.000 No   
TSB vs. 3.125mg 0.00346 0.0398 1.000 No   
TSB vs. 0.09765625mg 0.00328 0.0376 1.000 No   
TSB vs. 0.78125mg 0.00285 0.0327 1.000 No   
TSB vs. 1.5625mg 0.00134 0.0154 1.000 No   
TSB vs. 6.25mg 0.00125 0.0144 1.000 No   
TSB vs. 0.04882813mg 0.000600 0.00689 1.000 No   
TSB vs. 0.390625mg 0.0000875 0.00101 1.000 No   








New Antibiotic Testing on 10/1/14 at 48 Hours- Higher Rifampicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0326 0.0384 1.5012 0.7745 0.3736 0.1823 0.0944 0.0552 0.0465 0.0399 0.0354 0.0328
B 0.0295 0.0382 1.6053 0.7834 0.3863 0.1880 0.1010 0.0589 0.0496 0.0378 0.0353 0.0380
C 0.0275 0.0441 1.6394 0.7977 0.3917 0.1935 0.1142 0.0652 0.0454 0.0405 0.0400 0.0392
D 0.0311 0.0463 1.6316 0.8047 0.3843 0.2033 0.1167 0.0631 0.0485 0.0404 0.0309 0.0391
E 0.0321 0.0579 1.6296 0.8099 0.3993 0.1991 0.1254 0.0736 0.0488 0.0400 0.0380 0.0413
F 0.0352 0.0460 1.6227 0.7732 0.4028 0.1979 0.1051 0.0766 0.0574 0.0358 0.0407 0.0509
G 0.0324 0.0694 1.6708 0.8464 0.4479 0.2071 0.1226 0.0839 0.0679 0.0531 0.0466 0.0524
H 0.0390 0.0803 1.6085 0.8136 0.4117 0.2079 0.1218 0.0988 0.0670 0.0545 0.0595 0.0712
average 0.0324 0.0526 1.6136 0.8004 0.3997 0.1974 0.1127 0.0719 0.0539 0.0428 0.0408 0.0456
range 0.0115 0.0421 0.1696 0.0732 0.0743 0.0256 0.0310 0.0436 0.0225 0.0187 0.0286 0.0384  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0397 0.0211 0.00372 0.00759  
Control 32 0 0.325 0.444 0.0784 0.160  
0.625mg 8 0 1.614 0.0498 0.0176 0.0416  
0.3125mg 8 0 0.800 0.0242 0.00856 0.0202  
0.15625mg 8 0 0.400 0.0228 0.00806 0.0191  
0.078125mg 8 0 0.197 0.00905 0.00320 0.00757  
0.0390625mg 8 0 0.113 0.0113 0.00399 0.00943  
0.01953125mg 8 0 0.0719 0.0145 0.00511 0.0121  
0.00976563mg 8 0 0.0539 0.00911 0.00322 0.00761  
0.00488281mg 8 0 0.0427 0.00701 0.00248 0.00586  
0.00244141mg 8 0 0.0408 0.00886 0.00313 0.00741  
0.0012207mg 8 0 0.0456 0.0123 0.00434 0.0103  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0974 0.117 0.0201 0.0321 0.0295 0.0391  
Control 1.079 1.115 0.0359 0.0832 0.0488 0.799  
0.625mg 0.170 1.671 1.501 1.626 1.606 1.637  
0.3125mg 0.0732 0.846 0.773 0.801 0.777 0.813  
0.15625mg 0.0743 0.448 0.374 0.395 0.385 0.409  
0.078125mg 0.0256 0.208 0.182 0.199 0.189 0.206  
0.0390625mg 0.0310 0.125 0.0944 0.115 0.102 0.122  
0.01953125mg 0.0436 0.0988 0.0552 0.0694 0.0599 0.0821  
0.00976563mg 0.0225 0.0679 0.0454 0.0492 0.0470 0.0646  
0.00488281mg 0.0187 0.0545 0.0358 0.0402 0.0383 0.0500  
0.00244141mg 0.0286 0.0595 0.0309 0.0390 0.0353 0.0451  
0.0012207mg 0.0384 0.0712 0.0328 0.0403 0.0383 0.0520  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 2.366 5.838 0.292 <0.001 0.696 <0.001  
Control 1.199 -0.568 0.380 <0.001 0.603 <0.001  
0.625mg -1.868 4.674 0.308 0.024 0.801 0.030  
0.3125mg 0.775 0.672 0.168 0.621 0.927 0.489  
0.15625mg 1.436 2.680 0.196 0.440 0.891 0.239  
0.078125mg -0.521 -0.709 0.148 0.731 0.947 0.683  
0.0390625mg -0.558 -1.164 0.180 0.548 0.923 0.452  
0.01953125mg 0.846 0.270 0.179 0.554 0.942 0.634  
0.00976563mg 0.925 -0.997 0.306 0.026 0.811 0.038  
0.00488281mg 1.218 -0.130 0.376 0.001 0.770 0.014  
0.00244141mg 1.485 2.610 0.255 0.133 0.875 0.168  
0.0012207mg 1.450 2.156 0.262 0.107 0.853 0.103  
 
Column Sum Sum of Squares  
TSB 1.269 0.0641  
Control 10.406 9.482  
0.625mg 12.909 20.848  
0.3125mg 6.403 5.130  
0.15625mg 3.198 1.282  
0.078125mg 1.579 0.312  
0.0390625mg 0.901 0.102  
0.01953125mg 0.575 0.0428  
0.00976563mg 0.431 0.0238  
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0.00488281mg 0.342 0.0150  
0.00244141mg 0.326 0.0139  
0.0012207mg 0.365 0.0177  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0397 0.0211 0.00372  
Control 32 0 0.325 0.444 0.0784  
0.625mg 8 0 1.614 0.0498 0.0176  
0.3125mg 8 0 0.800 0.0242 0.00856  
0.15625mg 8 0 0.400 0.0228 0.00806  
0.078125mg 8 0 0.197 0.00905 0.00320  
0.0390625mg 8 0 0.113 0.0113 0.00399  
0.01953125mg 8 0 0.0719 0.0145 0.00511  
0.00976563mg 8 0 0.0539 0.00911 0.00322  
0.00488281mg 8 0 0.0427 0.00701 0.00248  
0.00244141mg 8 0 0.0408 0.00886 0.00313  
0.0012207mg 8 0 0.0456 0.0123 0.00434  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 20.787 1.890 40.614 <0.001  
Residual 132 6.142 0.0465    
Total 143 26.929     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. 0.625mg 1.288 15.111 <0.001 Yes   
Control vs. 0.3125mg 0.475 5.573 <0.001 Yes   
Control vs. TSB 0.286 5.295 <0.001 Yes   
Control vs. 0.00244141mg 0.284 3.335 0.009 Yes   
Control vs. 0.00488281mg 0.282 3.313 0.008 Yes   
Control vs. 0.0012207mg 0.280 3.279 0.008 Yes   
Control vs. 0.00976563mg 0.271 3.182 0.009 Yes   
Control vs. 0.01953125mg 0.253 2.971 0.014 Yes   
Control vs. 0.0390625mg 0.213 2.493 0.041 Yes   
Control vs. 0.078125mg 0.128 1.499 0.254 No   
Control vs. 0.15625mg 0.0745 0.874 0.384 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. 0.625mg 1.574 18.460 <0.001 Yes   
TSB vs. 0.3125mg 0.761 8.922 <0.001 Yes   
TSB vs. Control 0.286 5.295 <0.001 Yes   
TSB vs. 0.15625mg 0.360 4.223 <0.001 Yes   
TSB vs. 0.078125mg 0.158 1.850 0.383 No   
TSB vs. 0.0390625mg 0.0730 0.856 0.950 No   
TSB vs. 0.01953125mg 0.0323 0.378 0.998 No   
TSB vs. 0.00976563mg 0.0142 0.167 1.000 No   
TSB vs. 0.0012207mg 0.00595 0.0698 1.000 No   
TSB vs. 0.00488281mg 0.00309 0.0362 0.999 No   









New Antibiotic Testing on 10/1/14 at 48 Hours- Lower Rifampicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0228 0.9746 1.0091 0.5168 0.2450 0.1319 0.0661 0.0713 0.1658 0.1767 0.1882 0.2267
B 0.0252 1.1134 1.0729 0.5391 0.2587 0.1302 0.0694 0.1309 0.1615 0.2110 0.2449 0.2895
C 0.0272 1.0970 1.1363 0.5564 0.2684 0.1388 0.0880 0.1055 0.2221 0.4077 0.3484 0.3865
D 0.0274 1.1584 1.0816 0.5235 0.2745 0.1561 0.0768 0.1682 0.2380 0.2991 0.3625 0.4047
E 0.0283 1.2008 1.2185 0.5494 0.2853 0.1485 0.0849 0.1884 0.2588 0.3232 0.4408 0.4386
F 0.0280 1.1885 1.1213 0.5684 0.2910 0.1575 0.0844 0.1801 0.2759 0.3560 0.4962 0.5183
G 0.0304 1.1656 1.1224 0.5867 0.3138 0.1706 0.1029 0.1881 0.2569 0.3380 0.5258 0.6153
H 0.0564 1.1193 1.1198 0.5788 0.3016 0.1769 0.1369 0.1548 0.2544 0.2993 0.4206 0.5485
average 0.0307 1.1272 1.1102 0.5524 0.2798 0.1513 0.0887 0.1484 0.2292 0.3014 0.3784 0.4285
range 0.0336 0.2262 0.2094 0.0699 0.0688 0.0467 0.0708 0.1171 0.1144 0.2310 0.3376 0.3886  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0319 0.00942 0.00167 0.00340  
Control 32 0 0.466 0.454 0.0803 0.164  
0.3125mg 8 0 1.110 0.0600 0.0212 0.0502  
0.15625mg 8 0 0.552 0.0252 0.00890 0.0210  
0.078125mg 8 0 0.280 0.0227 0.00802 0.0190  
0.0390625mg 8 0 0.151 0.0172 0.00609 0.0144  
0.01953125mg 8 0 0.0887 0.0226 0.00800 0.0189  
0.00976563mg 8 0 0.148 0.0426 0.0151 0.0356  
0.00488281mg 8 0 0.229 0.0434 0.0153 0.0363  
0.00244141mg 8 0 0.301 0.0754 0.0267 0.0631  
0.0012207mg 8 0 0.378 0.117 0.0415 0.0981  
0.00061035 8 0 0.429 0.131 0.0463 0.109  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0363 0.0564 0.0201 0.0284 0.0255 0.0334  
Control 1.162 1.201 0.0391 0.275 0.0674 0.946  
0.3125mg 0.209 1.218 1.009 1.121 1.075 1.133  
0.15625mg 0.0699 0.587 0.517 0.553 0.527 0.576  
0.078125mg 0.0688 0.314 0.245 0.280 0.261 0.299  
0.0390625mg 0.0467 0.177 0.130 0.152 0.134 0.167  
0.01953125mg 0.0708 0.137 0.0661 0.0847 0.0712 0.0992  
0.00976563mg 0.117 0.188 0.0713 0.161 0.112 0.186  
0.00488281mg 0.114 0.276 0.162 0.246 0.180 0.258  
0.00244141mg 0.231 0.408 0.177 0.311 0.233 0.351  
0.0012207mg 0.338 0.526 0.188 0.392 0.271 0.482  
0.00061035 0.389 0.615 0.227 0.422 0.314 0.541  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.518 1.520 0.245 <0.001 0.809 <0.001  
Control 0.547 -1.418 0.281 <0.001 0.798 <0.001  
0.3125mg 0.159 1.582 0.207 0.369 0.941 0.618  
0.15625mg -0.102 -1.251 0.124 0.798 0.962 0.829  
0.078125mg -0.0293 -0.675 0.0960 0.775 0.992 0.997  
0.0390625mg 0.208 -1.254 0.141 0.756 0.942 0.627  
0.01953125mg 1.555 2.778 0.262 0.109 0.857 0.113  
0.00976563mg -0.928 -0.212 0.185 0.516 0.890 0.235  
0.00488281mg -0.929 -0.685 0.219 0.294 0.846 0.087  
0.00244141mg -0.555 -0.165 0.238 0.199 0.943 0.641  
0.0012207mg -0.488 -0.725 0.149 0.724 0.953 0.746  
0.00061035 -0.172 -0.776 0.129 0.791 0.976 0.942  
 
Column Sum Sum of Squares  
TSB 1.020 0.0353  
Control 14.922 13.347  
0.3125mg 8.882 9.886  
0.15625mg 4.419 2.445  
0.078125mg 2.238 0.630  
0.0390625mg 1.210 0.185  
0.01953125mg 0.709 0.0665  
0.00976563mg 1.187 0.189  
0.00488281mg 1.833 0.433  
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0.00244141mg 2.411 0.766  
0.0012207mg 3.027 1.242  
0.00061035 3.428 1.589  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0319 0.00942 0.00167  
Control 32 0 0.466 0.454 0.0803  
0.3125mg 8 0 1.110 0.0600 0.0212  
0.15625mg 8 0 0.552 0.0252 0.00890  
0.078125mg 8 0 0.280 0.0227 0.00802  
0.0390625mg 8 0 0.151 0.0172 0.00609  
0.01953125mg 8 0 0.0887 0.0226 0.00800  
0.00976563mg 8 0 0.148 0.0426 0.0151  
0.00488281mg 8 0 0.229 0.0434 0.0153  
0.00244141mg 8 0 0.301 0.0754 0.0267  
0.0012207mg 8 0 0.378 0.117 0.0415  
0.00061035 8 0 0.429 0.131 0.0463  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 9.859 0.896 17.624 <0.001  
Residual 132 6.713 0.0509    
Total 143 16.572     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.434 7.705 <0.001 Yes   
Control vs. 0.3125mg 0.644 7.224 <0.001 Yes   
Control vs. 0.01953125mg 0.378 4.236 <0.001 Yes   
Control vs. 0.00976563mg 0.318 3.566 0.004 Yes   
Control vs. 0.0390625mg 0.315 3.534 0.004 Yes   
Control vs. 0.00488281mg 0.237 2.660 0.052 No   
Control vs. 0.078125mg 0.187 2.092 0.177 No   
Control vs. 0.00244141mg 0.165 1.850 0.241 No   
Control vs. 0.0012207mg 0.0879 0.986 0.694 No   
Control vs. 0.15625mg 0.0861 0.966 0.559 No   
Control vs. 0.00061035 0.0378 0.424 0.672 No   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. 0.3125mg 1.078 12.097 <0.001 Yes   
TSB vs. Control 0.434 7.705 <0.001 Yes   
TSB vs. 0.15625mg 0.521 5.839 <0.001 Yes   
TSB vs. 0.00061035 0.397 4.449 <0.001 Yes   
TSB vs. 0.0012207mg 0.347 3.888 0.001 Yes   
TSB vs. 0.00244141mg 0.269 3.023 0.018 Yes   
TSB vs. 0.078125mg 0.248 2.781 0.031 Yes   
TSB vs. 0.00488281mg 0.197 2.213 0.110 No   
TSB vs. 0.0390625mg 0.119 1.340 0.454 No   
TSB vs. 0.00976563mg 0.117 1.307 0.349 No   








New Antibiotic Testing on 10/1/14 at 48 Hours- Higher Polymyxin B 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0256 1.0062 0.0319 0.0331 0.0379 0.0339 0.0327 0.0292 0.0307 0.0292 0.0271 0.0274
B 0.0219 1.0796 0.0325 0.0368 0.0327 0.0295 0.0308 0.0311 0.0306 0.0314 0.0259 0.0316
C 0.0295 1.0711 0.0319 0.0406 0.0340 0.0344 0.0369 0.0310 0.0276 0.0348 0.0298 0.0349
D 0.0245 1.0734 0.0356 0.0347 0.0347 0.0351 0.0375 0.0300 0.0309 0.0319 0.0290 0.0351
E 0.0250 1.1151 0.0398 0.0408 0.0447 0.0414 0.0380 0.0371 0.0314 0.0301 0.0266 0.0358
F 0.0307 1.1044 0.0460 0.0415 0.0420 0.0406 0.0405 0.0338 0.0308 0.0383 0.0307 0.0436
G 0.0321 1.1014 0.0526 0.0412 0.0589 0.0411 0.0454 0.0418 0.0393 0.0372 0.0315 0.0479
H 0.0313 1.0799 0.0566 0.0482 0.0509 0.0552 0.0522 0.0493 0.0424 0.0399 0.0595 0.0641
average 0.0276 1.0789 0.0409 0.0396 0.0420 0.0389 0.0393 0.0354 0.0330 0.0341 0.0325 0.0401
range 0.0102 0.1089 0.0247 0.0151 0.0262 0.0257 0.0214 0.0201 0.0148 0.0107 0.0336 0.0367  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0397 0.0211 0.00372 0.00759  
Control 32 0 0.325 0.444 0.0784 0.160  
12.5mg 8 0 0.0409 0.00979 0.00346 0.00819  
6.25mg 8 0 0.0396 0.00473 0.00167 0.00396  
3.125mg 8 0 0.0420 0.00920 0.00325 0.00769  
1.5625mg 8 0 0.0389 0.00782 0.00276 0.00654  
0.78125mg 8 0 0.0393 0.00688 0.00243 0.00575  
0.390625mg 8 0 0.0354 0.00702 0.00248 0.00587  
0.1963125mg 8 0 0.0330 0.00507 0.00179 0.00424  
0.09765625mg 8 0 0.0341 0.00403 0.00142 0.00337  
0.04882813mg 8 0 0.0325 0.0111 0.00392 0.00927  
0.02441406mg 8 0 0.0401 0.0117 0.00413 0.00976  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0974 0.117 0.0201 0.0321 0.0295 0.0391  
Control 1.079 1.115 0.0359 0.0832 0.0488 0.799  
12.5mg 0.0247 0.0566 0.0319 0.0377 0.0320 0.0510  
6.25mg 0.0151 0.0482 0.0331 0.0407 0.0352 0.0414  
3.125mg 0.0262 0.0589 0.0327 0.0399 0.0342 0.0494  
1.5625mg 0.0257 0.0552 0.0295 0.0378 0.0340 0.0413  
0.78125mg 0.0214 0.0522 0.0308 0.0377 0.0338 0.0442  
0.390625mg 0.0201 0.0493 0.0292 0.0325 0.0302 0.0406  
0.1963125mg 0.0148 0.0424 0.0276 0.0309 0.0306 0.0373  
0.09765625mg 0.0107 0.0399 0.0292 0.0333 0.0304 0.0380  
0.04882813mg 0.0336 0.0595 0.0259 0.0294 0.0267 0.0313  
0.02441406mg 0.0367 0.0641 0.0274 0.0354 0.0324 0.0468  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 2.366 5.838 0.292 <0.001 0.696 <0.001  
Control 1.199 -0.568 0.380 <0.001 0.603 <0.001  
12.5mg 0.706 -1.187 0.205 0.384 0.865 0.134  
6.25mg 0.413 0.510 0.220 0.291 0.930 0.514  
3.125mg 0.934 0.0249 0.171 0.604 0.907 0.331  
1.5625mg 1.300 2.420 0.250 0.150 0.880 0.190  
0.78125mg 0.878 0.685 0.197 0.433 0.937 0.580  
0.390625mg 1.307 1.019 0.230 0.234 0.849 0.093  
0.1963125mg 1.304 0.529 0.371 0.002 0.778 0.017  
0.09765625mg 0.255 -1.713 0.208 0.365 0.925 0.472  
0.04882813mg 2.647 7.236 0.411 <0.001 0.591 <0.001  
0.02441406mg 1.376 1.958 0.267 0.097 0.878 0.179  
 
Column Sum Sum of Squares  
TSB 1.269 0.0641  
Control 10.406 9.482  
12.5mg 0.327 0.0140  
6.25mg 0.317 0.0127  
3.125mg 0.336 0.0147  
1.5625mg 0.311 0.0125  
0.78125mg 0.314 0.0127  
0.390625mg 0.283 0.0104  
0.1963125mg 0.264 0.00887  
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0.09765625mg 0.273 0.00942  
0.04882813mg 0.260 0.00932  
0.02441406mg 0.320 0.0138  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0397 0.0211 0.00372  
Control 32 0 0.325 0.444 0.0784  
12.5mg 8 0 0.0409 0.00979 0.00346  
6.25mg 8 0 0.0396 0.00473 0.00167  
3.125mg 8 0 0.0420 0.00920 0.00325  
1.5625mg 8 0 0.0389 0.00782 0.00276  
0.78125mg 8 0 0.0393 0.00688 0.00243  
0.390625mg 8 0 0.0354 0.00702 0.00248  
0.1963125mg 8 0 0.0330 0.00507 0.00179  
0.09765625mg 8 0 0.0341 0.00403 0.00142  
0.04882813mg 8 0 0.0325 0.0111 0.00392  
0.02441406mg 8 0 0.0401 0.0117 0.00413  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 2.052 0.187 4.025 <0.001  
Residual 132 6.116 0.0463    
Total 143 8.168     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.984 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.286 5.306 <0.001 Yes   
Control vs. 0.04882813mg 0.293 3.440 0.008 Yes   
Control vs. 0.1963125mg 0.292 3.435 0.007 Yes   
Control vs. 0.09765625mg 0.291 3.421 0.007 Yes   
Control vs. 0.390625mg 0.290 3.406 0.006 Yes   
Control vs. 1.5625mg 0.286 3.365 0.006 Yes   
Control vs. 0.78125mg 0.286 3.361 0.005 Yes   
Control vs. 6.25mg 0.286 3.356 0.004 Yes   
Control vs. 0.02441406mg 0.285 3.351 0.003 Yes   
Control vs. 12.5mg 0.284 3.342 0.002 Yes   
Control vs. 3.125mg 0.283 3.329 0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.286 5.306 <0.001 Yes   
TSB vs. 0.04882813mg 0.00715 0.0840 1.000 No   
TSB vs. 0.1963125mg 0.00670 0.0787 1.000 No   
TSB vs. 0.09765625mg 0.00556 0.0653 1.000 No   
TSB vs. 0.390625mg 0.00425 0.0499 1.000 No   
TSB vs. 3.125mg 0.00232 0.0272 1.000 No   
TSB vs. 12.5mg 0.00120 0.0141 1.000 No   
TSB vs. 1.5625mg 0.000759 0.00892 1.000 No   
TSB vs. 0.78125mg 0.000409 0.00481 1.000 No   
TSB vs. 0.02441406mg 0.000391 0.00459 1.000 No   









New Antibiotic Testing on 10/1/14 at 48 Hours- Lower Polymyxin B 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0240 0.5183 0.0237 0.0386 0.0317 0.0358 0.0341 0.0337 0.0345 0.0254 0.0315 0.0278
B 0.0249 0.7960 0.0312 0.0320 0.0335 0.0320 0.0354 0.0292 0.0322 0.0283 0.0325 0.0390
C 0.0263 0.4360 0.0273 0.0386 0.0445 0.0424 0.0349 0.0327 0.0309 0.0306 0.0279 0.0353
D 0.0233 0.4642 0.0277 0.0350 0.0349 0.0319 0.0365 0.0305 0.0308 0.0301 0.0290 0.0328
E 0.0253 0.4914 0.0273 0.0475 0.0433 0.0361 0.0421 0.0362 0.0373 0.0329 0.0296 0.0364
F 0.0334 0.8586 0.0345 0.0415 0.0301 0.0358 0.0311 0.0316 0.0344 0.0316 0.0363 0.0451
G 0.0321 0.7307 0.0562 0.0717 0.0615 0.0615 0.0372 0.0582 0.0431 0.0376 0.0369 0.0482
H 0.0261 0.4889 0.0449 0.0487 0.0508 0.0490 0.0482 0.0349 0.0502 0.0473 0.0651 0.0492
average 0.0269 0.5980 0.0341 0.0442 0.0413 0.0406 0.0374 0.0359 0.0367 0.0330 0.0361 0.0392
range 0.0101 0.4226 0.0325 0.0397 0.0314 0.0296 0.0171 0.0290 0.0194 0.0219 0.0372 0.0214  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 32 0 0.0319 0.00942 0.00167 0.00340  
Control 32 0 0.466 0.454 0.0803 0.164  
6.25mg 8 0 0.0341 0.0111 0.00391 0.00924  
3.125mg 8 0 0.0442 0.0125 0.00441 0.0104  
1.5625mg 8 0 0.0413 0.0109 0.00385 0.00911  
0.78125mg 8 0 0.0406 0.0102 0.00360 0.00852  
0.390625mg 8 0 0.0374 0.00535 0.00189 0.00447  
0.1963125mg 8 0 0.0359 0.00930 0.00329 0.00778  
0.09765625mg 8 0 0.0367 0.00679 0.00240 0.00567  
0.04882813mg 8 0 0.0330 0.00678 0.00240 0.00567  
0.02441406mg 8 0 0.0361 0.0122 0.00430 0.0102  
0.01220703mg 8 0 0.0392 0.00765 0.00271 0.00640  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0363 0.0564 0.0201 0.0284 0.0255 0.0334  
Control 1.162 1.201 0.0391 0.275 0.0674 0.946  
6.25mg 0.0325 0.0562 0.0237 0.0294 0.0273 0.0423  
3.125mg 0.0397 0.0717 0.0320 0.0401 0.0359 0.0484  
1.5625mg 0.0314 0.0615 0.0301 0.0391 0.0321 0.0492  
0.78125mg 0.0296 0.0615 0.0319 0.0359 0.0330 0.0473  
0.390625mg 0.0171 0.0482 0.0311 0.0359 0.0343 0.0409  
0.1963125mg 0.0290 0.0582 0.0292 0.0332 0.0308 0.0359  
0.09765625mg 0.0194 0.0502 0.0308 0.0345 0.0312 0.0417  
0.04882813mg 0.0219 0.0473 0.0254 0.0311 0.0287 0.0364  
0.02441406mg 0.0372 0.0651 0.0279 0.0320 0.0292 0.0367  
0.01220703mg 0.0214 0.0492 0.0278 0.0377 0.0334 0.0474  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.518 1.520 0.245 <0.001 0.809 <0.001  
Control 0.547 -1.418 0.281 <0.001 0.798 <0.001  
6.25mg 1.412 1.299 0.236 0.210 0.833 0.064  
3.125mg 1.758 3.624 0.234 0.216 0.829 0.058  
1.5625mg 0.903 0.0683 0.221 0.285 0.905 0.321  
0.78125mg 1.477 1.773 0.294 0.040 0.823 0.051  
0.390625mg 1.282 1.662 0.268 0.095 0.888 0.225  
0.1963125mg 2.495 6.614 0.361 0.003 0.659 <0.001  
0.09765625mg 1.360 1.229 0.251 0.146 0.844 0.083  
0.04882813mg 1.506 2.642 0.254 0.133 0.871 0.155  
0.02441406mg 2.441 6.326 0.349 0.005 0.665 <0.001  
0.01220703mg 0.0335 -1.237 0.154 0.702 0.945 0.664  
 
Column Sum Sum of Squares  
TSB 1.020 0.0353  
Control 14.922 13.347  
6.25mg 0.273 0.0102  
3.125mg 0.354 0.0167  
1.5625mg 0.330 0.0145  
0.78125mg 0.325 0.0139  
0.390625mg 0.299 0.0114  
0.1963125mg 0.287 0.0109  
0.09765625mg 0.293 0.0111  
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0.04882813mg 0.264 0.00902  
0.02441406mg 0.289 0.0115  
0.01220703mg 0.314 0.0127  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 32 0 0.0319 0.00942 0.00167  
Control 32 0 0.466 0.454 0.0803  
6.25mg 8 0 0.0341 0.0111 0.00391  
3.125mg 8 0 0.0442 0.0125 0.00441  
1.5625mg 8 0 0.0413 0.0109 0.00385  
0.78125mg 8 0 0.0406 0.0102 0.00360  
0.390625mg 8 0 0.0374 0.00535 0.00189  
0.1963125mg 8 0 0.0359 0.00930 0.00329  
0.09765625mg 8 0 0.0367 0.00679 0.00240  
0.04882813mg 8 0 0.0330 0.00678 0.00240  
0.02441406mg 8 0 0.0361 0.0122 0.00430  
0.01220703mg 8 0 0.0392 0.00765 0.00271  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 4.607 0.419 8.640 <0.001  
Residual 132 6.398 0.0485    
Total 143 11.005     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.434 7.892 <0.001 Yes   
Control vs. 0.04882813mg 0.433 4.979 <0.001 Yes   
Control vs. 6.25mg 0.432 4.966 <0.001 Yes   
Control vs. 0.1963125mg 0.430 4.946 <0.001 Yes   
Control vs. 0.02441406mg 0.430 4.943 <0.001 Yes   
Control vs. 0.09765625mg 0.430 4.937 <0.001 Yes   
Control vs. 0.390625mg 0.429 4.928 <0.001 Yes   
Control vs. 0.01220703mg 0.427 4.907 <0.001 Yes   
Control vs. 0.78125mg 0.426 4.892 <0.001 Yes   
Control vs. 1.5625mg 0.425 4.884 <0.001 Yes   
Control vs. 3.125mg 0.422 4.850 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.434 7.892 <0.001 Yes   
TSB vs. 3.125mg 0.0123 0.141 1.000 No   
TSB vs. 1.5625mg 0.00940 0.108 1.000 No   
TSB vs. 0.78125mg 0.00868 0.0997 1.000 No   
TSB vs. 0.01220703mg 0.00734 0.0843 1.000 No   
TSB vs. 0.390625mg 0.00555 0.0638 1.000 No   
TSB vs. 0.09765625mg 0.00479 0.0550 1.000 No   
TSB vs. 0.02441406mg 0.00421 0.0484 1.000 No   
TSB vs. 0.1963125mg 0.00399 0.0458 1.000 No   
TSB vs. 6.25mg 0.00221 0.0254 1.000 No   








New Antibiotic Testing on 10/15/14 at 48 Hours- Gentamicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0587 0.8453 0.0708 0.0690 0.0696 0.0657 0.0662 0.0674 0.0646 0.0643 0.0571 0.0671
B 0.0589 0.8846 0.0693 0.0741 0.0668 0.0699 0.0614 0.0617 0.0595 0.0899 0.0629 0.0652
C 0.0590 0.8625 0.0830 0.0858 0.0724 0.0869 0.0699 0.0805 0.0705 0.0687 0.0709 0.0686
D 0.0797 0.8818 0.0815 0.0882 0.0730 0.0848 0.0713 0.0742 0.0687 0.0684 0.0802 0.0751
E 0.0668 0.8879 0.1134 0.1003 0.0942 0.0728 0.1017 0.0799 0.0898 0.0796 0.0702 0.0792
F 0.0716 0.8810 0.0892 0.0908 0.0799 0.0757 0.0675 0.0787 0.0724 0.0701 0.0788 0.0914
G 0.0712 0.9105 0.1504 0.1381 0.1403 0.0884 0.1222 0.1019 0.1194 0.1057 0.0917 0.1038
H 0.0797 0.8618 0.1186 0.1333 0.1112 0.1055 0.1278 0.1040 0.1057 0.0902 0.1263 0.1256
average 0.0682 0.8769 0.0970 0.0975 0.0884 0.0812 0.0860 0.0810 0.0813 0.0796 0.0798 0.0845
range 0.0210 0.0652 0.0811 0.0691 0.0735 0.0398 0.0664 0.0423 0.0599 0.0414 0.0692 0.0604  
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0544 0.9603 0.0676 0.0788 0.0694 0.0697 0.0647 0.0636 0.0604 0.0631 0.0656 0.0584
B 0.0605 0.9545 0.0749 0.0726 0.0661 0.0637 0.0634 0.1469 0.0622 0.0569 0.0598 0.0660
C 0.0605 0.9375 0.0778 0.0770 0.0762 0.0657 0.0709 0.0678 0.0716 0.0744 0.0710 0.0782
D 0.0889 0.9845 0.0947 0.0937 0.0847 0.0842 0.0759 0.0886 0.0718 0.0631 0.0713 0.0766
E 0.0800 0.9846 0.0935 0.0926 0.0951 0.0880 0.0997 0.0814 0.0834 0.0778 0.0770 0.0839
F 0.0678 0.9378 0.0901 0.0905 0.0789 0.0873 0.0832 0.0828 0.0775 0.0723 0.0798 0.0920
G 0.0668 0.9671 0.1141 0.1155 0.1061 0.0960 0.1067 0.0949 0.0895 0.0888 0.0769 0.0916
H 0.0708 0.9132 0.1012 0.1116 0.0878 0.1030 0.0931 0.0966 0.0980 0.0767 0.0964 0.0903
average 0.0687 0.9549 0.0892 0.0915 0.0830 0.0822 0.0822 0.0903 0.0768 0.0716 0.0747 0.0796
range 0.0345 0.0714 0.0465 0.0429 0.0400 0.0393 0.0433 0.0833 0.0376 0.0319 0.0366 0.0336  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 48 0 0.0691 0.0115 0.00166 0.00334  
Control 48 0 0.854 0.0611 0.00881 0.0177  
5mg 16 0 0.0931 0.0222 0.00555 0.0118  
2.5mg 16 0 0.0945 0.0207 0.00517 0.0110  
1.25mg 16 0 0.0857 0.0200 0.00500 0.0106  
0.625mg 16 0 0.0817 0.0132 0.00330 0.00704  
0.3125mg 16 0 0.0841 0.0216 0.00541 0.0115  
0.15625mg 16 0 0.0857 0.0209 0.00522 0.0111  
0.078125mg 16 0 0.0791 0.0173 0.00433 0.00923  
0.0390625mg 16 0 0.0756 0.0128 0.00320 0.00681  
0.01953125mg 16 0 0.0772 0.0168 0.00419 0.00893  
0.009765625mg 16 0 0.0821 0.0170 0.00425 0.00905  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0596 0.114 0.0544 0.0678 0.0598 0.0762  
Control 0.255 0.985 0.729 0.849 0.825 0.882  
5mg 0.0828 0.150 0.0676 0.0897 0.0756 0.110  
2.5mg 0.0691 0.138 0.0690 0.0907 0.0774 0.109  
1.25mg 0.0742 0.140 0.0661 0.0794 0.0703 0.0949  
0.625mg 0.0418 0.106 0.0637 0.0845 0.0697 0.0883  
0.3125mg 0.0664 0.128 0.0614 0.0736 0.0665 0.101  
0.15625mg 0.0852 0.147 0.0617 0.0809 0.0694 0.0962  
0.078125mg 0.0599 0.119 0.0595 0.0721 0.0656 0.0897  
0.0390625mg 0.0488 0.106 0.0569 0.0733 0.0653 0.0865  
0.01953125mg 0.0692 0.126 0.0571 0.0741 0.0668 0.0801  
0.009765625mg 0.0672 0.126 0.0584 0.0787 0.0675 0.0915  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.423 3.685 0.114 0.119 0.890 <0.001  
Control 0.219 0.0159 0.103 0.226 0.965 0.164  
5mg 1.174 1.511 0.159 0.325 0.905 0.097  
2.5mg 0.946 0.179 0.203 0.078 0.905 0.096  
1.25mg 1.530 2.517 0.177 0.193 0.853 0.015  
0.625mg 0.285 -0.904 0.137 0.528 0.933 0.273  
0.3125mg 0.858 -0.512 0.223 0.033 0.870 0.027  
0.15625mg 1.700 4.173 0.180 0.177 0.856 0.017  
0.078125mg 1.014 0.414 0.212 0.052 0.904 0.093  
0.0390625mg 0.828 0.505 0.128 0.618 0.942 0.375  
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0.01953125mg 1.764 4.230 0.243 0.013 0.847 0.012  
0.009765625mg 1.050 1.557 0.154 0.370 0.925 0.206  
 
Column Sum Sum of Squares 
TSB 3.315 0.235  
Control 40.999 35.195  
5mg 1.490 0.146  
2.5mg 1.512 0.149  
1.25mg 1.372 0.124  
0.625mg 1.307 0.109  
0.3125mg 1.346 0.120  
0.15625mg 1.371 0.124  
0.078125mg 1.265 0.105  
0.0390625mg 1.210 0.0940  
0.01953125mg 1.236 0.0997  
0.009765625mg 1.313 0.112  
 
One Way Analysis of Variance 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 48 0 0.0691 0.0115 0.00166  
Control 48 0 0.854 0.0611 0.00881  
5mg 16 0 0.0931 0.0222 0.00555  
2.5mg 16 0 0.0945 0.0207 0.00517  
1.25mg 16 0 0.0857 0.0200 0.00500  
0.625mg 16 0 0.0817 0.0132 0.00330  
0.3125mg 16 0 0.0841 0.0216 0.00541  
0.15625mg 16 0 0.0857 0.0209 0.00522  
0.078125mg 16 0 0.0791 0.0173 0.00433  
0.0390625mg 16 0 0.0756 0.0128 0.00320  
0.01953125mg 16 0 0.0772 0.0168 0.00419  
0.009765625mg 16 0 0.0821 0.0170 0.00425  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 23.359 2.124 2224.134 <0.001  
Residual 244 0.233 0.000955    
Total 255 23.592     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.785 124.474 <0.001 Yes   
Control vs. 0.0390625mg 0.779 87.280 <0.001 Yes   
Control vs. 0.01953125mg 0.777 87.098 <0.001 Yes   
Control vs. 0.078125mg 0.775 86.895 <0.001 Yes   
Control vs. 0.625mg 0.772 86.598 <0.001 Yes   
Control vs. 0.009765625mg 0.772 86.558 <0.001 Yes   
Control vs. 0.3125mg 0.770 86.330 <0.001 Yes   
Control vs. 0.15625mg 0.768 86.153 <0.001 Yes   
Control vs. 1.25mg 0.768 86.147 <0.001 Yes   
Control vs. 5mg 0.761 85.317 <0.001 Yes   
Control vs. 2.5mg 0.760 85.165 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.785 124.474 <0.001 Yes   
TSB vs. 2.5mg 0.0254 2.852 0.046 Yes   
TSB vs. 5mg 0.0241 2.699 0.065 No   
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TSB vs. 1.25mg 0.0167 1.869 0.405 No   
TSB vs. 0.15625mg 0.0166 1.864 0.368 No   
TSB vs. 0.3125mg 0.0150 1.687 0.443 No   
TSB vs. 0.009765625mg 0.0130 1.458 0.546 No   
TSB vs. 0.625mg 0.0126 1.418 0.496 No   
TSB vs. 0.078125mg 0.0100 1.122 0.600 No   
TSB vs. 0.01953125mg 0.00819 0.918 0.590 No   
TSB vs. 0.0390625mg 0.00657 0.736 0.462 No   
 
New Antibiotic Testing on 10/15/14 at 48 Hours- Rifampicin 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0547 0.7596 0.0890 0.0793 0.0773 0.5273 1.0028 1.1103 1.1826 1.2402 1.2765 1.2655
B 0.0558 0.8474 0.0898 0.0839 0.0762 0.6952 1.0314 1.1865 1.2040 1.3166 1.3210 1.2546
C 0.0610 0.8305 0.1069 0.0835 0.0805 0.8388 1.0682 1.2171 1.2554 1.2791 1.3146 1.2738
D 0.0602 0.8434 0.1021 0.0919 0.1395 0.7757 1.0501 1.2205 1.2290 1.3109 1.3119 1.2802
E 0.0723 0.8499 0.1294 0.1136 0.0921 0.8192 1.0569 1.2152 1.2855 1.3133 1.3298 1.2938
F 0.0687 0.8103 0.1169 0.2664 0.0891 0.7210 1.0752 1.2020 1.2726 1.3059 1.3178 1.2890
G 0.0673 0.8280 0.1652 0.1214 0.1338 0.6630 1.0607 1.2364 1.2173 1.3292 1.2902 1.2900
H 0.0791 0.7904 0.1584 0.1333 0.1210 0.6696 1.0679 1.1572 1.2320 1.2346 1.2583 1.2230
average 0.0649 0.8199 0.1197 0.1217 0.1012 0.7137 1.0517 1.1932 1.2348 1.2912 1.3025 1.2712
range 0.0244 0.0903 0.0762 0.1871 0.0633 0.3115 0.0724 0.1261 0.1029 0.0946 0.0715 0.0708  
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0555 0.7727 0.0929 0.1608 0.0785 0.5364 0.9815 1.1146 1.1974 1.2306 1.2285 1.1964
B 0.0562 0.8705 0.0886 0.0810 0.0810 0.8583 1.0437 1.2010 1.2088 1.2446 1.2706 1.2223
C 0.0588 0.8480 0.1112 0.0916 0.1066 0.6070 0.9992 1.2328 1.2247 1.2708 1.2459 1.2647
D 0.0654 0.8697 0.1021 0.0955 0.0861 0.7640 1.0184 1.1992 1.2318 1.2416 1.2813 1.2959
E 0.0678 0.8820 0.1273 0.1261 0.0991 0.7787 1.0579 1.2172 1.2495 1.2905 1.3333 1.2993
F 0.0805 0.8231 0.1312 0.1202 0.2356 0.6569 1.0244 1.2089 1.2487 1.2886 1.2751 1.3024
G 0.0745 0.8612 0.1597 0.1433 0.1478 0.6828 1.0909 1.2252 1.2448 1.2721 1.3055 1.3204
H 0.0786 0.7804 0.1333 0.1414 0.2375 0.7069 1.0681 1.1654 1.2090 1.2729 1.2056 1.2990
average 0.0672 0.8385 0.1183 0.1200 0.1340 0.6989 1.0355 1.1955 1.2268 1.2640 1.2682 1.2751
range 0.0250 0.1093 0.0711 0.0798 0.1590 0.3219 0.1094 0.1182 0.0521 0.0599 0.1277 0.1240  
Descriptive Statistics:  
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 48 0 0.0691 0.0115 0.00166 0.00334  
Control 48 0 0.854 0.0611 0.00881 0.0177  
0.15625mg 16 0 0.119 0.0258 0.00646 0.0138  
0.078125mg 16 0 0.121 0.0464 0.0116 0.0247  
0.0390625mg 16 0 0.118 0.0519 0.0130 0.0277  
0.01953125mg 16 0 0.706 0.0980 0.0245 0.0522  
0.00976563mg 16 0 1.044 0.0310 0.00774 0.0165  
0.00488281mg 16 0 1.194 0.0386 0.00966 0.0206  
0.00244141mg 16 0 1.231 0.0278 0.00694 0.0148  
0.0012207mg 16 0 1.278 0.0322 0.00806 0.0172  
0.00061035mg 16 0 1.285 0.0373 0.00933 0.0199  
0.00030675mg 16 0 1.273 0.0341 0.00852 0.0182  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0596 0.114 0.0544 0.0678 0.0598 0.0762  
Control 0.255 0.985 0.729 0.849 0.825 0.882  
0.15625mg 0.0766 0.165 0.0886 0.114 0.0952 0.133  
0.078125mg 0.187 0.266 0.0793 0.117 0.0858 0.139  
0.0390625mg 0.161 0.237 0.0762 0.0956 0.0806 0.138  
0.01953125mg 0.331 0.858 0.527 0.701 0.658 0.778  
0.00976563mg 0.109 1.091 0.982 1.054 1.020 1.068  
0.00488281mg 0.126 1.236 1.110 1.205 1.171 1.220  
0.00244141mg 0.103 1.286 1.183 1.230 1.209 1.249  
0.0012207mg 0.0986 1.329 1.231 1.276 1.242 1.310  
0.00061035mg 0.128 1.333 1.206 1.286 1.261 1.317  
0.00030675mg 0.124 1.320 1.196 1.285 1.257 1.298  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.423 3.685 0.114 0.119 0.890 <0.001  
Control 0.219 0.0159 0.103 0.226 0.965 0.164  
0.15625mg 0.547 -0.840 0.124 0.655 0.909 0.110  
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0.078125mg 2.181 6.212 0.189 0.128 0.774 0.001  
0.0390625mg 1.649 1.978 0.213 0.051 0.756 <0.001  
0.01953125mg -0.299 -0.433 0.120 0.692 0.962 0.692  
0.00976563mg -0.582 -0.537 0.166 0.268 0.946 0.423  
0.00488281mg -1.269 0.778 0.238 0.016 0.847 0.012  
0.00244141mg 0.263 -0.302 0.108 0.778 0.984 0.988  
0.0012207mg -0.0301 -1.307 0.159 0.325 0.933 0.274  
0.00061035mg -0.658 -0.252 0.143 0.477 0.943 0.386  
0.00030675mg -1.003 0.351 0.179 0.182 0.902 0.085  
 
Column Sum Sum of Squares  
TSB 3.315 0.235  
Control 40.999 35.195  
0.15625mg 1.904 0.237  
0.078125mg 1.933 0.266  
0.0390625mg 1.882 0.262  
0.01953125mg 11.301 8.126  
0.00976563mg 16.697 17.439  
0.00488281mg 19.110 22.846  
0.00244141mg 19.693 24.250  
0.0012207mg 20.441 26.132  
0.00061035mg 20.566 26.456  
0.00030675mg 20.370 25.952  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 48 0 0.0691 0.0115 0.00166  
Control 48 0 0.854 0.0611 0.00881  
0.15625mg 16 0 0.119 0.0258 0.00646  
0.078125mg 16 0 0.121 0.0464 0.0116  
0.0390625mg 16 0 0.118 0.0519 0.0130  
0.01953125mg 16 0 0.706 0.0980 0.0245  
0.00976563mg 16 0 1.044 0.0310 0.00774  
0.00488281mg 16 0 1.194 0.0386 0.00966  
0.00244141mg 16 0 1.231 0.0278 0.00694  
0.0012207mg 16 0 1.278 0.0322 0.00806  
0.00061035mg 16 0 1.285 0.0373 0.00933  
0.00030675mg 16 0 1.273 0.0341 0.00852  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 62.824 5.711 2728.768 <0.001  
Residual 244 0.511 0.00209    
Total 255 63.335     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. TSB 0.785 84.071 <0.001 Yes   
Control vs. 0.0390625mg 0.737 55.771 <0.001 Yes   
Control vs. 0.15625mg 0.735 55.665 <0.001 Yes   
Control vs. 0.078125mg 0.733 55.527 <0.001 Yes   
Control vs. 0.00061035mg 0.431 32.652 <0.001 Yes   
Control vs. 0.0012207mg 0.423 32.063 <0.001 Yes   
Control vs. 0.00030675mg 0.419 31.726 <0.001 Yes   
Control vs. 0.00244141mg 0.377 28.521 <0.001 Yes   
Control vs. 0.00488281mg 0.340 25.759 <0.001 Yes   
Control vs. 0.00976563mg 0.189 14.344 <0.001 Yes   
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Control vs. 0.01953125mg 0.148 11.195 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. 0.00061035mg 1.216 92.098 <0.001 Yes   
TSB vs. 0.0012207mg 1.209 91.510 <0.001 Yes   
TSB vs. 0.00030675mg 1.204 91.173 <0.001 Yes   
TSB vs. 0.00244141mg 1.162 87.968 <0.001 Yes   
TSB vs. 0.00488281mg 1.125 85.206 <0.001 Yes   
TSB vs. Control 0.785 84.071 <0.001 Yes   
TSB vs. 0.00976563mg 0.975 73.790 <0.001 Yes   
TSB vs. 0.01953125mg 0.637 48.252 <0.001 Yes   
TSB vs. 0.078125mg 0.0518 3.920 <0.001 Yes   
TSB vs. 0.15625mg 0.0499 3.782 <0.001 Yes   
TSB vs. 0.0390625mg 0.0485 3.676 <0.001 Yes   
 
New Antibiotic Testing on 10/15/14 at 48 Hours- Polymyxin B 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0932 0.7294 0.0855 0.0912 0.0861 0.0881 0.0769 0.0660 0.0729 0.0720 0.0664 0.0732
B 0.0559 0.8304 0.0837 0.0958 0.0905 0.0998 0.0639 0.0627 0.0711 0.0726 0.0638 0.0726
C 0.0657 0.8075 0.1019 0.0920 0.0898 0.0820 0.0728 0.0691 0.0743 0.0778 0.0684 0.0656
D 0.1140 0.8239 0.0884 0.0995 0.0850 0.0777 0.0772 0.0702 0.0736 0.0648 0.0793 0.0670
E 0.0774 0.8350 0.1068 0.1232 0.1155 0.0867 0.0887 0.0903 0.0872 0.0806 0.0736 0.0784
F 0.0709 0.8270 0.1012 0.1189 0.1030 0.0885 0.0936 0.0876 0.0758 0.0720 0.0844 0.0813
G 0.0701 0.8483 0.1498 0.1411 0.1391 0.1186 0.1119 0.1037 0.1113 0.1023 0.0972 0.0963
H 0.0768 0.7601 0.1334 0.1484 0.1112 0.0919 0.1100 0.0857 0.0959 0.0803 0.0991 0.1159
average 0.0780 0.8077 0.1063 0.1138 0.1025 0.0917 0.0869 0.0794 0.0828 0.0778 0.0790 0.0813
range 0.0581 0.1189 0.0661 0.0572 0.0541 0.0409 0.0480 0.0410 0.0402 0.0375 0.0353 0.0503  
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0800 0.7412 0.0864 0.0911 0.0804 0.0838 0.0673 0.0713 0.0620 0.0695 0.0556 0.0570
B 0.0601 0.8685 0.0910 0.0873 0.0835 0.0729 0.0685 0.0619 0.0627 0.0617 0.0608 0.0674
C 0.0589 0.8538 0.0941 0.0960 0.0894 0.0750 0.0807 0.0690 0.0925 0.0642 0.0637 0.0634
D 0.0597 0.8418 0.0876 0.1119 0.0794 0.0857 0.0660 0.0626 0.0713 0.5801 0.0687 0.0718
E 0.0617 0.8494 0.1146 0.1090 0.1153 0.1143 0.0828 0.0828 0.0755 0.0773 0.0747 0.0726
F 0.0737 0.8463 0.1157 0.1096 0.0998 0.1092 0.0832 0.0684 0.0665 0.0726 0.0897 0.0857
G 0.0711 0.8585 0.1363 0.1441 0.1315 0.1132 0.1004 0.1038 0.1005 0.0993 0.0890 0.0894
H 0.0738 0.7561 0.1174 0.1366 0.1038 0.0866 0.1109 0.0883 0.0866 0.0805 0.1236 0.0994
average 0.0674 0.8270 0.1054 0.1107 0.0979 0.0926 0.0825 0.0760 0.0772 0.1382 0.0782 0.0758
range 0.0211 0.1273 0.0499 0.0568 0.0521 0.0414 0.0449 0.0419 0.0385 0.5184 0.0680 0.0424  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 48 0 0.0691 0.0115 0.00166 0.00334  
Control 48 0 0.854 0.0611 0.00881 0.0177  
4mg 16 0 0.106 0.0204 0.00510 0.0109  
2mg 16 0 0.112 0.0209 0.00522 0.0111  
1mg 16 0 0.100 0.0182 0.00454 0.00968  
0.5mg 16 0 0.0921 0.0145 0.00363 0.00773  
0.25mg 16 0 0.0847 0.0164 0.00410 0.00874  
0.125mg 16 0 0.0777 0.0141 0.00353 0.00752  
0.0625mg 16 0 0.0800 0.0142 0.00355 0.00757  
0.03125mg 16 0 0.108 0.126 0.0316 0.0673  
0.015625mg 16 0 0.0786 0.0178 0.00444 0.00947  
0.0078125mg 16 0 0.0786 0.0155 0.00387 0.00824  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0596 0.114 0.0544 0.0678 0.0598 0.0762  
Control 0.255 0.985 0.729 0.849 0.825 0.882  
4mg 0.0661 0.150 0.0837 0.102 0.0878 0.117  
2mg 0.0611 0.148 0.0873 0.109 0.0929 0.133  
1mg 0.0597 0.139 0.0794 0.0951 0.0853 0.114  
0.5mg 0.0457 0.119 0.0729 0.0874 0.0824 0.107  
0.25mg 0.0480 0.112 0.0639 0.0817 0.0696 0.0987  
0.125mg 0.0419 0.104 0.0619 0.0708 0.0666 0.0881  
0.0625mg 0.0493 0.111 0.0620 0.0749 0.0711 0.0912  
0.03125mg 0.518 0.580 0.0617 0.0749 0.0701 0.0806  
0.015625mg 0.0680 0.124 0.0556 0.0741 0.0644 0.0895  
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0.0078125mg 0.0589 0.116 0.0570 0.0729 0.0671 0.0885  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.423 3.685 0.114 0.119 0.890 <0.001  
Control 0.219 0.0159 0.103 0.226 0.965 0.164  
4mg 0.842 -0.244 0.155 0.359 0.898 0.073  
2mg 0.555 -1.135 0.166 0.269 0.895 0.068  
1mg 0.850 -0.126 0.203 0.076 0.907 0.103  
0.5mg 0.668 -0.783 0.224 0.032 0.900 0.080  
0.25mg 0.544 -0.962 0.161 0.313 0.909 0.113  
0.125mg 0.674 -0.750 0.238 0.016 0.880 0.039  
0.0625mg 0.805 -0.0933 0.241 0.014 0.920 0.166  
0.03125mg 3.948 15.698 0.455 <0.001 0.346 <0.001  
0.015625mg 1.089 1.229 0.150 0.409 0.919 0.165  
0.0078125mg 1.007 0.796 0.198 0.093 0.927 0.222  
 
Column Sum Sum of Squares  
TSB 3.315 0.235  
Control 40.999 35.195  
4mg 1.694 0.186  
2mg 1.796 0.208  
1mg 1.603 0.166  
0.5mg 1.474 0.139  
0.25mg 1.355 0.119  
0.125mg 1.243 0.0996  
0.0625mg 1.280 0.105  
0.03125mg 1.728 0.426  
0.015625mg 1.258 0.104  
0.0078125mg     1.257                  0.102  
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 48 0 0.0691 0.0115 0.00166  
Control 48 0 0.854 0.0611 0.00881  
4mg 16 0 0.106 0.0204 0.00510  
2mg 16 0 0.112 0.0209 0.00522  
1mg 16 0 0.100 0.0182 0.00454  
0.5mg 16 0 0.0921 0.0145 0.00363  
0.25mg 16 0 0.0847 0.0164 0.00410  
0.125mg 16 0 0.0777 0.0141 0.00353  
0.0625mg 16 0 0.0800 0.0142 0.00355  
0.03125mg 16 0 0.108 0.126 0.0316  
0.015625mg 16 0 0.0786 0.0178 0.00444  
0.0078125mg 16 0 0.0786 0.0155 0.00387  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 11 23.025 2.093 1109.414 <0.001  
Residual 244 0.460 0.00189    
Total 255 23.486     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. TSB 0.785 88.546 <0.001 Yes   
Control vs. 0.125mg 0.776 61.921 <0.001 Yes   
Control vs. 0.0078125mg 0.776 61.853 <0.001 Yes   
Control vs. 0.015625mg 0.776 61.848 <0.001 Yes   
Control vs. 0.0625mg 0.774 61.740 <0.001 Yes   
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Control vs. 0.25mg 0.769 61.366 <0.001 Yes   
Control vs. 0.5mg 0.762 60.771 <0.001 Yes   
Control vs. 1mg 0.754 60.127 <0.001 Yes   
Control vs. 4mg 0.748 59.676 <0.001 Yes   
Control vs. 0.03125mg 0.746 59.507 <0.001 Yes   
Control vs. 2mg 0.742 59.168 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.785 88.546 <0.001 Yes   
TSB vs. 2mg 0.0432 3.443 0.007 Yes   
TSB vs. 0.03125mg 0.0389 3.104 0.019 Yes   
TSB vs. 4mg 0.0368 2.935 0.029 Yes   
TSB vs. 1mg 0.0311 2.484 0.092 No   
TSB vs. 0.5mg 0.0231 1.840 0.340 No   
TSB vs. 0.25mg 0.0156 1.246 0.700 No   
TSB vs. 0.0625mg 0.0109 0.871 0.856 No   
TSB vs. 0.015625mg 0.00957 0.763 0.830 No   
TSB vs. 0.0078125mg 0.00951 0.758 0.697 No   
TSB vs. 0.125mg 0.00866 0.690 0.491 No   
 
Clinical Isolate 1 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0516 0.0340 0.6169 0.0364 0.0606 0.0590 0.0329 0.0745 0.0697 0.0330 0.1441 0.1375
B 0.0523 0.0345 0.7012 0.0345 0.0621 0.0577 0.0383 0.0780 0.0742 0.0352 0.1210 0.1282
C 0.0549 0.0379 0.7348 0.0347 0.0659 0.0642 0.0392 0.0786 0.0773 0.0338 0.1282 0.1293
D 0.0648 0.0348 0.7027 0.0364 0.0666 0.0676 0.0340 0.0961 0.0753 0.0332 0.1153 0.1394
E 0.0603 0.0356 0.7460 0.0341 0.0865 0.0904 0.0344 0.0878 0.0849 0.1037 0.1363 0.1151
F 0.0689 0.0406 0.6690 0.0368 0.0880 0.0822 0.0352 0.0982 0.0902 0.0342 0.1465 0.1543
G 0.0716 0.0372 0.8166 0.0399 0.1211 0.0963 0.0378 0.1177 0.1153 0.0333 0.1457 0.1466
H 0.0675 0.0353 0.6792 0.0355 0.1041 0.0924 0.0393 0.0952 0.0916 0.0362 0.1251 0.1540
average 0.0615 0.0362 0.7083 0.0360 0.0819 0.0762 0.0364 0.0908 0.0848 0.0428 0.1328 0.1381
range 0.0200 0.0066 0.1997 0.0058 0.0605 0.0386 0.0064 0.0432 0.0456 0.0707 0.0312 0.0392  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0615 0.00785 0.00278 0.00656  
Control 8 0 0.708 0.0594 0.0210 0.0496  
Gentamicin 16 0 0.0790 0.0188 0.00470 0.0100  
Rifampicin 16 0 0.0878 0.0143 0.00356 0.00760  
Polymyxin B 16 0 0.135 0.0127 0.00318 0.00678  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0200 0.0716 0.0516 0.0625 0.0529 0.0686  
Control 0.200 0.817 0.617 0.702 0.672 0.743  
Gentamicin 0.0634 0.121 0.0577 0.0749 0.0626 0.0919  
Rifampicin 0.0480 0.118 0.0697 0.0864 0.0758 0.0959  
Polymyxin B 0.0392 0.154 0.115 0.137 0.126 0.146  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.132 -1.877 0.174 0.583 0.910 0.355  
Control 0.449 0.974 0.163 0.655 0.974 0.924  
Gentamicin 0.713 -0.247 0.228 0.025 0.903 0.090  
Rifampicin 0.899 0.198 0.178 0.189 0.905 0.096  
Polymyxin B -0.143 -1.080 0.128 0.620 0.947 0.438  
 
Column Sum Sum of Squares  
TSB 0.492 0.0307  
Control 5.666 4.038  
Gentamicin 1.265 0.105  
Rifampicin 1.405 0.126  
Polymyxin B 2.167 0.296  
 
One Way Analysis of Variance  
 




Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0615 0.00785 0.00278  
Control 8 0 0.708 0.0594 0.0210  
Gentamicin 16 0 0.0790 0.0188 0.00470  
Rifampicin 16 0 0.0878 0.0143 0.00356  
Polymyxin B 16 0 0.135 0.0127 0.00318  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 2.672 0.668 1097.913 <0.001  
Residual 59 0.0359 0.000608    
Total 63 2.708     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.629 58.917 <0.001 Yes   
Control vs. Rifampicin 0.621 58.098 <0.001 Yes   
Control vs. Polymyxin B 0.573 53.639 <0.001 Yes   
Control vs. TSB 0.647 52.447 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.647 52.447 <0.001 Yes   
TSB vs. Polymyxin B 0.0739 6.922 <0.001 Yes   
TSB vs. Rifampicin 0.0263 2.462 0.033 Yes   
TSB vs. Gentamicin 0.0176 1.644 0.106 No   
 
Clinical Isolate 2 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0504 0.0376 0.7675 0.0342 0.0609 0.0599 0.0327 0.0732 0.0702 0.0322 0.4342 0.8918
B 0.0543 0.0349 0.8484 0.0420 0.0603 0.0581 0.0337 0.0703 0.3240 0.0345 0.0889 0.4900
C 0.0557 0.0402 0.8551 0.0375 0.0648 0.0640 0.0353 0.3740 0.0788 0.0323 0.0741 0.0846
D 0.0604 0.0335 0.7810 0.0368 0.0655 0.0647 0.0336 0.0802 0.3078 0.0337 0.4508 0.1125
E 0.0619 0.0328 0.6790 0.0339 0.0756 0.0797 0.0350 0.0889 0.0897 0.0336 0.0897 0.0893
F 0.0664 0.0337 0.7710 0.0338 0.0790 0.0717 0.0402 0.0882 0.0863 0.0350 0.1136 0.0908
G 0.0756 0.0322 0.8852 0.0341 0.0872 0.0972 0.0335 0.0883 0.1061 0.0326 0.4872 0.1328
H 0.0707 0.0326 0.8513 0.0340 0.1029 0.1006 0.0339 0.4190 0.1000 0.0350 0.4621 0.6692
average 0.0619 0.0347 0.8048 0.0358 0.0745 0.0745 0.0347 0.1603 0.1454 0.0336 0.2751 0.3201
range 0.0252 0.0080 0.2062 0.0082 0.0426 0.0425 0.0075 0.3487 0.2538 0.0028 0.4131 0.8072  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0619 0.00859 0.00304 0.00718  
Bacteria 8 0 0.805 0.0676 0.0239 0.0565  
Gentamicin 16 0 0.0745 0.0152 0.00380 0.00811  
Rifampicin 16 0 0.153 0.124 0.0309 0.0659  
Polymyxin B 16 0 0.298 0.258 0.0644 0.137  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0252 0.0756 0.0504 0.0611 0.0546 0.0696  
Bacteria 0.206 0.885 0.679 0.815 0.768 0.854  
Gentamicin 0.0448 0.103 0.0581 0.0686 0.0617 0.0853  
Rifampicin 0.349 0.419 0.0702 0.0886 0.0791 0.257  
Polymyxin B 0.818 0.892 0.0741 0.123 0.0894 0.481  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.332 -0.874 0.141 0.758 0.972 0.911  
Bacteria -0.781 0.200 0.240 0.187 0.907 0.335  
Gentamicin 0.821 -0.665 0.223 0.032 0.869 0.026  
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Rifampicin 1.384 0.177 0.397 <0.001 0.659 <0.001  
Polymyxin B 0.942 -0.0291 0.301 <0.001 0.801 0.003  
 
Column Sum Sum of Squares  
TSB 0.495 0.0312  
Bacteria 6.439 5.214  
Gentamicin 1.192 0.0923  
Rifampicin 2.445 0.603  
Polymyxin B 4.762 2.414  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0619 0.00859 0.00304  
Bacteria 8 0 0.805 0.0676 0.0239  
Gentamicin 16 0 0.0745 0.0152 0.00380  
Rifampicin 16 0 0.153 0.124 0.0309  
Polymyxin B 16 0 0.298 0.258 0.0644  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.419 0.855 39.943 <0.001  
Residual 59 1.262 0.0214    
Total 63 4.681     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Bacteria vs. Gentamicin 0.730 11.530 <0.001 Yes   
Bacteria vs. Rifampicin 0.652 10.294 <0.001 Yes   
Bacteria vs. TSB 0.743 10.157 <0.001 Yes   
Bacteria vs. Polymyxin B 0.507 8.008 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Bacteria 0.743 10.157 <0.001 Yes   
TSB vs. Polymyxin B 0.236 3.721 0.001 Yes   
TSB vs. Rifampicin 0.0909 1.435 0.289 No   
TSB vs. Gentamicin 0.0126 0.199 0.843 No   
 
Clinical Isolate 3 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0503 0.0368 0.7640 0.0340 0.0807 0.0573 0.0329 0.0777 0.0741 0.0329 0.1128 0.4641
B 0.0527 0.0355 0.8010 0.0377 0.0594 0.0552 0.0334 0.0769 0.0704 0.0326 0.0837 0.0870
C 0.0565 0.0317 0.8304 0.0320 0.0641 0.0577 0.0329 0.0828 0.0760 0.0324 0.1010 0.4186
D 0.0585 0.0397 0.8582 0.0355 0.0641 0.0585 0.0341 0.0804 0.0730 0.0349 0.4071 0.0838
E 0.0615 0.0336 0.8064 0.0343 0.0730 0.0662 0.0391 0.0801 0.0924 0.0455 0.4261 0.0822
F 0.0658 0.0322 0.8709 0.0342 0.0834 0.0681 0.0365 0.0850 0.0894 0.0329 0.1117 0.7808
G 0.0668 0.0379 0.8656 0.0381 0.1006 0.0996 0.0347 0.0855 0.1027 0.0337 0.1227 0.7124
H 0.0692 0.0488 0.8005 0.0379 0.1061 0.0909 0.0343 0.1035 0.0992 0.0358 0.1313 0.1545
average 0.0602 0.0370 0.8246 0.0355 0.0789 0.0692 0.0347 0.0840 0.0847 0.0351 0.1871 0.3479
range 0.0189 0.0171 0.1069 0.0061 0.0467 0.0444 0.0062 0.0266 0.0323 0.0131 0.3424 0.6986  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0602 0.00685 0.00242 0.00573  
Control 8 0 0.825 0.0380 0.0134 0.0318  
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Gentamicin 16 0 0.0741 0.0172 0.00431 0.00918  
Rifampicin 16 0 0.0843 0.0105 0.00262 0.00559  
Polymyxin B 16 0 0.267 0.235 0.0588 0.125  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0189 0.0692 0.0503 0.0600 0.0536 0.0665  
Control 0.107 0.871 0.764 0.818 0.801 0.864  
Gentamicin 0.0509 0.106 0.0552 0.0671 0.0587 0.0890  
Rifampicin 0.0331 0.103 0.0704 0.0816 0.0762 0.0916  
Polymyxin B 0.699 0.781 0.0822 0.127 0.0905 0.424  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.128 -1.415 0.170 0.612 0.953 0.743  
Control -0.174 -1.142 0.186 0.504 0.922 0.448  
Gentamicin 0.726 -0.917 0.198 0.095 0.877 0.035  
Rifampicin 0.700 -0.591 0.146 0.449 0.919 0.164  
Polymyxin B 1.155 0.163 0.309 <0.001 0.771 0.001  
 
Column Sum Sum of Squares  
TSB 0.481 0.0293  
Control 6.597 5.450  
Gentamicin 1.185 0.0922  
Rifampicin 1.349 0.115  
Polymyxin B 4.280 1.975  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0602 0.00685 0.00242  
Control 8 0 0.825 0.0380 0.0134  
Gentamicin 16 0 0.0741 0.0172 0.00431  
Rifampicin 16 0 0.0843 0.0105 0.00262  
Polymyxin B 16 0 0.267 0.235 0.0588  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.800 0.950 66.190 <0.001  
Residual 59 0.847 0.0144    
Total 63 4.647     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.751 14.469 <0.001 Yes   
Control vs. Rifampicin 0.740 14.271 <0.001 Yes   
Control vs. TSB 0.764 12.762 <0.001 Yes   
Control vs. Polymyxin B 0.557 10.740 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.764 12.762 <0.001 Yes   
TSB vs. Polymyxin B 0.207 3.997 <0.001 Yes   
TSB vs. Rifampicin 0.0242 0.466 0.873 No   








Clinical Isolate 4 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0569 0.0330 0.3789 0.0444 0.0581 0.0573 0.0334 0.0752 0.0676 0.0347 0.1050 0.1183
B 0.0592 0.0405 0.3469 0.0388 0.1219 0.0497 0.0381 0.0693 0.0703 0.0326 0.0993 0.1069
C 0.0600 0.0322 0.3300 0.0331 0.0737 0.0596 0.0328 0.0640 0.0748 0.0360 0.1297 0.1103
D 0.0609 0.0346 0.3303 0.0339 0.0649 0.0584 0.0327 0.0622 0.0820 0.0398 0.0955 0.0937
E 0.0634 0.0329 0.3597 0.0329 0.0774 0.0624 0.0362 0.0865 0.0750 0.0424 0.1286 0.1402
F 0.0694 0.0340 0.3499 0.0356 0.0791 0.0630 0.0368 0.0722 0.0899 0.0369 0.1094 0.1186
G 0.0689 0.0342 0.3918 0.0340 0.0931 0.1151 0.0334 0.0885 0.0990 0.0335 0.1226 0.1419
H 0.0756 0.0367 0.4163 0.0340 0.1116 0.1062 0.0345 0.1034 0.0885 0.0334 0.1722 0.1908
average 0.0643 0.0348 0.3630 0.0358 0.0850 0.0715 0.0347 0.0777 0.0809 0.0362 0.1203 0.1276
range 0.0187 0.0083 0.0863 0.0115 0.0638 0.0654 0.0054 0.0412 0.0314 0.0098 0.0767 0.0971  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0643 0.00640 0.00226 0.00535  
Control 8 0 0.363 0.0305 0.0108 0.0255  
Gentamicin 16 0 0.0782 0.0238 0.00594 0.0127  
Rifampicin 16 0 0.0793 0.0123 0.00307 0.00654  
Polymyxin B 16 0 0.124 0.0269 0.00673 0.0144  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0187 0.0756 0.0569 0.0621 0.0594 0.0693  
Control 0.0863 0.416 0.330 0.355 0.334 0.389  
Gentamicin 0.0722 0.122 0.0497 0.0693 0.0587 0.103  
Rifampicin 0.0412 0.103 0.0622 0.0751 0.0696 0.0885  
Polymyxin B 0.0971 0.191 0.0937 0.118 0.105 0.138  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.747 -0.472 0.202 0.402 0.921 0.435  
Control 0.686 -0.455 0.168 0.624 0.929 0.503  
Gentamicin 0.746 -0.944 0.213 0.052 0.870 0.028  
Rifampicin 0.513 -0.645 0.193 0.113 0.944 0.406  
Polymyxin B 1.320 1.544 0.165 0.277 0.880 0.039  
 
Column Sum Sum of Squares  
TSB 0.514 0.0333  
Control 2.904 1.061  
Gentamicin 1.252 0.106  
Rifampicin 1.268 0.103  
Polymyxin B 1.983 0.257  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0643 0.00640 0.00226  
Control 8 0 0.363 0.0305 0.0108  
Gentamicin 16 0 0.0782 0.0238 0.00594  
Rifampicin 16 0 0.0793 0.0123 0.00307  
Polymyxin B 16 0 0.124 0.0269 0.00673  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 0.551 0.138 286.005 <0.001  
Residual 59 0.0284 0.000482    
Total 63 0.579     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 




Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.285 29.967 <0.001 Yes   
Control vs. Rifampicin 0.284 29.856 <0.001 Yes   
Control vs. TSB 0.299 27.222 <0.001 Yes   
Control vs. Polymyxin B 0.239 25.155 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.299 27.222 <0.001 Yes   
TSB vs. Polymyxin B 0.0596 6.277 <0.001 Yes   
TSB vs. Rifampicin 0.0150 1.577 0.226 No   
TSB vs. Gentamicin 0.0139 1.466 0.148 No   
 
Clinical Isolate 5 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0517 0.0601 0.8129 0.0421 0.0584 0.0559 0.0561 0.0710 0.0699 0.0432 0.1293 0.0960
B 0.0578 0.0650 0.8582 0.1204 0.0603 0.0699 0.1411 0.0690 0.0719 0.1140 0.1372 0.1250
C 0.0847 0.1156 0.8409 0.1531 0.0749 0.0646 0.1473 0.0900 0.0689 0.1307 0.1189 0.1128
D 0.0708 0.1138 0.8495 0.1411 0.0734 0.0878 0.1528 0.0859 0.0770 0.1235 0.1035 0.1034
E 0.0748 0.1097 0.8397 0.1417 0.0779 0.0654 0.1446 0.0917 0.0714 0.1212 0.1231 0.1130
F 0.0685 0.1007 0.8215 0.1581 0.0725 0.0676 0.1335 0.0827 0.0727 0.1282 0.1325 0.1204
G 0.0803 0.0374 0.8047 0.0977 0.0961 0.0856 0.1116 0.0833 0.0821 0.0992 0.1434 0.1261
H 0.0683 0.0414 0.7855 0.0372 0.0936 0.0871 0.0414 0.0858 0.0842 0.0387 0.1297 0.1574
average 0.0696 0.0805 0.8266 0.1114 0.0759 0.0730 0.1161 0.0824 0.0748 0.0998 0.1272 0.1193
range 0.0330 0.0782 0.0727 0.1209 0.0377 0.0319 0.1114 0.0227 0.0153 0.0920 0.0399 0.0614  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0696 0.0109 0.00386 0.00912  
Control 8 0 0.827 0.0247 0.00874 0.0207  
Gentamicin 16 0 0.0744 0.0126 0.00314 0.00669  
Rifampicin 16 0 0.0786 0.00793 0.00198 0.00423  
Polymyxin B 16 0 0.123 0.0157 0.00393 0.00838  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0330 0.0847 0.0517 0.0697 0.0604 0.0789  
Control 0.0727 0.858 0.785 0.831 0.807 0.847  
Gentamicin 0.0402 0.0961 0.0559 0.0730 0.0648 0.0867  
Rifampicin 0.0228 0.0917 0.0689 0.0796 0.0711 0.0854  
Polymyxin B 0.0614 0.157 0.0960 0.124 0.113 0.132  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.382 -0.354 0.202 0.400 0.964 0.851  
Control -0.429 -0.809 0.202 0.403 0.959 0.804  
Gentamicin 0.293 -1.015 0.126 0.640 0.954 0.550  
Rifampicin 0.172 -1.538 0.209 0.060 0.894 0.064  
Polymyxin B 0.277 0.293 0.0904 0.850 0.982 0.977  
 
Column Sum Sum of Squares  
TSB 0.557 0.0396  
Control 6.613 5.471  
Gentamicin 1.191 0.0910  
Rifampicin 1.258 0.0998  
Polymyxin B 1.972 0.247  
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0696 0.0109 0.00386  
Control 8 0 0.827 0.0247 0.00874  
Gentamicin 16 0 0.0744 0.0126 0.00314  
Rifampicin 16 0 0.0786 0.00793 0.00198  
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Polymyxin B 16 0 0.123 0.0157 0.00393  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.837 0.959 4664.813 <0.001  
Residual 59 0.0121 0.000206    
Total 63 3.849     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. Gentamicin 0.752 121.140 <0.001 Yes   
Control vs. Rifampicin 0.748 120.471 <0.001 Yes   
Control vs. Polymyxin B 0.703 113.282 <0.001 Yes   
Control vs. TSB 0.757 105.584 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.757 105.584 <0.001 Yes   
TSB vs. Polymyxin B 0.0536 8.635 <0.001 Yes   
TSB vs. Rifampicin 0.00898 1.446 0.283 No   
TSB vs. Gentamicin 0.00483 0.777 0.440 No   
 
Clinical Isolate 6 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0559 0.0342 1.0119 0.0417 0.0662 0.0627 0.0602 0.0750 0.0696 0.0405 0.0779 0.1153
B 0.0535 0.0947 1.1285 0.1356 0.0595 0.0587 0.1675 0.0698 0.0676 0.1480 0.1151 0.1022
C 0.0592 0.1481 1.1201 0.1754 0.0689 0.0620 0.1858 0.0683 0.0693 0.1478 0.0897 0.0951
D 0.0632 0.1428 1.1005 0.1981 0.0679 0.0634 0.1867 0.0686 0.0775 0.1717 0.1295 0.0979
E 0.0754 0.1913 1.1076 0.1949 0.0860 0.0723 0.2184 0.0884 0.0754 0.1776 0.1047 0.1039
F 0.0769 0.1396 1.1457 0.1768 0.0851 0.0691 0.1679 0.0902 0.0837 0.1748 0.1103 0.1029
G 0.0735 0.0473 1.1723 0.1489 0.1137 0.1007 0.1437 0.0862 0.1062 0.1653 0.1333 0.1532
H 0.0952 0.0443 1.1452 0.0337 0.1003 0.0988 0.0339 0.1177 0.1107 0.0445 0.1093 0.1448
average 0.0691 0.1053 1.1165 0.1381 0.0810 0.0735 0.1455 0.0830 0.0825 0.1338 0.1087 0.1144
range 0.0417 0.1571 0.1604 0.1644 0.0542 0.0420 0.1845 0.0494 0.0431 0.1371 0.0554 0.0581  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0691 0.0139 0.00491 0.0116  
Control 8 0 1.116 0.0481 0.0170 0.0402  
Gentamicin 16 0 0.0772 0.0177 0.00441 0.00941  
Rifampicin 16 0 0.0828 0.0162 0.00406 0.00865  
Polymyxin B 16 0 0.112 0.0200 0.00500 0.0107  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0417 0.0952 0.0535 0.0683 0.0567 0.0765  
Control 0.160 1.172 1.012 1.124 1.102 1.146  
Gentamicin 0.0550 0.114 0.0587 0.0690 0.0629 0.0956  
Rifampicin 0.0501 0.118 0.0676 0.0764 0.0694 0.0897  
Polymyxin B 0.0753 0.153 0.0779 0.107 0.0990 0.126  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.804 0.343 0.164 0.644 0.922 0.443  
Control -1.577 3.450 0.245 0.168 0.864 0.132  
Gentamicin 0.839 -0.664 0.239 0.015 0.861 0.020  
Rifampicin 1.080 0.0761 0.190 0.126 0.843 0.011  
Polymyxin B 0.638 0.143 0.176 0.201 0.951 0.503  
 
Column Sum Sum of Squares  
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TSB 0.553 0.0396  
Control 8.932 9.988  
Gentamicin 1.235 0.100  
Rifampicin 1.324 0.114  
Polymyxin B 1.785 0.205  
 
One Way Analysis of Variance Thursday, April 02, 2015, 1:32:20 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0691 0.0139 0.00491  
Control 8 0 1.116 0.0481 0.0170  
Gentamicin 16 0 0.0772 0.0177 0.00441  
Rifampicin 16 0 0.0828 0.0162 0.00406  
Polymyxin B 16 0 0.112 0.0200 0.00500  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 7.426 1.857 3400.672 <0.001  
Residual 59 0.0322 0.000546    
Total 63 7.458     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. Gentamicin 1.039 102.720 <0.001 Yes   
Control vs. Rifampicin 1.034 102.171 <0.001 Yes   
Control vs. Polymyxin B 1.005 99.324 <0.001 Yes   
Control vs. TSB 1.047 89.652 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 1.047 89.652 <0.001 Yes   
TSB vs. Polymyxin B 0.0425 4.198 <0.001 Yes   
TSB vs. Rifampicin 0.0137 1.350 0.331 No   
TSB vs. Gentamicin 0.00811 0.801 0.426 No   
 
Clinical Isolate 7 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0646 0.0408 0.9249 0.0331 0.0582 0.0571 0.0345 0.0684 0.0671 0.0336 0.0961 0.1054
B 0.0532 0.0342 0.8606 0.0335 0.0573 0.0566 0.0329 0.0669 0.0638 0.0339 0.1075 0.0973
C 0.0581 0.0320 0.9169 0.0321 0.0650 0.0586 0.0339 0.0711 0.0665 0.0324 0.0988 0.1030
D 0.0777 0.0332 0.8858 0.0342 0.0624 0.0653 0.0324 0.0700 0.1192 0.0332 0.0906 0.1103
E 0.0622 0.0385 0.9242 0.0388 0.0695 0.0774 0.0321 0.0826 0.0697 0.0408 0.0918 0.1240
F 0.0713 0.0362 0.8953 0.0325 0.0773 0.0693 0.0335 0.0703 0.0689 0.0363 0.1074 0.1049
G 0.0648 0.0324 0.9563 0.0347 0.0968 0.0778 0.0333 0.0747 0.0811 0.0327 0.1176 0.1587
H 0.0712 0.0328 0.9648 0.0443 0.0977 0.0884 0.0325 0.0959 0.0891 0.0357 0.1213 0.1412
average 0.0654 0.0350 0.9161 0.0354 0.0730 0.0688 0.0331 0.0750 0.0782 0.0348 0.1039 0.1181
range 0.0245 0.0088 0.1042 0.0122 0.0404 0.0318 0.0024 0.0290 0.0554 0.0084 0.0307 0.0614  
Descriptive Statistics: Thursday, April 02, 2015, 1:44:04 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0654 0.00787 0.00278 0.00658  
Control 8 0 0.916 0.0350 0.0124 0.0292  
Gentamicin 16 0 0.0709 0.0138 0.00345 0.00736  
Rifampicin 16 0 0.0766 0.0145 0.00362 0.00771  




Column Range Max Min  Median  25% 75%  
TSB 0.0245 0.0777 0.0532 0.0647 0.0591 0.0713  
Control 0.104 0.965 0.861 0.921 0.888 0.948  
Gentamicin 0.0411 0.0977 0.0566 0.0673 0.0583 0.0777  
Rifampicin 0.0554 0.119 0.0638 0.0702 0.0674 0.0822  
Polymyxin B 0.0681 0.159 0.0906 0.106 0.0977 0.120  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.0154 -0.392 0.155 0.697 0.979 0.955  
Control -0.116 -0.600 0.151 0.717 0.966 0.864  
Gentamicin 0.859 -0.337 0.166 0.272 0.875 0.033  
Rifampicin 2.011 4.318 0.273 0.002 0.758 <0.001  
Polymyxin B 1.442 2.081 0.203 0.078 0.871 0.028  
 
Column Sum Sum of Squares  
TSB 0.523 0.0346  
Control 7.329 6.722  
Gentamicin 1.135 0.0833  
Rifampicin 1.225 0.0970  
Polymyxin B 1.776 0.202  
 
One Way Analysis of Variance Thursday, April 02, 2015, 1:44:28 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0654 0.00787 0.00278  
Control 8 0 0.916 0.0350 0.0124  
Gentamicin 16 0 0.0709 0.0138 0.00345  
Rifampicin 16 0 0.0766 0.0145 0.00362  
Polymyxin B 16 0 0.111 0.0183 0.00457  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 4.874 1.219 3593.613 <0.001  
Residual 59 0.0200 0.000339    
Total 63 4.894     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
Control vs. Gentamicin 0.845 105.998 <0.001 Yes   
Control vs. Rifampicin 0.840 105.288 <0.001 Yes   
Control vs. Polymyxin B 0.805 100.972 <0.001 Yes   
Control vs. TSB 0.851 92.398 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.851 92.398 <0.001 Yes   
TSB vs. Polymyxin B 0.0456 5.720 <0.001 Yes   
TSB vs. Rifampicin 0.0112 1.404 0.304 No   












Clinical Isolate 8 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0538 0.0362 0.9312 0.0514 0.0603 0.0606 0.0329 0.0842 0.0773 0.0319 0.1039 0.0875
B 0.0617 0.0332 0.9517 0.0349 0.0615 0.0603 0.0323 0.0692 0.0723 0.0321 0.0925 0.0943
C 0.0612 0.0347 0.9642 0.0325 0.0698 0.0645 0.0328 0.0768 0.0759 0.0329 0.0903 0.0915
D 0.0600 0.0348 1.0494 0.0365 0.0683 0.0639 0.0347 0.0784 0.0781 0.0331 0.0923 0.1078
E 0.0634 0.0340 1.0424 0.0335 0.0733 0.0638 0.0334 0.0755 0.0797 0.0322 0.0951 0.1047
F 0.0704 0.0341 1.0239 0.0404 0.0766 0.0671 0.0325 0.0785 0.0820 0.0337 0.1094 0.1207
G 0.0691 0.0334 1.0475 0.0335 0.1030 0.0950 0.0329 0.0802 0.1041 0.0330 0.1068 0.1412
H 0.0715 0.0361 1.0329 0.0325 0.0974 0.0973 0.0327 0.1774 0.0996 0.0542 0.1066 0.1347
average 0.0639 0.0346 1.0054 0.0369 0.0763 0.0716 0.0330 0.0900 0.0836 0.0354 0.0996 0.1103
range 0.0177 0.0030 0.1182 0.0189 0.0427 0.0370 0.0024 0.1082 0.0318 0.0223 0.0191 0.0537  
Descriptive Statistics: Thursday, April 02, 2015, 1:56:09 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0639 0.00606 0.00214 0.00506  
Control 8 0 1.005 0.0482 0.0170 0.0403  
Gentamicin 16 0 0.0739 0.0152 0.00381 0.00812  
Rifampicin 16 0 0.0868 0.0258 0.00644 0.0137  
Polymyxin B 16 0 0.105 0.0157 0.00393 0.00838  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0177 0.0715 0.0538 0.0625 0.0603 0.0701  
Control 0.118 1.049 0.931 1.028 0.955 1.046  
Gentamicin 0.0427 0.103 0.0603 0.0677 0.0621 0.0904  
Rifampicin 0.108 0.177 0.0692 0.0784 0.0761 0.0837  
Polymyxin B 0.0537 0.141 0.0875 0.104 0.0923 0.109  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.220 -0.678 0.180 0.544 0.934 0.549  
Control -0.673 -1.663 0.274 0.077 0.828 0.056  
Gentamicin 1.010 -0.623 0.232 0.022 0.796 0.002  
Rifampicin 3.267 11.552 0.353 <0.001 0.549 <0.001  
Polymyxin B 1.194 0.880 0.201 0.083 0.864 0.022  
Column Sum Sum of Squares  
TSB 0.511 0.0329  
Control 8.043 8.103  
Gentamicin 1.183 0.0909  
Rifampicin 1.389 0.131  
Polymyxin B 1.679 0.180  
 
One Way Analysis of Variance Thursday, April 02, 2015, 1:56:42 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0639 0.00606 0.00214  
Control 8 0 1.005 0.0482 0.0170  
Gentamicin 16 0 0.0739 0.0152 0.00381  
Rifampicin 16 0 0.0868 0.0258 0.00644  
Polymyxin B 16 0 0.105 0.0157 0.00393  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 5.941 1.485 2602.060 <0.001  
Residual 59 0.0337 0.000571    
Total 63 5.975     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 




Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.931 90.036 <0.001 Yes   
Control vs. Rifampicin 0.919 88.789 <0.001 Yes   
Control vs. Polymyxin B 0.900 87.036 <0.001 Yes   
Control vs. TSB 0.942 78.814 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.942 78.814 <0.001 Yes   
TSB vs. Polymyxin B 0.0411 3.970 <0.001 Yes   
TSB vs. Rifampicin 0.0229 2.217 0.060 No   
TSB vs. Gentamicin 0.0100 0.970 0.336 No   
 
Clinical Isolate 10 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0503 0.0382 0.5673 0.0346 0.0578 0.0575 0.0331 0.2400 0.2521 0.0332 0.0882 0.1063
B 0.0541 0.0386 0.7256 0.0373 0.0570 0.0553 0.0323 0.2211 0.2352 0.0337 0.1104 0.0887
C 0.0556 0.0335 0.7119 0.0324 0.0627 0.0571 0.0322 0.2338 0.2096 0.0324 0.0999 0.0943
D 0.0608 0.0368 0.7403 0.0358 0.0623 0.0618 0.0326 0.2363 0.2082 0.0361 0.0920 0.0939
E 0.0627 0.0330 0.7411 0.0343 0.0808 0.0696 0.0328 0.2644 0.2514 0.0332 0.1042 0.1231
F 0.0696 0.0379 0.7207 0.0365 0.0822 0.0782 0.0350 0.2535 0.2274 0.0330 0.1124 0.1093
G 0.0736 0.0329 0.6808 0.0325 0.1158 0.1075 0.0333 0.3019 0.2580 0.0345 0.1129 0.1422
H 0.0693 0.0327 0.5865 0.0332 0.0924 0.0876 0.0378 0.2402 0.2563 0.0354 0.1089 0.1318
average 0.0620 0.0355 0.6843 0.0346 0.0764 0.0718 0.0336 0.2489 0.2373 0.0339 0.1036 0.1112
range 0.0233 0.0059 0.1738 0.0049 0.0588 0.0522 0.0056 0.0808 0.0498 0.0037 0.0247 0.0535  
Descriptive Statistics: Thursday, April 02, 2015, 2:17:36 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0620 0.00835 0.00295 0.00698  
Control 8 0 0.684 0.0691 0.0244 0.0578  
Gentamicin 16 0 0.0741 0.0190 0.00475 0.0101  
Rifampicin 16 0 0.243 0.0229 0.00572 0.0122  
Polymyxin B 16 0 0.107 0.0153 0.00382 0.00814  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0233 0.0736 0.0503 0.0617 0.0545 0.0695  
Control 0.174 0.741 0.567 0.716 0.610 0.737  
Gentamicin 0.0605 0.116 0.0553 0.0662 0.0576 0.0862  
Rifampicin 0.0937 0.302 0.208 0.240 0.229 0.256  
Polymyxin B 0.0540 0.142 0.0882 0.108 0.0940 0.113  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.0101 -1.469 0.184 0.519 0.948 0.693  
Control -1.176 -0.325 0.280 0.064 0.787 0.021  
Gentamicin 0.985 0.0518 0.226 0.029 0.866 0.023  
Rifampicin 0.796 1.866 0.132 0.578 0.937 0.315  
Polymyxin B 0.820 0.432 0.172 0.227 0.929 0.239  
 
Column Sum Sum of Squares  
TSB 0.496 0.0312  
Control 5.474 3.779  
Gentamicin 1.186 0.0933  
Rifampicin 3.889 0.953  
Polymyxin B 1.718 0.188  
 
One Way Analysis of Variance Thursday, April 02, 2015, 2:17:57 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0620 0.00835 0.00295  
Control 8 0 0.684 0.0691 0.0244  
Gentamicin 16 0 0.0741 0.0190 0.00475  
Rifampicin 16 0 0.243 0.0229 0.00572  
Polymyxin B 16 0 0.107 0.0153 0.00382  
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Source of Variation  DF   SS   MS    F    P   
Between Groups 4 2.449 0.612 712.852 <0.001  
Residual 59 0.0507 0.000859    
Total 63 2.500     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.610 48.083 <0.001 Yes   
Control vs. Polymyxin B 0.577 45.458 <0.001 Yes   
Control vs. TSB 0.622 42.467 <0.001 Yes   
Control vs. Rifampicin 0.441 34.766 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.622 42.467 <0.001 Yes   
TSB vs. Rifampicin 0.181 14.270 <0.001 Yes   
TSB vs. Polymyxin B 0.0454 3.578 0.001 Yes   
TSB vs. Gentamicin 0.0121 0.953 0.344 No   
 
Clinical Isolate 11 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0517 0.0344 0.3971 0.0506 0.0803 0.0805 0.0506 0.1046 0.0964 0.0344 0.1162 0.1205
B 0.0651 0.0771 0.3981 0.1083 0.0752 0.0726 0.1099 0.0929 0.1068 0.0870 0.1138 0.1469
C 0.0587 0.0943 0.4180 0.1042 0.0839 0.0759 0.1168 0.0956 0.0951 0.0981 0.1035 0.1248
D 0.0624 0.1001 0.4315 0.1214 0.0731 0.0758 0.1270 0.0958 0.0967 0.0990 0.1006 0.1138
E 0.0709 0.1102 0.4409 0.1096 0.1093 0.0974 0.1207 0.1044 0.1112 0.0954 0.1088 0.1722
F 0.0699 0.0645 0.4221 0.1043 0.0899 0.0917 0.1016 0.1159 0.1033 0.0835 0.1352 0.1427
G 0.0744 0.0330 0.4750 0.0454 0.1179 0.1211 0.0649 0.1306 0.1514 0.0371 0.1265 0.1322
H 0.0692 0.0407 0.4068 0.0327 0.1132 0.1150 0.0333 0.1368 0.1185 0.0344 0.1350 0.1591
average 0.0653 0.0693 0.4237 0.0846 0.0929 0.0913 0.0906 0.1096 0.1099 0.0711 0.1175 0.1390
range 0.0227 0.0772 0.0779 0.0887 0.0448 0.0485 0.0937 0.0439 0.0563 0.0646 0.0346 0.0584  
Descriptive Statistics: Thursday, April 02, 2015, 2:30:44 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0653 0.00744 0.00263 0.00622  
Control 8 0 0.424 0.0258 0.00913 0.0216  
Gentamicin 16 0 0.0920 0.0177 0.00443 0.00943  
Rifampicin 16 0 0.110 0.0171 0.00426 0.00909  
Polymyxin B 16 0 0.128 0.0199 0.00498 0.0106  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0227 0.0744 0.0517 0.0672 0.0596 0.0707  
Control 0.0779 0.475 0.397 0.420 0.400 0.439  
Gentamicin 0.0485 0.121 0.0726 0.0869 0.0758 0.112  
Rifampicin 0.0585 0.151 0.0929 0.105 0.0959 0.118  
Polymyxin B 0.0716 0.172 0.101 0.126 0.114 0.141  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.799 0.0911 0.201 0.410 0.945 0.663  
Control 1.106 1.284 0.152 0.712 0.911 0.359  
Gentamicin 0.514 -1.419 0.180 0.174 0.868 0.025  
Rifampicin 1.279 1.009 0.194 0.109 0.853 0.015  
Polymyxin B 0.703 0.116 0.113 0.742 0.957 0.612  
 
Column Sum Sum of Squares  
TSB 0.522 0.0345  
Control 3.390 1.441   
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Gentamicin 1.473 0.140  
Rifampicin 1.756 0.197  
Polymyxin B 2.052 0.269  
 
One Way Analysis of Variance Thursday, April 02, 2015, 2:31:04 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0653 0.00744 0.00263  
Control 8 0 0.424 0.0258 0.00913  
Gentamicin 16 0 0.0920 0.0177 0.00443  
Rifampicin 16 0 0.110 0.0171 0.00426  
Polymyxin B 16 0 0.128 0.0199 0.00498  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 0.741 0.185 544.836 <0.001  
Residual 59 0.0201 0.000340    
Total 63 0.761     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.332 41.527 <0.001 Yes   
Control vs. Rifampicin 0.314 39.311 <0.001 Yes   
Control vs. TSB 0.358 38.866 <0.001 Yes   
Control vs. Polymyxin B 0.295 36.996 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.358 38.866 <0.001 Yes   
TSB vs. Polymyxin B 0.0630 7.883 <0.001 Yes   
TSB vs. Rifampicin 0.0445 5.568 <0.001 Yes   
TSB vs. Gentamicin 0.0268 3.351 0.001 Yes   
 
Clinical Isolate 12 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0503 0.0366 0.7012 0.0383 0.0606 0.0597 0.0336 0.0880 0.0778 0.0476 0.0855 0.0820
B 0.0555 0.0351 0.7126 0.0472 0.0651 0.0574 0.0389 0.0805 0.0759 0.0348 0.0627 0.0656
C 0.0587 0.0495 0.6783 0.0339 0.0631 0.0605 0.0380 0.0882 0.0788 0.0329 0.0622 0.0692
D 0.0583 0.0346 0.7234 0.0346 0.0586 0.0563 0.0379 0.0830 0.0767 0.0355 0.0724 0.0824
E 0.0648 0.0348 0.7267 0.0391 0.0646 0.0602 0.0332 0.1021 0.0914 0.0387 0.0909 0.0869
F 0.0670 0.0323 0.7519 0.0340 0.0596 0.0660 0.0369 0.0966 0.0847 0.0436 0.0889 0.0751
G 0.0710 0.0326 0.7608 0.0366 0.0790 0.0642 0.0364 0.1032 0.1008 0.0359 0.0854 0.0909
H 0.0727 0.0413 0.7926 0.0369 0.0910 0.0822 0.0409 0.1066 0.1001 0.0362 0.0957 0.1413
average 0.0623 0.0371 0.7309 0.0376 0.0677 0.0633 0.0370 0.0935 0.0858 0.0382 0.0805 0.0867
range 0.0224 0.0172 0.1143 0.0133 0.0324 0.0259 0.0077 0.0261 0.0249 0.0147 0.0335 0.0757  
Descriptive Statistics: Thursday, April 02, 2015, 2:45:23 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0623 0.00785 0.00278 0.00656  
Control 8 0 0.731 0.0363 0.0128 0.0303  
Gentamicin 16 0 0.0655 0.00988 0.00247 0.00526  
Rifampicin 16 0 0.0896 0.0106 0.00265 0.00564  
Polymyxin B 16 0 0.0836 0.0187 0.00468 0.00997  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0224 0.0727 0.0503 0.0617 0.0562 0.0700  
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Control 0.114 0.793 0.678 0.725 0.704 0.759  
Gentamicin 0.0347 0.0910 0.0563 0.0619 0.0596 0.0658  
Rifampicin 0.0307 0.107 0.0759 0.0881 0.0792 0.101  
Polymyxin B 0.0791 0.141 0.0622 0.0839 0.0700 0.0904  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.0922 -1.177 0.176 0.571 0.958 0.786  
Control 0.366 -0.132 0.172 0.601 0.983 0.975  
Gentamicin 1.678 2.063 0.293 <0.001 0.770 0.001  
Rifampicin 0.209 -1.516 0.151 0.403 0.915 0.139  
Polymyxin B 1.923 5.788 0.223 0.033 0.811 0.004  
 
Column Sum Sum of Squares  
TSB 0.498 0.0315  
Control 5.848 4.283  
Gentamicin 1.048 0.0701  
Rifampicin 1.434 0.130  
Polymyxin B 1.337 0.117  
 
One Way Analysis of Variance Thursday, April 02, 2015, 2:45:41 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0623 0.00785 0.00278  
Control 8 0 0.731 0.0363 0.0128  
Gentamicin 16 0 0.0655 0.00988 0.00247  
Rifampicin 16 0 0.0896 0.0106 0.00265  
Polymyxin B 16 0 0.0836 0.0187 0.00468  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.000 0.750 2453.447 <0.001  
Residual 59 0.0180 0.000306    
Total 63 3.018     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.665 87.900 <0.001 Yes   
Control vs. Polymyxin B 0.647 85.515 <0.001 Yes   
Control vs. Rifampicin 0.641 84.711 <0.001 Yes   
Control vs. TSB 0.669 76.492 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.669 76.492 <0.001 Yes   
TSB vs. Rifampicin 0.0274 3.614 0.002 Yes   
TSB vs. Polymyxin B 0.0213 2.811 0.013 Yes   














Clinical Isolate 13 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0501 0.0326 0.7383 0.0409 0.0573 0.0539 0.0331 0.0723 0.0721 0.0323 0.0693 0.0668
B 0.0530 0.0337 0.8821 0.0330 0.0540 0.0510 0.0346 0.0710 0.0698 0.0329 0.0743 0.0715
C 0.0527 0.0322 0.8305 0.0325 0.0577 0.0593 0.0337 0.0793 0.0771 0.0376 0.0551 0.0971
D 0.0560 0.0341 0.8542 0.0324 0.0583 0.0568 0.0336 0.0763 0.0771 0.0324 0.0545 0.0809
E 0.0580 0.0357 0.8725 0.0367 0.0660 0.0653 0.0454 0.0808 0.0910 0.0328 0.0660 0.1074
F 0.0629 0.0338 0.7921 0.0342 0.0636 0.0672 0.0337 0.0864 0.0924 0.0325 0.0619 0.0836
G 0.0631 0.0332 0.7921 0.0321 0.0592 0.0956 0.0341 0.0941 0.1093 0.0321 0.0689 0.0892
H 0.0684 0.0326 0.8594 0.0322 0.0901 0.0845 0.0327 0.0985 0.0929 0.0383 0.1246 0.0912
average 0.0580 0.0335 0.8277 0.0343 0.0633 0.0667 0.0351 0.0823 0.0852 0.0339 0.0718 0.0860
range 0.0183 0.0035 0.1438 0.0088 0.0361 0.0446 0.0127 0.0275 0.0395 0.0062 0.0701 0.0406  
Descriptive Statistics: Thursday, April 02, 2015, 3:02:48 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0580 0.00630 0.00223 0.00527  
Control 8 0 0.828 0.0496 0.0175 0.0415  
Gentamicin 16 0 0.0650 0.0134 0.00335 0.00713  
Rifampicin 16 0 0.0838 0.0115 0.00288 0.00614  
Polymyxin B 16 0 0.0789 0.0192 0.00481 0.0102  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0183 0.0684 0.0501 0.0570 0.0528 0.0630  
Control 0.144 0.882 0.738 0.842 0.792 0.869  
Gentamicin 0.0446 0.0956 0.0510 0.0592 0.0569 0.0669  
Rifampicin 0.0395 0.109 0.0698 0.0800 0.0733 0.0928  
Polymyxin B 0.0701 0.125 0.0545 0.0729 0.0662 0.0907  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.442 -0.931 0.163 0.655 0.946 0.672  
Control -0.783 -0.289 0.204 0.389 0.916 0.400  
Gentamicin 1.414 0.966 0.247 0.010 0.805 0.003  
Rifampicin 0.681 -0.283 0.164 0.284 0.923 0.186  
Polymyxin B 0.949 0.661 0.157 0.346 0.931 0.256  
 
Column Sum Sum of Squares  
TSB 0.464 0.0272  
Control 6.621 5.497  
Gentamicin 1.040 0.0703  
Rifampicin 1.340 0.114  
Polymyxin B 1.262 0.105  
 
One Way Analysis of Variance Thursday, April 02, 2015, 3:03:12 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0580 0.00630 0.00223  
Control 8 0 0.828 0.0496 0.0175  
Gentamicin 16 0 0.0650 0.0134 0.00335  
Rifampicin 16 0 0.0838 0.0115 0.00288  
Polymyxin B 16 0 0.0789 0.0192 0.00481  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.988 0.997 2122.835 <0.001  
Residual 59 0.0277 0.000470    
Total 63 4.016     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
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Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.763 81.270 <0.001 Yes   
Control vs. Polymyxin B 0.749 79.789 <0.001 Yes   
Control vs. Rifampicin 0.744 79.268 <0.001 Yes   
Control vs. TSB 0.770 71.025 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.770 71.025 <0.001 Yes   
TSB vs. Rifampicin 0.0258 2.744 0.024 Yes   
TSB vs. Polymyxin B 0.0209 2.224 0.059 No   
TSB vs. Gentamicin 0.00696 0.742 0.461 No   
 
Clinical Isolate 14 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0515 0.0318 0.8234 0.0322 0.0577 0.0531 0.0329 0.0623 0.0663 0.0339 0.1644 0.1692
B 0.0569 0.0332 0.8829 0.0328 0.0539 0.0522 0.0378 0.0605 0.0626 0.0332 0.1298 0.1554
C 0.0528 0.0360 0.8859 0.0379 0.0600 0.0590 0.0342 0.0609 0.0679 0.0378 0.0590 0.1115
D 0.0557 0.0413 0.8849 0.0378 0.0635 0.0591 0.0362 0.0663 0.0665 0.0324 0.1180 0.1495
E 0.0582 0.0334 0.9017 0.0329 0.0744 0.0675 0.0331 0.0711 0.0728 0.0326 0.1196 0.1622
F 0.0616 0.0354 0.8826 0.0337 0.0661 0.0685 0.0366 0.0740 0.0762 0.0323 0.0807 0.1049
G 0.0642 0.0333 0.8716 0.0328 0.0806 0.0757 0.0331 0.1080 0.0814 0.0374 0.1613 0.1535
H 0.0705 0.0324 0.8537 0.0322 0.0823 0.0832 0.0331 0.1040 0.0949 0.0329 0.1383 0.1567
average 0.0589 0.0346 0.8733 0.0340 0.0673 0.0648 0.0346 0.0759 0.0736 0.0341 0.1214 0.1454
range 0.0190 0.0095 0.0783 0.0057 0.0284 0.0310 0.0049 0.0475 0.0323 0.0055 0.1054 0.0643  
Descriptive Statistics: Thursday, April 02, 2015, 3:23:59 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0589 0.00629 0.00222 0.00526  
Control 8 0 0.873 0.0244 0.00861 0.0204  
Gentamicin 16 0 0.0660 0.0105 0.00263 0.00560  
Rifampicin 16 0 0.0747 0.0150 0.00376 0.00801  
Polymyxin B 16 0 0.133 0.0323 0.00806 0.0172  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0190 0.0705 0.0515 0.0576 0.0535 0.0635  
Control 0.0783 0.902 0.823 0.883 0.858 0.886  
Gentamicin 0.0310 0.0832 0.0522 0.0648 0.0580 0.0754  
Rifampicin 0.0475 0.108 0.0605 0.0695 0.0635 0.0801  
Polymyxin B 0.110 0.169 0.0590 0.144 0.113 0.160  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.794 0.226 0.171 0.605 0.950 0.708  
Control -1.371 1.981 0.273 0.081 0.864 0.130  
Gentamicin 0.379 -1.164 0.155 0.363 0.925 0.202  
Rifampicin 1.326 0.722 0.211 0.055 0.820 0.005  
Polymyxin B -0.999 0.331 0.191 0.118 0.895 0.067  
 
Column Sum Sum of Squares  
TSB 0.471 0.0281  
Control 6.987 6.106  
Gentamicin 1.057 0.0715  
Rifampicin 1.196 0.0927  
Polymyxin B 2.134 0.300  
 
One Way Analysis of Variance Thursday, April 02, 2015, 3:24:20 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0589 0.00629 0.00222  
Control 8 0 0.873 0.0244 0.00861  
Gentamicin 16 0 0.0660 0.0105 0.00263  
Rifampicin 16 0 0.0747 0.0150 0.00376  
Polymyxin B 16 0 0.133 0.0323 0.00806  
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Source of Variation  DF   SS   MS    F    P   
Between Groups 4 4.381 1.095 2575.929 <0.001  
Residual 59 0.0251 0.000425    
Total 63 4.406     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.807 90.412 <0.001 Yes   
Control vs. Rifampicin 0.799 89.440 <0.001 Yes   
Control vs. Polymyxin B 0.740 82.872 <0.001 Yes   
Control vs. TSB 0.814 78.990 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.814 78.990 <0.001 Yes   
TSB vs. Polymyxin B 0.0744 8.338 <0.001 Yes   
TSB vs. Rifampicin 0.0158 1.770 0.157 No   
TSB vs. Gentamicin 0.00712 0.798 0.428 No   
 
Clinical Isolate 15 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0490 0.0374 0.4274 0.0460 0.0625 0.0702 0.0343 0.0825 0.0770 0.0402 0.0924 0.0732
B 0.0499 0.0332 0.4167 0.0454 0.0631 0.0627 0.0327 0.0763 0.0852 0.0322 0.0523 0.0644
C 0.0599 0.0322 0.4243 0.0450 0.0740 0.0670 0.0349 0.0853 0.0768 0.0345 0.0556 0.0705
D 0.0578 0.0342 0.4382 0.0372 0.0676 0.0655 0.0450 0.0828 0.0772 0.0331 0.0592 0.0905
E 0.0594 0.0324 0.4633 0.0354 0.0874 0.0856 0.0327 0.0962 0.0908 0.0323 0.0897 0.0875
F 0.0635 0.0318 0.4491 0.0351 0.0977 0.0740 0.0364 0.0995 0.0901 0.0324 0.0901 0.0827
G 0.0719 0.0322 0.4704 0.0329 0.1121 0.0766 0.0329 0.1117 0.1241 0.0349 0.0701 0.0845
H 0.0690 0.0328 0.4580 0.0328 0.1075 0.1001 0.0331 0.1156 0.1068 0.0343 0.0859 0.1032
average 0.0601 0.0333 0.4434 0.0387 0.0840 0.0752 0.0353 0.0937 0.0910 0.0342 0.0744 0.0821
range 0.0229 0.0056 0.0537 0.0132 0.0496 0.0374 0.0123 0.0393 0.0473 0.0080 0.0401 0.0388  
Descriptive Statistics: Thursday, April 02, 2015, 3:49:08 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0600 0.00813 0.00288 0.00680  
Control 8 0 0.443 0.0198 0.00698 0.0165  
Gentamicin 16 0 0.0796 0.0167 0.00418 0.00891  
Rifampicin 16 0 0.0924 0.0152 0.00380 0.00809  
Polymyxin B 16 0 0.0782 0.0149 0.00373 0.00795  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0229 0.0719 0.0490 0.0597 0.0519 0.0676  
Control 0.0537 0.470 0.417 0.444 0.425 0.462  
Gentamicin 0.0496 0.112 0.0625 0.0740 0.0659 0.0951  
Rifampicin 0.0478 0.124 0.0763 0.0877 0.0785 0.105  
Polymyxin B 0.0509 0.103 0.0523 0.0836 0.0658 0.0900  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.00545 -0.840 0.144 0.746 0.945 0.665  
Control 0.0103 -1.652 0.166 0.632 0.945 0.660  
Gentamicin 0.803 -0.714 0.196 0.098 0.874 0.032  
Rifampicin 0.816 -0.433 0.179 0.181 0.895 0.068  
Polymyxin B -0.338 -0.911 0.180 0.176 0.941 0.356  
 
Column Sum Sum of Squares  
TSB 0.480 0.0293  
Control 3.547 1.576  
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Gentamicin 1.274 0.106  
Rifampicin 1.478 0.140  
Polymyxin B 1.252 0.101  
 
One Way Analysis of Variance Thursday, April 02, 2015, 3:49:27 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0600 0.00813 0.00288  
Control 8 0 0.443 0.0198 0.00698  
Gentamicin 16 0 0.0796 0.0167 0.00418  
Rifampicin 16 0 0.0924 0.0152 0.00380  
Polymyxin B 16 0 0.0782 0.0149 0.00373  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 0.930 0.232 966.931 <0.001  
Residual 59 0.0142 0.000240    
Total 63 0.944     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Polymyxin B 0.365 54.391 <0.001 Yes   
Control vs. Gentamicin 0.364 54.188 <0.001 Yes   
Control vs. Rifampicin 0.351 52.286 <0.001 Yes   
Control vs. TSB 0.383 49.450 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.383 49.450 <0.001 Yes   
TSB vs. Rifampicin 0.0323 4.814 <0.001 Yes   
TSB vs. Gentamicin 0.0196 2.912 0.010 Yes   
TSB vs. Polymyxin B 0.0182 2.709 0.009 Yes   
 
Clinical Isolate 16 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0497 0.0436 0.6902 0.0395 0.0600 0.0589 0.0328 0.0824 0.0767 0.0413 0.0778 0.0774
B 0.0511 0.0451 0.8318 0.0902 0.0634 0.0592 0.0974 0.0753 0.0830 0.0979 0.0696 0.1041
C 0.0540 0.0793 0.8714 0.1051 0.0672 0.0641 0.1007 0.0852 0.0849 0.0993 0.0722 0.0933
D 0.0614 0.0786 0.8174 0.1335 0.0692 0.0706 0.1075 0.0885 0.0850 0.0995 0.0795 0.1054
E 0.0568 0.0664 0.8895 0.1209 0.0706 0.0909 0.1220 0.1003 0.5148 0.0968 0.0825 0.0824
F 0.0635 0.0342 0.8799 0.0966 0.0931 0.0802 0.0890 0.1141 0.0923 0.0953 0.1292 0.1030
G 0.0664 0.0335 0.8899 0.0336 0.0831 0.0905 0.0422 0.1049 0.1136 0.0365 0.0939 0.0853
H 0.0678 0.0444 0.7749 0.0346 0.0793 0.0924 0.0369 0.1062 0.0979 0.0429 0.1162 0.0900
average 0.0588 0.0531 0.8306 0.0818 0.0732 0.0759 0.0786 0.0946 0.1435 0.0762 0.0901 0.0926
range 0.0181 0.0458 0.1997 0.0999 0.0331 0.0335 0.0892 0.0388 0.4381 0.0630 0.0596 0.0280  
Descriptive Statistics: Thursday, April 02, 2015, 4:02:17 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0588 0.00694 0.00245 0.00580  
Control 8 0 0.831 0.0698 0.0247 0.0583  
Gentamicin 16 0 0.0745 0.0125 0.00313 0.00667  
Rifampicin 16 0 0.119 0.106 0.0266 0.0566  
Polymyxin B 16 0 0.0914 0.0166 0.00414 0.00882  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0181 0.0678 0.0497 0.0591 0.0518 0.0657  
Control 0.200 0.890 0.690 0.852 0.786 0.887  
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Gentamicin 0.0342 0.0931 0.0589 0.0706 0.0636 0.0886  
Rifampicin 0.440 0.515 0.0753 0.0904 0.0835 0.106  
Polymyxin B 0.0596 0.129 0.0696 0.0877 0.0782 0.104  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.0441 -1.735 0.144 0.745 0.932 0.533  
Control -1.315 1.345 0.221 0.288 0.851 0.097  
Gentamicin 0.300 -1.459 0.186 0.143 0.896 0.070  
Rifampicin 3.909 15.483 0.456 <0.001 0.375 <0.001  
Polymyxin B 0.840 0.241 0.143 0.475 0.937 0.313  
 
Column Sum Sum of Squares  
TSB 0.471 0.0280  
Control 6.645 5.554  
Gentamicin 1.193 0.0913  
Rifampicin 1.905 0.396  
Polymyxin B 1.462 0.138  
 
One Way Analysis of Variance Thursday, April 02, 2015, 4:02:37 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0588 0.00694 0.00245  
Control 8 0 0.831 0.0698 0.0247  
Gentamicin 16 0 0.0745 0.0125 0.00313  
Rifampicin 16 0 0.119 0.106 0.0266  
Polymyxin B 16 0 0.0914 0.0166 0.00414  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.867 0.967 271.353 <0.001  
Residual 59 0.210 0.00356    
Total 63 4.077     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050  
Control vs. Gentamicin 0.756 29.255 <0.001 Yes   
Control vs. Polymyxin B 0.739 28.604 <0.001 Yes   
Control vs. Rifampicin 0.712 27.532 <0.001 Yes   
Control vs. TSB 0.772 25.862 <0.001 Yes   
 
Comparisons for factor:  
Comparison Diff of Means t P P<0.050   
TSB vs. Control 0.772 25.862 <0.001 Yes   
TSB vs. Rifampicin 0.0602 2.331 0.068 No   
TSB vs. Polymyxin B 0.0325 1.258 0.381 No   















Clinical Isolate 17 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0553 0.0343 0.8942 0.0328 0.0616 0.0583 0.0329 0.0795 0.0700 0.0327 0.1205 0.1162
B 0.0508 0.0323 0.9901 0.0443 0.0592 0.0557 0.0414 0.0683 0.0653 0.0334 0.0877 0.1369
C 0.0521 0.0343 0.9599 0.0344 0.0638 0.0584 0.0340 0.0756 0.0727 0.0348 0.1111 0.1388
D 0.0567 0.0359 0.9668 0.0330 0.0640 0.0598 0.0390 0.0705 0.0728 0.0331 1.0129 0.1107
E 0.0581 0.0403 0.9524 0.0400 0.0697 0.0791 0.0367 0.0785 0.0801 0.0332 0.1086 0.0875
F 0.0609 0.0448 0.9612 0.0370 0.0719 0.0652 0.0336 0.0821 0.0776 0.0382 0.1441 0.1462
G 0.0647 0.0339 0.9828 0.0334 0.0781 0.0680 0.0378 0.0970 0.1040 0.0385 0.1079 0.1041
H 0.0727 0.0362 1.0278 0.0370 0.0879 0.0972 0.0343 0.0995 0.0904 0.0438 0.1249 0.1602
average 0.0589 0.0365 0.9669 0.0365 0.0695 0.0677 0.0362 0.0814 0.0791 0.0360 0.2272 0.1251
range 0.0219 0.0125 0.1336 0.0115 0.0287 0.0415 0.0085 0.0312 0.0387 0.0111 0.9252 0.0727  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
Polymyxin B 16 0 0.176 0.224 0.0560 0.119  
TSB 8 0 0.0589 0.00716 0.00253 0.00598  
Untreated Bacteria 8 0 0.967 0.0379 0.0134 0.0317  
Gentamicin 16 0 0.0686 0.0117 0.00292 0.00623  
Rifampicin 16 0 0.0802 0.0116 0.00291 0.00620  
Polymyxin B 16 0 0.176 0.224 0.0560 0.119  
 
Column Range Max Min  Median  25% 75%  
Polymyxin B 0.925 1.013 0.0875 0.118 0.108 0.141  
TSB 0.0219 0.0727 0.0508 0.0574 0.0537 0.0628  
Untreated Bacteria 0.134 1.028 0.894 0.964 0.956 0.986  
Gentamicin 0.0415 0.0972 0.0557 0.0646 0.0595 0.0750  
Rifampicin 0.0387 0.104 0.0653 0.0781 0.0716 0.0862  
Polymyxin B 0.925 1.013 0.0875 0.118 0.108 0.141  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
Polymyxin B 3.942 15.674 0.466 <0.001 0.355 <0.001  
TSB 0.995 0.850 0.170 0.609 0.934 0.554  
Untreated Bacteria -0.507 2.064 0.226 0.257 0.935 0.566  
Gentamicin 1.245 1.054 0.178 0.191 0.879 0.037  
Rifampicin 0.884 -0.223 0.192 0.114 0.903 0.089  
Polymyxin B                      3.94             15.674             0.466                <0.001          0.355              <0.001 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0589 0.00716 0.00253  
Untreated Bacteria 8 0 0.967 0.0379 0.0134  
Gentamicin 16 0 0.0686 0.0117 0.00292  
Rifampicin 16 0 0.0802 0.0116 0.00291  
Polymyxin B 16 0 0.176 0.224 0.0560  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 5.373 1.343 103.238 <0.001  
Residual 59 0.768 0.0130    
Total 63 6.141     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin           0.898 18.186 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin            0.887 17.951 <0.001 0.017 Yes  
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Untreated Ba vs. Polymyxin B         0.791 16.009 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB              0.908 15.920 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                         Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.908 15.920 <0.001 0.013 Yes  
TSB vs. Polymyxin B                 0.117 2.373 0.021 0.017 No  
TSB vs. Rifampicin                   0.0213 0.432 0.667 0.025 No  
TSB vs. Gentamicin                  0.00971 0.197 0.845 0.050 No  
 
Clinical Isolate 18 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0530 0.0367 0.7461 0.0326 0.0568 0.0572 0.0324 0.0693 0.0687 0.0320 0.3351 0.0864
B 0.0542 0.0322 0.7902 0.0334 0.0563 0.0542 0.0328 0.0661 0.0638 0.0320 0.1126 0.1251
C 0.0561 0.0339 0.8074 0.0326 0.0611 0.0573 0.0343 0.0708 0.0729 0.0326 0.1423 0.1213
D 0.0594 0.0336 0.8220 0.0359 0.0626 0.0569 0.0337 0.0701 0.0721 0.0327 0.4980 0.1307
E 0.0605 0.0326 0.8154 0.0334 0.0810 0.0598 0.0339 0.0816 0.0864 0.0328 0.3835 0.4875
F 0.0641 0.0337 0.7997 0.0344 0.0840 0.0652 0.0334 0.0751 0.0831 0.0334 0.0982 0.1489
G 0.0695 0.0335 0.8525 0.0345 0.0941 0.1023 0.0342 0.0908 0.1199 0.0336 1.1282 0.1357
H 0.0746 0.0317 0.7845 0.0334 0.1026 0.1021 0.0328 0.1180 0.1032 0.0367 0.1908 0.1943
average 0.0614 0.0335 0.8022 0.0338 0.0748 0.0694 0.0334 0.0802 0.0838 0.0332 0.3611 0.1787
range 0.0216 0.0050 0.1064 0.0033 0.0463 0.0481 0.0019 0.0519 0.0561 0.0047 1.0300 0.4011  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0614 0.00758 0.00268 0.00634  
Untreated Bacteria 8 0 0.802 0.0310 0.0110 0.0259  
Gentamicin 16 0 0.0721 0.0189 0.00471 0.0100  
Rifampicin 16 0 0.0820 0.0177 0.00442 0.00943  
Polymyxin B 16 0 0.270 0.266 0.0666 0.142  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0216 0.0746 0.0530 0.0600 0.0551 0.0668  
Untreated Bacteria 0.106 0.853 0.746 0.804 0.787 0.819  
Gentamicin 0.0484 0.103 0.0542 0.0619 0.0571 0.0891  
Rifampicin 0.0561 0.120 0.0638 0.0740 0.0697 0.0886  
Polymyxin B 1.042 1.128 0.0864 0.146 0.123 0.359  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.742 -0.438 0.174 0.588 0.932 0.539  
Untreated Bacteria -0.299 1.255 0.159 0.675 0.976 0.943  
Gentamicin 0.777 -1.197 0.268 0.003 0.788 0.002  
Rifampicin 1.263 0.597 0.214 0.048 0.832 0.007  
Polymyxin B 2.518 7.224 0.299 <0.001 0.669 <0.001  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0614 0.00758 0.00268  
Untreated Bacteria 8 0 0.802 0.0310 0.0110  
Gentamicin 16 0 0.0721 0.0189 0.00471  
Rifampicin 16 0 0.0820 0.0177 0.00442  
Polymyxin B 16 0 0.270 0.266 0.0666  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.605 0.901 49.166 <0.001  
Residual 59 1.082 0.0183    
Total 63 4.687     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
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Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                               Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin            0.730 12.453 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin            0.720 12.285 <0.001 0.017 Yes  
Untreated Bacteria vs. TSB              0.741 10.943 <0.001 0.025 Yes  
Untreated Ba vs. Polymyxin B         0.532 9.079 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.741 10.943 <0.001 0.013 Yes  
TSB vs. Polymyxin B                 0.208 3.556 <0.001 0.017 Yes  
TSB vs. Rifampicin                    0.0206 0.351 0.727 0.025 No  
TSB vs. Gentamicin                    0.0107 0.182 0.856 0.050 No  
 
Clinical Isolate 19 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0500 0.0342 0.8721 0.0328 0.0595 0.0577 0.0335 0.0736 0.0718 0.0327 0.0905 0.1032
B 0.0535 0.0337 0.9258 0.0322 0.0590 0.0595 0.0336 0.4233 0.0701 0.0331 0.0800 0.0974
C 0.0516 0.0373 0.9884 0.0359 0.0614 0.0645 0.0358 0.0828 0.4418 0.0368 0.5579 0.0653
D 0.0556 0.0327 0.9827 0.0331 0.0670 0.0673 0.0323 0.0822 0.0784 0.0330 0.1022 0.1015
E 0.0571 0.0334 0.9944 0.0328 0.0712 0.0927 0.0412 0.0979 0.0886 0.0338 0.0984 0.1191
F 0.0636 0.0336 0.9888 0.0377 0.0779 0.0739 0.0330 0.0958 0.0906 0.0345 0.1068 0.1105
G 0.0866 0.0329 1.0739 0.0328 0.0745 0.0772 0.0381 0.1219 0.1083 0.0337 0.1273 0.1268
H 0.0676 0.0343 0.9751 0.0327 0.1007 0.0946 0.0376 0.1038 0.0959 0.0339 0.1028 0.1611
average 0.0607 0.0340 0.9752 0.0338 0.0714 0.0734 0.0356 0.1352 0.1307 0.0339 0.1582 0.1106
range 0.0366 0.0046 0.2018 0.0055 0.0417 0.0369 0.0089 0.3497 0.3717 0.0041 0.4779 0.0958  
 
Descriptive Statistics: Thursday, April 16, 2015, 12:44:39 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0607 0.0120 0.00426 0.0101  
Untreated Bacteria 8 0 0.975 0.0581 0.0205 0.0485  
Gentamicin 16 0 0.0724 0.0135 0.00338 0.00719  
Rifampicin 16 0 0.133 0.118 0.0295 0.0628  
Polymyxin B 16 0 0.134 0.115 0.0287 0.0612  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0366 0.0866 0.0500 0.0563 0.0525 0.0656  
Untreated Bacteria 0.202 1.074 0.872 0.986 0.950 0.992  
Gentamicin 0.0430 0.101 0.0577 0.0693 0.0605 0.0776  
Rifampicin 0.372 0.442 0.0701 0.0932 0.0803 0.106  
Polymyxin B 0.493 0.558 0.0653 0.103 0.0979 0.123  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.658 2.860 0.243 0.179 0.832 0.062  
Untreated Bacteria -0.233 1.557 0.250 0.150 0.910 0.353  
Gentamicin 0.934 -0.0851 0.155 0.365 0.884 0.045  
Rifampicin 2.444 4.708 0.412 <0.001 0.513 <0.001  
Polymyxin B 3.769 14.677 0.400 <0.001 0.439 <0.001  
 
 
One Way Analysis of Variance Thursday, April 16, 2015, 12:44:57 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0607 0.0120 0.00426  
Untreated Bacteria 8 0 0.975 0.0581 0.0205  
Gentamicin 16 0 0.0724 0.0135 0.00338  
Rifampicin 16 0 0.133 0.118 0.0295  
Polymyxin B 16 0 0.134 0.115 0.0287  
 
Source of Variation  DF   SS   MS    F    P   
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Between Groups 4 5.350 1.338 181.913 <0.001  
Residual 59 0.434 0.00735    
Total 63 5.784     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                             Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin             0.903 24.313 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin              0.842 22.684 <0.001 0.017 Yes  
Untreated Ba vs. Polymyxin B          0.841 22.643 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB               0.914 21.329 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                          Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria          0.914 21.329 <0.001 0.013 Yes  
TSB vs. Polymyxin B                  0.0737 1.986 0.052 0.017 No  
TSB vs. Rifampicin                     0.0722 1.945 0.057 0.025 No  
TSB vs. Gentamicin                    0.0117 0.315 0.754 0.050 No  
 
Clinical Isolate 20 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0526 0.0330 0.8726 0.0325 0.0647 0.0619 0.0328 0.0718 0.0682 0.0369 0.0938 0.0571
B 0.0554 0.0340 0.8571 0.0383 0.0693 0.0655 0.0325 0.0705 0.0684 0.0331 0.0635 0.0722
C 0.0644 0.0390 0.7942 0.0323 0.0786 0.0729 0.0326 0.0763 0.0755 0.0336 0.0593 0.0633
D 0.0603 0.0350 0.7978 0.0399 0.0769 0.0764 0.0340 0.0793 0.0818 0.0325 0.0662 0.0614
E 0.0657 0.0323 0.7667 0.0340 0.0912 0.1034 0.0331 0.0879 0.0855 0.0329 0.0716 0.0762
F 0.0686 0.0336 0.8354 0.0321 0.1012 0.0869 0.0325 0.0931 0.3127 0.0334 0.0760 0.0716
G 0.0696 0.0484 0.8564 0.0374 0.1093 0.1076 0.0324 0.1350 0.1095 0.0330 0.0946 0.0875
H 0.0721 0.0326 0.8589 0.0328 0.1017 0.1036 0.0322 0.1088 0.0907 0.0349 0.1037 0.1058
average 0.0636 0.0360 0.8299 0.0349 0.0866 0.0848 0.0328 0.0903 0.1115 0.0338 0.0786 0.0744
range 0.0195 0.0161 0.1059 0.0078 0.0446 0.0457 0.0018 0.0645 0.2445 0.0044 0.0444 0.0487  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0636 0.00694 0.00245 0.00580  
Untreated Bacteria 8 0 0.830 0.0386 0.0137 0.0323  
Gentamicin 16 0 0.0857 0.0169 0.00421 0.00898  
Rifampicin 16 0 0.101 0.0593 0.0148 0.0316  
Polymyxin B 16 0 0.0765 0.0158 0.00396 0.00844  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0195 0.0721 0.0526 0.0650 0.0578 0.0691  
Untreated Bacteria 0.106 0.873 0.767 0.846 0.796 0.858  
Gentamicin 0.0474 0.109 0.0619 0.0828 0.0711 0.103  
Rifampicin 0.245 0.313 0.0682 0.0837 0.0736 0.101  
Polymyxin B 0.0487 0.106 0.0571 0.0719 0.0634 0.0906  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.535 -1.005 0.172 0.600 0.941 0.619  
Untreated Bacteria -0.627 -1.243 0.254 0.135 0.885 0.211  
Gentamicin 0.0582 -1.656 0.196 0.098 0.901 0.084  
Rifampicin 3.423 12.570 0.318 <0.001 0.530 <0.001  
Polymyxin B 0.693 -0.779 0.195 0.104 0.902 0.088  
 
 
One Way Analysis of Variance  
 




Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0636 0.00694 0.00245  
Untreated Bacteria 8 0 0.830 0.0386 0.0137  
Gentamicin 16 0 0.0857 0.0169 0.00421  
Rifampicin 16 0 0.101 0.0593 0.0148  
Polymyxin B 16 0 0.0765 0.0158 0.00396  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.901 0.975 804.618 <0.001  
Residual 59 0.0715 0.00121    
Total 63 3.972     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                               Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B         0.753 49.979 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin            0.744 49.368 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin             0.729 48.357 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB              0.766 44.024 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                          Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.766 44.024 <0.001 0.013 Yes  
TSB vs. Rifampicin                   0.0374 2.478 0.016 0.017 Yes  
TSB vs. Gentamicin                   0.0221 1.466 0.148 0.025 No  
TSB vs. Polymyxin B                0.0129 0.856 0.396 0.050 No  
 
Clinical Isolate 21 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0512 0.0330 0.7982 0.0333 0.0670 0.0646 0.0321 0.0807 0.0757 0.0327 0.0628 0.0657
B 0.0530 0.0323 0.7730 0.1150 0.0618 0.0639 0.1178 0.0816 0.0748 0.1176 0.1229 0.0728
C 0.0548 0.0631 0.7864 0.1247 0.0652 0.0705 0.1294 0.0830 0.0833 0.1297 0.0615 0.0726
D 0.0624 0.0533 0.7913 0.1386 0.0640 0.0705 0.1578 0.0896 0.0832 0.1367 0.0795 0.0604
E 0.0607 0.0634 0.7643 0.1405 0.0747 0.0896 0.1506 0.1112 0.1065 0.1262 0.0680 0.0749
F 0.0708 0.0411 0.7677 0.1297 0.0923 0.0895 0.1361 0.1110 0.0951 0.1208 0.0747 0.0681
G 0.0775 0.0339 0.7769 0.0727 0.1058 0.1071 0.1017 0.1196 0.4276 0.0743 0.0842 0.0820
H 0.0732 0.0318 0.7974 0.0324 0.1112 0.1003 0.0345 0.1080 0.0964 0.0338 0.1019 0.1355
average 0.0630 0.0440 0.7819 0.0984 0.0803 0.0820 0.1075 0.0981 0.1303 0.0965 0.0819 0.0790
range 0.0263 0.0316 0.0339 0.1081 0.0494 0.0432 0.1257 0.0389 0.3528 0.1040 0.0614 0.0751  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0630 0.00991 0.00350 0.00828  
Untreated Bacteria 8 0 0.782 0.0133 0.00469 0.0111  
Gentamicin 16 0 0.0811 0.0178 0.00446 0.00951  
Rifampicin 16 0 0.114 0.0848 0.0212 0.0452  
Polymyxin B 16 0 0.0805 0.0217 0.00544 0.0116  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0263 0.0775 0.0512 0.0615 0.0539 0.0720  
Untreated Bacteria 0.0339 0.798 0.764 0.782 0.770 0.794  
Gentamicin 0.0494 0.111 0.0618 0.0726 0.0649 0.0963  
Rifampicin 0.353 0.428 0.0748 0.0924 0.0823 0.110  
Polymyxin B 0.0751 0.136 0.0604 0.0738 0.0668 0.0831  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.290 -1.594 0.170 0.613 0.924 0.464  
Untreated Bacteria -0.0138 -1.791 0.147 0.734 0.920 0.432  
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Gentamicin 0.509 -1.428 0.224 0.031 0.858 0.018  
Rifampicin 3.813 14.933 0.412 <0.001 0.421 <0.001  
Polymyxin B 1.661 2.138 0.244 0.011 0.792 0.002  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0630 0.00991 0.00350  
Untreated Bacteria 8 0 0.782 0.0133 0.00469  
Gentamicin 16 0 0.0811 0.0178 0.00446  
Rifampicin 16 0 0.114 0.0848 0.0212  
Polymyxin B 16 0 0.0805 0.0217 0.00544  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.390 0.848 411.395 <0.001  
Residual 59 0.122 0.00206    
Total 63 3.512     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                               Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B         0.701 35.689 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin            0.701 35.656 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin             0.668 33.972 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB          0.719 31.679 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                            Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria          0.719 31.679 <0.001 0.013 Yes  
TSB vs. Rifampicin                     0.0513 2.608 0.012 0.017 Yes  
TSB vs. Gentamicin                    0.0182 0.925 0.359 0.025 No  
TSB vs. Polymyxin B                 0.0175 0.891 0.376 0.050 No  
 
Clinical Isolate 22 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0509 0.0318 0.2047 0.0420 0.0618 0.0604 0.0506 0.0699 0.0678 0.0349 0.1104 0.1041
B 0.0530 0.0331 0.2224 0.0332 0.0636 0.0589 0.0340 0.0711 0.0741 0.0350 0.1042 0.0592
C 0.0575 0.0350 0.2285 0.0337 0.0687 0.0560 0.0347 0.0814 0.0753 0.0347 0.0649 0.0631
D 0.0622 0.0320 0.2280 0.0349 0.0727 0.0629 0.0330 0.0843 0.0738 0.0368 0.0730 0.0711
E 0.0618 0.0333 0.2642 0.0326 0.0980 0.0699 0.0362 0.0932 0.0931 0.0434 0.0679 0.0848
F 0.0643 0.0335 0.2467 0.0320 0.0815 0.0731 0.0514 0.0880 0.0775 0.0424 0.0751 0.0969
G 0.0681 0.0369 0.2948 0.0338 0.1158 0.1037 0.0370 0.1021 0.1125 0.0337 0.0819 0.0961
H 0.0688 0.0340 0.2972 0.0352 0.0911 0.0875 0.0468 0.1025 0.0911 0.0366 0.1080 0.1460
average 0.0608 0.0337 0.2483 0.0347 0.0817 0.0716 0.0405 0.0866 0.0832 0.0372 0.0857 0.0902
range 0.0179 0.0051 0.0925 0.0100 0.0540 0.0477 0.0184 0.0326 0.0447 0.0097 0.0455 0.0868  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0608 0.00657 0.00232 0.00549  
Untreated Bacteria 8 0 0.248 0.0342 0.0121 0.0286  
Gentamicin 16 0 0.0766 0.0179 0.00447 0.00952  
Rifampicin 16 0 0.0849 0.0133 0.00333 0.00709  
Polymyxin B 16 0 0.0879 0.0232 0.00579 0.0123  
 
Column Range Max Min  Median  25% 75%  
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TSB 0.0179 0.0688 0.0509 0.0620 0.0553 0.0662  
Untreated Bacteria 0.0925 0.297 0.205 0.238 0.225 0.279  
Gentamicin 0.0598 0.116 0.0560 0.0713 0.0624 0.0893  
Rifampicin 0.0447 0.113 0.0678 0.0829 0.0740 0.0932  
Polymyxin B 0.0868 0.146 0.0592 0.0834 0.0695 0.104  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.373 -1.117 0.184 0.520 0.936 0.573  
Untreated Bacteria 0.499 -1.179 0.219 0.297 0.909 0.344  
Gentamicin 0.893 -0.162 0.203 0.078 0.904 0.092  
Rifampicin 0.592 -0.567 0.147 0.434 0.937 0.317  
Polymyxin B 0.955 1.006 0.148 0.431 0.916 0.145  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0608 0.00657 0.00232  
Untreated Bacteria 8 0 0.248 0.0342 0.0121  
Gentamicin 16 0 0.0766 0.0179 0.00447  
Rifampicin 16 0 0.0849 0.0133 0.00333  
Polymyxin B 16 0 0.0879 0.0232 0.00579  
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 0.203 0.0507 124.825 <0.001  
Residual 59 0.0240 0.000406    
Total 63 0.227     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin            0.172 19.669 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin             0.163 18.723 <0.001 0.017 Yes  
Untreated Bacteria vs. TSB              0.187 18.599 <0.001 0.025 Yes  
Untreated Ba vs. Polymyxin B         0.160 18.373 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.187 18.599 <0.001 0.013 Yes  
TSB vs. Polymyxin B                 0.0271 3.103 0.003 0.017 Yes  
TSB vs. Rifampicin                    0.0240 2.753 0.008 0.025 Yes  
TSB vs. Gentamicin                    0.0158 1.807 0.076 0.050 No  
 
Clinical Isolate 23 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0516 0.0326 0.7014 0.0355 0.0584 0.0583 0.0347 0.0687 0.0722 0.0333 0.0655 0.1035
B 0.0550 0.0395 0.6511 0.0329 0.0597 0.0596 0.0329 0.0740 0.0674 0.0378 0.0572 0.0876
C 0.0532 0.0379 0.6893 0.0369 0.0628 0.0665 0.0333 0.0864 0.0830 0.0336 0.0901 0.0814
D 0.0570 0.0327 0.6833 0.0365 0.0655 0.0682 0.0378 0.0827 0.0791 0.0338 0.0579 0.0993
E 0.0636 0.0334 0.7144 0.0413 0.0802 0.0817 0.0332 0.0944 0.0917 0.0327 0.0885 0.1110
F 0.0642 0.0318 0.6942 0.0329 0.0758 0.0794 0.0334 0.0881 0.0827 0.0341 0.0985 0.1272
G 0.0663 0.0332 0.7066 0.0369 0.1211 0.1013 0.0348 0.1097 0.1134 0.0365 0.0969 0.1229
H 0.0657 0.0339 0.7726 0.0382 0.0868 0.0979 0.0325 0.1112 0.1114 0.0402 0.1389 0.5173
average 0.0596 0.0344 0.7016 0.0364 0.0763 0.0766 0.0341 0.0894 0.0876 0.0353 0.0867 0.1563
range 0.0147 0.0077 0.1215 0.0084 0.0627 0.0430 0.0053 0.0425 0.0460 0.0075 0.0817 0.4359  
Descriptive Statistics:  
 




Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0596 0.00600 0.00212 0.00502  
Untreated Bacteria 8 0 0.702 0.0345 0.0122 0.0288  
Gentamicin 16 0 0.0765 0.0181 0.00453 0.00965  
Rifampicin 16 0 0.0885 0.0156 0.00390 0.00832  
Polymyxin B 16 0 0.121 0.108 0.0270 0.0576  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0147 0.0663 0.0516 0.0603 0.0541 0.0649  
Untreated Bacteria 0.121 0.773 0.651 0.698 0.686 0.711  
Gentamicin 0.0628 0.121 0.0583 0.0720 0.0612 0.0842  
Rifampicin 0.0460 0.113 0.0674 0.0847 0.0766 0.102  
Polymyxin B 0.460 0.517 0.0572 0.0977 0.0845 0.117  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.160 -2.164 0.249 0.153 0.873 0.159  
Untreated Bacteria 1.035 2.881 0.230 0.235 0.905 0.321  
Gentamicin 1.138 0.934 0.176 0.203 0.882 0.042  
Rifampicin 0.458 -1.019 0.163 0.298 0.906 0.100  
Polymyxin B 3.688 14.254 0.373 <0.001 0.475 <0.001  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0596 0.00600 0.00212  
Untreated Bacteria 8 0 0.702 0.0345 0.0122  
Gentamicin 16 0 0.0765 0.0181 0.00453  
Rifampicin 16 0 0.0885 0.0156 0.00390  
Polymyxin B 16 0 0.121 0.108 0.0270  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 2.642 0.660 202.568 <0.001  
Residual 59 0.192 0.00326    
Total 63 2.834     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin          0.625 25.285 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin          0.613 24.797 <0.001 0.017 Yes  
Untreated Ba vs. Polymyxin B       0.580 23.464 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB            0.642 22.489 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria           0.642 22.489 <0.001 0.013 Yes  
TSB vs. Polymyxin B                   0.0619 2.504 0.015 0.017 Yes  
TSB vs. Rifampicin                      0.0289 1.170 0.247 0.025 No  











Clinical Isolate 24 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0525 0.0318 0.7256 0.0325 0.0621 0.0613 0.0329 0.0755 0.0743 0.0324 0.0989 0.1237
B 0.0509 0.0320 0.7573 0.0323 0.0671 0.0644 0.0354 0.1054 0.0787 0.0502 0.3901 0.0590
C 0.0634 0.0321 0.7883 0.0331 0.0669 0.0698 0.0402 0.0902 0.0882 0.0324 0.0769 0.0999
D 0.0764 0.0338 0.8075 0.0378 0.0720 0.0768 0.0339 0.0944 0.0957 0.0351 0.0862 0.3365
E 0.0642 0.0321 0.8178 0.0341 0.0863 0.0858 0.0348 0.1048 0.0994 0.0325 0.0681 0.1250
F 0.0629 0.0322 0.7942 0.0339 0.0760 0.0875 0.0333 0.0857 0.0882 0.0351 0.1159 0.4809
G 0.0638 0.0436 0.8540 0.0347 0.1178 0.0944 0.0328 0.1249 0.1158 0.0332 0.1348 0.1322
H 0.0679 0.0333 0.8871 0.0359 0.0980 0.0978 0.0362 0.1092 0.1052 0.0360 0.1059 0.1256
average 0.0628 0.0339 0.8040 0.0343 0.0808 0.0797 0.0349 0.0988 0.0932 0.0359 0.1346 0.1854
range 0.0255 0.0118 0.1615 0.0055 0.0557 0.0365 0.0074 0.0494 0.0415 0.0178 0.3220 0.4219  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0628 0.00812 0.00287 0.00679  
Untreated Bacteria 8 0 0.804 0.0511 0.0181 0.0427  
Gentamicin 16 0 0.0803 0.0160 0.00401 0.00854  
Rifampicin 16 0 0.0960 0.0144 0.00360 0.00768  
Polymyxin B 16 0 0.160 0.125 0.0313 0.0668  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0255 0.0764 0.0509 0.0636 0.0577 0.0660  
Untreated Bacteria 0.161 0.887 0.726 0.801 0.773 0.836  
Gentamicin 0.0565 0.118 0.0613 0.0764 0.0670 0.0910  
Rifampicin 0.0506 0.125 0.0743 0.0950 0.0870 0.105  
Polymyxin B 0.422 0.481 0.0590 0.120 0.0925 0.134  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.0201 0.310 0.257 0.123 0.914 0.384  
Untreated Bacteria 0.163 -0.0429 0.143 0.748 0.986 0.985  
Gentamicin 0.821 0.231 0.148 0.429 0.922 0.178  
Rifampicin 0.267 -0.454 0.105 0.797 0.972 0.871  
Polymyxin B 1.825 2.229 0.392 <0.001 0.689 <0.001  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0628 0.00812 0.00287  
Untreated Bacteria 8 0 0.804 0.0511 0.0181  
Gentamicin 16 0 0.0803 0.0160 0.00401  
Rifampicin 16 0 0.0960 0.0144 0.00360  
Polymyxin B 16 0 0.160 0.125 0.0313  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.493 0.873 197.328 <0.001  
Residual 59 0.261 0.00443    
Total 63 3.755     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                                Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin            0.724 25.123 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin             0.708 24.577 <0.001 0.017 Yes  
Untreated Ba vs. Polymyxin B         0.644 22.355 <0.001 0.025 Yes  
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Untreated Bacteria vs. TSB              0.741 22.283 <0.001 0.050 Yes  
 
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria          0.741 22.283 <0.001 0.013 Yes  
TSB vs. Polymyxin B                  0.0972 3.375 0.001 0.017 Yes  
TSB vs. Rifampicin                     0.0332 1.153 0.253 0.025 No  
TSB vs. Gentamicin                     0.0175 0.607 0.546 0.050 No  
 
Clinical Isolate 25 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0499 0.0325 1.1111 0.0345 0.0613 0.0593 0.0352 0.0723 0.0747 0.0326 0.0595 0.1323
B 0.0510 0.0328 1.0861 0.0395 0.0629 0.0556 0.0348 0.0795 0.0764 0.0326 0.1034 0.0686
C 0.0514 0.0449 1.1279 0.0397 0.0688 0.0635 0.0369 0.0848 0.0862 0.0333 0.0881 0.0582
D 0.0581 0.0358 1.1207 0.0322 0.0729 0.0725 0.0356 0.0937 0.0893 0.0332 0.0774 0.0880
E 0.0599 0.0335 1.1138 0.0339 0.0850 0.0679 0.0387 0.2999 0.1143 0.0353 0.0975 0.1039
F 0.0716 0.0504 1.1030 0.0335 0.0782 0.0680 0.0360 0.0904 0.0928 0.0323 0.0911 0.1213
G 0.0679 0.0338 1.0737 0.0356 0.0994 0.0905 0.0341 0.1100 0.1097 0.0384 0.1026 0.1021
H 0.0656 0.0389 1.0309 0.0350 0.0888 0.0965 0.0323 0.1150 0.1141 0.0326 0.1042 0.0995
average 0.0594 0.0378 1.0959 0.0355 0.0772 0.0717 0.0355 0.1182 0.0947 0.0338 0.0905 0.0967
range 0.0217 0.0179 0.0970 0.0075 0.0381 0.0409 0.0064 0.2276 0.0396 0.0061 0.0447 0.0741  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0594 0.00833 0.00295 0.00697  
Untreated Bacteria 8 0 1.096 0.0317 0.0112 0.0265  
Gentamicin 16 0 0.0744 0.0137 0.00343 0.00732  
Rifampicin 16 0 0.106 0.0537 0.0134 0.0286  
Polymyxin B 16 0 0.0936 0.0203 0.00506 0.0108  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0217 0.0716 0.0499 0.0590 0.0512 0.0668  
Untreated Bacteria 0.0970 1.128 1.031 1.107 1.080 1.117  
Gentamicin 0.0438 0.0994 0.0556 0.0706 0.0632 0.0869  
Rifampicin 0.228 0.300 0.0723 0.0916 0.0822 0.112  
Polymyxin B 0.0741 0.132 0.0582 0.0985 0.0827 0.104  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.220 -1.631 0.207 0.367 0.912 0.371  
Untreated Bacteria -1.363 1.746 0.213 0.329 0.882 0.195  
Gentamicin 0.546 -0.937 0.170 0.244 0.929 0.233  
Rifampicin 3.493 13.151 0.374 <0.001 0.527 <0.001  
Polymyxin B -0.186 -0.00174 0.175 0.204 0.946 0.428  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0594 0.00833 0.00295  
Untreated Bacteria 8 0 1.096 0.0317 0.0112  
Gentamicin 16 0 0.0744 0.0137 0.00343  
Rifampicin 16 0 0.106 0.0537 0.0134  
Polymyxin B 16 0 0.0936 0.0203 0.00506  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 7.142 1.785 1763.051 <0.001  
Residual 59 0.0597 0.00101    
Total 63 7.201     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
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Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin           1.021 74.128 <0.001 0.013 Yes  
Untreated Ba vs. Polymyxin B        1.002 72.737 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin            0.989 71.806 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB             1.036 65.140 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria          1.036 65.140 <0.001 0.013 Yes  
TSB vs. Rifampicin                     0.0470 3.412 0.001 0.017 Yes  
TSB vs. Polymyxin B                  0.0342 2.481 0.016 0.025 Yes  
TSB vs. Gentamicin                     0.0150 1.090 0.280 0.050 No  
 
Clinical Isolate 26 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0522 0.0439 0.5266 0.0334 0.0714 0.0664 0.0324 0.0811 0.0821 0.0516 0.0683 0.1055
B 0.0840 0.0391 0.6900 0.0345 0.0693 0.0712 0.0335 0.0803 0.0800 0.0412 0.1041 0.0716
C 0.0766 0.0454 0.7201 0.0328 0.0766 0.0685 0.0381 0.1085 0.1017 0.0514 0.7051 0.1263
D 0.0656 0.0333 0.6886 0.0445 0.0867 0.0708 0.0402 0.0922 0.0815 0.0365 0.1135 0.0815
E 0.0754 0.0333 0.6563 0.0334 0.0779 0.0683 0.0333 0.1017 0.1096 0.0389 0.1026 0.0945
F 0.0659 0.0331 0.7267 0.0324 0.0961 0.0793 0.0380 0.1072 0.0954 0.0405 0.0827 0.0855
G 0.0683 0.0327 0.6326 0.0362 0.1200 0.0852 0.0340 0.1329 0.1339 0.0335 0.1272 0.1155
H 0.0750 0.0323 0.6761 0.0383 0.1061 0.1019 0.0320 0.1117 0.1403 0.0327 0.1097 0.4704
average 0.0704 0.0366 0.6646 0.0357 0.0880 0.0765 0.0352 0.1020 0.1031 0.0408 0.1767 0.1439










Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0704 0.00963 0.00340 0.00805  
Untreated Bacteria 8 0 0.665 0.0637 0.0225 0.0533  
Gentamicin 16 0 0.0822 0.0160 0.00400 0.00852  
Rifampicin 16 0 0.103 0.0200 0.00500 0.0107  
Polymyxin B 16 0 0.160 0.173 0.0433 0.0923  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0318 0.0840 0.0522 0.0716 0.0658 0.0760  
Untreated Bacteria 0.200 0.727 0.527 0.682 0.644 0.705  
Gentamicin 0.0536 0.120 0.0664 0.0772 0.0701 0.0914  
Rifampicin 0.0603 0.140 0.0800 0.102 0.0818 0.111  
Polymyxin B 0.637 0.705 0.0683 0.105 0.0841 0.121  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.687 0.977 0.185 0.514 0.946 0.666  
Untreated Bacteria -1.635 3.189 0.198 0.426 0.849 0.093  
Gentamicin 1.157 0.498 0.198 0.095 0.858 0.018  
Rifampicin 0.600 -0.619 0.159 0.331 0.896 0.070  
Polymyxin B 2.750 7.107 0.451 <0.001 0.512 <0.001  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0704 0.00963 0.00340  
Untreated Bacteria 8 0 0.665 0.0637 0.0225  
Gentamicin 16 0 0.0822 0.0160 0.00400  
Rifampicin 16 0 0.103 0.0200 0.00500  
Polymyxin B 16 0 0.160 0.173 0.0433  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 2.230 0.558 67.285 <0.001  
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Residual 59 0.489 0.00829    
Total 63 2.719     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin           0.582 14.776 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin            0.562 14.261 <0.001 0.017 Yes  
Untreated Bacteria vs. TSB              0.594 13.057 <0.001 0.025 Yes  
Untreated Ba vs. Polymyxin B         0.504 12.796 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                            Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria           0.594 13.057 <0.001 0.013 Yes  
TSB vs. Polymyxin B                  0.0899 2.280 0.026 0.017 No  
TSB vs. Rifampicin                     0.0321 0.815 0.418 0.025 No  
TSB vs. Gentamicin                    0.0119 0.301 0.765 0.050 No  
 
Clinical Isolate 27 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0534 0.0344 0.7270 0.0355 0.0620 0.0613 0.0438 0.0789 0.0780 0.0343 0.0665 0.1000
B 0.0867 0.0329 0.8468 0.0355 0.0634 0.0618 0.0377 0.0785 0.0750 0.0332 0.0907 0.0923
C 0.0705 0.0338 0.7707 0.0326 0.0758 0.0656 0.0344 0.0887 0.0825 0.0334 0.0967 0.0909
D 0.0616 0.0355 0.8210 0.0369 0.0840 0.0779 0.0425 0.1011 0.0804 0.0348 0.0977 0.0876
E 0.0628 0.0325 0.8334 0.0343 0.0953 0.0768 0.0334 0.1101 0.0979 0.0349 0.1295 0.0906
F 0.0654 0.0328 0.8206 0.0336 0.0937 0.0832 0.0334 0.0985 0.0856 0.0362 0.0993 0.0747
G 0.0666 0.0354 0.8494 0.0328 0.1196 0.0952 0.0427 0.1181 0.0945 0.0332 0.0905 0.1148
H 0.0746 0.0344 0.7272 0.0390 0.1082 0.1181 0.0325 0.1182 0.1105 0.0345 0.1181 0.1530
average 0.0677 0.0340 0.7995 0.0350 0.0878 0.0800 0.0376 0.0990 0.0881 0.0343 0.0986 0.1005
range 0.0333 0.0030 0.1224 0.0064 0.0576 0.0568 0.0113 0.0397 0.0355 0.0030 0.0630 0.0783  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0677 0.00992 0.00351 0.00829  
Untreated Bacteria 8 0 0.800 0.0508 0.0180 0.0425  
Gentamicin 16 0 0.0839 0.0196 0.00491 0.0105  
Rifampicin 16 0 0.0935 0.0148 0.00370 0.00788  
Polymyxin B 16 0 0.0996 0.0209 0.00523 0.0111  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0333 0.0867 0.0534 0.0660 0.0622 0.0726  
Untreated Bacteria 0.122 0.849 0.727 0.821 0.749 0.840  
Gentamicin 0.0583 0.120 0.0613 0.0805 0.0645 0.0953  
Rifampicin 0.0432 0.118 0.0750 0.0916 0.0796 0.106  
Polymyxin B 0.0865 0.153 0.0665 0.0945 0.0905 0.107  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.767 1.351 0.169 0.615 0.957 0.784  
Untreated Bacteria -0.718 -1.381 0.286 0.053 0.835 0.066  
Gentamicin 0.560 -0.740 0.137 0.536 0.909 0.112  
Rifampicin 0.449 -1.171 0.147 0.435 0.908 0.110  
Polymyxin B 1.107 1.891 0.242 0.013 0.901 0.083  
 
 
One Way Analysis of Variance  
 




Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0677 0.00992 0.00351  
Untreated Bacteria 8 0 0.800 0.0508 0.0180  
Gentamicin 16 0 0.0839 0.0196 0.00491  
Rifampicin 16 0 0.0935 0.0148 0.00370  
Polymyxin B 16 0 0.0996 0.0209 0.00523  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.542 0.885 1518.497 <0.001  
Residual 59 0.0344 0.000583    
Total 63 3.576     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.00 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                               Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin           0.716 68.441 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin            0.706 67.516 <0.001 0.017 Yes  
Untreated Ba vs. Polymyxin B        0.700 66.940 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB           0.732 60.610 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                          Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria          0.732 60.610 <0.001 0.013 Yes  
TSB vs. Polymyxin B                  0.0319 3.047 0.003 0.017 Yes  
TSB vs. Rifampicin                     0.0258 2.470 0.016 0.025 Yes  
TSB vs. Gentamicin                    0.0162 1.546 0.127 0.050 No  
 
Clinical Isolate 28 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0522 0.0346 0.7687 0.0414 0.0691 0.0727 0.0344 0.0884 0.0852 0.0391 0.0630 0.0797
B 0.0562 0.0511 0.8391 0.0945 0.0914 0.0747 0.1156 0.0900 0.0863 0.1115 0.0827 0.1080
C 0.0566 0.0337 0.8089 0.1485 0.0829 0.0809 0.1532 0.1080 0.0945 0.1436 0.0739 0.0694
D 0.0612 0.0338 0.8165 0.1653 0.0847 0.0900 0.1644 0.1148 0.1022 0.1394 0.0700 0.0839
E 0.0604 0.0340 0.8156 0.1399 0.0835 0.0858 0.1379 0.1269 0.1105 0.1279 0.0833 0.1371
F 0.0656 0.0423 0.8079 0.0902 0.0906 0.0820 0.1007 0.1100 0.0954 0.1066 0.1569 0.0913
G 0.0662 0.0374 0.8683 0.0349 0.1085 0.1034 0.0413 0.1222 0.1161 0.0348 0.1391 0.1511
H 0.0664 0.0346 0.7635 0.0343 0.1007 0.1032 0.0345 0.1153 0.1103 0.0360 0.1405 0.1651
Average 0.0606 0.0377 0.8111 0.0936 0.0889 0.0866 0.0978 0.1095 0.1001 0.0924 0.1012 0.1107
Range 0.0142 0.0174 0.1048 0.1310 0.0394 0.0307 0.1300 0.0385 0.0309 0.1088 0.0939 0.0957  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0606 0.00530 0.00187 0.00443  
Untreated Bacteria 8 0 0.811 0.0342 0.0121 0.0286  
Gentamicin 16 0 0.0878 0.0115 0.00288 0.00613  
Rifampicin 16 0 0.105 0.0133 0.00332 0.00708  
Polymyxin B 16 0 0.106 0.0359 0.00898 0.0191  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0142 0.0664 0.0522 0.0608 0.0564 0.0659  
Untreated Bacteria 0.105 0.868 0.763 0.812 0.788 0.828  
Gentamicin 0.0394 0.109 0.0691 0.0852 0.0814 0.0960  
Rifampicin 0.0417 0.127 0.0852 0.109 0.0922 0.115  
Polymyxin B 0.102 0.165 0.0630 0.0876 0.0768 0.140  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.315 -1.260 0.202 0.398 0.911 0.364  
Untreated Bacteria 0.125 0.0391 0.213 0.331 0.937 0.581  
Gentamicin 0.291 -0.667 0.130 0.599 0.956 0.584  
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Rifampicin -0.0950 -1.225 0.159 0.328 0.936 0.306  
Polymyxin B 0.455 -1.555 0.230 0.023 0.866 0.024  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0606 0.00530 0.00187  
Untreated Bacteria 8 0 0.811 0.0342 0.0121  
Gentamicin 16 0 0.0878 0.0115 0.00288  
Rifampicin 16 0 0.105 0.0133 0.00332  
Polymyxin B 16 0 0.106 0.0359 0.00898  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.614 0.903 1647.310 <0.001  
Residual 59 0.0324 0.000548    
Total 63 3.646     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                                Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin             0.723 71.329 <0.001 0.013 Yes  
Untreated Ba vs. Rifampicin              0.706 69.653 <0.001 0.017 Yes  
Untreated Ba vs. Polymyxin B          0.705 69.536 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB               0.750 64.092 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                         Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria        0.750 64.092 <0.001 0.013 Yes  
TSB vs. Polymyxin B                0.0453 4.471 <0.001 0.017 Yes  
TSB vs. Rifampicin                   0.0442 4.354 <0.001 0.025 Yes  
TSB vs. Gentamicin                   0.0272 2.678 0.010 0.050 Yes  
 
Clinical Isolate 29 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0659 0.0350 0.7821 0.0420 0.0776 0.0516 0.0347 0.7275 0.7484 0.0412 0.0524 0.0511
B 0.0804 0.0340 0.9104 0.0371 0.0590 0.0543 0.0326 0.8035 0.8472 0.0543 0.0544 0.0583
C 0.0563 0.0337 0.9247 0.0439 0.0660 0.0595 0.0355 0.8672 0.8561 0.0556 0.0672 0.0630
D 0.0605 0.0358 0.9074 0.0444 0.0721 0.0591 0.0334 0.8833 0.8666 0.0567 0.0621 0.0625
E 0.0604 0.0496 0.9382 0.0358 0.0755 0.0627 0.0354 0.8385 0.8968 0.0343 0.0772 0.0654
F 0.0649 0.0340 0.8989 0.0360 0.0828 0.0614 0.0342 0.8452 0.8648 0.0391 0.0634 0.1036
G 0.0899 0.0334 0.8832 0.0331 0.0886 0.0656 0.0384 0.8969 0.8870 0.0327 0.0783 0.0931
H 0.0732 0.0340 0.7811 0.0325 0.0873 0.0843 0.0331 0.8478 0.8272 0.0335 0.1012 0.0917
average 0.0689 0.0362 0.8783 0.0381 0.0761 0.0623 0.0347 0.8387 0.8493 0.0434 0.0695 0.0736
range 0.0336 0.0162 0.1571 0.0119 0.0296 0.0327 0.0058 0.1694 0.1484 0.0240 0.0488 0.0525  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0689 0.0115 0.00405 0.00958  
Untreated Bacteria 8 0 0.878 0.0618 0.0219 0.0517  
Gentamicin 16 0 0.0692 0.0121 0.00302 0.00644  
Rifampicin 16 0 0.844 0.0485 0.0121 0.0258  
Polymyxin B 16 0 0.0716 0.0173 0.00432 0.00921  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0336 0.0899 0.0563 0.0654 0.0605 0.0768  
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Untreated Bacteria 0.157 0.938 0.781 0.903 0.833 0.918  
Gentamicin 0.0370 0.0886 0.0516 0.0658 0.0593 0.0802  
Rifampicin 0.169 0.897 0.728 0.852 0.833 0.875  
Polymyxin B 0.0525 0.104 0.0511 0.0644 0.0602 0.0850  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.946 0.0194 0.230 0.239 0.912 0.367  
Untreated Bacteria -1.146 -0.350 0.282 0.061 0.790 0.022  
Gentamicin 0.318 -1.275 0.167 0.262 0.929 0.234  
Rifampicin -1.372 1.557 0.205 0.071 0.857 0.017  
Polymyxin B 0.762 -0.729 0.225 0.030 0.885 0.047  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0689 0.0115 0.00405  
Untreated Bacteria 8 0 0.878 0.0618 0.0219  
Gentamicin 16 0 0.0692 0.0121 0.00302  
Rifampicin 16 0 0.844 0.0485 0.0121  
Polymyxin B 16 0 0.0716 0.0173 0.00432  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 9.257 2.314 1960.286 <0.001  
Residual 59 0.0697 0.00118    
Total 63 9.327     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                               Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin            0.809 54.377 <0.001 0.013 Yes  
Untreated Ba vs. Polymyxin B         0.807 54.220 <0.001 0.017 Yes  
Untreated Bacteria vs. TSB              0.809 47.108 <0.001 0.025 Yes  
Untreated Ba vs. Rifampicin           0.0343 2.302 0.025 0.050 Yes  
 
Comparisons for factor:  
Comparison                        Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Rifampicin                    0.775 52.094 <0.001 0.013 Yes  
TSB vs. Untreated Bacteria        0.809 47.108 <0.001 0.017 Yes  
TSB vs. Polymyxin B               0.00262 0.176 0.861 0.025 No  
TSB vs. Gentamicin                 0.000275 0.0185 0.985 0.050 No  
 
Clinical Isolate 30 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0653 0.0329 0.9902 0.0324 0.0592 0.0596 0.0327 0.0758 0.0748 0.0478 0.0565 0.0605
B 0.0542 0.0324 0.9351 0.0323 0.0612 0.0647 0.0395 0.0712 0.0679 0.0472 0.0605 0.0568
C 0.0569 0.0335 0.9421 0.0409 0.0688 0.0623 0.0333 0.0734 0.0693 0.0496 0.0623 0.0654
D 0.0603 0.0344 0.9194 0.0344 0.0664 0.0659 0.0335 0.0858 0.0765 0.0369 0.0610 0.0748
E 0.0619 0.0366 0.9053 0.0345 0.0645 0.0541 0.0336 0.1268 0.0785 0.0414 0.0778 0.0709
F 0.0722 0.0356 0.9358 0.0438 0.0830 0.0569 0.0401 0.1085 0.0806 0.0334 0.0885 0.0750
G 0.0721 0.0391 0.9506 0.0343 0.0927 0.0681 0.0500 0.1143 0.1179 0.0357 0.0980 0.1015
H 0.0767 0.0396 0.9663 0.0410 0.1250 0.1047 0.0385 0.1060 0.1074 0.0339 0.1149 0.1090
average 0.0650 0.0355 0.9431 0.0367 0.0776 0.0670 0.0377 0.0952 0.0841 0.0407 0.0774 0.0767
range 0.0225 0.0072 0.0849 0.0115 0.0658 0.0506 0.0173 0.0556 0.0500 0.0162 0.0584 0.0522  
Descriptive Statistics:  
 




Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0649 0.00805 0.00284 0.00673  
Untreated Bacteria 8 0 0.943 0.0265 0.00937 0.0222  
Gentamicin 16 0 0.0723 0.0195 0.00488 0.0104  
Rifampicin 16 0 0.0897 0.0200 0.00501 0.0107  
Polymyxin B 16 0 0.0771 0.0194 0.00486 0.0104  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0225 0.0767 0.0542 0.0636 0.0586 0.0721  
Untreated Bacteria 0.0849 0.990 0.905 0.939 0.927 0.958  
Gentamicin 0.0709 0.125 0.0541 0.0653 0.0604 0.0759  
Rifampicin 0.0589 0.127 0.0679 0.0796 0.0741 0.108  
Polymyxin B 0.0584 0.115 0.0565 0.0728 0.0607 0.0933  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.174 -1.419 0.188 0.494 0.947 0.677  
Untreated Bacteria 0.502 0.356 0.140 0.760 0.975 0.934  
Gentamicin 1.765 2.656 0.322 <0.001 0.772 0.001  
Rifampicin 0.620 -1.284 0.237 0.017 0.856 0.017  
Polymyxin B 0.793 -0.713 0.173 0.222 0.878 0.036  
 
 
One Way Analysis of Variance Friday, April 17, 2015, 10:36:10 AM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0649 0.00805 0.00284  
Untreated Bacteria 8 0 0.943 0.0265 0.00937  
Gentamicin 16 0 0.0723 0.0195 0.00488  
Rifampicin 16 0 0.0897 0.0200 0.00501  
Polymyxin B 16 0 0.0771 0.0194 0.00486  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 5.248 1.312 3400.559 <0.001  
Residual 59 0.0228 0.000386    
Total 63 5.271     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Ba vs. Gentamicin 0.871 102.382 <0.001 0.013  
Untreated Ba vs. Polymyxin B 0.866 101.821 <0.001 0.017  
Untreated Ba vs. Rifampicin 0.853 100.342 <0.001 0.025  
Untreated Bacteria vs. TSB 0.878 89.415 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Gentamicin Yes  
Untreated Ba vs. Polymyxin B Yes  
Untreated Ba vs. Rifampicin Yes  
Untreated Bacteria vs. TSB Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.878 89.415 <0.001 0.013 Yes  
TSB vs. Rifampicin                    0.0247 2.906 0.005 0.017 Yes  
TSB vs. Polymyxin B                 0.0121 1.427 0.159 0.025 No  





Clinical Isolate 33 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0507 0.0329 0.9653 0.0405 0.0608 0.0594 0.0410 0.0908 0.0736 0.0398 0.0530 0.0531
B 0.0518 0.0334 1.0184 0.0410 0.0608 0.0661 0.0359 0.0877 0.0742 0.0563 0.0518 0.0518
C 0.0542 0.0328 1.0382 0.0390 0.0655 0.0656 0.0390 0.0794 0.0906 0.0382 0.0847 0.0576
D 0.0570 0.0333 1.0791 0.0383 0.0714 0.0659 0.0457 0.0808 0.0824 0.0334 0.0584 0.0636
E 0.0658 0.0349 1.0534 0.0348 0.0730 0.0647 0.0530 0.0848 0.1043 0.0371 0.0622 0.0655
F 0.0658 0.0414 1.0738 0.0372 0.0678 0.0621 0.0371 0.0949 0.0876 0.0339 0.0713 0.0731
G 0.0647 0.0373 1.0510 0.0425 0.1002 0.0768 0.0496 0.1296 0.1113 0.0330 0.0712 0.0797
H 0.0684 0.0334 1.0843 0.0423 0.0944 0.1000 0.0404 0.1073 0.1025 0.0356 0.0846 0.0986
average 0.0598 0.0349 1.0454 0.0395 0.0742 0.0701 0.0427 0.0944 0.0908 0.0384 0.0672 0.0679
range 0.0177 0.0086 0.1190 0.0077 0.0394 0.0406 0.0171 0.0502 0.0377 0.0233 0.0329 0.0468  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0598 0.00713 0.00252 0.00596  
Untreated Bacteria 8 0 1.045 0.0392 0.0139 0.0328  
Gentamicin 16 0 0.0722 0.0138 0.00344 0.00733  
Rifampicin 16 0 0.0926 0.0151 0.00377 0.00803  
Polymyxin B 16 0 0.0675 0.0139 0.00348 0.00741  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0177 0.0684 0.0507 0.0609 0.0530 0.0658  
Untreated Bacteria 0.119 1.084 0.965 1.052 1.028 1.076  
Gentamicin 0.0408 0.100 0.0594 0.0660 0.0634 0.0749  
Rifampicin 0.0560 0.130 0.0736 0.0892 0.0816 0.103  
Polymyxin B 0.0468 0.0986 0.0518 0.0645 0.0553 0.0764  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.146 -2.164 0.254 0.134 0.871 0.153  
Untreated Bacteria -1.312 1.790 0.181 0.537 0.886 0.214  
Gentamicin 1.381 0.589 0.249 0.009 0.771 0.001  
Rifampicin 0.978 0.881 0.173 0.222 0.929 0.237  
Polymyxin B 0.748 -0.0980 0.129 0.605 0.922 0.179  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0598 0.00713 0.00252  
Untreated Bacteria 8 0 1.045 0.0392 0.0139  
Gentamicin 16 0 0.0722 0.0138 0.00344  
Rifampicin 16 0 0.0926 0.0151 0.00377  
Polymyxin B 16 0 0.0675 0.0139 0.00348  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 6.601 1.650 4807.395 <0.001  
Residual 59 0.0203 0.000343    
Total 63 6.622     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Ba vs. Polymyxin B 0.978 121.892 <0.001 0.013  
Untreated Ba vs. Gentamicin 0.973 121.313 <0.001 0.017  
Untreated Ba vs. Rifampicin 0.953 118.763 <0.001 0.025  
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Untreated Bacteria vs. TSB 0.986 106.394 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Polymyxin B Yes  
Untreated Ba vs. Gentamicin Yes  
Untreated Ba vs. Rifampicin Yes  
Untreated Bacteria vs. TSB Yes  
 
Comparisons for factor:  
Comparison                         Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.986 106.394 <0.001 0.013 Yes  
TSB vs. Rifampicin                    0.0328 4.090 <0.001 0.017 Yes  
TSB vs. Gentamicin                    0.0124 1.540 0.129 0.025 No  
TSB vs. Polymyxin B                0.00771 0.961 0.340 0.050 No  
 
Clinical Isolate 34 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0566 0.0399 0.7802 0.0328 0.0656 0.1267 0.0384 0.0802 0.0798 0.0421 0.0546 0.0559
B 0.0580 0.0436 0.8024 0.0354 0.1551 0.0665 0.0345 0.0856 0.0777 0.0356 0.0578 0.0704
C 0.0524 0.0356 0.8248 0.0402 0.0739 0.0707 0.0336 0.0795 0.0767 0.0417 0.0660 0.0635
D 0.0600 0.0334 0.8348 0.0334 0.0687 0.0639 0.0344 0.1018 0.0764 0.0370 0.0625 0.0610
E 0.0580 0.0403 0.8378 0.0369 0.0770 0.0585 0.0364 0.0866 0.0841 0.0408 0.0705 0.0703
F 0.0959 0.0348 0.7985 0.0353 0.0833 0.0627 0.0339 0.1561 0.0848 0.0411 0.0713 0.0738
G 0.0693 0.0432 0.8160 0.0352 0.0971 0.0663 0.0332 0.1115 0.0999 0.0343 0.0856 0.0797
H 0.0707 0.0328 0.8007 0.0422 0.0822 0.0859 0.0333 0.1057 0.2714 0.0376 0.1055 0.0962
average 0.0651 0.0380 0.8119 0.0364 0.0879 0.0752 0.0347 0.1009 0.1064 0.0388 0.0717 0.0714
range 0.0435 0.0108 0.0576 0.0094 0.0895 0.0682 0.0052 0.0766 0.1950 0.0078 0.0509 0.0403  
Descriptive Statistics: Friday, April 17, 2015, 12:05:13 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0651 0.0139 0.00492 0.0116  
Untreated Bacteria 8 0 0.812 0.0199 0.00704 0.0167  
Gentamicin 16 0 0.0815 0.0258 0.00645 0.0137  
Rifampicin 16 0 0.104 0.0491 0.0123 0.0262  
Polymyxin B 16 0 0.0715 0.0142 0.00356 0.00759  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0435 0.0959 0.0524 0.0590 0.0573 0.0700  
Untreated Bacteria 0.0576 0.838 0.780 0.809 0.800 0.830  
Gentamicin 0.0966 0.155 0.0585 0.0723 0.0660 0.0846  
Rifampicin 0.195 0.271 0.0764 0.0852 0.0796 0.104  
Polymyxin B 0.0509 0.106 0.0546 0.0703 0.0617 0.0767  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.826 3.635 0.268 0.094 0.796 0.026  
Untreated Bacteria -0.119 -0.942 0.183 0.525 0.948 0.690  
Gentamicin 2.021 3.997 0.245 0.011 0.755 <0.001  
Rifampicin 3.054 10.051 0.311 <0.001 0.571 <0.001  
Polymyxin B 1.150 1.001 0.194 0.107 0.899 0.079  
 
 
One Way Analysis of Variance Friday, April 17, 2015, 12:05:37 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0651 0.0139 0.00492  
Untreated Bacteria 8 0 0.812 0.0199 0.00704  
Gentamicin 16 0 0.0815 0.0258 0.00645  
Rifampicin 16 0 0.104 0.0491 0.0123  
Polymyxin B 16 0 0.0715 0.0142 0.00356  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.734 0.934 1032.671 <0.001  
Residual 59 0.0533 0.000904    
Total 63 3.788     
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The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                             Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B       0.740 56.866 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin          0.730 56.100 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin           0.708 54.402 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB        0.747 49.674 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                         Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria        0.747 49.674 <0.001 0.013 Yes  
TSB vs. Rifampicin                   0.0385 2.957 0.004 0.017 Yes  
TSB vs. Gentamicin                   0.0164 1.259 0.213 0.025 No  
TSB vs. Polymyxin B               0.00643 0.493 0.623 0.050 No  
 
Clinical Isolate 35 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0528 0.0345 0.8113 0.0359 0.8329 0.8736 0.0369 0.8603 0.9248 0.0334 0.0624 0.0565
B 0.0547 0.0651 0.8673 0.1166 0.9444 0.9288 0.1402 0.8517 1.0811 0.1071 0.0537 0.0640
C 0.0577 0.1066 0.8898 0.1166 0.9444 0.9669 0.1312 1.1712 0.9176 0.1145 0.0587 0.0631
D 0.0600 0.0880 0.8883 0.1142 0.9436 0.8574 0.1182 1.0895 1.1828 0.1100 0.0638 0.0623
E 0.0689 0.1008 0.8636 0.1250 0.9480 0.9484 0.1071 0.9856 1.0878 0.1199 0.0770 0.0710
F 0.0702 0.0847 0.8517 0.1196 0.8797 0.8976 0.0983 1.3894 0.8635 0.1106 0.0731 0.0731
G 0.0715 0.0370 0.8334 0.0359 0.9405 0.9415 0.0635 0.9107 0.8578 0.0348 0.0751 0.0805
H 0.0758 0.0481 0.7560 0.0351 0.8776 0.9017 0.0454 0.8632 0.8839 0.0485 0.1090 0.1061
average 0.0640 0.0706 0.8452 0.0874 0.9139 0.9145 0.0926 1.0152 0.9749 0.0849 0.0716 0.0721
range 0.0230 0.0721 0.1338 0.0899 0.1151 0.1095 0.1033 0.5377 0.3250 0.0865 0.0553 0.0496  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0640 0.00866 0.00306 0.00724  
Untreated Bacteria 8 0 0.845 0.0447 0.0158 0.0373  
Gentamicin 16 0 0.914 0.0399 0.00997 0.0213  
Rifampicin 16 0 0.995 0.157 0.0392 0.0836  
Polymyxin B 16 0 0.0718 0.0159 0.00397 0.00847  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0230 0.0758 0.0528 0.0645 0.0562 0.0708  
Untreated Bacteria 0.134 0.890 0.756 0.858 0.822 0.878  
Gentamicin 0.134 0.967 0.833 0.935 0.879 0.944  
Rifampicin 0.538 1.389 0.852 0.921 0.863 1.089  
Polymyxin B 0.0553 0.109 0.0537 0.0675 0.0624 0.0761  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB -0.00691 -1.881 0.216 0.313 0.914 0.386  
Untreated Bacteria -1.204 1.336 0.183 0.526 0.897 0.273  
Gentamicin -0.643 -0.799 0.245 0.011 0.893 0.061  
Rifampicin 1.190 0.983 0.235 0.018 0.843 0.011  
Polymyxin B 1.463 1.776 0.189 0.129 0.832 0.008  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0640 0.00866 0.00306  
Untreated Bacteria 8 0 0.845 0.0447 0.0158  
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Gentamicin 16 0 0.914 0.0399 0.00997  
Rifampicin 16 0 0.995 0.157 0.0392  
Polymyxin B 16 0 0.0718 0.0159 0.00397  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 11.314 2.829 405.465 <0.001  
Residual 59 0.412 0.00698    
Total 63 11.726     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                                Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B           0.773 21.383 <0.001 0.013 Yes  
Untreated Bacteria vs. TSB                0.781 18.707 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin               0.150 4.144 <0.001 0.025 Yes  
Untreated Ba vs. Gentamicin             0.0690 1.908 0.061 0.050 No  
 
Comparisons for factor:  
Comparison                         Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Rifampicin                      0.931 25.745 <0.001 0.013 Yes  
TSB vs. Gentamicin                     0.850 23.509 <0.001 0.017 Yes  
TSB vs. Untreated Bacteria          0.781 18.707 <0.001 0.025 Yes  
TSB vs. Polymyxin B                 0.00789 0.218 0.828 0.050 No  
 
Clinical Isolate 37 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0566 0.0356 0.8485 0.0467 0.0640 0.0618 0.0358 0.0784 0.0786 0.0401 0.0818 0.0582
B 0.0575 0.0416 0.9187 0.0345 0.0624 0.0681 0.0483 0.0820 0.0992 0.0409 0.0610 0.0631
C 0.0654 0.0532 0.9090 0.0377 0.0750 0.0630 0.0374 0.0793 0.0766 0.0366 0.0624 0.0600
D 0.0631 0.0386 0.9131 0.0415 0.1432 0.0789 0.0353 0.1006 0.0784 0.0358 0.0663 0.0936
E 0.0606 0.0351 0.9386 0.0423 0.0728 0.0670 0.0368 0.0864 0.0959 0.0364 0.1330 0.0771
F 0.0663 0.0333 0.9443 0.0415 0.0672 0.0796 0.0395 0.0888 0.0897 0.0397 0.0725 0.0731
G 0.1088 0.0343 0.9686 0.0427 0.0891 0.0875 0.0343 0.1298 0.1133 0.0328 0.1287 0.1093
H 0.0780 0.0355 0.9515 0.0360 0.0883 0.0885 0.0356 0.1069 0.1103 0.0378 0.1062 0.0999
average 0.0695 0.0384 0.9240 0.0404 0.0828 0.0743 0.0379 0.0940 0.0928 0.0375 0.0890 0.0793
range 0.1088 0.0532 0.9686 0.0467 0.1432 0.0885 0.0483 0.1298 0.1133 0.0409 0.1330 0.1093  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0695 0.0172 0.00609 0.0144  
Untreated Bacteria 8 0 0.924 0.0367 0.0130 0.0307  
Gentamicin 16 0 0.0785 0.0200 0.00499 0.0106  
Rifampicin 16 0 0.0934 0.0156 0.00390 0.00831  
Polymyxin B 16 0 0.0841 0.0247 0.00618 0.0132  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0522 0.109 0.0566 0.0643 0.0591 0.0721  
Untreated Bacteria 0.120 0.969 0.849 0.929 0.911 0.948  
Gentamicin 0.0814 0.143 0.0618 0.0739 0.0655 0.0879  
Rifampicin 0.0532 0.130 0.0766 0.0892 0.0789 0.104  
Polymyxin B 0.0748 0.133 0.0582 0.0751 0.0628 0.103  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob
  
TSB 2.096 4.623 0.325 0.013 0.741 0.006  
Untreated Bacteria -1.212 2.137 0.216 0.313 0.910 0.354  
Gentamicin 2.435 7.475 0.236 0.018 0.728 <0.001  
Rifampicin 0.897 0.210 0.156 0.354 0.901 0.083  
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Polymyxin B 0.828 -0.512 0.175 0.210 0.880 0.038  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0695 0.0172 0.00609  
Untreated Bacteria 8 0 0.924 0.0367 0.0130  
Gentamicin 16 0 0.0785 0.0200 0.00499  
Rifampicin 16 0 0.0934 0.0156 0.00390  
Polymyxin B 16 0 0.0841 0.0247 0.00618  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 4.954 1.238 2410.940 <0.001  
Residual 59 0.0303 0.000514    
Total 63 4.984     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Ba vs. Gentamicin 0.846 86.153 <0.001 0.013  
Untreated Ba vs. Polymyxin B 0.840 85.581 <0.001 0.017  
Untreated Ba vs. Rifampicin 0.831 84.639 <0.001 0.025  
Untreated Bacteria vs. TSB 0.855 75.404 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Gentamicin Yes  
Untreated Ba vs. Polymyxin B Yes  
Untreated Ba vs. Rifampicin Yes  
Untreated Bacteria vs. TSB Yes  
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
TSB vs. Untreated Bacteria 0.855 75.404 <0.001 0.013  
TSB vs. Rifampicin 0.0238 2.430 0.018 0.017  
TSB vs. Polymyxin B 0.0146 1.488 0.142 0.025  
TSB vs. Gentamicin 0.00899 0.916 0.364 0.050  
 
Comparison Significant?  
TSB vs. Untreated Bacteria Yes  
TSB vs. Rifampicin No  
TSB vs. Polymyxin B No  
TSB vs. Gentamicin No  
 
Clinical Isolate 38 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0764 0.0345 0.9470 0.0337 0.0601 0.0973 0.0351 0.0836 0.0785 0.0357 0.0624 0.0593
B 0.0756 0.0419 0.9697 0.0465 0.0736 0.0672 0.0454 0.1027 0.0787 0.0329 0.0597 0.0572
C 0.0586 0.0355 0.9625 0.0448 0.0622 0.0676 0.0407 0.0948 0.0824 0.0323 0.0602 0.0619
D 0.0605 0.0335 0.9817 0.0340 0.0715 0.0574 0.0405 0.0865 0.0793 0.0343 0.0709 0.0789
E 0.0982 0.0377 0.9925 0.0370 0.0636 0.0654 0.0373 0.0920 0.0975 0.0362 0.0678 0.0638
F 0.0696 0.0328 0.9973 0.0375 0.0672 0.0664 0.0340 0.0819 0.0814 0.0338 0.0718 0.0922
G 0.0907 0.0343 0.9975 0.0366 0.1192 0.0855 0.0437 0.1040 0.1113 0.0350 0.0915 0.0870
H 0.0984 0.0456 1.0141 0.0366 0.1067 0.1041 0.0362 0.1037 0.1187 0.0352 0.1053 0.1128
average 0.0785 0.0370 0.9828 0.0383 0.0780 0.0764 0.0391 0.0937 0.0910 0.0344 0.0737 0.0766
range 0.0398 0.0128 0.0671 0.0128 0.0591 0.0467 0.0114 0.0221 0.0402 0.0039 0.0456 0.0556  




Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0785 0.0158 0.00558 0.0132  
Untreated Bacteria 8 0 0.983 0.0219 0.00775 0.0183  
Gentamicin 16 0 0.0772 0.0192 0.00480 0.0102  
Rifampicin 16 0 0.0923 0.0128 0.00319 0.00680  
Polymyxin B 16 0 0.0752 0.0176 0.00439 0.00936  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0398 0.0984 0.0586 0.0760 0.0650 0.0945  
Untreated Bacteria 0.0671 1.014 0.947 0.987 0.966 0.997  
Gentamicin 0.0618 0.119 0.0574 0.0674 0.0645 0.0914  
Rifampicin 0.0402 0.119 0.0785 0.0892 0.0817 0.103  
Polymyxin B 0.0556 0.113 0.0572 0.0693 0.0610 0.0892  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.140 -1.602 0.178 0.560 0.905 0.322  
Untreated Bacteria -0.335 -0.601 0.171 0.604 0.969 0.889  
Gentamicin 1.117 -0.0634 0.262 0.005 0.827 0.006  
Rifampicin 0.657 -0.692 0.190 0.124 0.900 0.080  
Polymyxin B 0.962 -0.190 0.201 0.083 0.867 0.025  
 
 
One Way Analysis of Variance Friday, April 17, 2015, 1:13:02 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0785 0.0158 0.00558  
Untreated Bacteria 8 0 0.983 0.0219 0.00775  
Gentamicin 16 0 0.0772 0.0192 0.00480  
Rifampicin 16 0 0.0923 0.0128 0.00319  
Polymyxin B 16 0 0.0752 0.0176 0.00439  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 5.694 1.423 4744.843 <0.001  
Residual 59 0.0177 0.000300    
Total 63 5.712     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Ba vs. Polymyxin B 0.908 121.015 <0.001 0.013  
Untreated Ba vs. Gentamicin 0.906 120.746 <0.001 0.017  
Untreated Ba vs. Rifampicin 0.890 118.729 <0.001 0.025  
Untreated Bacteria vs. TSB 0.904 104.417 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Polymyxin B Yes  
Untreated Ba vs. Gentamicin Yes  
Untreated Ba vs. Rifampicin Yes  
Untreated Bacteria vs. TSB Yes  
 
Comparisons for factor:  
Comparison                        Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria      0.904 104.417 <0.001 0.013 Yes  
TSB vs. Rifampicin                0.0138 1.842 0.071 0.017 No  
TSB vs. Polymyxin B            0.00333 0.444 0.659 0.025 No  
TSB vs. Gentamicin               0.00131 0.175 0.862 0.050 No  
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Clinical Isolate 39 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0917 0.0367 0.9430 0.0401 0.0763 0.0690 0.0350 0.0757 0.1433 0.0329 0.0566 0.0532
B 0.1391 0.0327 0.9874 0.0332 0.0791 0.0673 0.0329 0.0808 0.0695 0.0356 0.0591 0.0601
C 0.0555 0.0388 0.9293 0.0340 0.0766 0.0708 0.0411 0.1022 0.0722 0.0409 0.0626 0.0638
D 0.0588 0.0324 0.9316 0.0351 0.0795 0.0726 0.0407 0.0989 0.0789 0.0345 0.0702 0.0724
E 0.0856 0.0327 0.9177 0.0325 0.0752 0.0781 0.0443 0.0988 0.0868 0.0350 0.0677 0.0687
F 0.0662 0.0330 0.9455 0.0333 0.0732 0.0707 0.0335 0.1161 0.0861 0.0356 0.0766 0.0788
G 0.0777 0.0406 0.9918 0.0348 0.0984 0.0878 0.0372 0.1258 0.0949 0.0374 0.0819 0.0862
H 0.0744 0.0332 0.9843 0.0413 0.1045 0.1096 0.0355 0.1322 0.1113 0.0414 0.0962 0.1020
average 0.0811 0.0350 0.9538 0.0355 0.0829 0.0782 0.0375 0.1038 0.0929 0.0367 0.0714 0.0732
range 0.0836 0.0082 0.0741 0.0088 0.0313 0.0423 0.0114 0.0565 0.0738 0.0085 0.0396 0.0488  
Descriptive Statistics:  
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0811 0.0265 0.00938 0.0222  
Untreated Bacteria 8 0 0.954 0.0295 0.0104 0.0246  
Gentamicin 16 0 0.0805 0.0129 0.00321 0.00685  
Rifampicin 16 0 0.0983 0.0223 0.00556 0.0119  
Polymyxin B 16 0 0.0723 0.0140 0.00350 0.00746  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0836 0.139 0.0555 0.0761 0.0625 0.0887  
Untreated Bacteria 0.0741 0.992 0.918 0.944 0.930 0.986  
Gentamicin 0.0423 0.110 0.0673 0.0765 0.0717 0.0837  
Rifampicin 0.0738 0.143 0.0695 0.0968 0.0799 0.114  
Polymyxin B 0.0488 0.102 0.0532 0.0694 0.0614 0.0804  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.678 3.431 0.220 0.290 0.846 0.087  
Untreated Bacteria 0.343 -1.933 0.236 0.207 0.866 0.137  
Gentamicin 1.342 0.750 0.282 0.001 0.821 0.005  
Rifampicin 0.612 -0.542 0.136 0.546 0.944 0.395  
Polymyxin B 0.765 -0.0273 0.121 0.681 0.945 0.418  
 
 
One Way Analysis of Variance  
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0811 0.0265 0.00938  
Untreated Bacteria 8 0 0.954 0.0295 0.0104  
Gentamicin 16 0 0.0805 0.0129 0.00321  
Rifampicin 16 0 0.0983 0.0223 0.00556  
Polymyxin B 16 0 0.0723 0.0140 0.00350  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 5.310 1.327 3282.706 <0.001  
Residual 59 0.0239 0.000404    
Total 63 5.334     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Ba vs. Polymyxin B 0.882 101.242 <0.001 0.013  
Untreated Ba vs. Gentamicin 0.873 100.290 <0.001 0.017  
Untreated Ba vs. Rifampicin 0.855 98.246 <0.001 0.025  
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Untreated Bacteria vs. TSB 0.873 86.796 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Polymyxin B Yes  
Untreated Ba vs. Gentamicin Yes  
Untreated Ba vs. Rifampicin Yes  
Untreated Bacteria vs. TSB Yes  
 
Comparisons for factor:  
Comparison                          Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria           0.873 86.796 <0.001 0.013 Yes  
TSB vs. Rifampicin                      0.0172 1.977 0.053 0.017 No  
TSB vs. Polymyxin B                  0.00887 1.019 0.313 0.025 No  
TSB vs. Gentamicin                    0.000581 0.0668 0.947 0.050 No  
 
Clinical Isolate 40 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0532 0.0337 0.8712 0.0454 0.0635 0.0690 0.0393 0.0855 0.0757 0.0516 0.0508 0.0694
B 0.0529 0.0457 0.8945 0.1350 0.0627 0.0601 0.1245 0.0726 0.0701 0.1269 0.0528 0.0658
C 0.0823 0.0957 0.9126 0.1432 0.0668 0.0600 0.1415 0.0771 0.0787 0.1407 0.0581 0.0577
D 0.0609 0.1259 0.9098 0.1486 0.0617 0.0702 0.1584 0.0818 0.0723 0.1426 0.0641 0.0589
E 0.0625 0.0881 0.9132 0.1577 0.0862 0.0647 0.1568 0.0960 0.0840 0.1498 0.0675 0.0660
F 0.1217 0.0909 0.9018 0.1794 0.0764 0.0686 0.1460 0.0849 0.0874 0.1467 0.0683 0.0779
G 0.0713 0.0342 0.9138 0.1514 0.1066 0.0855 0.1516 0.1130 0.1069 0.1233 0.0723 0.0839
H 0.0749 0.0329 0.8038 0.0356 0.0928 0.0983 0.0391 0.1146 0.0989 0.0352 0.0891 0.1033
average 0.0725 0.0684 0.8901 0.1245 0.0771 0.0721 0.1197 0.0907 0.0843 0.1146 0.0654 0.0729
range 0.0688 0.0930 0.1100 0.1438 0.0449 0.0383 0.1193 0.0420 0.0368 0.1146 0.0383 0.0456  
Descriptive Statistics: Saturday, April 18, 2015, 9:23:48 AM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0725 0.0224 0.00792 0.0187  
Untreated Bacteria 8 0 0.890 0.0377 0.0133 0.0315  
Gentamicin 16 0 0.0746 0.0148 0.00369 0.00787  
Rifampicin 16 0 0.0875 0.0144 0.00359 0.00766  
Polymyxin B 16 0 0.0691 0.0139 0.00346 0.00738  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0688 0.122 0.0529 0.0669 0.0571 0.0786  
Untreated Bacteria 0.110 0.914 0.804 0.906 0.883 0.913  
Gentamicin 0.0466 0.107 0.0600 0.0688 0.0631 0.0859  
Rifampicin 0.0445 0.115 0.0701 0.0844 0.0764 0.0975  
Polymyxin B 0.0525 0.103 0.0508 0.0668 0.0585 0.0751  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.746 3.528 0.207 0.371 0.823 0.050  
Untreated Bacteria -2.142 4.702 0.297 0.037 0.700 0.002  
Gentamicin 0.992 -0.195 0.241 0.013 0.861 0.020  
Rifampicin 0.779 -0.529 0.189 0.127 0.902 0.087  
Polymyxin B 1.067 1.168 0.179 0.180 0.924 0.193  
 
 
One Way Analysis of Variance Saturday, April 18, 2015, 9:24:09 AM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0725 0.0224 0.00792  
Untreated Bacteria 8 0 0.890 0.0377 0.0133  
Gentamicin 16 0 0.0746 0.0148 0.00369  
Rifampicin 16 0 0.0875 0.0144 0.00359  
Polymyxin B 16 0 0.0691 0.0139 0.00346  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 4.638 1.159 3010.830 <0.001  
Residual 59 0.0227 0.000385    
Total 63 4.660     
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The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                               Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B         0.821 96.616 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin            0.816 95.975 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin             0.803 94.457 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB              0.818 83.331 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.818 83.331 <0.001 0.013 Yes  
TSB vs. Rifampicin                    0.0150 1.766 0.083 0.017 No  
TSB vs. Polymyxin B                0.00334 0.394 0.695 0.025 No  
TSB vs. Gentamicin                   0.00211 0.248 0.805 0.050 No  
 
Clinical Isolate 42 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0640 0.0377 0.5644 0.0440 0.0607 0.0741 0.0395 0.0902 0.0981 0.0485 0.0690 0.0559
B 0.0568 0.0374 0.5898 0.0470 0.0744 0.0626 0.0368 0.0783 0.0816 0.0471 0.0796 0.0779
C 0.0668 0.0414 0.6103 0.0802 0.0788 0.0662 0.0791 0.0808 0.0848 0.1039 0.0788 0.0647
D 0.0620 0.0413 0.6331 0.0781 0.0656 0.0680 0.1200 0.0807 0.0745 0.1018 0.0688 0.0672
E 0.0662 0.0483 0.6212 0.0540 0.0775 0.0744 0.0945 0.1002 0.0998 0.0861 0.0698 0.0820
F 0.0676 0.0355 0.5952 0.0412 0.0857 0.0763 0.0505 0.1082 0.0989 0.0428 0.0734 0.1021
G 0.0710 0.0352 0.5843 0.0452 0.1251 0.1151 0.0434 0.1228 0.1250 0.0342 0.0881 0.1044
H 0.0783 0.0351 0.6228 0.0355 0.1010 0.1057 0.0399 0.1332 0.1111 0.0428 0.1157 0.1078
average 0.0666 0.0390 0.6026 0.0532 0.0836 0.0803 0.0630 0.0993 0.0967 0.0634 0.0804 0.0828
range 0.0215 0.0132 0.0687 0.0447 0.0644 0.0525 0.0832 0.0549 0.0505 0.0697 0.0469 0.0519  
Descriptive Statistics: Saturday, April 18, 2015, 1:48:43 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0666 0.00634 0.00224 0.00530  
Untreated Bacteria 8 0 0.603 0.0232 0.00819 0.0194  
Gentamicin 16 0 0.0819 0.0195 0.00486 0.0104  
Rifampicin 16 0 0.0980 0.0181 0.00452 0.00964  
Polymyxin B 16 0 0.0816 0.0174 0.00435 0.00927  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0215 0.0783 0.0568 0.0665 0.0630 0.0693  
Untreated Bacteria 0.0687 0.633 0.564 0.603 0.587 0.622  
Gentamicin 0.0644 0.125 0.0607 0.0754 0.0671 0.0934  
Rifampicin 0.0587 0.133 0.0745 0.0985 0.0812 0.110  
Polymyxin B 0.0598 0.116 0.0559 0.0784 0.0689 0.0951  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.480 1.223 0.187 0.503 0.970 0.896  
Untreated Bacteria -0.326 -0.816 0.164 0.649 0.961 0.824  
Gentamicin 1.115 0.225 0.252 0.008 0.862 0.021  
Rifampicin 0.562 -0.709 0.142 0.479 0.929 0.234  
Polymyxin B 0.688 -0.539 0.178 0.190 0.920 0.168  
 
 
One Way Analysis of Variance Saturday, April 18, 2015, 1:49:50 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0666 0.00634 0.00224  
Untreated Bacteria 8 0 0.603 0.0232 0.00819  
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Gentamicin 16 0 0.0819 0.0195 0.00486  
Rifampicin 16 0 0.0980 0.0181 0.00452  
Polymyxin B 16 0 0.0816 0.0174 0.00435  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 1.887 0.472 1452.614 <0.001  
Residual 59 0.0192 0.000325    
Total 63 1.906     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                                Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B            0.521 66.776 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin               0.521 66.728 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin                0.505 64.669 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB                 0.536 59.493 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                         Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.536 59.493 <0.001 0.013 Yes  
TSB vs. Rifampicin                    0.0314 4.027 <0.001 0.017 Yes  
TSB vs. Gentamicin                    0.0154 1.969 0.054 0.025 No  
TSB vs. Polymyxin B                 0.0150 1.921 0.060 0.050 No  
 
Clinical Isolate 44 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0529 0.0333 0.9237 0.0330 0.0581 0.0581 0.0325 0.0776 0.0762 0.0381 0.0541 0.0518
B 0.0524 0.0328 0.9542 0.0324 0.0562 0.0518 0.0336 0.0799 0.0689 0.0344 0.0576 0.0555
C 0.0552 0.0327 0.9811 0.0326 0.0603 0.0651 0.0318 0.0782 0.0777 0.0329 0.0579 0.0600
D 0.0583 0.0331 0.9646 0.0325 0.0628 0.0642 0.0345 0.0773 0.0894 0.0340 0.0598 0.0591
E 0.0588 0.0328 0.9621 0.0329 0.0775 0.0742 0.0364 0.0860 0.0910 0.0339 0.0664 0.0645
F 0.0644 0.0324 0.9812 0.0326 0.0747 0.0731 0.0377 0.0818 0.0842 0.0356 0.0674 0.0715
G 0.0660 0.0355 0.9118 0.0391 0.1092 0.0658 0.0335 0.1083 0.1105 0.0380 0.0799 0.0763
H 0.0687 0.0331 0.9307 0.0327 0.0896 0.0824 0.0333 0.0936 0.0993 0.0396 0.0957 0.0948
average 0.0596 0.0332 0.9512 0.0335 0.0736 0.0668 0.0342 0.0853 0.0872 0.0358 0.0674 0.0667
range 0.0163 0.0031 0.0694 0.0067 0.0530 0.0306 0.0059 0.0310 0.0416 0.0067 0.0416 0.0430  
Descriptive Statistics: Saturday, April 18, 2015, 2:10:28 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0596 0.00616 0.00218 0.00515  
Untreated Bacteria 8 0 0.951 0.0263 0.00929 0.0220  
Gentamicin 16 0 0.0702 0.0146 0.00365 0.00779  
Rifampicin 16 0 0.0862 0.0118 0.00295 0.00629  
Polymyxin B 16 0 0.0670 0.0135 0.00338 0.00720  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0163 0.0687 0.0524 0.0585 0.0541 0.0652  
Untreated Bacteria 0.0694 0.981 0.912 0.958 0.927 0.973  
Gentamicin 0.0574 0.109 0.0518 0.0655 0.0592 0.0761  
Rifampicin 0.0416 0.111 0.0689 0.0830 0.0776 0.0923  
Polymyxin B 0.0439 0.0957 0.0518 0.0623 0.0577 0.0739  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.306 -1.517 0.176 0.573 0.923 0.454  
Untreated Bacteria -0.344 -1.436 0.171 0.605 0.916 0.401  
Gentamicin 1.335 2.166 0.181 0.173 0.899 0.076  
Rifampicin 0.865 0.0858 0.147 0.439 0.914 0.134  
Polymyxin B 1.173 0.562 0.198 0.093 0.864 0.022  
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One Way Analysis of Variance Saturday, April 18, 2015, 2:11:17 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0596 0.00616 0.00218  
Untreated Bacteria 8 0 0.951 0.0263 0.00929  
Gentamicin 16 0 0.0702 0.0146 0.00365  
Rifampicin 16 0 0.0862 0.0118 0.00295  
Polymyxin B 16 0 0.0670 0.0135 0.00338  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 5.411 1.353 6077.871 <0.001  
Residual 59 0.0131 0.000223    
Total 63 5.424     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Ba vs. Polymyxin B 0.884 136.864 <0.001 0.013  
Untreated Ba vs. Gentamicin 0.881 136.372 <0.001 0.017  
Untreated Ba vs. Rifampicin 0.865 133.888 <0.001 0.025  
Untreated Bacteria vs. TSB 0.892 119.524 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Polymyxin B Yes  
Untreated Ba vs. Gentamicin Yes  
Untreated Ba vs. Rifampicin Yes  
Untreated Bacteria vs. TSB Yes  
 
Comparisons for factor:  
Comparison                        Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria        0.892 119.524 <0.001 0.013 Yes  
TSB vs. Rifampicin                   0.0267 4.126 <0.001 0.017 Yes  
TSB vs. Gentamicin                  0.0106 1.642 0.106 0.025 No  
TSB vs. Polymyxin B              0.00743 1.150 0.255 0.050 No  
 
Clinical Isolate 45 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0578 0.0401 0.7786 0.0339 0.0587 0.0652 0.0349 0.1170 0.1515 0.0356 0.0545 0.0559
B 0.0540 0.0321 0.8753 0.0425 0.0582 0.0620 0.0341 0.1004 0.1317 0.0351 0.0576 0.0584
C 0.0574 0.0322 0.8948 0.0334 0.0609 0.0573 0.0332 0.1929 0.1558 0.0328 0.0601 0.0722
D 0.0756 0.0338 0.9060 0.0380 0.0631 0.0565 0.0410 0.0794 0.1686 0.0334 0.0701 0.0653
E 0.0620 0.0325 0.8931 0.0343 0.0733 0.0577 0.0361 0.1716 0.1010 0.0332 0.0656 0.0751
F 0.0649 0.0345 0.8857 0.0326 0.0805 0.0647 0.0337 0.0939 0.1592 0.0330 0.0800 0.1155
G 0.0715 0.0353 0.8956 0.0330 0.0975 0.0964 0.0413 0.1619 0.2587 0.0362 0.0904 0.1056
H 0.0765 0.0324 0.8576 0.0327 0.0952 0.1292 0.0355 0.1225 0.2206 0.0329 0.1017 0.1173
average 0.0650 0.0341 0.8733 0.0351 0.0734 0.0736 0.0362 0.1300 0.1684 0.0340 0.0725 0.0832
range 0.0225 0.0080 0.1274 0.0099 0.0393 0.0727 0.0081 0.1135 0.1577 0.0034 0.0472 0.0614  
Descriptive Statistics: Saturday, April 18, 2015, 2:24:48 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0650 0.00867 0.00307 0.00725  
Untreated Bacteria 8 0 0.873 0.0410 0.0145 0.0343  
Gentamicin 16 0 0.0735 0.0209 0.00521 0.0111  
Rifampicin 16 0 0.149 0.0482 0.0121 0.0257  




Column Range Max Min  Median  25% 75%  
TSB 0.0225 0.0765 0.0540 0.0635 0.0576 0.0736  
Untreated Bacteria 0.127 0.906 0.779 0.889 0.866 0.895  
Gentamicin 0.0727 0.129 0.0565 0.0639 0.0585 0.0879  
Rifampicin 0.179 0.259 0.0794 0.154 0.109 0.170  
Polymyxin B 0.0628 0.117 0.0545 0.0711 0.0592 0.0960  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.256 -1.701 0.171 0.607 0.914 0.382  
Untreated Bacteria -2.173 5.052 0.269 0.091 0.732 0.005  
Gentamicin 1.537 1.993 0.280 0.002 0.784 0.002  
Rifampicin 0.673 0.342 0.133 0.567 0.955 0.572  
Polymyxin B 0.777 -0.804 0.175 0.206 0.875 0.032  
 
 
One Way Analysis of Variance Saturday, April 18, 2015, 2:25:16 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0650 0.00867 0.00307  
Untreated Bacteria 8 0 0.873 0.0410 0.0145  
Gentamicin 16 0 0.0735 0.0209 0.00521  
Rifampicin 16 0 0.149 0.0482 0.0121  
Polymyxin B 16 0 0.0778 0.0216 0.00541  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 4.305 1.076 1045.650 <0.001  
Residual 59 0.0607 0.00103    
Total 63 4.366     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin          0.800 57.571 <0.001 0.013 Yes  
Untreated Ba vs. Polymyxin B       0.796 57.261 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin           0.724 52.126 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB            0.808 50.392 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                        Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria        0.808 50.392 <0.001 0.013 Yes  
TSB vs. Rifampicin                   0.0842 6.061 <0.001 0.017 Yes  
TSB vs. Polymyxin B                0.0129 0.926 0.358 0.025 No  
TSB vs. Gentamicin                  0.00856 0.616 0.540 0.050 No  
 
Clinical Isolate 47 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0571 0.0427 0.7931 0.0379 0.0758 0.0596 0.0491 0.0879 0.0884 0.0387 0.0543 0.0689
B 0.0605 0.0907 0.7610 0.1340 0.0727 0.0631 0.1432 0.4181 0.1058 0.1430 0.0546 0.0659
C 0.0591 0.1110 0.8468 0.1686 0.0680 0.0586 0.1508 0.0819 0.0822 0.1408 0.0666 0.0652
D 0.0650 0.1221 0.8257 0.1653 0.0770 0.0753 0.1697 0.0800 0.0808 0.1449 0.0723 0.0615
E 0.0656 0.1257 0.8526 0.1651 0.0821 0.0854 0.1566 0.0923 0.3798 0.1514 0.0659 0.0625
F 0.0714 0.1056 0.8542 0.1530 0.0784 0.0840 0.1441 0.0961 0.0846 0.1446 0.0659 0.0706
G 0.0741 0.0510 0.7865 0.1452 0.1050 0.1138 0.1309 0.1036 0.1097 0.1142 0.0811 0.0819
H 0.0730 0.0351 0.8811 0.0372 0.0968 0.0881 0.0393 0.1145 0.1068 0.0384 0.0811 0.0835
average 0.0657 0.0855 0.8251 0.1258 0.0820 0.0785 0.1230 0.1343 0.1298 0.1145 0.0677 0.0700
range 0.0170 0.0906 0.1201 0.1314 0.0370 0.0552 0.1304 0.3381 0.2990 0.1130 0.0268 0.0220  




Data source: Data 1 in Notebook1 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0657 0.00656 0.00232 0.00549  
Untreated Bacteria 8 0 0.825 0.0411 0.0145 0.0344  
Gentamicin 16 0 0.0802 0.0154 0.00386 0.00822  
Rifampicin 16 0 0.132 0.105 0.0263 0.0560  
Polymyxin B 16 0 0.0689 0.00914 0.00229 0.00487  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0170 0.0741 0.0571 0.0653 0.0598 0.0722  
Untreated Bacteria 0.120 0.881 0.761 0.836 0.790 0.853  
Gentamicin 0.0552 0.114 0.0586 0.0777 0.0703 0.0867  
Rifampicin 0.338 0.418 0.0800 0.0942 0.0834 0.108  
Polymyxin B 0.0292 0.0835 0.0543 0.0663 0.0638 0.0767  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.0538 -1.763 0.181 0.537 0.917 0.406  
Untreated Bacteria -0.338 -1.120 0.201 0.407 0.944 0.651  
Gentamicin 0.660 0.225 0.119 0.699 0.953 0.542  
Rifampicin 2.475 4.898 0.441 <0.001 0.505 <0.001  
Polymyxin B 0.227 -0.697 0.160 0.317 0.921 0.177  
 
 
One Way Analysis of Variance Saturday, April 18, 2015, 2:38:22 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0657 0.00656 0.00232  
Untreated Bacteria 8 0 0.825 0.0411 0.0145  
Gentamicin 16 0 0.0802 0.0154 0.00386  
Rifampicin 16 0 0.132 0.105 0.0263  
Polymyxin B 16 0 0.0689 0.00914 0.00229  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.827 0.957 309.476 <0.001  
Residual 59 0.182 0.00309    
Total 63 4.010     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.0 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
Comparisons for factor:  
Comparison                               Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B          0.756 31.409 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin             0.745 30.937 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin              0.693 28.786 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB               0.759 27.314 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                        Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria         0.759 27.314 <0.001 0.013 Yes  
TSB vs. Rifampicin                    0.0663 2.754 0.008 0.017 Yes  
TSB vs. Gentamicin                   0.0145 0.602 0.549 0.025 No  













Clinical Isolate 49 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0585 0.0725 0.5874 0.1178 0.0637 0.0591 0.1230 0.0803 0.0938 0.1128 0.0564 0.0575
B 0.0565 0.1720 0.5275 0.1699 0.0614 0.0525 0.1894 0.0659 0.0715 0.1660 0.0634 0.0531
C 0.0590 0.1764 0.5869 0.1949 0.0626 0.0542 0.1905 0.0689 0.0716 0.1712 0.0635 0.0574
D 0.0644 0.2056 0.5848 0.1982 0.0628 0.0534 0.1962 0.0700 0.0671 0.1758 0.0583 0.0728
E 0.0707 0.1598 0.5559 0.2050 0.0743 0.0578 0.1971 0.0689 0.0756 0.1544 0.0640 0.0721
F 0.0657 0.1705 0.6266 0.1946 0.0775 0.0712 0.1779 0.0718 0.0848 0.1727 0.0708 0.0827
G 0.0704 0.1333 0.6040 0.1537 0.0993 0.0917 0.1625 0.0989 0.1040 0.1440 0.0664 0.0909
H 0.0906 0.0467 0.5553 0.0341 0.0861 0.0824 0.0568 0.0987 0.0896 0.0406 0.0822 0.0954
average 0.0670 0.1421 0.5786 0.1585 0.0735 0.0653 0.1617 0.0779 0.0823 0.1422 0.0656 0.0727
range 0.0341 0.1589 0.0991 0.1709 0.0379 0.0392 0.1403 0.0330 0.0369 0.1352 0.0258 0.0423  
Descriptive Statistics: Saturday, April 18, 2015, 2:53:08 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0670 0.0109 0.00387 0.00914  
Untreated Bacteria 8 0 0.579 0.0312 0.0110 0.0261  
Gentamicin 16 0 0.0694 0.0144 0.00361 0.00770  
Rifampicin 16 0 0.0801 0.0130 0.00325 0.00692  
Polymyxin B 16 0 0.0692 0.0128 0.00320 0.00681  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0341 0.0906 0.0565 0.0650 0.0587 0.0706  
Untreated Bacteria 0.0991 0.627 0.527 0.586 0.556 0.596  
Gentamicin 0.0468 0.0993 0.0525 0.0633 0.0585 0.0799  
Rifampicin 0.0381 0.104 0.0659 0.0737 0.0695 0.0917  
Polymyxin B 0.0423 0.0954 0.0531 0.0652 0.0579 0.0775  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.601 3.086 0.242 0.182 0.843 0.080  
Untreated Bacteria -0.178 -0.142 0.204 0.385 0.964 0.851  
Gentamicin 0.737 -0.509 0.215 0.046 0.916 0.146  
Rifampicin 0.680 -1.107 0.238 0.016 0.867 0.024  
Polymyxin B 0.792 -0.330 0.157 0.342 0.915 0.140  
 
 
One Way Analysis of Variance Saturday, April 18, 2015, 2:53:36 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0670 0.0109 0.00387  
Untreated Bacteria 8 0 0.579 0.0312 0.0110  
Gentamicin 16 0 0.0694 0.0144 0.00361  
Rifampicin 16 0 0.0801 0.0130 0.00325  
Polymyxin B 16 0 0.0692 0.0128 0.00320  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 1.797 0.449 1682.915 <0.001  
Residual 59 0.0158 0.000267    
Total 63 1.813     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B        0.509 71.990 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin           0.509 71.963 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin            0.498 70.449 <0.001 0.025 Yes  
234 
 
Untreated Bacteria vs. TSB             0.512 62.615 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria           0.512 62.615 <0.001 0.013 Yes  
TSB vs. Rifampicin                      0.0131 1.853 0.069 0.017 No  
TSB vs. Gentamicin                     0.00240 0.339 0.736 0.025 No  
TSB vs. Polymyxin B                   0.00221 0.312 0.756 0.050 No  
 
Clinical Isolate 50 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0558 0.0334 0.6187 0.0343 0.0595 0.0588 0.0433 0.0827 0.0842 0.0365 0.0567 0.0589
B 0.0565 0.0353 0.7324 0.0333 0.0606 0.0682 0.0339 0.0750 0.0732 0.0329 0.0510 0.0566
C 0.0641 0.0320 0.7642 0.0365 0.0672 0.0645 0.0333 0.0784 0.0730 0.0352 0.0577 0.0614
D 0.0620 0.0322 0.8008 0.0397 0.0649 0.0644 0.0332 0.0816 0.0704 0.0353 0.0632 0.0610
E 0.0631 0.0330 0.8145 0.0354 0.0669 0.0663 0.0355 0.0822 0.0774 0.0322 0.0592 0.0667
F 0.0692 0.0322 0.7834 0.0515 0.0693 0.0895 0.0331 0.0842 0.0802 0.0384 0.0644 0.0734
G 0.0845 0.0334 0.7990 0.0351 0.1186 0.1008 0.0344 0.1122 0.1203 0.0431 0.0771 0.0858
H 0.0797 0.0338 0.6815 0.0419 0.0906 0.1047 0.0331 0.1169 0.1125 0.0403 0.0955 0.0943
average 0.0669 0.0332 0.7493 0.0385 0.0747 0.0772 0.0350 0.0892 0.0864 0.0367 0.0656 0.0698
range 0.0287 0.0033 0.1958 0.0182 0.0591 0.0459 0.0102 0.0419 0.0499 0.0109 0.0445 0.0377  
Descriptive Statistics: Saturday, April 18, 2015, 3:04:58 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0669 0.0104 0.00368 0.00869  
Untreated Bacteria 8 0 0.749 0.0683 0.0242 0.0571  
Gentamicin 16 0 0.0759 0.0186 0.00466 0.00993  
Rifampicin 16 0 0.0878 0.0171 0.00427 0.00911  
Polymyxin B 16 0 0.0677 0.0137 0.00343 0.00730  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0287 0.0845 0.0558 0.0636 0.0592 0.0744  
Untreated Bacteria 0.196 0.815 0.619 0.774 0.707 0.800  
Gentamicin 0.0598 0.119 0.0588 0.0670 0.0645 0.0900  
Rifampicin 0.0499 0.120 0.0704 0.0819 0.0762 0.0982  
Polymyxin B 0.0445 0.0955 0.0510 0.0623 0.0583 0.0753  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.841 -0.459 0.230 0.238 0.895 0.260  
Untreated Bacteria -1.173 0.519 0.211 0.342 0.873 0.161  
Gentamicin 1.204 0.227 0.326 <0.001 0.799 0.003  
Rifampicin 1.100 -0.436 0.333 <0.001 0.781 0.002  
Polymyxin B 1.097 0.101 0.220 0.038 0.855 0.016  
 
 
One Way Analysis of Variance Saturday, April 18, 2015, 3:05:17 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0669 0.0104 0.00368  
Untreated Bacteria 8 0 0.749 0.0683 0.0242  
Gentamicin 16 0 0.0759 0.0186 0.00466  
Rifampicin 16 0 0.0878 0.0171 0.00427  
Polymyxin B 16 0 0.0677 0.0137 0.00343  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 3.181 0.795 1023.005 <0.001  
Residual 59 0.0459 0.000777    
Total 63 3.226     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 




Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                              Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B        0.682 56.463 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin           0.673 55.780 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin            0.662 54.798 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB             0.682 48.957 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                        Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria        0.682 48.957 <0.001 0.013 Yes  
TSB vs. Rifampicin                   0.0209 1.732 0.088 0.017 No  
TSB vs. Gentamicin                  0.00906 0.751 0.456 0.025 No  
TSB vs. Polymyxin B              0.000819 0.0678 0.946 0.050 No  
 
Clinical Isolate 52 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0558 0.0324 0.4841 0.0317 0.0596 0.0605 0.0320 0.0833 0.0813 0.0328 0.0496 0.0535
B 0.0723 0.0334 0.6172 0.0319 0.0514 0.0507 0.0322 0.0739 0.0728 0.0426 0.0525 0.0562
C 0.0608 0.0378 0.7196 0.0323 0.0556 0.0591 0.0330 0.0717 0.0790 0.0323 0.0564 0.0593
D 0.0735 0.0334 0.7489 0.0391 0.0546 0.0573 0.0399 0.0875 0.0788 0.0327 0.0621 0.0629
E 0.0643 0.0322 0.7927 0.0331 0.0582 0.0557 0.0348 0.0733 0.0757 0.0332 0.0574 0.0728
F 0.0686 0.0455 0.7644 0.0340 0.0615 0.0548 0.0337 0.0898 0.0760 0.0336 0.0745 0.0814
G 0.0735 0.0327 0.7329 0.0332 0.0908 0.0791 0.0344 0.1099 0.1270 0.0367 0.0865 0.0941
H 0.0876 0.0327 0.5777 0.0335 0.1046 0.0978 0.0369 0.1151 0.1118 0.0339 0.0994 0.1084
average 0.0696 0.0350 0.6797 0.0336 0.0670 0.0644 0.0346 0.0881 0.0878 0.0347 0.0673 0.0736
range 0.0318 0.0133 0.3086 0.0074 0.0532 0.0471 0.0079 0.0434 0.0542 0.0103 0.0498 0.0549  
Descriptive Statistics: Saturday, April 18, 2015, 3:16:15 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0696 0.00970 0.00343 0.00811  
Untreated Bacteria 8 0 0.680 0.108 0.0382 0.0903  
Gentamicin 16 0 0.0657 0.0173 0.00432 0.00921  
Rifampicin 16 0 0.0879 0.0178 0.00445 0.00948  
Polymyxin B 16 0 0.0704 0.0184 0.00461 0.00983  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0318 0.0876 0.0558 0.0704 0.0625 0.0735  
Untreated Bacteria 0.309 0.793 0.484 0.726 0.597 0.757  
Gentamicin 0.0539 0.105 0.0507 0.0587 0.0552 0.0703  
Rifampicin 0.0553 0.127 0.0717 0.0801 0.0748 0.0998  
Polymyxin B 0.0588 0.108 0.0496 0.0625 0.0563 0.0839  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.545 0.872 0.217 0.308 0.955 0.760  
Untreated Bacteria -0.935 -0.284 0.269 0.091 0.889 0.231  
Gentamicin 1.437 0.686 0.346 <0.001 0.747 <0.001  
Rifampicin 1.149 -0.0269 0.228 0.026 0.812 0.004  
Polymyxin B 0.824 -0.539 0.221 0.035 0.891 0.057 
 
One Way Analysis of Variance Saturday, April 18, 2015, 3:18:11 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0696 0.00970 0.00343  
Untreated Bacteria 8 0 0.680 0.108 0.0382  
Gentamicin 16 0 0.0657 0.0173 0.00432  
Rifampicin 16 0 0.0879 0.0178 0.00445  
Polymyxin B 16 0 0.0704 0.0184 0.00461  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 2.573 0.643 392.423 <0.001  
Residual 59 0.0967 0.00164    
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Total 63 2.670     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                             Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Gentamicin           0.614 35.023 <0.001 0.013 Yes  
Untreated Ba vs. Polymyxin B        0.609 34.753 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin            0.592 33.755 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB             0.610 30.141 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                           Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria           0.610 30.141 <0.001 0.013 Yes  
TSB vs. Rifampicin                       0.0184 1.048 0.299 0.017 No  
TSB vs. Gentamicin                      0.00384 0.219 0.827 0.025 No  
TSB vs. Polymyxin B                   0.000887 0.0506 0.960 0.050 No  
 
Clinical Isolate 53a 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0516 0.0390 1.0032 0.0478 0.0593 0.0581 0.0389 0.0777 0.0787 0.0345 0.0537 0.0520
B 0.0519 0.0323 1.1053 0.0337 0.0606 0.0615 0.0318 0.0774 0.0719 0.0374 0.0531 0.0561
C 0.0529 0.0317 1.0712 0.0335 0.0683 0.0656 0.0341 0.0755 0.0783 0.0330 0.0602 0.0580
D 0.0576 0.0323 1.1471 0.0318 0.0671 0.0633 0.0317 0.0702 0.0685 0.0331 0.0588 0.0588
E 0.0592 0.0324 1.0905 0.0326 0.0850 0.0688 0.0343 0.0770 0.0795 0.0334 0.0612 0.0608
F 0.0628 0.0339 1.0848 0.0331 0.0790 0.0773 0.0324 0.0800 0.0751 0.0321 0.0611 0.0621
G 0.0668 0.0332 1.1107 0.0332 0.1073 0.0872 0.0328 0.1122 0.1012 0.0325 0.0677 0.0704
H 0.0718 0.0321 1.0532 0.0318 0.0919 0.0947 0.0324 0.0949 0.0965 0.0323 0.0731 0.0847
average 0.0593 0.0334 1.0833 0.0347 0.0773 0.0721 0.0336 0.0831 0.0812 0.0335 0.0611 0.0629
range 0.0202 0.0073 0.1439 0.0160 0.0480 0.0366 0.0072 0.0420 0.0327 0.0053 0.0200 0.0327  
Descriptive Statistics: Saturday, April 18, 2015, 3:29:13 PM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0593 0.00739 0.00261 0.00618  
Untreated Bacteria 8 0 1.083 0.0428 0.0151 0.0358  
Gentamicin 16 0 0.0747 0.0148 0.00370 0.00788  
Rifampicin 16 0 0.0822 0.0123 0.00308 0.00655  
Polymyxin B 16 0 0.0620 0.00843 0.00211 0.00449  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0202 0.0718 0.0516 0.0584 0.0524 0.0648  
Untreated Bacteria 0.144 1.147 1.003 1.088 1.062 1.108  
Gentamicin 0.0492 0.107 0.0581 0.0686 0.0624 0.0861  
Rifampicin 0.0437 0.112 0.0685 0.0780 0.0753 0.0875  
Polymyxin B 0.0327 0.0847 0.0520 0.0605 0.0571 0.0649  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.594 -0.792 0.183 0.529 0.920 0.427  
Untreated Bacteria -0.606 1.157 0.139 0.762 0.970 0.898  
Gentamicin 0.814 -0.274 0.217 0.042 0.906 0.100  
Rifampicin 1.333 1.021 0.320 <0.001 0.827 0.006  
Polymyxin B 1.430 2.395 0.245 0.011 0.875 0.032  
 
One Way Analysis of Variance Saturday, April 18, 2015, 3:29:38 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0593 0.00739 0.00261  
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Untreated Bacteria 8 0 1.083 0.0428 0.0151  
Gentamicin 16 0 0.0747 0.0148 0.00370  
Rifampicin 16 0 0.0822 0.0123 0.00308  
Polymyxin B 16 0 0.0620 0.00843 0.00211  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 7.177 1.794 5339.753 <0.001  
Residual 59 0.0198 0.000336    
Total 63 7.197     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Ba vs. Polymyxin B 1.021 128.662 <0.001 0.013  
Untreated Ba vs. Gentamicin 1.009 127.062 <0.001 0.017  
Untreated Ba vs. Rifampicin 1.001 126.121 <0.001 0.025  
Untreated Bacteria vs. TSB 1.024 111.715 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Polymyxin B Yes  
Untreated Ba vs. Gentamicin Yes  
Untreated Ba vs. Rifampicin Yes  
Untreated Bacteria vs. TSB Yes  
 
Comparisons for factor:  
Comparison                       Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria       1.024 111.715 <0.001 0.013 Yes  
TSB vs. Rifampicin                   0.0228 2.877 0.006 0.017 Yes  
TSB vs. Gentamicin                   0.0154 1.935 0.058 0.025 No  
TSB vs. Polymyxin B                0.00266 0.335 0.738 0.050 No  
 
Clinical Isolate 53b 
<> 1 2 3 4 5 6 7 8 9 10 11 12
A 0.0579 0.0384 0.9231 0.0374 0.0618 0.0587 0.0407 0.0894 0.0902 0.0451 0.0532 0.0552
B 0.0569 0.0813 1.0846 0.1218 0.0632 0.0589 0.1252 0.0746 0.0835 0.1131 0.0615 0.0577
C 0.0588 0.1165 1.0623 0.1362 0.0724 0.0665 0.1439 0.0871 0.0794 0.1356 0.0694 0.0665
D 0.0626 0.1210 1.0525 0.1591 0.0758 0.0628 0.1439 0.0749 0.0772 0.1428 0.0778 0.0631
E 0.0742 0.1147 1.0325 0.1526 0.0824 0.0668 0.1395 0.0788 0.0954 0.1341 0.0831 0.0691
F 0.0679 0.0915 1.0517 0.1447 0.0765 0.0903 0.1496 0.0996 0.1054 0.1301 0.0717 0.0790
G 0.0772 0.0635 1.0478 0.1035 0.1178 0.1054 0.1078 0.1186 0.1170 0.1153 0.0808 0.0812
H 0.0801 0.0323 0.9680 0.0348 0.0994 0.0973 0.0395 0.1171 0.1006 0.0415 0.0935 0.0945
average 0.0670 0.0824 1.0278 0.1113 0.0812 0.0758 0.1113 0.0925 0.0936 0.1072 0.0739 0.0708
range 0.0232 0.0887 0.1615 0.1243 0.0560 0.0467 0.1101 0.0440 0.0398 0.1013 0.0403 0.0393  
Descriptive Statistics: Saturday, April 18, 2015, 3:40:39 PM 
Data source: Data 1 in Notebook1 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 8 0 0.0669 0.00926 0.00327 0.00774  
Untreated Bacteria 8 0 1.028 0.0542 0.0192 0.0453  
Gentamicin 16 0 0.0785 0.0184 0.00460 0.00980  
Rifampicin 16 0 0.0930 0.0153 0.00383 0.00816  
Polymyxin B 16 0 0.0723 0.0127 0.00317 0.00675  
Column Range Max Min  Median  25% 75%  
TSB 0.0232 0.0801 0.0569 0.0653 0.0583 0.0757  
Untreated Bacteria 0.161 1.085 0.923 1.050 1.000 1.057  
Gentamicin 0.0591 0.118 0.0587 0.0741 0.0630 0.0938  
Rifampicin 0.0440 0.119 0.0746 0.0898 0.0791 0.103  
Polymyxin B 0.0413 0.0945 0.0532 0.0706 0.0623 0.0810  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 0.325 -1.846 0.186 0.508 0.893 0.248  
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Untreated Bacteria -1.318 0.892 0.284 0.056 0.838 0.072  
Gentamicin 0.815 -0.422 0.175 0.207 0.898 0.074  
Rifampicin 0.511 -1.012 0.136 0.539 0.907 0.104  
Polymyxin B 0.221 -0.782 0.104 0.799 0.960 0.655  
 
 
One Way Analysis of Variance Saturday, April 18, 2015, 3:41:02 PM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 8 0 0.0669 0.00926 0.00327  
Untreated Bacteria 8 0 1.028 0.0542 0.0192  
Gentamicin 16 0 0.0785 0.0184 0.00460  
Rifampicin 16 0 0.0930 0.0153 0.00383  
Polymyxin B 16 0 0.0723 0.0127 0.00317  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 6.303 1.576 2890.469 <0.001  
Residual 59 0.0322 0.000545    
Total 63 6.336     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison                             Diff of Means t Unadjusted P Critical Level Significant?  
Untreated Ba vs. Polymyxin B       0.955 94.503 <0.001 0.013 Yes  
Untreated Ba vs. Gentamicin          0.949 93.893 <0.001 0.017 Yes  
Untreated Ba vs. Rifampicin          0.935 92.454 <0.001 0.025 Yes  
Untreated Bacteria vs. TSB            0.961 82.303 <0.001 0.050 Yes  
 
Comparisons for factor:  
Comparison                        Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria        0.961 82.303 <0.001 0.013 Yes  
TSB vs. Rifampicin                   0.0261 2.581 0.012 0.017 Yes  
TSB vs. Gentamicin                   0.0116 1.142 0.258 0.025 No  
TSB vs. Polymyxin B               0.00538 0.532 0.597 0.050 No  
 
Gentamicin Source Comparison 
 
Descriptive Statistics: Friday, May 01, 2015, 9:11:27 AM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 336 0 0.0646 0.0110 0.000601 0.00118  
Untreated Bacteria 336 0 0.817 0.195 0.0107 0.0210  
Sputum 192 0 0.0769 0.0168 0.00121 0.00240  
Sputum without CF 144 0 0.0780 0.0167 0.00139 0.00275  
Sputum with CF 48 0 0.0738 0.0171 0.00246 0.00495  
Catheter Tip 64 0 0.0751 0.0173 0.00216 0.00432  
Urine 128 0 0.0720 0.0165 0.00146 0.00288  
Fluid 16 0 0.0782 0.0238 0.00594 0.0127  
Blood 64 0 0.0758 0.0171 0.00214 0.00427  
Tissue 16 0 0.0709 0.0138 0.00345 0.00736  
Wound 16 0 0.0822 0.0160 0.00400 0.00852  
Routine 64 0 0.0802 0.0186 0.00233 0.00465  
Bone 16 0 0.0805 0.0129 0.00321 0.00685  
Unknown 96 0 0.214 0.315 0.0322 0.0639  
 
Column Range Max Min  Median  25% 75%  
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TSB 0.0901 0.139 0.0490 0.0631 0.0569 0.0701  
Untreated Bacteria 0.968 1.172 0.205 0.850 0.744 0.944  
Sputum 0.0689 0.121 0.0522 0.0720 0.0633 0.0895  
Sputum without CF 0.0686 0.121 0.0525 0.0736 0.0641 0.0907  
Sputum with CF 0.0636 0.116 0.0522 0.0680 0.0609 0.0827  
Catheter Tip 0.0914 0.143 0.0518 0.0678 0.0633 0.0839  
Urine 0.104 0.155 0.0510 0.0660 0.0595 0.0822  
Fluid 0.0722 0.122 0.0497 0.0693 0.0590 0.0997  
Blood 0.0727 0.129 0.0565 0.0694 0.0621 0.0869  
Tissue 0.0411 0.0977 0.0566 0.0673 0.0584 0.0776  
Wound 0.0536 0.120 0.0664 0.0772 0.0701 0.0914  
Routine 0.0691 0.125 0.0560 0.0758 0.0635 0.0945  
Bone 0.0423 0.110 0.0673 0.0765 0.0717 0.0837  
Unknown 0.915 0.967 0.0516 0.0730 0.0638 0.0991  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.987 8.421 0.0858 <0.001 0.869 <0.001  
Untreated Bacteria -0.981 0.907 0.122 <0.001 0.931 <0.001  
Sputum 0.737 -0.425 0.136 <0.001 0.925 <0.001  
Sputum without CF 0.711 -0.463 0.129 <0.001 0.926 <0.001  
Sputum with CF 0.914 -0.0958 0.159 0.004 0.901 <0.001  
Catheter Tip 1.560 2.981 0.173 <0.001 0.862 <0.001  
Urine 1.687 4.503 0.171 <0.001 0.848 <0.001  
Fluid 0.746 -0.944 0.213 0.052 0.870 0.028  
Blood 1.034 0.437 0.154 <0.001 0.882 <0.001  
Tissue 0.859 -0.337 0.166 0.272 0.875 0.033  
Wound 1.157 0.498 0.198 0.095 0.858 0.018  
Routine 0.789 -0.441 0.144 0.002 0.905 <0.001  
Bone 1.342 0.750 0.282 0.001 0.821 0.005  
Unknown 1.818 1.368 0.445 <0.001 0.499 <0.001  
 
 
One Way Analysis of Variance Friday, May 01, 2015, 9:12:55 AM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 336 0 0.0646 0.0110 0.000601  
Untreated Bacteria 336 0 0.817 0.195 0.0107  
Sputum 192 0 0.0769 0.0168 0.00121  
Sputum without CF 144 0 0.0780 0.0167 0.00139  
Sputum with CF 48 0 0.0738 0.0171 0.00246  
Catheter Tip 64 0 0.0751 0.0173 0.00216  
Urine 128 0 0.0720 0.0165 0.00146  
Fluid 16 0 0.0782 0.0238 0.00594  
Blood 64 0 0.0758 0.0171 0.00214  
Tissue 16 0 0.0709 0.0138 0.00345  
Wound 16 0 0.0822 0.0160 0.00400  
Routine 64 0 0.0802 0.0186 0.00233  
Bone 16 0 0.0805 0.0129 0.00321  
Unknown 96 0 0.214 0.315 0.0322  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 13 142.844 10.988 743.415 <0.001  
Residual 1522 22.496 0.0148    
Total 1535 165.340     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
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Untreated Ba vs. Sputum witho 0.739 61.030 <0.001 0.004  
Untreated Bacteria vs. TSB 0.752 80.219 <0.001 0.004  
Untreated Bacteria vs. Sputum 0.740 67.287 <0.001 0.005  
Untreated Bacteria vs. Urine 0.745 58.999 <0.001 0.005  
Untreated Ba vs. Catheter Tip 0.742 44.743 <0.001 0.006  
Untreated Bacteria vs. Blood 0.741 44.698 <0.001 0.006  
Untreated Bacteria vs. Routine 0.737 44.433 <0.001 0.007  
Untreated Bacteria vs. Unknown 0.603 42.836 <0.001 0.009  
Untreated Ba vs. Sputum with  0.743 39.619 <0.001 0.010  
Untreated Bacteria vs. Tissue 0.746 23.982 <0.001 0.013  
Untreated Bacteria vs. Fluid 0.739 23.748 <0.001 0.017  
Untreated Bacteria vs. Bone 0.736 23.673 <0.001 0.025  
Untreated Bacteria vs. Wound 0.735 23.619 <0.001 0.050  
 
Comparison Significant?  
Untreated Ba vs. Sputum witho Yes  
Untreated Bacteria vs. TSB Yes  
Untreated Bacteria vs. Sputum Yes  
Untreated Bacteria vs. Urine Yes  
Untreated Ba vs. Catheter Tip Yes  
Untreated Bacteria vs. Blood Yes  
Untreated Bacteria vs. Routine Yes  
Untreated Bacteria vs. Unknown Yes  
Untreated Ba vs. Sputum with  Yes  
Untreated Bacteria vs. Tissue Yes  
Untreated Bacteria vs. Fluid Yes  
Untreated Bacteria vs. Bone Yes  
Untreated Bacteria vs. Wound Yes  
 
Comparisons for factor:  
Comparison                          Diff of Means t Unadjusted P Critical Level Significant?  
TSB vs. Untreated Bacteria          0.752 80.219 <0.001 0.004 Yes  
TSB vs. Unknown                        0.150 10.643 <0.001 0.004 Yes  
TSB vs. Sputum                           0.0124 1.124 0.261 0.005 No  
TSB vs. Sputum without CF        0.0134 1.108 0.268 0.005 No  
TSB vs. Routine                           0.0157 0.945 0.345 0.006 No  
TSB vs. Blood                              0.0113 0.681 0.496 0.006 No  
TSB vs. Catheter Tip                    0.0105 0.636 0.525 0.007 No  
TSB vs. Urine                               0.00740 0.586 0.558 0.009 No  
TSB vs. Wound                            0.0177 0.568 0.570 0.010 No  
TSB vs. Bone                               0.0160 0.514 0.607 0.013 No  
TSB vs. Sputum with CF             0.00920 0.491 0.624 0.017 No  
TSB vs. Fluid                               0.0137 0.439 0.661 0.025 No  
TSB vs. Tissue                             0.00636 0.205 0.838 0.050 No  
 
Rifampicin Source Comparison 
Descriptive Statistics: Friday, May 01, 2015, 9:41:32 AM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 336 0 0.0646 0.0110 0.000601 0.00118  
Untreated Bacteria 336 0 0.817 0.195 0.0107 0.0210  
Sputum 192 0 0.107 0.0614 0.00443 0.00874  
Sputum without CF 144 0 0.0947 0.0431 0.00359 0.00710  
Sputum just CF 48 0 0.144 0.0884 0.0128 0.0257  
Catheter Tip 64 0 0.106 0.0672 0.00840 0.0168  
Urine 128 0 0.0886 0.0288 0.00254 0.00503  
Fluid 16 0 0.0793 0.0123 0.00307 0.00654  
Blood 64 0 0.115 0.0686 0.00858 0.0171  
Tissue 16 0 0.0766 0.0145 0.00362 0.00771  
Wound 16 0 0.103 0.0200 0.00500 0.0107  
Routine 64 0 0.0924 0.0158 0.00198 0.00396  
Bone 16 0 0.0983 0.0223 0.00556 0.0119  
Unknown 96 0 0.373 0.399 0.0408 0.0809  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0901 0.139 0.0490 0.0631 0.0569 0.0701  
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Untreated Bacteria 0.968 1.172 0.205 0.850 0.744 0.944  
Sputum 0.454 0.515 0.0605 0.0882 0.0769 0.107  
Sputum without CF 0.449 0.515 0.0659 0.0875 0.0771 0.101  
Sputum just CF 0.367 0.428 0.0605 0.100 0.0753 0.234  
Catheter Tip 0.350 0.419 0.0689 0.0882 0.0790 0.102  
Urine 0.236 0.300 0.0638 0.0827 0.0757 0.0928  
Fluid 0.0412 0.103 0.0622 0.0751 0.0698 0.0885  
Blood 0.374 0.442 0.0676 0.0958 0.0791 0.117  
Tissue 0.0554 0.119 0.0638 0.0702 0.0678 0.0819  
Wound 0.0603 0.140 0.0800 0.102 0.0818 0.111  
Routine 0.0654 0.133 0.0678 0.0898 0.0789 0.102  
Bone 0.0738 0.143 0.0695 0.0968 0.0799 0.114  
Unknown 1.321 1.389 0.0679 0.106 0.0799 0.850  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.987 8.421 0.0858 <0.001 0.869 <0.001  
Untreated Bacteria -0.981 0.907 0.122 <0.001 0.931 <0.001  
Sputum 3.429 14.640 0.297 <0.001 0.578 <0.001  
Sputum without CF 7.490 67.613 0.255 <0.001 0.392 <0.001  
Sputum just CF 1.044 0.418 0.270 <0.001 0.806 <0.001  
Catheter Tip 3.650 12.794 0.364 <0.001 0.438 <0.001  
Urine 5.309 34.715 0.217 <0.001 0.513 <0.001  
Fluid 0.513 -0.645 0.193 0.113 0.944 0.406  
Blood 3.435 13.460 0.256 <0.001 0.594 <0.001  
Tissue 2.011 4.318 0.273 0.002 0.758 <0.001  
Wound 0.600 -0.619 0.159 0.331 0.896 0.070  
Routine 0.591 -0.527 0.111 0.049 0.946 0.007  
Bone 0.612 -0.542 0.136 0.546 0.944 0.395  
Unknown 0.828 -1.034 0.366 <0.001 0.706 <0.001  
 
 
One Way Analysis of Variance Friday, May 01, 2015, 9:41:50 AM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 336 0 0.0646 0.0110 0.000601  
Untreated Bacteria 336 0 0.817 0.195 0.0107  
Sputum 192 0 0.107 0.0614 0.00443  
Sputum without CF 144 0 0.0947 0.0431 0.00359  
Sputum just CF 48 0 0.144 0.0884 0.0128  
Catheter Tip 64 0 0.106 0.0672 0.00840  
Urine 128 0 0.0886 0.0288 0.00254  
Fluid 16 0 0.0793 0.0123 0.00307  
Blood 64 0 0.115 0.0686 0.00858  
Tissue 16 0 0.0766 0.0145 0.00362  
Wound 16 0 0.103 0.0200 0.00500  
Routine 64 0 0.0924 0.0158 0.00198  
Bone 16 0 0.0983 0.0223 0.00556  
Unknown 96 0 0.373 0.399 0.0408  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 13 137.579 10.583 535.883 <0.001  
Residual 1522 30.058 0.0197    
Total 1535 167.637     
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Bacteria vs. TSB 0.752 69.399 <0.001 0.004  
Untreated Ba vs. Sputum witho 0.722 51.603 <0.001 0.004  
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Untreated Bacteria vs. Sputum 0.710 55.843 <0.001 0.005  
Untreated Bacteria vs. Urine 0.728 49.902 <0.001 0.005  
Untreated Bacteria vs. Routine 0.725 37.807 <0.001 0.006  
Untreated Ba vs. Catheter Tip 0.711 37.086 <0.001 0.006  
Untreated Bacteria vs. Blood 0.702 36.615 <0.001 0.007  
Untreated Ba vs. Sputum just  0.673 31.035 <0.001 0.009  
Untreated Bacteria vs. Unknown 0.444 27.327 <0.001 0.010  
Untreated Bacteria vs. Tissue 0.740 20.590 <0.001 0.013  
Untreated Bacteria vs. Fluid 0.738 20.515 <0.001 0.017  
Untreated Bacteria vs. Bone 0.719 19.985 <0.001 0.025  
Untreated Bacteria vs. Wound 0.714 19.869 <0.001 0.050  
 
Comparison Significant?  
Untreated Bacteria vs. TSB Yes  
Untreated Ba vs. Sputum witho Yes  
Untreated Bacteria vs. Sputum Yes  
Untreated Bacteria vs. Urine Yes  
Untreated Bacteria vs. Routine Yes  
Untreated Ba vs. Catheter Tip Yes  
Untreated Bacteria vs. Blood Yes  
Untreated Ba vs. Sputum just  Yes  
Untreated Bacteria vs. Unknown Yes  
Untreated Bacteria vs. Tissue Yes  
Untreated Bacteria vs. Fluid Yes  
Untreated Bacteria vs. Bone Yes  
Untreated Bacteria vs. Wound Yes  
 
Comparisons for factor:  
Comparison                       Diff of Means t Unadjusted P  Critical Level            Significant?  
TSB vs. Untreated Bacteria     0.752 69.399 <0.001 0.004 Yes  
TSB vs. Unknown                   0.308 18.939 <0.001 0.004 Yes  
TSB vs. Sputum just CF          0.0795 3.664 <0.001 0.005 Yes  
TSB vs. Sputum                       0.0425 3.340 <0.001 0.005 Yes  
TSB vs. Blood                         0.0507 2.643 0.008 0.006 No  
TSB vs. Catheter Tip               0.0416 2.172 0.030 0.006 No  
TSB vs. Sputum without CF   0.0301 2.153 0.031 0.007 No  
TSB vs. Urine                          0.0240 1.646 0.100 0.009 No  
TSB vs. Routine                      0.0278 1.451 0.147 0.010 No  
TSB vs. Wound                       0.0380 1.055 0.291 0.013 No  
TSB vs. Bone                          0.0338 0.940 0.348 0.017 No  
TSB vs. Fluid                          0.0147 0.409 0.682 0.025 No  
TSB vs. Tissue                        0.0120 0.334 0.738 0.050 No  
 
Polymyxin B Source Comparison 
Descriptive Statistics: Friday, May 01, 2015, 9:55:33 AM 
 
Data source: Data 1 in Notebook1 
 
Column Size Missing Mean Std Dev Std. Error C.I. of Mean  
TSB 336 0 0.0646 0.0110 0.000601 0.00118  
Untreated Bacteria 336 0 0.817 0.195 0.0107 0.0210  
Sputum 192 0 0.0916 0.0313 0.00226 0.00446  
Sputum without CF 144 0 0.0864 0.0293 0.00245 0.00483  
Sputum with CF 48 0 0.107 0.0322 0.00464 0.00934  
Catheter Tip 64 0 0.131 0.160 0.0200 0.0399  
Urine 128 0 0.146 0.165 0.0146 0.0288  
Fluid 16 0 0.124 0.0269 0.00673 0.0144  
Blood 64 0 0.121 0.0895 0.0112 0.0224  
Tissue 16 0 0.111 0.0183 0.00457 0.00974  
Wound 16 0 0.160 0.173 0.0433 0.0923  
Routine 64 0 0.0853 0.0210 0.00263 0.00525  
Bone 16 0 0.0723 0.0140 0.00350 0.00746  
Unknown 96 0 0.0770 0.0199 0.00203 0.00403  
 
Column Range Max Min  Median  25% 75%  
TSB 0.0901 0.139 0.0490 0.0631 0.0569 0.0701  
Untreated Bacteria 0.968 1.172 0.205 0.850 0.744 0.944  
Sputum 0.121 0.172 0.0508 0.0841 0.0656 0.113  
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Sputum without CF 0.121 0.172 0.0508 0.0776 0.0633 0.104  
Sputum with CF 0.110 0.169 0.0590 0.106 0.0801 0.131  
Catheter Tip 0.840 0.892 0.0518 0.0767 0.0621 0.103  
Urine 1.074 1.128 0.0545 0.102 0.0803 0.130  
Fluid 0.0971 0.191 0.0937 0.118 0.106 0.135  
Blood 0.503 0.558 0.0545 0.103 0.0800 0.121  
Tissue 0.0681 0.159 0.0906 0.106 0.0980 0.119  
Wound 0.637 0.705 0.0683 0.105 0.0841 0.121  
Routine 0.0998 0.153 0.0532 0.0815 0.0691 0.0973  
Bone 0.0488 0.102 0.0532 0.0694 0.0614 0.0804  
Unknown 0.0902 0.141 0.0510 0.0709 0.0622 0.0920  
 
Column Skewness Kurtosis K-S Dist. K-S Prob. SWilk W SWilk Prob  
TSB 1.987 8.421 0.0858 <0.001 0.869 <0.001  
Untreated Bacteria -0.981 0.907 0.122 <0.001 0.931 <0.001  
Sputum 0.726 -0.511 0.128 <0.001 0.919 <0.001  
Sputum without CF 0.904 -0.163 0.153 <0.001 0.898 <0.001  
Sputum with CF 0.321 -0.946 0.0742 0.670 0.951 0.043  
Catheter Tip 3.107 9.807 0.387 <0.001 0.484 <0.001  
Urine 3.966 17.440 0.359 <0.001 0.471 <0.001  
Fluid 1.320 1.544 0.165 0.277 0.880 0.039  
Blood 3.575 13.376 0.329 <0.001 0.528 <0.001  
Tissue 1.442 2.081 0.203 0.078 0.871 0.028  
Wound 2.750 7.107 0.451 <0.001 0.512 <0.001  
Routine 0.968 1.182 0.0945 0.164 0.940 0.004  
Bone 0.765 -0.0273 0.121 0.681 0.945 0.418  
Unknown 0.957 0.364 0.158 <0.001 0.907 <0.001  
 
 
One Way Analysis of Variance Friday, May 01, 2015, 9:55:58 AM 
 
Data source: Data 1 in Notebook1 
 
Group Name  N  Missing Mean Std Dev SEM  
TSB 336 0 0.0646 0.0110 0.000601  
Untreated Bacteria 336 0 0.817 0.195 0.0107  
Sputum 192 0 0.0916 0.0313 0.00226  
Sputum without CF 144 0 0.0864 0.0293 0.00245  
Sputum with CF 48 0 0.107 0.0322 0.00464  
Catheter Tip 64 0 0.131 0.160 0.0200  
Urine 128 0 0.146 0.165 0.0146  
Fluid 16 0 0.124 0.0269 0.00673  
Blood 64 0 0.121 0.0895 0.0112  
Tissue 16 0 0.111 0.0183 0.00457  
Wound 16 0 0.160 0.173 0.0433  
Routine 64 0 0.0853 0.0210 0.00263  
Bone 16 0 0.0723 0.0140 0.00350  
Unknown 96 0 0.0770 0.0199 0.00203  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 13 138.396 10.646 840.571 <0.001  
Residual 1522 19.276 0.0127    
Total 1535 157.672     
The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically 
significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
Multiple Comparisons versus Control Group (Holm-Sidak method): 
Overall significance level = 0.05 
 
Comparisons for factor:  
Comparison Diff of Means t Unadjusted P Critical Level  
Untreated Bacteria vs. TSB 0.752 86.660 <0.001 0.004  
Untreated Bacteria vs. Sputum 0.725 71.251 <0.001 0.004  
Untreated Bacteria vs. Unknown 0.740 56.818 <0.001 0.005  
Untreated Bacteria vs. Urine 0.671 57.441 <0.001 0.005  
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Untreated Ba vs. Sputum witho 0.731 65.178 <0.001 0.006  
Untreated Bacteria vs. Routine 0.732 47.668 <0.001 0.006  
Untreated Bacteria vs. Blood 0.696 45.348 <0.001 0.007  
Untreated Ba vs. Catheter Tip 0.686 44.695 <0.001 0.009  
Untreated Ba vs. Sputum with  0.710 40.881 <0.001 0.010  
Untreated Bacteria vs. Bone 0.745 25.862 <0.001 0.013  
Untreated Bacteria vs. Tissue 0.706 24.516 <0.001 0.017  
Untreated Bacteria vs. Fluid 0.693 24.067 <0.001 0.025  
Untreated Bacteria vs. Wound 0.657 22.806 <0.001 0.050  
 
Comparison Significant?  
Untreated Bacteria vs. TSB Yes  
Untreated Bacteria vs. Sputum Yes  
Untreated Bacteria vs. Unknown Yes  
Untreated Bacteria vs. Urine Yes  
Untreated Ba vs. Sputum witho Yes  
Untreated Bacteria vs. Routine Yes  
Untreated Bacteria vs. Blood Yes  
Untreated Ba vs. Catheter Tip Yes  
Untreated Ba vs. Sputum with  Yes  
Untreated Bacteria vs. Bone Yes  
Untreated Bacteria vs. Tissue Yes  
Untreated Bacteria vs. Fluid Yes  
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23.) Routine 
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52.) Catheter tip 
53.) A. Sputum 
B. Routine 
 
 
